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Abstract 
Adults, and more recently, children with T1D have been found to have a significantly 
increased risk of fractures compared to the general population. The increased fracture risk is 
disproportioned to the marginal reduction in bone mineral density (BMD) observed in T1D 
suggesting that factors other than bone mineral status contribute to skeletal fragility. The 
National Institute of Health (NIH) Consensus Development Panel on Osteoporosis 
highlighted that bone strength is in fact dependent on two main factors: bone density and 
bone quality. Recognising the importance of bone quality as a factor determining bone 
health, this work set out to examine bone microarchitecture using novel imaging techniques 
of high-resolution magnetic resonance imaging (HR-MRI). Furthermore, HR-MRI enables 
the use of magnetic resonance spectroscopy (MRS) to quantify the amount of bone marrow 
fat, providing invaluable insight into the relationship between bone marrow adiposity and 
skeletal fragility. The background to this work, the current body of evidence and the rationale 
for the studies are therefore laid out in Chapter 1. All the methodology used in the thesis is 
summarised in Chapter 2, including the laboratory techniques carried out.  
The clinical study was conducted in children with T1D as not only have these children been 
shown to have increased fracture risk, but also given that childhood and adolescence are 
important physiological periods for optimal bone development, it is therefore possible that 
they may be especially predisposed to abnormalities of bone health. The use of MRI as a 
research tool in children is relatively new, so I started this work exploring the practicality of 
this technique in children and using data from a previous HR-MRI study to determine the 
feasibility of partial set analysis of the images, the latter detailed in Chapter 3. This straight-
forward exercise confirmed that partial MRI data sets can reliably represent a larger 
complete set of images when assessing trabecular bone microarchitecture parameters. 
The overall objective of this thesis is to assess the bone health of children with Type 1 
diabetes, by using HR-MRI to study the trabecular bone microarchitecture, in addition to 
bone mineral density and bone turnover status as detailed in Chapter 4. A cross-sectional 
case control study was conducted in 32 children with T1D and compared to 26 healthy age- 
and gender- matched controls. The primary hypothesis of the study was proven, in that 
children with T1D were found to have poorer bone microarchitecture with lower trabecular 
bone volume compared to the controls. Children with T1D also had lower number of 
trabeculae and the trabeculae were spaced further apart from one another. Although this 
study demonstrated that children with T1D fracture more than children without the 
iii 
condition, it did not however show any relationship between the compromised bone 
microarchitecture to fracture. In fact, the children with T1D who fractured were found to 
have significantly lower bone mineral density and poorer glycaemic control. There was also 
no significant disparity in the bone marrow adiposity between the two groups. 
In parallel, I performed one year of laboratory-based experiments to study the differentiation 
of mesenchymal stem cells (MSCs), which are the precursors to bone (osteoblasts) and fat 
cells (adipocytes), as detailed in Chapter 5. My main aim was to study the effects of 
metformin, a drug increasingly used in patients with T1D, on the MSC differentiation in 
order to determine if metformin may have a therapeutic bone protective role. My studies 
successfully demonstrated in vitro that metformin exerted reciprocal control over the 
osteogenic transcription factor Runx2, and the adipogenic transcription factor, PPARγ; 
promoting osteogenesis through an increase in Runx2 transcriptional activities, 
independently of Runx2 protein expression, and suppressing adipogenesis, through 
suppression of PPARγ protein expression and activity. I proceeded to study the underlying 
molecular mechanisms of the metformin action, starting with AMP-activated protein kinase 
(AMPK) given that metformin is a known AMPK activator. To our fascination, the study 
found that the suppression of adipogenesis by metformin appeared to be independent of 
AMPK activation but rather through the suppression of the mTOR/p70S6K signalling 
pathway. 
Chapter 6 summarised all my work for this thesis, highlighting its strengths and limitations 
as well as providing my perspectives into the future directions of this work. 
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1 Introduction 
1.1 Background to the thesis 
T1D affects 300,000 people in the UK, of which 35,000 are children. The incidence of T1D 
is 1:4000, with peak age at diagnosis between 9-14 years old. In addition to the many target 
organs that are typically associated with dysfunction in diabetes mellitus, the skeleton has 
now been recognised as another organ adversely affected in diabetes mellitus. The effects 
on bone health manifest clinically as early osteoporosis and fragility fractures, with increased 
incidence of hip fractures particularly in patients with T1D compared to age-matched non-
diabetics (Vestergaard 2007, Hothersall et al. 2014). In addition, this increased risk is also 
evident in young adults (Hothersall et al. 2014). Given that childhood and adolescence are 
important physiological periods for optimal bone development, it is possible that children 
and adolescents with T1D may be especially predisposed to abnormalities of bone health. 
In adults, patients with T1D have a modest 10% lower BMD than the general population 
(Vestergaard 2007) which generates an estimated relative hip fracture risk of 1.4-fold (Table 
1.1) but instead, a meta-analysis of several large cohort studies demonstrated a 
disproportionately higher risk of hip fractures by 7-folds (Figure 1.1) (Janghorbani et al. 
2007). Such disparities between dual x-ray absorptiometry (DXA)-derived BMD and actual 
fracture risk in T1D suggest that factors other than BMD need to be considered more 
comprehensively. This is acknowledged by the National Institute of Health (NIH) Consensus 
Development Panel on Osteoporosis which recognises the importance of bone 
microarchitecture as a factor determining bone health (NIH Consensus Development 
Conference Panel 1993) High resolution MRI provides the necessary information of cortical 
and trabecular microarchitecture, analogous to high resolution computed-tomography (CT) 
but without the radiation (Seeman and Delmas 2006, Wehrli 2007). In addition, 
spectroscopic imaging in MRI also enables evaluation of bone marrow adiposity (BMA) 
(Wehrli et al. 2000), an issue which is gaining increasing attention in the field of osteoporosis 
because of the connection between adipogenesis and osteogenesis (Fazeli et al. 2013). 
Table 1.1 Observed changes in BMD and expected change in fracture risk 
Type of diabetes  Spine Z-score Hip z-score 
T1D  -0.22 ± 0.01 -0.37± 0.16 
T2D  0.41± 0.01 0.27± 0.01 
Expected relative fracture risk  Any fracture Hip fracture 
T1D  1.09 1.42 
T2D  0.85 0.77 
2 
 
 
Figure 1.1 Meta-analysis of the association between T1D and risk of hip fracture. Results from 
6 studies showed that adults with T1D have an almost 7-fold increase in relative risk of hip fracture 
compared to that of the general population. This is disproportionately high for the expected risk of 
fracture predicted from the marginal reduction in bone mineral density (see Table 1.1). [Adapted from 
(Janghorbani et al. 2007)] 
NHS Greater Glasgow and Clyde Paediatric Diabetes Service is one of the largest paediatric 
diabetes centre in the UK looking after over 750 children with Type 1 diabetes. In 2015 the 
Royal Hospital for Children in Glasgow moved to one of the largest biomedical campuses 
in Europe with a dedicated £10million clinical research facility and state-of-the-art MRI 
imaging facilities. This provided me an ideal opportunity to carry out a comprehensive multi-
modality assessment looking at the bone health of children with Type 1 diabetes, without 
radiation exposure. 
Evidence suggests that diabetic bone loss involves a complex interplay of chronic 
hyperglycaemia, insulin deficiency, increased marrow adiposity, inflammation and 
vasculopathy, although the exact underlying pathogenesis remains unclear. In vitro and in 
vivo studies in T1D point towards a defect in bone formation (Rico et al. 1989, Verhaeghe 
et al. 1990, Pater et al. 2010), in contrast to bone resorption which is the underlying 
mechanism of age-related osteoporosis. Importantly, this highlights therapeutic implications 
for treating diabetic bone loss with bisphosphonates, which is current practice for age-related 
osteoporosis and fragility fracture, as it will not be mechanistically sound. The anti-diabetic 
drug metformin, however, may have a bone protective effect as reduction in fracture risks 
has been noted in Type 2 diabetes mellitus (T2D) patients on this medication (Vestergaard 
et al. 2005, Zinman et al. 2010). Metformin is also increasingly used in T1D to improve 
insulin sensitivity and glycaemic control (Vella et al. 2010), so it would be advantageous to 
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ascertain the underlying mechanisms by which metformin protects bones. This led me to a 
one-year laboratory research at the Institute of Molecular, Cell and Systems Biology, 
University of Glasgow, studying the effects of metformin on mesenchymal stem cell 
differentiation into bone (osteoblasts) and fat cells (adipocytes). 
I hope that this work will contribute to a better understanding of the extent of skeletal 
morbidity in children with Type 1 diabetes and its relationship to the disease. I further hope 
that it will not only elucidate the causes, but also provide evidence for measures to protect 
bone health in this cohort of children from an early age. Based on my laboratory research, I 
hope to establish the bone protective mechanisms of metformin as a therapeutic potential for 
use in diabetic osteopathy. 
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1.2 Bone development and its components 
Bone is a mineralised connective tissue with an impressive hierarchical organisation from a 
macroscopic to microscopic level.  This confers it a combination of stiffness and toughness 
allowing it to perform its multifunctional role from locomotion, support and protection of 
vital organs such as heart, lungs and brain, to mineral homeostasis and haematopoiesis. More 
recent discoveries revealed that bone also has an endocrine function, in particular through 
osteocalcin and its role in glucose metabolism. Circulating undercarboxylated osteocalcin, 
itself regulated by insulin acts on pancreatic β-cells to further increase β-cell mass and 
subsequent  insulin secretion in a feed-forward loop (Ducy et al. 1996, Lee et al. 2007, 
Ferron et al. 2010).  
1.2.1 Bone architecture 
On a macroscopic level, bone is made up of two main entities: cortical and trabecular bone, 
giving rise to four distinct surfaces called skeletal envelopes which are morphologically 
distinct with different roles: periosteal, endocortical, trabecular and intracortical envelopes 
(Figure 1.2).  
 
Figure 1.2 Bone structure.  (A) Macroscopically, bone appears as either lace-like trabecular bone 
or denser cortical bone. These create four different kinds of surfaces. called envelopes, upon which 
bone cells act. (B) Trabeculae in the cancellous bone compartment consist mostly of primary 
lamellae. However remodelled areas (areas in which bone has been resorbed and reformed) can 
also form hemiosteons, similar to half osteons). (C) The intracortical envelope in humans is packed 
with secondary osteons, or Haversian systems. [Adapted from (Burr and Akkus 2014)]. 
Trabecular  
envelope  
Periosteal  
envelope  
Endocortical envelope  
Intracortical  
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Trabecular lamellae 
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The adult skeleton is composed of 80% cortical bone and 20% trabecular bone (Eriksen et 
al. 1994). The ratio of cortical to trabecular bone varies in different bones and skeletal sites. 
Whilst the radial diaphysis is 95:5 cortical to trabecular bone, the vertebra is only 25:75 with 
trabecular predominance. Within the long bone, the hollow shaft, or diaphysis, is composed 
primarily of cortical bone whereas the metaphysis and epiphyses are composed of mainly 
trabecular bone with only a thin shell of cortical bone. Both cortical and trabecular bones are 
composed of osteons. 
1.2.1.1 Cortical bone 
Cortical bone is the dense and solid thick outer shell of bones, also known as the “compact” 
bone. Although it constitutes 80% of the total bone mass, cortical bone has a substantially 
smaller surface area than trabecular bone (Weatherholt et al. 2012). Osteons are the basic 
units in the cortical bone orientated along the long axis of the bone with a central Haversian 
canal, together forming the Haversian system. They are cylindrical in shape with 
circumferential bands of bone where collagen and mineral exist in discrete sheets (known as 
concentric lamellae) in the walls of the Haversian system, as shown in Figure 1.3. The 
collagen fibres of the concentric lamellae are orientated in alternating directions to give 
strength to the tissue.  
 
Figure 1.3 The hierarchical organisation of bone on a microscopic level. (A) Schematic diagram 
of a bone microstructure. (B) Cortical bone osteon or Haversian system with a central Haversian 
canal, with concentric lamellae and uniformly spaced lacunae. (C) Cross section of a cortical bone 
osteoid under light microscopy. (D) Trabeculae shown in cross section with lamellae of bone, lacunae 
and outer covering of endosteum. [Adapted from (Weatherholt et al. 2012)]  
A 
B 
C 
D 
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There are many interconnected canals (lacunae and canaliculi) through which bone cells 
communicate and receive vascular supply. These canals give rise to the low 3-5% of porosity 
in cortical bone (Burr and Akkus 2014). Increased cortical remodeling causes an increase in 
cortical porosity and decrease in cortical bone mass (reduction in cortical volumetric bone 
mineral density (vBMD) (Clarke 2008). 
Cortical bone has an outer periosteal surface and an inner endosteal surface. On the periosteal 
surface, bone formation exceeds resorption, hence bone increases in diameter (appositional 
growth) with aging. On the endosteal surface, the opposite is true with bone resorption 
typically exceeding formation, so the marrow space expands with aging. Higher remodelling 
activity takes place on the endosteal surface, with greater biomechanical strain and greater 
inflammatory exposure from the adjacent marrow (Clarke 2008). Trabecular bone loss 
begins first, in early adulthood for both sexes, before cortical bone which begins during 
middle age for women, though much later in men (after age 75 years) (Riggs et al. 2008). 
By age 50 years, approximately 40% of total lifetime trabecular loss has occurred, in contrast 
to only 15% of cortical bone lost (Riggs et al. 2008). 
1.2.1.2 Trabecular bone 
Trabecular bone, also known as the “spongy” bone, or cancellous bone, is the honeycomb-
like network of plate and rod-like structures found predominantly in the metaphyses of long 
bones, vertebrae and ribs (Figure 1.4A). Trabecular bone constitutes 20% of the total bone 
mass in the skeleton. Unlike the cortical osteons, the trabecular osteons are hemiosteons 
without central Harversian canal due to bone remodelling on the longer surface of the 
trabeculae. The lamellae are arranged parallel to this longer trabecular surface (Burr and 
Akkus 2014). Trabecular bone has 50-90% higher porosity relative to the cortical bone 
(Weatherholt et al. 2012).  
The porosity helps trabecular bone to be light yet add strength to the skeleton by providing 
a honeycomb scaffolding to reinforce the ends of long bones, close to the joints, which are 
often subjected to mechanical stresses from the sides. The trabecular bones help to channel 
the mechanical stresses imposed on it to the stronger, and more solid cortical bones. In the 
vertebrae, it helps to cushion axial loading forces on the skeleton.  
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Figure 1.4 Trabecular bone.  (A) Trabecular bone is composed of broader plates and thinner rods 
When bone is lost, more of the trabecular plates convert to being rod-like. (B) Impact of trabecular 
number and trabecular thickness on bone strength. Reduction in trabecular number has a greater 
negative impact on bone strength than does the loss of an equal amount of bone through trabecular 
thinning [Adapted from (Mosekilde 1990), (Burr and Akkus 2014)] 
In healthy humans, the trabeculae tend to be shaped as plates rather than circular or elliptical 
rods. The architecture of the trabecular bone can be characterised by the number of 
trabeculae (TbN), how thick they are (TbTh), and how far apart they are (TbSp) all 
contributing to the overall trabecular bone volume (BV). TbTh ranges between 50-400µm, 
averaging about 200µm in adults (Eriksen et al. 1994) and 150µm in children up to 16 years 
(Glorieux et al. 2000), with an estimated total trabecular area of 7m2 (Clarke 2008).  
The ideal relationship between TbN and TbTh is not only dependent on the site, but also the 
primary direction of the loading forces (Burr and Akkus 2014). Most importantly, TbN have 
a bigger impact on the strength of the bone than TbTh, with the loss of a complete trabeculae 
(reduced TbN) weakening the bone by 2-3 folds more compared to losing the same amount 
through thinning of the trabeculae (reduced TbTh) (Figure 1.4B). This highlights the 
importance of connectivity within the trabecular architecture. The loss of connectivity can 
also occur when trabecular bone plates become more rod-like, as with the case in 
osteoporosis. Trabecular bone is also preferentially lost; earlier and at a greater rate than 
cortical bone during aging resulting in skeletal fragility at trabecular rich sites such as distal 
radius (Riggs et al. 2008) and femoral head (Li and Aspden 1997, Ciarelli et al. 2000). 
  
Trabecular plates 
Trabecular rods 
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1.2.2 Bone cells and matrix 
Bone is a living tissue made up of minerals, organic matrix, water and lipids, as seen in 
Figure 1.5. The organic matrix is 90% Type 1 collagen with a trace amount of Type III and 
V collagen, providing bone its elasticity and flexibility (Clarke 2008). The collagen fibres 
are made up of triple helixes of three polypeptide chains, connected by different kinds of 
cross-links. which can alter the material properties of the tissue, and ultimately the 
mechanical behaviour of the whole bone. These cross links, such as pyridinoline and 
deoxypyridinoline, can be formed through enzymatic processes, or through non-enzymatic 
glycation, creating advanced glycation end products (AGEs) such as pentosidine. 
 
Figure 1.5 Bone composition.  Bone is comprised predominantly of calcium hydroxyapatite mineral, 
with Type I collagen making up most of the organic matrix. 
The inorganic matrix is predominantly calcium hydroxyapatite which is interspersed with 
the collagen fibres conferring bone the mechanical rigidity and load-bearing strength to 
bone. Human bones are 60% mineralised (Seeman and Delmas 2006). The balance of 
distribution between collagen and mineral is crucial to ensure bone is stiff enough to provide 
mechanical support yet has the flexibility to absorb and redistribute loading stresses. 
Alteration in this balance with aging and with diseases can therefore compromise the 
structural integrity of bone resulting in increased susceptibility to fracture. In diabetes, 
especially when free sugar is in abundance due to poor glycaemic control, AGEs accumulate 
in the extracellular matrix (Yamamoto et al. 2001). The increased cross linking increases the 
stiffness of the bone ultimately making it too brittle resulting in fragility fracture (Vashishth 
et al. 2001).  
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There are three distinct types of cells found within bone: i) the Osteoblasts (3-4% of the 
cells in bone) which synthesise and regulate the deposition and mineralisation of the 
extracellular matrix of bone. These cells are derived from pluripotent mesenchymal stem 
cells, as described in detail in section 1.3, and have a lifespan of up to 8 weeks in humans, 
during which time they lay down osteoid (including proteoglycans, glycoproteins and 
collagen fibres) before becoming embedded in their own calcified matrix and developing 
morphologically into an osteocyte. ii) Osteocytes, are the most abundant bone cells (90-
95%) and the longest lived with a life span of up to 25 years (Capulli et al. 2014). Although 
derived from osteoblasts, they are distinctively different in function. These spider-shaped 
cells have long and branched cellular processes that extend throughout bone aiding cell to 
cell communication and intracellular transport of small signalling molecules.  iii) 
Osteoclasts are derived from haematopoetic stem cells, although their formation 
(osteoclastogenesis) remains dependent on osteoblasts and osteoblast precursors. The 
osteoblasts secrete receptor activator of nuclear factor-ƙB ligand (RANKL) and macrophage 
colony-stimulating factor (CSF) to recruit and activate the differentiation of osteoclast 
precursors into osteoclasts (Figure 1.6). Osteoprotegerin (OPG), also produced by 
osteoblasts, is a competitive inhibitor of RANKL binding to RANK receptor so the ratio of 
RANKL:OPG determines osteoclastogenesis. Functionally, osteoclasts are the only cells 
capable of resorbing mineralised bone. 
  
Figure 1.6 Regulation of Osteoclastogenesis by RANKL and OPG.  Osteoclasts are derived from 
haematopoetic stem cells although their formation remains dependent on osteoblasts. Osteoblasts 
and osteoblast precursors produce two forms of RANKL which stimulate osteoclast recruitment and 
activation. The membrane-bound form directly interacts with membrane-bound RANK molecules on 
adjacent osteoclast precursors. The soluble form diffuses through the intercellular space and 
interacts with the membrane-bound RANK molecules on nearby osteoclast precursors. 
Osteoprotegerin (OPG) acts as a decoy receptor (inhibitor) to prevent RANKL or sRANKL from 
interacting with RANK. The ratio between RANKL and OPG produced determines 
osteoclastogenesis. [Adapted from (Clarke 2008)]  
Mature Osteoclast Osteoclast Precursor 
Mature Osteoblast Osteoblast Precursor 
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1.2.3 Bone growth, modelling and remodelling 
Bone is a highly dynamic and metabolically active tissue, which undergoes constant growth, 
modelling and remodelling. Longitudinal growth occurs at the growth plates during 
childhood and adolescence to allow for growth and attainment of peak bone mass. Cartilages 
proliferate in the epiphyseal and metaphyseal areas of long bones, before undergoing 
mineralisation to form primary new bone. Modelling is the process by which bones change 
their overall shape to accommodate for skeletal loading and radial growth, which continues 
throughout life although less frequent in adulthood. During bone modelling, bone formation 
and resorption are not tightly coupled, in that osteoblasts and osteoclasts act independently 
in response to biomechanical forces. Bones normally widen with age when bone formation 
at the periosteal envelope exceeds bone resorption at the endosteal surface (Clarke 2008). 
Bone remodelling is the process whereby old bone is replaced by newly formed bone, which 
allows self-repair in both childhood and adulthood. More acutely, remodelling also helps to 
maintain calcium homeostasis. The process of remodelling occurs at all four skeletal 
envelopes: endocortical, intracortical and trabecular, with a lesser extent on the periosteal 
envelope. It involves four sequential phases: activation, resorption, reversal and formation, 
as shown in Figure 1.7. Osteocytes are thought to sense bone deformation or microdamage 
(Han et al. 2004), initiating the need for remodelling during which bone resorption by 
osteoclasts precedes bone formation by osteoblasts. The osteocytes, through their long 
cytoplasmic processes, relay the information to the osteoblast lining-cells and osteoblast 
precursors, which in turn activates osteoclastogenesis (as described in Section 1.2.2) and is 
believed to orchestrate the bone remodelling process (Verborgt et al. 2000, Parfitt 2002). 
The mononuclear monocyte-macrophage osteoclast precursors recruited from the circulation 
lift off the bone-lining cells from the endosteum, fuse to form multinucleated osteoclasts 
underneath, then bind to the matrix resorbing old bone before undergoing apoptosis at the 
end. Osteoclast-mediated bone resorption takes only approximately 2-4 weeks during each 
remodelling cycle. Bone resorption transitions to bone formation in the reversal phase, 
where monocytes, osteocytes released from bone matrix and the osteoblast precursors from 
the same multicellular remodelling unit migrate to the resorption cavities, under the 
influence of several growth factors such as TGFβ, IGF-1 and BMPs (Hock et al. 1988, 
Bonewald and Mundy 1990). The osteoblast precursors then mature to become osteoblasts 
promoting bone formation, through synthesis of new collagenous organic matrix and 
regulation of the matrix mineralisation by releasing small membrane-bound matrix vesicles 
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that concentrate calcium and phosphate. Bone formation takes longer, up to 4-6 months to 
complete (Clarke 2008).  
 
Figure 1.7 Sequential Bone Remodelling Processes on a Trabecula. When microcracks sever 
canaliculi, the osteocytes sense the damage and signals the osteoblast lining cells to activate 
osteoclastogenesis (activation phase). The activated osteoclast binds to the matrix and resorbs old 
bone and the microcrack (resorption phase), taking 2-4 weeks to complete, following which 
osteoclasts undergo apoptosis and osteoblast precursors migrate to the area under the influence of 
growth factors (reversal phase). These osteoblast precursors mature into osteoblasts and begin 
synthesizing new collagenous organic matrix bone formation, laying down osteoid which becomes 
mineralised over the next 4-6 months (formation phase). [Adapted from (Seeman and Delmas 2006)] 
The remodeling process begins before birth and continues until death. The rate, however, 
decreases as longitudinal growth ceases with epiphyseal closure (Parfitt et al. 2000). Bone 
remodelling, in particular bone resorption, increases with age in both men and women, 
although more marked in the latter especially in peri-menopausal and early postmenopausal 
women, accounting for the higher rate of osteoporosis and fragility fracture in this group. 
Bone turnover is the process of bone remodelling, where bone formation and bone resorption 
are tightly coupled in space and time (Delmas 1991). Biochemical markers of bone 
formation and resorption enable the assessment of bone turnover as described above. This 
can allow insight into the effects of diseases on bone health in childhood. Interpretation of 
the results, however, can be challenging as they depend on age, gender, pubertal stage, 
nutritional status and other hormonal regulation. Skeletal growth and puberty can lead to 
substantial changes in raw levels of bone formation and resorption markers with age, as seen 
with their correlation with growth velocity (van Coeverden et al. 2002). In children, there is 
Formation 
4-6mths 
2-4wks 
Reversal 
Resorption Activation 
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added variability and reduced specificity as these markers are released into the circulation 
during the process of growth in length, when the actions of osteoclasts and osteoblasts are 
not coupled. Some markers can also be affected by circadian variation and day-to-day 
fluctuations. This can be further compounded by methodologic issues with assay sensitivity 
and specificity.  
1.2.3.1 Bone formation markers 
The commonly used serum markers for bone formation are bone-specific alkaline 
phosphatase (BAP) and osteocalcin (OC), which are released at different stages of osteoblast 
proliferation and differentiation (Calvo et al. 1996). 
1.2.3.1.1 Bone Alkaline Phosphatase (BAP) 
Serum total alkaline phosphatase (AP) is a combination of four isoenzymes; liver/bone, 
placental, intestinal and germ cell. The first two, liver and bone isoenzymes, differ only by 
post-translational glycosylation. Current immunoassays for BAP therefore possess a low 
cross-reactivity (16%) with the circulating liver isoenzyme (Delmas 1995). It has a relatively 
long half-life of 1 to 2 days and no circadian variation (Yang and Grey 2006). BAP is 
produced by osteoblasts and is involved in the initialisation process of osteoid 
mineralisation. 
BAP is a very sensitive diagnostic tool in adults where a small increase is easily detectable 
and indicating possible pathology (Delmas 1995). In infants, BAP increases after birth due 
mainly to skeletal growth and is less predictive of bone mineral accrual. In rapidly growing 
children and adolescents, BAP increases until mid-puberty and decreases in late puberty 
(after menarche in girls) (Magnusson et al. 1995, Tobiume et al. 1997) (Figure 1.8), 
correlating positively and significantly with height velocity in both genders. BAP is about 
10 times higher than adult values in pubertal girls in contrast to liver AP which remains 
within normal adult values (Blumsohn et al. 1994). BAP increase has been shown to 
correlate with the increase in bone mineral density in growth hormone-treated children 
(Tobiume et al. 1997). 
1.2.3.1.2 Osteocalcin 
Osteocalcin (OC) is a sensitive and specific marker for bone formation. It is produced almost 
exclusively by the osteoblasts during the matrix mineralisation phase and incorporated 
directly into the bone matrix (Delmas 1995). Circulating OC has a short half-life and is 
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rapidly (5mins) cleared by the kidneys. In adults, one third of the circulating OC is an intact 
molecule, one third is a large N-terminal mid-region fragment and the rest is N-terminal 
midregion and C-terminal fragments (Garnero et al. 1994). The distribution of these 
immunoreactive forms of OC is unknown in children. Serum OC results can vary 
considerably depending on which immunoreactive forms (intact molecules or OC fragments) 
the immunoassay measures. Assays that measure the intact molecule and large N-terminal 
fragment aremore robust as well as sensitive.  
 
Figure 1.8 Serum bone alkaline phosphatase (BAP) in children and adolescents. Females had 
their peak serum BAP levels during puberty about two years earlier than males [Adapted from 
(Tobiume et al. 1997). 
 
Figure 1.9 Serum osteocalcin levels in children and adolescents. Values are presented as mean 
and standard error of mean. [Adapted from (Johansen et al. 1988)]  
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Similar to BAP, circulating OC varies with age and pubertal stage in children as shown in 
Figure 1.9 (Johansen et al. 1988). The concentration is 10-20 times higher in growing 
children compared to pre-menopausal women (Matikainen et al. 1999). Additionally, there 
is also a circadian rhythm to OC production with the highest levels in the morning (Heuck 
et al. 1998). Circulating OC detectable in urine also demonstrates a similar diurnal variation 
(Taylor et al. 1990, Matikainen et al. 1999). 
1.2.3.2 Bone resorption markers 
The commonly used bone resorption markers are urinary hydroxyproline (HPro), 
pyridinoline (Pyr) and deoxypyridinoline (Dpyr) released during matrix resorption into the 
blood and excreted in the urine. They reflect bone resorption as they are not reutilised in 
collagen synthesis. Urinary bone markers have several limitations including the practical 
difficulties associated with serial urine collection, units of expression which may need size 
correction and expression in concentration relative to creatinine which itself is subjected to 
age-related changes due to muscle mass variation (Forbes and Bruining 1976, Rauch et al. 
1994). Hence, the measurement of serum bone resorption marker, C-terminal telopeptide of 
type I collagen (CTX), in particular, is preferred.  
1.2.3.2.1 Cross-linked Telopeptides (CTX) 
During bone resorption, osteoclasts cleave off short fragments of the N- and C-terminal 
domains of collagen molecules into the circulation. The level of circulating CTX is highest 
in neonates and then markedly decreased in children after 1 year of age. The second peak 
was observed in girls 11-13 years old and in boys who were 14-17 years old (Crofton et al. 
2002, Rauchenzauner et al. 2007), again demonstrating the effects of puberty, as seen in 
Figure 1.10. Urinary crosslinks show diurnal variation; highest in the morning and lowest 
late evening although this has not been shown in serum CTX.  
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Figure 1.10 Reference curves for CTX resorption markers in childhood and adolescence. 
Curves represent the 50th centile (solid line) and 3rd/97th centile (dotted lines) [Adapted from 
(Rauchenzauner et al. 2007)] 
1.2.3.3 Other markers 
1.2.3.3.1 Sclerostin 
Sclerostin is the product of SOST gene, secreted by osteocytes, and expressed almost 
exclusively in bone (Bellido T 2014). It is an inhibitor of the Wnt signalling pathway and 
thus inhibits bone formation. Sclerostin competes with Wnt ligands to bind to LRP5/6 co-
receptors resulting in degradation of the intracellular β-catenin and hence impair osteoblast 
differentiation and function (Li et al. 2005, Bellido T 2014). Mechanical loading in rats and 
mice suppresses sclerostin level resulting in greater bone formation (Robling et al. 2008) 
whilst immobilisation in humans increases sclerostin levels leading to bone loss (Gaudio et 
al. 2010). These strongly suggest sclerostin as the crucial link between osteocytic 
mechanosensing and osteoblastic bone formation. Sclerostin level rises from early childhood 
and peaks at mid puberty (Tanner stage 3), and diminishes thereafter (Tsentidis et al. 2016). 
Boys have higher sclerostin levels than girls (Tsentidis et al. 2016). Most importantly, 
sclerostin has been shown to be an independent predictor of fracture risks (Ardawi et al. 
2012, Starup-Linde et al. 2016). 
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1.2.4 Bone marrow and its composition 
Bone marrow occupies approximately 85% of the medullary cavity, surrounded by a network 
of trabecular bone. In addition to the mesenchymal stem cells (described in section 1.3), it 
contains haematopoietic elements (red marrow) and a variable amount of fat (yellow 
marrow). At birth, the bone cavities are filled mainly with haematopoietic marrow, which is 
gradually replaced by fatty yellow marrow during childhood. By early adulthood, 
approximately 50% of the bone marrow volume is yellow marrow confined primarily in the 
appendicular skeleton, whilst the red marrow is concentrated to the axial skeleton (including 
proximal humerus and femur).  
This physiological conversion occurs in a centripetal fashion from the distal to the more 
proximal appendicular skeleton (Vande Berg et al. 1998).Within the long bones, the fatty 
marrow conversion begins in the epiphyses at the onset of epiphyseal ossification and is 
completed within 6-8 months, followed by the diaphysis before extending to the metaphyses 
(Vogler and Murphy 1988, Jaramillo et al. 1991). The conversion also occurs concurrently 
from the central medullary canal to the endosteum. In the tibia specifically, the conversion 
begins in the diaphysis between age 1-5, and is completed by age 10-15 years (Vande Berg 
et al. 1998). The marrow conversion continues throughout adult life, although at a slower 
pace than during childhood (Vogler and Murphy 1988, Vande Berg et al. 1998) resulting in 
a positive correlation between bone marrow adiposity (BMA) and age (Meunier et al. 1971, 
Wehrli et al. 2000).  
There is no gender differences in the rate of marrow conversion during childhood (Dooms 
et al. 1985, Waitches et al. 1994), although males have 6-10% more fat than females between 
the ages 20-60 years. This gender difference in BMA is reversed in adults >60 years. 
Vertebral bone fat increases sharply in females in the post-menopausal years between ages 
55-65 years and stays approximately 10% higher in males thereafter (Kugel et al. 2001, 
Griffith et al. 2012).  
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1.3 Mesenchymal stem cells and bone biology 
1.3.1 Origins 
Bone marrow was thought to be the home of the haematopoetic stem cells, until the German 
pathologist Cohnheim elucidated the presence of non-haematopoetic stem cells as the source 
of fibroblasts within the same compartment in the late 1800s (Prockop 1997).  It was not 
until the 1970s when Friedenstein discovered that the whole bone marrow he cultured in 
petri dishes, after discarding the haematopoetic cells, could differentiate into colonies of 
spindly-shaped fibroblasts and small deposits of bone or cartilage, suggesting that these 
marrow cells were multi-potential (Friedenstein et al. 1976). Since then, it has been 
established that the non-haematopoetic stem cells, now referred to as mesenchymal stem 
cells (MSCs) or marrow stromal cells, are capable of: i) self-renewing, i.e. proliferating in 
the undifferentiated form, and ii) pluripotency, i.e. differentiating into ‘committed’ 
progenitor cells such as osteoblasts, chondrocytes, adipocytes and even myoblasts, to give 
rise to the mesenchymal tissues bone, cartilage, adipose tissue and muscle respectively 
(Figure 1.11). 
 
Figure 1.11 The differentiation of mesenchymal stem cells (MSCs). MSCs are pluripotent cells 
capable of differentiating into bone, muscle, fat and other connective tissues. [Adapted from image 
source: frontiersin.org] 
Mesenchymal Stem Cells  (MSCs) 
18 
Apart from the bone marrow, MSCs can also be isolated from periosteum, adipose tissue, 
amniotic fluid, and fetal tissues (Nakahara et al. 1991, Zuk et al. 2002, Anker et al. 2003). 
These are sometimes referred to as mesenchymal precursor cells which can be 
phenotypically similar to MSCs but exhibit heterogeneity in differentiation potential 
compared to the more traditional bone marrow-derived MSCs (Anker et al. 2003). Indeed, 
cultured human MSCs can have differentiation capacity not present in primary fibroblasts, 
which are mature mesenchymal cells (Pittenger et al. 1999). 
Importantly, bone-marrow-derived MSCs (BMMSCs) express signature cell markers such 
as CD29, CD44, CD73, CD105 and CD166 and are negative for haematopoietic markers, 
specifically CD45, CD34, CD14 or CD11 (Chamberlain et al. 2007). The gene expression 
of MSCs continues to shift once induced to commit to a specific lineage, during 
differentiation and until the phenotype is characteristic of the target cell, for instance the 
expression of CD24, CD29 and CD36 among others in lipid-laden mature adipocytes (Berry 
and Rodeheffer 2013, Vroegrijk et al. 2013).  
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1.3.2 MSC Differentiation and signalling cascades involved 
Pluripotent MSCs undergo “commitment” to a more lineage-specific cell line before 
differentiating into its respective mesenchymal tissue (Figure 1.12). This process of 
“commitment” happens under the influence of factors/cytokines that activate the expression 
of certain genes, or proteins which direct the MSCs down a designated cell line (Davis et al. 
1987, Tang et al. 2004b). It is less well understood compared to the differentiation process 
of the more committed progenitor cells.  
 
Figure 1.12 Osteogenic and adipogenic commitment and differentiation pathways in 
mesenchymal stem cells (MSCs). MSCs are pluripotent progenitor cells capable of differentiating 
into adipocytes and osteocytes, depending upon the stimulation cues. The lineage-specific 
differentiation is a multiple stage and well coordinated process regulated by master regulators such 
as PPARγ and C/EBPβ for adipogenesis and Runx2 and Osterix for osteogenesis. Osteogenic 
differentiation can be staged by measuring alkaline phosphatase (early marker) and osteocalcin and 
osteopontin (late markers). Expression of FABPs and production of lipids are indicators of terminal 
adipogenic differentiation. [Adapted from (Wagner et al. 2010)] 
The differentiation of MSCs to adipocytes is not completely understood as yet. It can be 
broadly categorised into two phases: the determination phase and the terminal differentiation 
phase (Muruganandan et al. 2009). The determination phase is when multipotent MSCs 
commit to the adipocyte lineage, becoming pre-adipocytes which have a fibroblastic 
phenotype morphologically but are not readily distinguishable from their MSC precursors. 
This phase is believed to be ligand-dependent, with endogenous molecules such as fatty 
acids (Schopfer et al. 2005) and exogenous ligands such as thiazolidinediones which are 
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potent peroxisome proliferator-activated receptor γ (PPARγ) agonists (Lehmann et al. 1995), 
although some studies have shown otherwise (Walkey and Spiegelman 2008). In the terminal 
differentiation phase, pre-adipocytes become mature adipocytes with distinctive gene 
expression markers and new functions including lipid synthesis, storage and adipocyte-
specific protein production. This is a sequentially and temporally ordered process involving 
multiple signalling cascades that converges at PPARγ transcriptional activity. 
Similarly in MSC differentiation to osteoblasts, the process starts with commitment of 
osteoprogenitor cells and differentiation into pre-osteoblasts, which eventually develop into 
mature osteoblasts (Neve et al. 2011). The development of an immature osteoblast into a 
mature one involves proliferation, maturation, matrix synthesis and mineralisation before 
becoming entombed in osteoid to turn into an osteocyte. Osteoblast differentiation requires 
the key transcription factors runt-related transcription factor 2 (Runx2) as described above, 
but also others such as BMPs.  
The differentiation of MSC towards an adipogenic or osteogenic cell fate depends on a 
variety of transcription factors and signalling cascades. The two main lineage-specific 
transcription factors are Runx2 for osteogenesis and PPARγ for adipogenesis. Due to its 
common precursor from the pluripotent MSC, in vitro evidence exist to suggest a mutually 
exclusive and reciprocal lineage selection of one or the other, whereby adipogenesis occur 
at the expense of osteogenesis and vice versa (Figure 1.13) (Beresford et al. 1992, Yang et 
al. 2008). Typically, increased expression of one is associated with downregulation of the 
other (Li et al. 2003, Zhang et al. 2006), further affirming the bone-fat balance hypothesis. 
 
Figure 1.13 Bone-fat balance. Osteogenesis and adipogenesis are proposed to be mutually 
exclusive given that osteoblasts and adipocytes originate from the common progenitor mesenchymal 
stem cells. PPARγ is the key regulator of adipogenesis whilst Runx2 activation determines 
osteogenesis. [Adapted from (Yang et al. 2008)] 
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1.3.2.1 PPARγ: The master regulator of adipogenesis 
Peroxisome proliferator-activated receptors (PPAR) are members of steroid/thyroid 
hormone receptor gene superfamily with three structural analogs: PPARα, PPARδ and 
PPARγ. All three are expressed during adipogenesis, but PPARγ expression is exclusive to 
adipocytes and increases more rapidly during early adipogenesis (Wagner et al. 2010). 
PPARγ is expressed in two isoforms, PPARγ1 and PPARγ2, generated by alternative 
splicing, during adipogenesis. In response to PPARγ activators, such as thiazolidinediones 
(TZDs) and free fatty acid molecules, PPARγ heterodimerises with the nuclear receptor, 
retinoid X receptor (RXR) to form a transcription complex that can bind to DNA and regulate 
transcription of the adipogenic genes (Figure 1.14). 
PPARγ plays a very diverse role in different tissues including its function in adipogenesis, 
atherosclerosis, inflammation and insulin sensitisation (Kliewer et al. 1995, Lehmann et al. 
1995, Takeda et al. 2000). It is considered the master regulator of adipogenesis as no other 
factor can rescue adipocyte formation when PPARγ is knocked out. Selective deletion of 
PPARγ in murine adipose tissue leads to a loss of both brown and white adipocytes (Rosen 
and MacDougald 2006). PPARγ-deficient (-/-) embryonic stem cells from genetically 
manipulated mice failed to differentiate into adipocytes, and instead differentiated into 
osteoblasts (Tzameli et al. 2004). In addition, cells derived from PPARγ+/- mice 
demonstrated a reduced ability to differentiate into adipocytes with increased 
osteoblastogenesis instead. 
 
Figure 1.14 Mode of action for PPARγ.  PPARγ and RXR form a heterodimer which is activated 
by the respective ligands. The activated PPARγ/RXR heterodimer will be translocated into the 
nucleus and regulates downstream target genes in concert with nuclear receptor co-activators. 
[PGJ2 prostaglandin J2; Adapted from (Wagner et al. 2010)] 
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1.3.2.2 Runx2: The master regulator of osteogenesis 
The Runx family consists of three distinct proteins: Runx1-3 which share a common β 
subunit, but a different α subunit (Ogawa et al. 1993). Runx proteins have a DNA-binding 
domain, known as Runt, homologous to that identified in the Drosophila melanogaster. 
Similar to PPARy, Runx proteins form a heterodimer with core binding factor β (Cbfβ), a 
co-transcriptional factor, which displaces the inhibitory domain and allows binding to DNA 
to effect downstream targets. Runx have distinct tissue-specific expression and their 
functions are dependent on cellular context as summarised in Table 1.2 (Ito et al. 2015). 
Phosphorylated Runx proteins are very susceptible to degradation (Biggs et al. 2006, Shen 
et al. 2006). Runx genes are intimately linked to carcinogenesis so its protein levels need to 
be tightly regulated in order to switch between tumour suppressive and oncogenic functions. 
Runx1 aberrations have been associated with leukaemia, Runx2 with osteosarcoma and 
Runx3 with stomach, colon and bladder cancers to name a few (Nomoto et al. 2008, Mangan 
and Speck 2011, Martin et al. 2011). They are expressed interdependently and often, more 
than one Runx family member is expressed in the same cell. Levels of Runx1 and Runx2 
mRNAs are inversely correlated in skeletal development (van der Deen et al. 2012). 
Importantly, Runx protein levels oscillate during cell differentiation with Runx2 expression 
in osteoblasts highest at G0-G1 phases (early differentiation) of the cell cycle and 
downregulated during G1-S transition (mid differentiation) (Galindo et al. 2005). Runx have 
the ability to exert opposite effects on transcription due to its complex post-translational 
modifications, which modulate its interactions with DNA. 
Table 1.2 Function of Runx proteins 
Protein Function  Phenotype 
Runx1 Haematopoeisis  Haematopoeitic stem cell maintenance 
Immune response  T-cell and B-cell development 
Runx2  Skeletal development  Differentiation of osteoblasts and chondrocytes 
Directs MSCs to the osteoblast lineage 
Alveolar cell 
maturation in 
mammary glands  
 Regulates mammary epithelial progenitors during 
pregnancy 
Necessary for the specification of luminal progenitor 
cells 
Runx3 Stomach  Required for proper differentiation 
Nervous system   Involved in neuronal cell fate 
Immune response  Required for macrophage and T-cell differentiation, 
and dendritic cell maturation 
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In the mesenchymal stem cells, Runx participates in the decision to proliferate or 
differentiate. Specifically, Runx2 directs MSCs to the osteoblast lineage for bone 
development. Runx2 level, however, must be tightly regulated in osteogenesis. Its 
expression increases at the onset of quiescence in preparation for differentiation, but must 
reduce in time for osteoblast maturation as overexpression results in the accumulation of a 
larger immature osteoblast population (Pratap et al. 2003, Komori 2010). Heterozygous 
mutation of Runx2 (Runx2+/-) causes hypoplastic clavicles and open fontanelles in a 
condition called cleidocranial hypoplasia (Mundlos et al. 1997) whilst Runx2-/- mice die 
soon after birth from respiratory failure due to lack of bone ossification in the thoracic cage 
(Komori et al. 1997). Due to defective osteoblast differentiation, the skeleton of Runx2-/- 
mice are cartilaginous with the complete absence of mineralisation, with the exception of 
very mild calcification at tibia, fibula, radius and ulna detectable on Alizarin staining. It has 
been noted that Runx2-/- mesenchymal stem cells are capable of differentiating into 
adipocytes and chondrocytes, but completely lack the potential to differentiate into 
osteoblasts indicating its key role in skeletal development (Kobayashi et al. 2000). 
1.3.2.3 Signalling pathways in MSC differentiation 
In addition to the transcription factors, many complex signalling pathways are involved in 
the commitment and differentiation of MSC towards adipocytes or osteocytes. There are 
several pro-osteogenic/anti-adipogenic signalling pathways including (i) β-catenin 
dependent Wnt signalling (as well as the non-canonical β-catenin Wnt signalling) 
(Taipaleenmaki et al. 2011, D'Alimonte et al. 2013), (ii) Hedgehog signalling (Fontaine et 
al. 2008, James et al. 2010) and (iii) NEL-like protein 1 (NELL-1) signalling (James et al. 
2011, James et al. 2012). The β-catenin-dependent Wnt signalling pathway is the most well-
established one involved in both bone formation. β-catenin plays a direct role in the 
regulation of osteoblasts with deficiency causing arrest in pre-osteoblast development at an 
early stage and impaired maturation and mineralisation in more committed osteoblasts, and 
consequent embryonic skeletal defects (Day et al. 2005, Holmen et al. 2005, Chen and Long 
2013). There is also an antagonistic effect on osteoclastogenesis with suppression of bone 
resorption through the canonical β-catenin/Wnt signalling pathway (through upregulation of 
OPG expression and down-regulation of RANKL expression) and increased bone resorption 
through activation of the non-canonical pathway (Takahashi et al. 2011). Accordingly, trials 
involving antibody against sclerostin, which is a Wnt inhibitor, have shown promising 
results in phase II clinical trials demonstrating increased bone mineral density (Padhi et al. 
2011). Its reciprocal anti-adipogenic effect is exerted through several members of the Wnt 
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family, such as Wnt10b and Wnt3a, which inhibits adipogenesis mainly through suppression 
of PPARγ and/or C/EBP-α expressions (Ross et al. 2000, Kawai et al. 2007). 
Contradicting the bone-fat balance, there are signalling cascades which demonstrate dual 
pro-osteogenic and pro-adipogenic effects, namely (i) BMP signalling and (ii) IGF 
signalling. The precise determinant that governs the cell fate of BMP signalling is not well 
understood. Studies in mouse MSCs have shown a lower concentration of BMP-2 favouring 
adipogenesis and a higher concentration directing MSCs towards osteogenic differentiation 
(Wang et al. 1993).The effects of different BMP receptor expression on the lineage 
differentiation of MSCs have also been shown (Chen et al. 1998).  
The identification of the genes/proteins involved in the signalling pathway for these 
commitment and differentiation steps in MSC differentiation is crucial as it may lead to 
potential targets for therapeutic interventions, as seen with the anti-sclerostin described 
above. Of note, MSC differentiation can also be influenced by many micro-environmental 
factors such as mechanical forces (Kelly and Jacobs 2010), electrical currents (Hronik-Tupaj 
et al. 2011) and magnetic fields (Yan et al. 2010). 
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1.3.3 C3H10T1/2 Mesenchymal stem cell model 
Human bone-marrow-derived MSCs (BMMSCs) are ideal for in vitro studies investigating 
their own multi-lineage differentiation potential (Pittenger et al. 1999) and the various 
signalling pathways involved. This attractive cell source, however, can be difficult to obtain, 
usually dependent on invasive marrow aspirates of volunteer donors or samples obtained 
during orthopaedic surgery for an unrelated reason. In addition, BMMSCs can show variable 
heterogeneity in colony sizes, colony-forming rates and cell morphology during cell 
isolation/expansion (Bianco et al. 2001) which may have a false positive or false negative 
impact on study findings. 
In contrast, the mouse mesenchymal stem cells C3H10T1/2, which are commercially 
available, have a homogenous population and do not undergo spontaneous differentiation 
under normal culture conditions making it an ideal alternative. The C3H10T1/2 cell line was 
established in 1973 from 14-17 day old C3H mouse embryos (Reznikoff et al. 1973). These 
cells display a fibroblastic morphology under normal culture conditions and are functionally 
similar to mesenchymal stem cells in their ability to develop into osteoblasts, chondrocytes 
and adipocytes with specific inductions (Katagiri et al. 1990, Tang et al. 2004a). It is worth 
noting that the C3H10T1/2 cell line has been reported to have a lower adipogenic 
differentiation potential of only 10% compared to 70% in primary BMMSCs (Zhao et al. 
2009). 
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1.4 Bone fragility 
1.4.1 Normal bone mineral accrual  
The skeleton grows, in length, in breadth and in mass, as the body grows. Skeletal health is 
largely regulated by genetic factors, which determine up to 70% of peak bone mass (Gortz 
and Fassbender 2001) with other key environmental factors such as body composition 
(Baxter-Jones et al. 2003, Farr et al. 2014a), physical activity (Bailey et al. 1999, Baxter-
Jones et al. 2008) and nutrition (Whiting et al. 2004, Vatanparast et al. 2005) affecting its 
accrual. Bone mass increases substantially in the first two decades of life, reaching a plateau 
in the late-teens or young adulthood before declining after the age of about 50 years (Figure 
1.15). The actions of sex steroids, growth hormone (GH) and insulin-like growth factors 
released and active during the adolescent growth periods (Saggese et al. 2002) also 
contribute significantly to bone mineral acquisition and skeletal changes, underpinning the 
effects of puberty and the accompanying growth spurt on bone health.  
 
Figure 1.15 Bone mass accrual throughout life.  Diagramatic representation of the bone mass 
accrual in individuals who achieve their full genetic potential (solid line) and in those who did not 
(dashed line), with the latter having lower peak bone mass predisposing to skeletal fragility in later 
years. [Adapted from (Heaney et al. 2000)] 
As captured in a comprehensive longitudinal study, bone first plateaus in bone area, and then 
roughly 1 to 2 years later, plateaus in mineralisation (Baxter-Jones et al. 2011). Peak bone 
mass is reached approximately 7 years after peak height velocity (PHV), in both genders, at 
an approximate chronological age of 18.8 in females and 20.5 years in males (Baxter-Jones 
et al. 2011). The attainment of peak bone mass varied with skeletal site - femoral neck peak 
bone mass is attained first, 3 years after PHV, before that of lumbar spine at 5 years after 
PHV (Baxter-Jones et al. 2011). Similarly in another study in males, peak bone mass 
occurred by 18-20 years at the femoral neck, lumbar spine and total body but had not yet 
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been reached at the distal radius and tibia (Lorentzon et al. 2005). Depending on site, 33-
46% of the total adult bone mineral content is accrued in the adolescent growth period within 
the 5 years surrounding PHV (Baxter-Jones et al. 2011). In females, this represents double 
the amount of bone mineral that will be subsequently lost during the post-menopausal years 
from 50-80 years of age (Arlot et al. 1997). As bone mass tracks throughout life (Slemenda 
et al. 1990, Ferrari et al. 1998, Loro et al. 2000), achieving a higher peak bone mass is 
therefore crucial in the protection against later-life fragility fracture. Pre-pubertal children at 
the high end of the bone mass distribution gained the most bone across puberty and remained 
at the high end of the distribution 2 years later (Loro et al. 2000).  
In the same way that adolescence is a critical window for laying down bone, it is also a time 
of crucial vulnerability. Any interruption to the normal physiology by either illness (period 
of immobilisation, chronic inflammatory diseases, interruption to normal reproductive 
hormone production, eating disorders) and/or lifestyle factors (smoking, inadequate dietary 
intake, particularly of calcium or vitamin D, oral contraceptive use) may lead to a 
significantly lower peak bone mass constituted for by the genetic potential. There is a 
controversy that combined oral contraceptive, especially very low dose ethinyl oestradiol, 
during adolescent age can be detrimental to the acquisition of peak bone mass, although 
subsequent prospective studies and RCT have shown otherwise (Cromer et al. 2004, Cibula 
et al. 2012, Gargano et al. 2008). Additionally, medication such as glucocorticoids and anti-
epileptics, necessary for the treatment in many childhood diseases, are detrimental to skeletal 
health. Young people affected by any of these factors will enter adulthood with low bone 
mass, and will have a higher long-term risk of fracture even if they lose only a modest 
amount of bone thereafter. Hence, optimal skeletal development during growth is protective 
against osteoporosis and fragility fracture in adulthood. 
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1.4.2 Determinants of bone strength and its clinical implications 
The mechanical competence, or strength, of any structure is dependent on a combination of 
the mass, the physical properties of the component materials, and their geometric 
arrangement in space (Figure 1.16). This is no different when it comes to bone. Bone strength 
is determined by the whole bone – bone mass, architecture and geometry.  
 
Figure 1.16 Determinants of mechanical competence or strength, of a structure. The strength 
of any structure is determined by the triad of the mass, physical properties of its components and the 
geometric arrangements of the structure. 
Bone mass is an important determinant of bone strength, accounting for approximately 60-
70% of the variation in bone strength (Cheng et al. 1997). The relationship between bone 
mass and structural strength holds at all ages, with a clear positive association between bone 
mass and fracture throughout life (Heaney et al. 2000). For the last several decades, as bone 
mass became measurable in vivo, quantified as bone mineral density by DXA, BMD has 
been used as the main surrogate for bone strength. However, when: i) useful anti-
osteoporosis medications produced a reduction in fracture risk with only marginal change in 
BMD (SR et al. 1996), and ii) BMD values of subjects with and without osteoporotic fracture 
imbricated (Siris et al. 2001, Schuit et al. 2004), there is an increasing realisation that bone 
fragility is not only dependent on bone mineral mass (bone quantity) but also alterations in 
bone quality including bone geometry and microarchitecture. 
Some of the important parameters of bone quality include bone size and shape, trabecular 
bone microarchitecture and cortical bone thickness and porosity. Trabecular and cortical 
bone parameters were found to be more discriminatory of men and women with and without 
fractures (Chang et al. 2015) compared to BMD. It also became clear from studying the 
microarchitecture of osteoporotic subjects and bone specimens that there was a 
predominance of cortical over trabecular bone loss in peripheral sites (Zebaze et al. 2010), 
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which helped explain why most fractures in old age are non-vertebral (Riggs et al. 1981). 
The study found a significant increase in cortical porosity which was poorly captured by 
densitometry (Zebaze et al. 2010). Increased porosity reduces bone strength as a 4% rise in 
porosity increases crack propagation through bone by 84% (Diab and Vashishth 2005), with 
a 10% rise in porosity halving the maximum load before fracture occur (Martin and Burr 
1989). As well as disruption to the lace-like trabecular scaffolding, another important finding 
of the paper from studying the post-mortem bone specimens was the presence of cortical 
remnants, or trabecularisation of the cortex, which can mislead cortical and trabecular 
quantification by non-invasive imaging methods. In addition, the apparent trabecular bone 
volume (BV/TV) was found to be the best morphometric predictor of bone strength amongst 
the trabecular parameters (Thomsen et al. 1998). The intrinsic material properties of bone 
including the matrix mineralisation and collagen cross-linking can also affect bone stiffness 
compromising bone strength. 
As there is currently no accurate measure of overall bone strength, fracture prediction may 
be more accurate when measures of bone mass and microarchitecture parameters can all be 
incorporated together. Advances in non-invasive imaging techniques such as HR-pQCT and 
micro-MRI can now provide information on bone quality that was not previously available 
to enhance the assessment of fracture risk and skeletal health in a variety of diseases related 
to bone abnormalities, which cannot be fully studied by DXA alone.  
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1.4.3 Osteoporosis in Adults 
Osteoporosis is a skeletal disorder characterised by the loss of bone mass (bone quantity), 
and deterioration of bone microarchitecture (bone quality) resulting in compromised bone 
strength and increased risk of fractures (NIH Consensus Development Panel on Osteoporosis 
Prevention and Therapy 2001, Camacho et al. 2016). A comparison of the bone 
microarchitecture of a normal vertebra and one with osteoporotic deficit is shown in Figure 
1.17. 
 
Figure 1.17 Bone microarchitecture of normal and osteoporotic specimen. (A) Healthy vertebra 
(B) Compressed osteoporotic vertebra with reduced trabecular number, connectivity and density with 
more trabecular spaces. [Adapted from (Lorentzon and Cummings 2015)] 
1.4.3.1 Epidemiology of osteoporosis 
Approximately 30% of all postmenopausal women are affected in the UK and 40% of them 
will go on to develop a fracture (Safaei et al. 2007). 1 in 2 women and 1 in 5 men over the 
age of 50 will suffer a fragility fracture (van Staa et al. 2001). Fragility fractures are fractures 
that result from low-level (or low energy) mechanical forces that would not ordinarily result 
in fracture (Kanis et al. 2001). The World Health Organisation has quantified this as forces 
equivalent to a fall from standing height or less. It is usually asymptomatic until fragility 
fracture occurs resulting in substantial pain and severe disability. Fractures of the hip 
(proximal femur), wrist (distal radius) and spine (vertebra) are most common. 
Osteoporosis is a significant public health problem affecting over 9 million people 
worldwide (Johnell and Kanis 2006) and 3 million people in the UK (National Osteoporosis 
Society 2015). Every year 500,000 people suffer a fragility fracture (British Orthopaedic 
Association 2007), including 90,000 hip fractures with a projected rise in the incidence to 
101,000 by 2020 (Department of Health (England) 2006). Hip fracture nearly always 
Normal bone Osteoporotic bone 
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requires hospitalisation, is fatal in 20% of cases and leaves 50% permanently disabled 
(Sernbo and Johnell 1993). Only 30% of patients fully recover. Fragility fractures have a 
massive impact on healthcare budget, costing the NHS an estimated annual cost of £2 billion 
(over £5 million per day) in combined hospital and social care for hip fracture alone (Burge 
et al. 2001). 
1.4.3.2 Risk factors of osteoporosis 
Although osteoporosis can occur at any age, the risk increases significantly with aging and 
after menopause in women. Osteoporosis can arise from secondary causes (Table 1.5) 
including glucocorticoid use and chronic diseases such as diabetes mellitus which is of 
particular relevance to this thesis. Other risk factors for osteoporosis includes premature 
menopause, amenorrhoea in women or hypogonadism in men, cigarette smoking, dietary 
factors such as low calcium intake and vitamin D deficiency, low body weight, 
glucocorticoid therapy, family history of osteoporosis, Asian or Caucasian ethnic origin,  and 
long term immobilisation (Kanis 2002). 
1.4.3.3 Diagnosis of osteoporosis  
The current clinical diagnosis of osteoporosis is based on densitometry cut-offs proposed by 
the World Health Organisation (WHO) and modified by the International Osteoporosis 
Foundation (WHO Study Group 1994, Kanis and Gluer 2000) as shown in Table 1.3. 
Because bone density values follow a normal Gaussian distribution, BMD values can be 
expressed in relation to a reference population in standard deviation (SD) units. When the 
reference population is that of a young healthy adult, the BMD values are expressed as T-
scores. 
Table 1.3 WHO/IOF Definition of osteoporosis in adults 
Definition of Osteoporosis in Adults 
WHO and International Osteoporosis Foundation Diagnostic Criteria 
Category BMD T-score 
Normal > -1.0 
Osteopenia Between -1.0 and -2.5 
Osteoporosis ≤ -2.5 
Severe osteoporosis ≤ -2.5 with one or more fragility fracture 
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Although there is set diagnostic criteria for the diagnosis of osteoporosis, the assessment of 
fracture risk which is of greater clinical interest is much less straight forward. DXA-derived 
measures of BMD have been an important determinant of fracture risk with an increase in 
the relative risk of fracture by approximately 2-fold for every 1 SD decrease in bone mineral 
density, depending on skeletal sites (Marshall et al. 1996). However, BMD alone has a very 
low sensitivity in predicting the likelihood of fractures as considerable overlap in BMD 
values was seen in patients with and without fragility fractures (Siris et al. 2001, Schuit et 
al. 2004). Furthermore, therapeutic interventions for osteoporosis demonstrated reduction in 
the risk of fractures with minimal change in BMD (Cummings et al. 1996). Kanis described 
the use of BMD alone to predict fracture risk is akin to the reckless use of blood pressure 
alone in predicting the risk of stroke, where there is not a clear discriminatory cut off. With 
this in mind, Kanis and McCloskey founded the Fracture Risk Assessment Tool (FRAX) to 
evaluate the 10-year probability of hip and other major osteoporotic fractures (Kanis et al. 
2008). This tool integrates clinical risk factors such as age, gender, previous fracture, 
glucocorticoid use, and BMD at femoral neck to give the fracture risk estimates. In FRAX, 
T1D and T2D has been recognised as a secondary cause of osteoporosis which increases the 
fracture probability independent of BMD (Giangregorio et al. 2012). 
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1.4.4 Osteoporosis in Children 
1.4.4.1 Definition of osteoporosis 
The 2013 International Society for Clinical Densitometry provided a position statement for 
the definition of osteoporosis in children which is clinically useful and enabled scientifically 
valid comparison between studies, as summarised in Table 1.4 (Bishop et al. 2014). 
Table 1.4 ISCD Definition of osteoporosis in children 
Definition of Osteoporosis in Children: 
ISCD 2013 Position Statement 
 
(1) The presence of one or more vertebral compression (crush) fracture,  
      or, 
(2) The presence of a clinically significant fracture and a BMD Z-score ≤ -2.0 
       A clinically significant fracture is: 
       (a) two or more long bone fractures by age 10 years 
       (b) three or more long bone fractures by age 19years 
BMC/BMD Z-score > -2.0 does not preclude the possibility of skeletal fragility and increased fracture risk. 
The term osteopenia should be avoided. 
  
This position statement emphasises that the diagnosis of osteoporosis in children in not based 
on densitometry alone and highlights the importance of establishing a detailed fracture 
history. In addition, vertebral fractures in children are themselves diagnostic of osteoporosis. 
It also recognises that children with bone fragility can have recurrent fractures despite 
normal bone mineral density values. 
1.4.4.2 Causes of Secondary Osteoporosis  
The aetiology of primary osteoporosis, where primary bone disorders result in recurrent 
fractures is out with the context on this thesis. Secondary osteoporosis is increasingly 
recognised in children with chronic diseases and is caused by the underlying disease or its 
treatment (Table 1.5) (Korula et al. 2015). 
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Table 1.5 Causes of secondary osteoporosis 
Causes of secondary osteoporosis 
Category Aetiological causes 
Reduced mobility Prolonged immobilisation, cerebral palsy, Duchenne muscular 
dystrophy (DMD), spinal cord injury and Rett syndrome 
Pubertal delay Chronic illness, primary hypogonadism and induction by drugs 
Chronic illnesses Haematological: leukaemia, childhood cancers, thalassaemia 
and post- bone marrow transplant 
Renal: chronic renal failure and post-renal transplant 
Gastrointestinal: inflammatory bowel disease, coeliac disease, 
and chronic liver disease 
Rheumatological: systemic lupus erythematosus (SLE) and 
juvenile idiopathic arthritis (JIA) 
Others: anorexia nervosa, cystic fibrosis, severe burns and HIV 
Endocrine causes Hypogonadism, diabetes mellitus, hyperthyroidism, 
hyperprolactinaemia, and metabolic bone disease of prematurity 
Drug-induced Glucocorticoids, methotrexate, GnRH analogues, cyclosporin, 
anticonvulsants, heparin and radiotherapy 
Inborn errors of 
metabolism 
Glycogen storage disorder, lysinuric protein intolerance, 
galactosaemia, Gaucher disease, homocystinuria and Menke’s 
disease 
 
1.4.4.2.1 Reduced mobility 
Normal bone development is dependent on mechanical loading and bone-muscle interaction 
which increase bone formation and bone mineral accrual (Hind and Burrows 2007). Reduced 
ambulation in children with cerebral palsy and DMD predisposes them to osteoporosis and 
lower limb fractures. (McDonald et al. 2002, Mergler et al. 2009). Vertebral fractures have 
also been found in up to 40% of children with DMD (McDonald et al. 2002). Studies have 
also found greater trabecular vBMD, tibial cortical thickness and tibial muscle cross-
sectional area Z-scores in children with partial spinal cord injury who can stand compared 
to those who are bed bound (Biggin et al. 2013). 
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1.4.4.2.2 Pubertal delay 
As described in section 1.4.1, sex steroids play a significant role in bone mineral accrual and 
longitudinal bone growth, hence the resultant growth spurt in puberty. Pubertal delay 
negatively affects skeletal development and increases long term fracture risk. The Bone 
Mineral Density in Childhood Study cohort demonstrated that age of onset of puberty was a 
strong negative predictor of DXA bone mineral density at skeletal maturity in both genders, 
independent of the BMD at the beginning of puberty and the length of puberty (Gilsanz et 
al. 2011). Hogler et al showed that pubertal induction halted the reduction in BMD which 
was seen in pre-pubertal children (Hogler et al. 2004). 
1.4.4.2.3 Drug-induced 
Many medications used to treat chronic illnesses in children predispose them to iatrogenic 
secondary osteoporosis. Glucocorticoid-induced osteoporosis is very well recognised with 
an increased risk of fracture in children with a history of frequent oral corticosteroid use 
[adjusted OR of 1.32 (95% CI, 1.03-1.69)] and a doubling of humeral fracture risk in those 
who receive four or more courses of oral corticosteroids in a year (van Staa et al. 2003). 
Impairment of bone health is through a direct effect on bone turnover with increase in bone 
resorption followed by a decrease in bone formation, and indirect influence on muscle and 
calcium homeostasis (Buckley and Humphrey 2018). In adults, studies have shown the 
greatest negative effect on trabecular bone in the spine with concomitant vertebral fractures 
being most common (De Vries et al. 2007). This is reversible with fracture rate reported to 
normalise one year after glucocorticoid discontinuation (Korula et al. 2015). 
1.4.4.2.4 Chronic inflammatory conditions 
A wide variety of chronic inflammatory diseases can result in secondary osteoporosis 
summarised beautifully in the review by Makitie (Makitie 2013). This occurs not only 
through the increased inflammatory milieu which is toxic to the bones but also often 
multifactorial from reduced mobility, pubertal delay, poor nutrition and drug-induced bone 
loss. Diabetes mellitus, in particular T1D, is one of the disorders where systemic and local 
inflammatory responses have been demonstrated from the onset of the disease with 
detrimental effects on bone turnover and resultant skeletal fragility as discussed in more 
details in section 1.5.3.5.  
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1.4.5 Fractures in Healthy Children 
Fractures in healthy children can be common. In the UK, approximately one third of children 
are reported to suffer a fracture before the age of 17 years, with a fracture incidence of 3% 
in boys and 1.5% in girls at their peak ages (Cooper et al. 2004) (Figure 1.18A), although 
other studies have reported differently (Jones et al. 2002, Mills and Simpson 2013). These 
differences could reflect the variation with the geographical area studied. 
The fracture incidence varied with age and gender; increasing through childhood, with a 
steady rise in each 5-year age group, starting at approximately 1% risk in the under 5s, 2% 
in the 5-9 year olds, 3% in the 10-14 year olds and 4% in the 15-19 years old. Boys 
consistently had higher fracture incidence than girls, with a widening gap in the teenage 
years, peaking at 5% in the older teenage boys. (Figure 1.18B) (Mills and Simpson 2013). 
Across the literature, there is generally an agreement in the peak age of fracture incidence 
around 14 years old for boys and 11 years old for girls (Jones et al. 2002, Cooper et al. 2004), 
with slightly later ages for the Scottish cohort (Mills and Simpson 2013).  
 
Figure 1.18 Fracture incidence at any site in childhood and adolescence. In England and Wales 
from 1988-1998 (B) In Scotland from 2005-2010. [Adapted from (Cooper et al. 2004) and (Mills and 
Simpson 2013)] 
Seasonal differences with peak in fractures during the summer and a much lower rate during 
the winter have been noted (Cooper et al. 2004). Evidence on socioeconomic status on the 
incidence of childhood fractures was conflicting. The study in Glasgow using 
neighbourhood-type analysis demonstrated higher fracture incidence in those living in 
deprived areas compared to those in more affluent areas (175.3/10,000 vs 140.1/10,000) 
(Stark et al. 2002) whilst the study in South Wales using Townsend scores found no 
association (Lyons et al. 2000). In a large prospective cohort study of over 1400 children 
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aged 6-17 from the US, children of white Caucasian origin have been found to have 
substantially higher fracture risk compared to children of black African origin (Wren et al. 
2012).  
A population-based study in Finland has shown a significantly decreased incidence of 
fractures in the last two decades, following a rise between the 1960s and 1980s (Mayranpaa 
et al. 2010), possibly due to the implementation of injury prevention measures over the years. 
Studies in Finland and Europe have found a changing pattern in the skeletal sites of 
childhood fractures with increase in forearm fractures (Oskam et al. 1998, Mayranpaa et al. 
2010) and decrease in femoral (Bridgman and Wilson 2004) and tibial (Emami et al. 1996) 
shaft fractures. Upper limb factures are more common in healthy children, accounting for 
65% of all the fractures compared to 7-28% of lower limb fractures (Lyons et al. 2000, Wren 
et al. 2012). The most common skeletal site is distal radius (25-43%), followed by fingers 
and carpal bones (Landin 1983, Moustaki et al. 2001). Vertebral fractures are uncommon, 
with one study reporting the incidence of traumatic fractures of 66 per million (Puisto et al. 
2010) although asymptomatic vertebral fractures have been identified in fracture-prone 
children (Mayranpaa et al. 2010), which should prompt further investigations into 
underlying skeletal fragility. Pelvic fracture is the least common in children (Cooper et al. 
2004).  
The risk of further fractures is doubled in children who have had a fracture, especially those 
in early childhood (Landin 1983, Wren et al. 2012). Up to 3% of children experience further 
fractures in their childhood (Cooper et al. 2004). 
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1.5 Type 1 Diabetes Mellitus (T1D) 
1.5.1 Background 
Type 1 diabetes (T1D) is a disorder characterised by severe insulin deficiency due to an 
autoimmune destruction of the pancreatic β cells in genetically predisposed individuals. The 
disorder affects 300,000 people in the UK, of which 35,000 are children. The incidence of 
T1D is 1:4000, with peak age at diagnosis between 9-14 years old. It is the second most 
common chronic disorder in childhood (Gale 2002), although it can occur at any age. 
1.5.2 Complications of T1D 
T1D is associated with well-known long term microvascular and macrovascular 
complications. The microvascular complications include retinopathy, nephropathy and 
neuropathy which lead to visual impairment, renal failure and loss of sensation in the feet 
with muscle weakness respectively. Macrovascular diseases, similar to that seen in Type 2 
diabetes, such as coronary heart disease, peripheral vascular disease and stroke also affect 
adults with Type 1 diabetes. Although clinically evident diabetes-related vascular 
complications are rare in childhood and adolescence, early functional and structural 
abnormalities may be present a few years after diagnosis. 
Landmark papers from the Diabetes Control and Complications Trial (DCCT), 
Epidemiology of Diabetes Interventions and Complications (EDIC) and large randomised 
controlled trials categorically demonstrated that glycaemic control is the single most 
important predictor of complications (Nathan et al. 1993, Fullerton et al. 2014, Lagani et al. 
2015, Nordwall et al. 2015). DCCT was a multicentre, randomised controlled trial involving 
1441 patients with Type 1 Diabetes conducted in North America from 1983-1993 whereby 
patients were randomised to two treatment arms of intensive and conventional treatment 
(Nathan et al. 1993). The intensive therapy group had average HbA1c of 7% whilst the 
conventional group had HbA1c of 9%. The trial results showed conclusively that intensive 
therapy reduced the risk of retinopathy and other microvascular complications by 35-76% 
in the primary prevention (no retinopathy at baseline) and secondary intervention cohorts. 
Results from the EDIC follow-up study showed that early intensive therapy reduced 
albuminuria and long term risk of developing clinically significant kidney dysfunction by 
50% (de Boer et al. 2011) Compared to the age-matched general population, people with 
T1D have 10-fold increased risk of cardiovascular death (Dorman et al. 1984, Krolewski et 
al. 1987) with 57% reduction in the risk of macrovascular complications including non-fatal 
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heart attack, stroke or death from cardiovascular diseases with intensive glycaemic control  
(The Diabetes Control and Complications Trial (DCCT) Research Group 1995). 
Apart from glycaemic control, the other main driver for the development of microvascular 
complications is the duration of diabetes. Longer duration of diabetes has been associated 
with increased risk of renal complications, including microalbuminuria, proteinuria and end-
stage renal disease (ESRD) (Elley et al. 2013, Lagani et al. 2015) and retinopathy (Lachin 
et al. 2008). Nordwall et al showed increasing cumulative incidence of retinopathy with 
longer diabetes duration, although the role of glycaemic control was difficult to be 
apportioned (Nordwall et al. 2015). Despite this, total glycaemic exposure (HbA1c and 
duration of diabetes) only explained 11% of the variation in retinopathy risk (Lachin et al. 
2008) with other factors including environmental and genetic factors, explaining the 
remaining 89% of the variation independent of HbA1c.  
Diabetic end-organ damage are rare before puberty, and the onset of puberty accelerates the 
microvascular complications, in particular nephropathy (Andersen et al. 1983, Krolewski et 
al. 1985). Lawson et al postulated that the physiological changes of increased renal volume 
and the accompanying macroalbuminuria during puberty may contribute to this (Lawson et 
al. 1996). Children with diabetes appear to go through puberty at the same time as their peers 
(Thorn et al. 2005, Ostman et al. 2008) although some studies have shown evidence of 
delayed menstruation (Kjaer et al. 1992, Lombardo et al. 2009, Deltsidou 2010). Indeed, the 
mechanism by which puberty contributes to the development of microvascular complication 
remains largely unclear. Women with diabetic retinopathy and nephropathy were found to 
undergo later menarche (Harjutsalo et al. 2016) and earlier menopause (Sjoberg et al. 2011), 
further providing evidence to support the effect of sex hormones on the risk of microvascular 
complications. 
Other specific risk factors such as hypertension and adverse cholesterol profile have been 
associated with retinopathy and diabetic kidney disease (Hovind et al. 2004, Gheith et al. 
2016) as well as macrovascular complications (Diabetes Control and Complications Trial/ 
Epidemiology of Diabetes and Complications Research Group 2016). A recent large cohort 
study (27,195 T1D patients) demonstrated that younger age at onset of T1D was not only 
associated with increased macrovascular complications but also all-cause mortality as shown 
in Figure 1.19 (Rawshani et al. 2018). 
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Figure 1.19 Life years lost in relation to age at onset T1D. Loss of life years was estimated by 
use of separate Cox regression analyses fitted to individuals with T1D and their matched controls 
within each age group. Conditional medial survival was estimated from the upper limit of each age 
interval. Life-years lost because of diabetes were calculated as the difference in the expected median 
survival between people with T1D and controls. [Adapted from (Rawshani et al. 2018)] 
Interestingly, complications are less likely to occur individually. Recent evidence has 
highlighted that micro- and macrovascular complications tend to co-occur (Bjerg et al. 2018, 
Sauder et al. 2019) with co-occurrence of T1D complications in 6% of adolescents and 
children, more than would be expected by chance alone (Sauder et al. 2019). Specifically, 
retinopathy with diabetic kidney disease, retinopathy with arterial stiffness, and arterial 
stiffness with cardiovascular autonomic neuropathy, co-exist most frequently in the 
ascending order (Sauder et al. 2019). Longer duration of diabetes, poor glycaemic control, 
non-Hispanic white and lower socioeconomic status were identified as predisposing risk 
factors. The presence of two complications increases the risk of developing another 
complication. (Bjerg et al. 2018). 
In the last decade or so, diabetes mellitus has also been implicated with rarer known 
complications such as hearing impairment (Bainbridge et al. 2008, Malucelli et al. 2012, 
Schade et al. 2018) and skeletal fragility. The latter may be manifested as reduced bone 
mass, abnormal bone microarchitecture, increased bone marrow adiposity or fragility 
fractures, as detailed in the rest of this thesis.  
1.5.3 Pathogenesis of altered bone metabolism 
1.5.3.1 Hyperglycaemia 
Hyperglycaemia contributes to diabetic osteopathy through a variety of effects on the bone 
cells. Acute hyperglycaemia causes direct glucose toxicity to osteoblast (Cunha et al. 2014) 
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affecting osteoblast numbers and function; suppresses genes involved in osteoblast 
maturation through osmotic and non-osmotic pathways (Zayzafoon et al. 2000, Botolin and 
McCabe 2006); and affects matrix mineralisation (Balint et al. 2001, Cunha et al. 2014). 
Chronic hyperglycaemia impairs osteoblast maturation from 1,25(OH)2D3-induced 
osteocalcin secretion by down regulation of vitamin D receptor (Inaba et al. 1995); and 
promotes osteoblast apoptosis through glucose autoxidation hydrogen peroxide-induced 
oxidative stress (Wolff et al. 1991, Fatokun et al. 2006). Hyperglycaemia-induced acidosis 
might also enhance bone resorption (Frassetto and Sebastian 2012). Emerging evidence 
suggests that hyperglycaemia may also alter the differentiation of the MSCs promoting 
adipogenesis instead of osteogenesis (Keats and Khan 2012). Hyperglycaemia diverts the 
MSC differentiation signalling pathways toward adipogenesis at the expense of 
osteogenesis. This effect is achieved via ERK-1/-2-activated P13K/Akt-regulated pathway 
in mouse MSCs (Chuang et al. 2007), and via suppression of HO-1 expression (Barbagallo 
et al. 2010) and Wnt/protein kinase C non-canonical pathway in human MSCs (Keats and 
Khan 2012), evidenced by increased PPARγ expression in high glucose stimuli and 
reduction of osteocalcin levels. Indeed, mice with spontaneously and pharmacologically 
induced diabetes with bone loss have shown increased marrow adiposity, determined by 
histology and by mRNA markers of adipogenesis (PPARγ and aP2) (Botolin and McCabe 
2007).Wang et al. demonstrated that hyperglycemia can also promote adipogenesis through 
synthesis of hyaluronan matrix which promotes an inflammatory response culminating in 
demineralisation of trabecular bone (Wang et al. 2014).  
In addition, hyperglycemia leads to increased non-enzymatic protein glycation and excessive 
formation of these modified proteins called advanced glycosylation end-products (AGEs). 
AGEs appear to be the common biochemical entity accumulating in individuals with long 
term diabetic complications. They are seen in various sites such as vascular tissues, kidneys 
and bones (Bucala and Vlassara 1995, Yamamoto et al. 2001, Bohlender et al. 2005). AGEs 
exert their biological effects by engaging the receptor for AGEs (RAGEs), a multiligand 
receptor involved in immune and inflammatory responses (Schmidt et al. 1999, Chavakis et 
al. 2003). Consequently, AGEs, largely via RAGE, cause oxidative stress contributing to 
cellular dysfunction and ultimately damage target organs leading to complications such as 
atherosclerosis (Cipollone et al. 2003, Wendt et al. 2006) and nephropathy (Tanji et al. 2000, 
Wendt et al. 2003).  
The accumulation of AGEs increases formation of collagen cross-links which results in 
increased stiffness of the collagen network in the cortical bone. This results in more brittle 
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bones that are less able to deform before fracturing. Accumulation of pentosidine, a well-
characterised AGE, is negatively correlated to trabecular bone volume and structural 
strength (Schwartz et al. 2009, Silva et al. 2009). Bones of diabetic rats with higher content 
of pentosidine correlated negatively with BMD and bone strength (Tomasek et al. 1994, 
Saito et al. 2006). The pentosidine content in cortical and trabecular bones of people with 
femoral neck fracture is higher compared to post-mortem controls (Saito et al. 2006). 
Urinary and serum pentosidine is also increased in diabetic patients with vertebral fractures 
(Yamamoto et al. 2001, Schwartz et al. 2009). Iliac crest biopsies showed a significantly 
higher level of pentosidine in the trabecular bone of fracturing T1D patients compared to 
non-fracturing T1D and healthy controls (Farlay et al. 2016). In addition to affecting bone 
physical properties, AGEs also have direct effects on bone cells. Elevated AGEs can inhibit 
osteoblast proliferation and differentiation (Kume et al. 2005), function (Sanguineti et al. 
2008), synthesis of type 1 collagen (Katayama et al. 1996) and osteoblast mineralisation 
(Ogawa et al. 2007). Okazaki et al. demonstrated that the inhibition of osteoblastic 
differentiation by AGEs can occur independently of hyperglycaemia (Okazaki et al. 2012).  
It is also associated with reduced osteocalcin mRNA expression as seen in rodents with 
diabetes (Tomasek et al. 1994). Furthermore, AGEs can also cause osteoblast death by 
provoking inflammation and generation of reactive oxygen species (ROS) which in turn lead 
to cell apoptosis as a result of oxidative stress (Coe et al. 2011b, Weinberg et al. 2014). The 
influence of AGEs on osteoclasts showed inconsistent effects with some evidence of 
increased (Miyata et al. 1997), as well as decreased (Valcourt et al. 2007) bone resorption.  
Not only does hyperglycaemia and AGEs suppress osteoblastic differentiation and 
mineralisation, the expression of RAGE is also enhanced (Ogawa et al. 2007). More 
importantly, the AGE-RAGE interaction has been shown to affect bone quality with 
increased risk of vertebral fractures independent of BMD in T2D patients (Yamamoto et al. 
2009). 
1.5.3.2 Insulin, IGF-1 and other growth factors 
Insulin has been shown to have an anabolic effect on bones that is distinct from the effect of 
its analogue IGF-1. This effect is mediated either indirectly through insulin regulation of 
renal 1alpha-hydroxylase activity and serum vitamin D levels in response to PTH (Hough et 
al. 1982, Ikeda et al. 1987), or directly on bone cells through specific insulin receptors (IRs) 
in osteoblasts. IRs are present on osteoblasts and its expression varies with differentiation 
status of the osteoblast (Levy et al. 1986, Thomas et al. 1996b). In vitro studies on primary 
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osteoblasts and clonal osteoblast cell lines show insulin promotes glucose uptake (Hahn et 
al. 1988), alkaline phosphatase activity, collagen synthesis (Canalis 1983, Pun 1989) and 
osteoblast proliferation (Wergedal and Baylink 1984) of these cells. Maor et al. 
demonstrated reduced IRs in the skeletal growth centres of mice with streptozotocin (STZ)-
induced diabetes and these were reversed with insulin therapy (Maor and Karnieli 1999). 
Evidence for a direct link between insulin action and bone formation in vivo can be observed 
in IR knock out mice which show altered bone formation (Ferron et al. 2010), abnormal 
trabecular microarchitecture (Fulzele et al. 2010) and reduced bone strength (Thrailkill et al. 
2014). Insulin positively regulates bone formation by stimulating osteocalcin production. 
Observational studies in people with T1D and T2D, with insulin deficiency and resistance 
respectively, demonstrate reduced osteocalcin levels compared with controls (Diaz-Lopez et 
al. 2013, Gower et al. 2013). Furthermore, there is a positive correlation between insulin 
dose and BMD (Weinstock et al. 1989, Fukunaga et al. 1997). The dichotomy of lower BMD 
in T1D with insulinopenia and higher BMD in T2D with clinical hyperinsulinemia further 
implicates a causal anabolic effect of insulin on bone.  
The direct effect on bone may also be mediated through the IGF-1 pathway. IGF-binding 
protein (IGFBP) serves as a carrier protein for IGF-1. Insulin inhibits IGFBP-1 and IGFBP-
4 expression in osteoblasts. Lack of insulin in T1D leads to an increase in these IGF-binding 
proteins hence reducing the availability of unbound IGF-1 for anabolic effects on bone 
(Conover et al. 1996). In addition to insulin deficiency, T1D individuals and animal models 
demonstrate dysregulation of a variety of endocrine factors including reduced amylin and 
IGF-1 (Rosen 2004, Hofbauer et al. 2007). Amylin is another osteotropic factor that is co-
secreted by pancreatic beta-cells and absent in T1D (Horcajada-Molteni et al. 2001). 
Amylin-deficient mice displayed low bone mass with increased number of osteoclasts 
(Dacquin et al. 2004) and that treatment with amylin in diabetic rat result in increased BMD 
and bone strength (Horcajada-Molteni et al. 2001). Similarly, diabetic animals with low 
blood IGF-1 and knock-out mice for its receptor displayed diminished bone formation 
(Bouxsein et al. 2002, Zhang et al. 2002). Furthermore, serum IGF-1 level was shown to be 
an independent predictor of vertebral fractures in postmenopausal women with T2D 
(Kanazawa et al. 2011). 
1.5.3.3 Calcium, Vitamin D and calciotropic hormones 
It is well known that calcium homeostasis plays a major role in regulating bone metabolism, 
Therefore, imbalance in systemic factors which are capable of regulating calcium balance 
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have been found to influence diabetic bone loss (Zhang et al. 2011). Studies in diabetic 
animal models suggested reduced levels of calcium, phosphate and PTH (McCabe et al. 
2011), with lower 1,25-dihydroxyvitamin D3 (Verhaeghe et al. 1990, McCabe et al. 2011) 
and vitamin-D binding proteins (Verhaeghe et al. 1990). Many studies have also shown 
vitamin D deficiency in T1D and T2D individuals albeit normal calcium, phosphate and low 
normal PTH (Frazer et al. 1981, Hampson et al. 1998). The effect of diabetes mellitus on 
calcium metabolism is complex, but essentially it is associated with a negative calcium 
balance hallmark by both bone and renal loss (Schwartz 2003). Children with T1D have been 
shown to have markedly reduced 1,25-dihydroxyvitamin–D but raised 24,25-
dihydroxyvitamin-D, and this was associated with a decrease in cortical bone mass (Frazer 
et al. 1981). This could be explained by the altered vitamin D metabolic enzyme expressions 
and decreased expression of renal calcium transporter found in STZ-induced diabetic mice 
although these mice have reduced pQCT measured trabecular BMD and histologically 
poorer trabecular, instead of cortical, bone microstructure (Zhang et al. 2011). In support of 
this, treatment with calcitriol in STZ-induced rats demonstrated recovery of BMD (Del Pino-
Montes et al. 2004). In terms of PTH, several in vivo and in vitro studies indicate that an 
imbalance in PTH was associated with bone loss and increased fracture risk (Wang et al. 
2005, Motyl et al. 2012). PTH encourages bone formation and turnover by increasing the 
expression of osteocalcin, IGF-1, IGFBP-3, β-fibroblast growth factors (FGF), matrix 
metallopeptidases (MMP)-1 and MMP-13 in rat osteoblasts in vitro (Schmid et al. 1994), as 
well as MMP-13 in mice in vivo (Porte et al. 1999). Moreover, treatment with PTH to T1D 
and T2D mice demonstrated reversal of trabecular bone parameters through its anabolic 
effects on osteoblast differentiation and maturation (Motyl et al. 2012, Hamann et al. 2014). 
PTH-treatment was also associated with reduced TUNEL-staining of osteoblast suggesting 
its antiapoptotic effect on osteoblasts. It has been suggested that PTH promotes repair of 
DNA damage by increasing proliferating cell nuclear antigen (PCNA) and forkhead box 
protein O3a (FoxO3a) (Schnoke et al. 2009), hence prolonging osteoblast survival. 
Intermittent PTH treatment reversed bone loss to baseline in mice compared to only partial 
reversal in continuous PTH-treatment, although this effect may be due to underlying 
differences between the T1D and T2D mouse models (Motyl et al. 2012, Hamann et al. 
2014). Similarly, treatment with PTH-related protein, which is produced at high levels by 
differentiating osteoblasts, also reverses trabecular bone loss in STZ-induced diabetic mice 
suggesting its modulatory effect on osteoblast function and role in diabetic osteopenia 
(Lozano et al. 2009).  
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1.5.3.4 Marrow adiposity and adipokines 
There is a growing body of evidence that suggests that the bone-fat connection plays an 
important role in the pathophysiology of bone loss. Osteoblasts and adipocytes share a 
common precursor, both derived from the pluripotent MSCs located in the bone marrow 
suggesting a mutually exclusive and reciprocal lineage selection of one or the other. The 
main lineage-specific transcription factor which controls adipogenesis is PPARγ (Rosen and 
MacDougald 2006). In mice, there is evidence of increased PPARγ expression and an 
increase in visible adipocytes in tibia of T1D mouse models (Botolin et al. 2005) and 
increase in bone marrow adiposity in both spontaneously and STZ-induced T1D mice 
compared to controls (Botolin and McCabe 2007, Lozano et al. 2009, Motyl et al. 2011). 
Rzonca et al. demonstrated in vivo that rosiglitazone (PPARγ agonist) administration results 
in significant bone loss (Rzonca et al. 2004) whilst Cock et al. demonstrated that 
congenitally PPARγ deficient mice had increased BMD and bone trabecular 
microarchitecture parameter including BV/TV and trabecular thickness (Cock et al. 2004). 
However, Botolin and McCabe found that inhibition of PPARγ by administration of an 
antagonist to insulin deficient T1D mice prevented bone marrow adiposity but not bone loss 
(Botolin and McCabe 2007). This inability in preventing bone loss in T1D mice suggested 
that bone marrow adiposity may only be partially responsible for diabetic bone loss. Bone 
marrow adiposity can also have direct effects on osteoblasts as demonstrated by several co-
culture studies in mouse and human cells (Maurin et al. 2000, Elbaz et al. 2010, Coe et al. 
2011a). The presence of adipocytes inhibits osteoblast proliferation (Maurin et al. 2000) 
through the lipotoxic effect of free fatty acid in the bone marrow microenvironment [81]. 
There have been limited studies looking at marrow fat content in diabetes individuals to date 
with paucity in those with T1D. Most clinical studies of bone marrow adiposity in T2D 
women have shown no difference in marrow fat content between cases and controls, 
although T2D women consistently had lower unsaturated lipids (Baum et al. 2012, Patsch et 
al. 2013b, Kim et al. 2017). Sheu et al demonstrated higher BMF content in men with T2D, 
although this became insignificant after excluding two individuals on thiazolidinediones 
(PPARγ agonists) (Sheu et al. 2017, Yu et al. 2017). However, a new study published has 
now demonstrated that the bone marrow in adults with T2D have increased fat accumulation 
compared to controls (Ferland-McCollough et al. 2018), with diabetes itself causing the 
preferential differentiation of the bone marrow stem cells into adipocytes. Importantly, a 
positive correlation between HbA1c and marrow fat content has been shown suggesting that 
BMA may influence or be influenced by glucose metabolism and glycaemic control (Baum 
et al. 2012).  
46 
In addition to releasing large amounts of free fatty acid, adipocytes in the bone marrow also 
secrete cytokines including leptin, adiponectin, monocyte chemoattractant protein-1 (MCP-
1) and TNFα, the last of which will be discussed in the next section. Leptin is an adipokine 
which has a complex regulatory role on bone metabolism, with an indirect inhibitory effect 
on osteoclastogenesis and a direct stimulatory effect on osteoblastogenesis through a central 
(hypothalamic) and peripheral pathway (Steppan et al. 2000, Reseland et al. 2001, Cornish 
et al. 2002). Despite being an adipokine, in vitro studies indicate that leptin promotes an 
osteoblast rather than adipocyte lineage (Reseland et al. 2001, Cornish et al. 2002). In 
contrast to T1D patients who demonstrate increased (Luna et al. 1999) or slightly decreased 
leptin level (Karaguzel et al. 2006), leptin levels were found to be significantly suppressed 
in T1D mice, its absence results in reducing bone mass with increasing marrow adiposity 
(Steppan et al. 2000). T2D is typically associated with obesity, which has been associated 
with higher leptin level and higher BMD. Vasilkova et al., however, demonstrated that leptin 
has an independent positive correlation to BMD, irrespective of BMI (Vasilkova et al. 2011). 
In addition, interventional studies in mice have demonstrated that leptin administration 
reduces bone marrow adiposity and increases bone mass (Hamrick et al. 2005, Martin et al. 
2005). However, similar to their work on PPARγ antagonist, Motyl and McCabe concluded 
that leptin administration to T1D mice modify and prevent marrow adiposity but did not 
prevent diabetic bone loss (Motyl and McCabe 2009).  
Adiponectin (APN), the most abundant adipokine secreted exclusively by adipocytes, 
regulates energy homeostasis and exerts well-characterized insulin sensitizing properties. 
The insulin-sensitising effect of OC is known be due to the upregulation of APN gene in 
adipocytes (Lee et al. 2007) but there is some suggestion that in humans the link between 
OC and APN may be gender specific (Buday et al. 2013). APN seems to have an anabolic 
effect on osteoblasts and an inhibitory effect on osteoclasts in vitro (Williams et al. 2009). 
The peripheral and central effects of APN on bone metabolism are beginning to be explored 
but are still not clearly understood. APN-knockout (APN-KO) mice fed a normal diet exhibit 
decreased trabecular structure and mineralisation and increased bone marrow adiposity 
whilst central administration of APN into the brain ventricles decreased osteoclast numbers 
and increased osteoblastogenic marker expression and trabecular bone mass, in both APN-
KO and WT mice (Wu et al. 2014). Clinically, serum APN levels have been shown to be 
positively associated with BMD at the distal radius in Japanese individuals with T2D, 
although the evidence linking adiponectin to bone mass is conflicting with some studies 
showing an inverse relationship (Lenchik et al. 2003, Tamura et al. 2007, Napoli et al. 2010).  
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1.5.3.5 Chronic inflammation 
The pathogenesis of both T1D and T2D are associated with activation of the immune system, 
especially so in T1D which involves an autoimmune destruction of pancreatic β-cells whilst 
T2D involves a more chronic low-grade inflammatory process (Bending et al. 2012, Esser 
et al. 2014). Several experimental studies using T1D mice model indicate that systemic and 
local inflammatory cytokines are increased at the onset of diabetes with rapid suppression 
of osteoblast markers and increase in adipocyte markers, indicating that bone inflammation 
may be another contributing factor to the diabetic bone pathology (Motyl et al. 2009, Coe et 
al. 2011a, Roszer 2011). Serum cytokine levels (TNFα, IFNγ, IL-1Rα and lymphotoxin-β) 
and corresponding bone cytokine mRNA expression were increased from as early as 5 days 
after induction of diabetes in mouse models (Botolin and McCabe 2007, Motyl et al. 2009) 
with decrease in osteocalcin mRNA expression in bone RNA extracts, and it remains 
suppressed at 40 days postinduction of diabetes in the mouse models. These inflammatory 
cytokines can either directly suppress osteoblast differentiation (Gilbert et al. 2000), promote 
osteoblast death directly (Coe et al. 2011a) or indirectly by contributing to elevation of ROS 
causing osteoblast apoptosis from oxidative stress (Hamada et al. 2009, Coe et al. 2011b), 
and activate osteoclastogenesis (Glantschnig et al. 2003). Coe et al. also found that TNFα in 
the bone marrow microenvironment directly mediates osteoblast death with increase in 
expression of proapoptotic factors and osteoblast TUNEL staining, further contributing to 
T1D bone loss (Coe et al. 2011a). Inhibition of the cytokines with TNFα neutralizing 
antibodies prevented osteoblast apoptosis (Coe et al. 2011a) but transgenic mice with IFNγ 
KO proceeded to have diabetic bone pathology (Motyl et al. 2009), supporting the idea that 
diabetic inflammatory bone loss involves an interplay of more than one cytokine and/or a 
combination of other factors. Apart from proinflammatory cytokines, abnormal hyaluronan 
production in bones of diabetic rodents also induced monocyte and macrophage infiltration 
into the bone collagen matrix, promoting adipogenesis at the expense of osteogenesis (Wang 
et al. 2014). The concept of T2D as an inflammatory disease is relatively new with increased 
fat depots in T2D implicated as the source for more proinflammatory cytokines and 
adipokines (Esser et al. 2014). The cytokine MCP-1, secreted by mature adipocytes in the 
bone marrow, acts in a paracrine manner, further promoting MSC differentiation into 
adipocytes (Ferland-McCollough et al. 2018). However, a large prospective population 
study (EPIC) in Germany found that systemic inflammatory markers are independent 
predictors for the development of T2D, independent of degree of insulin resistance and 
obesity (Spranger et al. 2003). 
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1.5.3.6 Vasculopathy 
Similar to other diabetic microvascular complications of retinopathy, nephropathy and 
neuropathy, bone microangiopathy has been insinuated as another possible mechanism for 
diabetic bone loss. In hypoxic condition (2% oxygen), the bone marrow shifts toward 
adipogenic lineage by enhancing expression of genes associated with adipogenic/lipogenic 
phenotype (C/EBPβ, PPARγ2, and aP2) and by suppressing expression of genes associated 
with osteoblast differentiation (AP) (Irwin et al. 2007). Oikawa et al. found that the 
cumulative vascular density was reduced by threefold in bone marrow of STZ-induced 
diabetic mice compared to control, along with reduction in blood flow (Oikawa et al. 2010). 
In addition, there is also evidence of reduction in bone marrow volume and bone marrow 
remodeling with cell depletion mainly affecting the osteoblastic niche secondary to 
hypoperfusion and oxidative stress (Oikawa et al. 2010). Correspondingly, boosting the 
antioxidative pentose phosphate pathway with benfotiamine supplementation prevented 
microangiopathy and hypoperfusion in the bone marrow with reduction in cell apoptosis, 
providing further compelling evidence for vasculopathy in diabetic bone pathology. 
Regenerating mouse tibia has reduction in blood vessels with lower expression of vascular 
endothelial growth factor (VEGF), a signalling protein which regulates angiogenesis, and its 
receptor (Lozano et al. 2009). Clinically, histomorphometric evaluation of iliac crest bone 
biopsy in 118 diabetic patients revealed evidence of diabetic bone microangiopathy in 82% 
with significant osteopenia and reduction in the sinusoidal capillaries (Burkhardt et al. 
1981). 
1.5.3.7 Anti-diabetic medications 
Different classes of anti-diabetic medication, such as thiazolidinediones (TZDs), metformin 
and glycogen-like peptide 1 (GLP-1) inhibitors have been reported to have varying effects 
on bone. 
1.5.3.7.1 Insulin 
Although insulin is considered to have an anabolic effect on bones, individuals with T1D on 
higher insulin dose have been shown to have lower BMD (Leger et al. 2006, Eller-Vainicher 
et al. 2011) whilst individuals with T2D on higher insulin dose have been shown to have 
increased risk of falls from hypoglycaemic attacks resulting in fractures (Monami et al. 2008, 
Johnston et al. 2012). The positive correlation between daily insulin dose and HbA1c 
(Hofbauer et al. 2007) may help explain the negative correlation between daily insulin dose 
with BMD, reflecting possibly an issue with compliance or possibly the presence of a more 
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severe disease (more inflammatory processes) in T1D (Leger et al. 2006). Findings from the 
HABC study showed that T2D insulin-treated patients with HbA1c ≤ 6% had an increased 
risk of falls (Schwartz et al. 2008). This finding should be interpreted with caution as T2D 
patients on insulin usually had longer duration of diabetes and other concurrent 
microvascular complications such as retinopathy and neuropathy which predispose to falls. 
Nephropathy with impaired renal function also has a linear correlation to falls (Schwartz et 
al. 2008), possibly as impaired renal function may interfere with vitamin D metabolism 
resulting in reduced muscle strength.  
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Figure 1.20 Pathophysiological mechanisms of diabetic bone disease.  Type 1 (T1D) and Type 2 Diabetes (T2D) mellitus affect bone turnover, bone mineral density 
and bone quality through a complex interplay of hyperglycaemia, insulinopenia, GH/IGF-1 deficit, chronic inflammation and vasculopathy to name a few, ultimately leading 
to osteoporosis and increased fracture risk. IGF-1 insulin growth factor-1, PTH parathyroid hormone, MVCs microvascular complications, AGEs advanced glycation end 
products, ROS reactive oxygen species, TNFα tumour necrosis factor-alpha, IFNγ interferon-gamma, IL(1,6,8); interleukin-(1,6,8), MCP-1 monocyte chemoattractant 
protein-1, MSCs mesenchymal stem cells, BMD bone mineral density. Solid lines represent pathways affecting both T1D and T2D, with broken lines specific to T2D only.   
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1.5.3.7.2 Thiazolidinediones 
TZDs such as pioglitazone and rosiglitazone have been shown to increase adipocyte 
differentiation and decreased osteoblast differentiation through activation of PPARγ activity 
(Rzonca et al. 2004, Ali et al. 2005, Schwartz 2008). Consistent with these preclinical 
observations, a comprehensive meta-analyses of 10 randomised controlled-trials (total 
13,715 participants) and 2 observational (total 31,679 participants) studies, clearly indicated 
an increased risk of fractures (OR 2.23, 95% CI 1.65-3.01) with TZD (both pioglitazone and 
rosiglitazone) use, particularly in women (Loke et al. 2009). A more recent meta-analysis, 
including 22 randomised controlled-trials (total 24,544 participants) further confirmed this 
gender difference in fracture risk (OR 1.94, 95% 1.6-2.35 in women vs OR 1.02, 95% CI 
0.83-1.27 in men), which is independent of age and duration of TZD exposure (Zhu et al. 
2014). Use of this medication should therefore be avoided in women.  
1.5.3.7.3 Metformin 
Metformin is the standard first line pharmacologic treatment for T2D. It exerts a direct 
osteogenic effect in vitro by stimulating proliferation and differentiation of osteoblasts 
(Cortizo et al. 2006, Gao et al. 2008, Kanazawa et al. 2008, Ma et al. 2010a, Jang et al. 
2011) through preventing AGE-induced deleterious effects in osteoblastic cells (Schurman 
et al. 2008) and various other signalling pathways including the PI3K/Akt pathway (Ma et 
al. 2010b), ERK-1/2 (Cortizo et al. 2006) and AMPK activation (Kanazawa et al. 2008, Jang 
et al. 2011). Zhen et al. also demonstrated an indirect effect of metformin on osteoblast 
survival through reduction of intracellular ROS (Zhen et al. 2010). In addition to its 
osteoblastogenic potency in vitro, metformin can further prevent bone loss by inhibiting 
osteoclastic differentiation (Mai et al. 2011). However, ovariectomized rodents treated with 
metformin demonstrated inconsistent radiological findings of no change in bone 
microarchitecture (Jeyabalan et al. 2013) to increased BMD (Mai et al. 2011). In clinical 
studies however, metformin has been shown to have a neutral (Monami et al. 2008, Colhoun 
et al. 2012, Napoli et al. 2014) or positive (Vestergaard et al. 2005, Zinman et al. 2010) 
effect on bone metabolism. One of the larger observational studies (total 498,617 
participants) reported that metformin was associated with a decreased risk of any fractures 
(HR 0.81; 95 % CI, 0.70–0.93) (Vestergaard et al. 2005). The only randomised trial, ADOPT 
(total 4351 participants, 1840 women) designed to compare metformin with rosiglitazone 
and glyburide found that the cumulative incidence of fracture is 1.2 per 100 patient years for 
metformin and glyburide but up to 9.3 per 100 in women for rosiglitazone (Kahn et al. 2006). 
To date, only one study has investigated the role of metformin in young patients. In the 
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Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) clinical trial, 
699 patients aged 10–17 years with T2D were divided into three different treatment groups: 
metformin plus rosiglitazone; metformin alone; metformin plus lifestyle. BMD and BMC 
increased in all groups, but increased less in metformin plus rosiglitazone compared with the 
other two groups after 24 months (0.06 g/cm2 in metformin plus rosiglitazone vs 0.076 
g/cm2 in metformin plus lifestyle; p=0.0041) (Today Study Group 2013). 
1.5.3.7.4 Sulphonylureas 
Sulphonylureas such as glimepiride and glyburide are anti-hyperglycaemic drugs which 
cause increased secretion of insulin by binding to the KATP-channel on the cell membrane of 
pancreatic beta cell. Consequently, these agents have been reported to cause increased risk 
of hypoglycaemia (Monami et al. 2008) and increased fracture risk. Similar to metformin, 
sulfonylureas have been reported to have either neutral (Melton et al. 2008, Monami et al. 
2008) or a reduction in risk of fractures in patients treated with these agents (Vestergaard et 
al. 2005, Zinman et al. 2010). The ADOPT RCT showed comparable cumulative incidence 
of fractures to metformin of 1.2 per 100 patient years, with 5 year cumulative incidence of 
fractures (95 % CI) of 5.7 % (3.9–7.6) (Kahn et al. 2006). A large population-based case–
control study in Denmark (total 124,655 cases with 3:1 age-and -gender matched controls of 
373,962) found that treatment with sulfonylureas was associated with a significant decrease 
in the risk of hip fracture (HR 0.74, 0.58–0.93) versus patients with T2D without treatment 
(Vestergaard et al. 2005). Given the high rate of hypoglycaemia with sulphonylureas, this 
group of antidiabetic drug should be used with caution in those at higher risks of fragility 
fractures. 
1.5.3.7.5  Incretin-based therapies 
Incretins are a group of gastrointestinal hormones which act to lower blood glucose levels 
by inhibiting glucagon release. It also reduces gastric emptying and can help to increase the 
secretion of insulin from pancreatic beta cells. The two main groups are the glucagon-like 
peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitor, the latter is an enzyme 
which inactivates GLP-1 (Drucker and Nauck 2006). Three meta-analyses have looked at 
the fracture incidence with GLP-1and DPP-4 inhibitors showing contradicting and 
favourable effects respectively on bone. GLP-1 liraglutide has been associated with reduced 
fracture risk (OR 0.38, 95% CI 0.17-0.87) whilst exenatide was correlated with increased 
fracture risk (OR 2.09, 95% CI 1.03-4.21) (Su et al. 2015). Although a meta analyses of 
DPP-4 inhibitors have shown a reduction in  fracture risk (OR 0.60, 95% CI 0.37-0.99) 
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(Monami et al. 2011), more recent studies have demonstrated varying results with sitagliptin 
reported to have anabolic effects on the bone (Hegazy 2015) but not with saxagliptin in the 
SAVOR-TIMI trial (Mosenzon et al. 2015).  
1.5.3.7.6 Sodium/glucose co-transporter 2 (SGLT-2) 
SGLT-2 such as dapagliflozin and canagliflozin are a new generation of antidiabetic drugs 
which work to reduce hyperglycaemia by inhibiting renal reabsorption of glucose from the 
proximal tubules (DeFronzo et al. 2012, Ljunggren et al. 2012, Bolinder et al. 2014). 
Dapagliflozin and empagliflozin seem to have a neutral effect on bone metabolism, with no 
significant changes in bone turnover or BMD parameters (Ljunggren et al. 2012). Concerns 
have been raised for canagliflozin, which might cause bone loss at the hip (Bilezikian et al. 
2016, Watts et al. 2016) and increase the risk of hip fractures (Watts et al. 2016). 
1.5.4 Clinical evidence of fractures 
1.5.4.1 Type 1 Diabetes (T1D) 
Adults with T1D have been shown to have a significantly higher risk of hip fractures, of 
eight- to 18-folds compared to the general population (Miao et al. 2005, Ahmed et al. 2006). 
Two large meta-analyses published following that confirmed the increased hip fracture risk 
of 6.9- and 6.3-folds respectively compared to individuals without T1D (Janghorbani et al. 
2007, Vestergaard 2007). In a large observational study in Scotland (total of 21,033 
individuals with T1D) a consistently increased but lower relative risk of hip fracture, of 3.2 
in men and 3.5 in women, was reported (Hothersall et al. 2014). A more recent meta-analysis 
(total 27,300 individuals with T1D) further validated this lower relative fracture risk of over 
three-folds in all fractures, and not just hip alone (Shah et al. 2015). Fractures at the spine, 
although less marked (OR 2.5, 95% CI 1.3-4.6), are also moderately increased in the T1D 
population (Vestergaard et al. 2005). Zhukouskaya et al reported a significantly higher risk 
of morphometric vertebral fractures, assessed by VFA, in young adults with T1D (24% vs 
6% in healthy controls) with a meta-analysis reporting a pooled relative risk of 2.88 (95% 
CI 1.71-4.82) in individuals with T1D (Zhukouskaya et al. 2013, Shah et al. 2015). 
Another most disconcerting finding is that the increased risk of fracture extends across all 
ages, affecting even young adults and children with T1D, with widening discrepancy in the 
risks from age 40 years. (Hothersall et al. 2014, Weber et al. 2015). Studies have shown an 
almost linear association between duration of disease (T1D) and fracture risk (Nicodemus et 
al. 2001, Miao et al. 2005), although this was contradicted by others (Ahmed et al. 2006). 
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There is an intriguing proposal of a bimodal relationship with the highest incidence of 
fracture occurring in the first 2.5 years of diagnosis and again beyond 5 years of diabetes 
being diagnosed (Vestergaard et al. 2005). Most studies, but not all (Neumann et al. 2011), 
have found no association between glycaemic control, as measured by HbA1c, with risk of 
fracture. Many studies have invariably reported an association between fracture risk and the 
presence of all types of diabetic complications (Miao et al. 2005), and more specifically 
retinopathy (Ivers et al. 2001, Weber et al. 2015), nephropathy (Miao et al. 2005), 
neuropathy (Miao et al. 2005, Weber et al. 2015) and cerebrovascular disease (Strotmeyer 
et al. 2005). 
Lower extremity fractures (hip/femur, lower leg/ankle and foot) were more common than 
upper extremity/vertebral fractures in those with T1D (31.1% vs 25.1% in males, 39.3% vs 
32% in females; p<0.001) (Weber et al. 2015). 
1.5.4.2 Type 2 Diabetes (T2D) 
T2D has also been associated with increased risk of fractures. The Study of Osteoporotic 
Fractures (SOF) cohort found that women with T2D have an increased risk of hip and 
proximal humeral fractures (RR 1.82, 95% CI 1.24-2.69 and RR 1.94, 95% CI 1.24-3.02) 
compared to the non-diabetic population (Schwartz et al. 2001). A meta-analysis of eight 
prospective studies for the hips and three studies for the wrists in adults with T2D concluded 
that the relative risk of hip and wrist fractures were 1.4 and 1.2, respectively with no increase 
in vertebral fracture risk (RR 0.93, 95% CI 0.63-1.37) (Vestergaard 2007). Another meta-
analysis published in the same year of 16 epidemiologic studies, of which 4 investigated 
vertebral fractures, substantiated the neutral vertebral fracture risk but found a slightly higher 
relative risk of hip fracture of 1.8. This relative risk rose to 2.7 (95% CI 1.7-4.4) when the 
analysis was restricted to four cohort studies with >10 years of follow-up (Janghorbani et al. 
2007). In fact, a history of T2D was shown to be the single most important and independent 
predictor of low-energy subtrochanteric and diaphyseal femoral fractures (Napoli et al. 
2013). Subsequent to the meta-analysis, more studies have suggested than T2D may also be 
associated with higher vertebral fracture risks with up to 23% of vertebral fractures reported 
in post-menopausal women (Ardawi et al. 2013). A Japanese cohort study (total participants 
996, 1 case:3 controls) further elucidated a gender preponderance with men (OR 4.7, 95% 
CI 2.19-10.20) more likely to have vertebral fractures than women (OR 1.9 (95% CI 1.11-
3.12) (Yamamoto et al. 2009, Viegas et al. 2011). Fractures of the wrists (de et al. 2005) and 
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foot (Schwartz et al. 2001, Bonds et al. 2006) also seemed to be more prevalent in 
individuals with T2D than the general population.  
Duration of T2D, glycaemic control, anti-diabetic medications, propensity to fall and T2D-
related complications were observed as possible predicting factors for the increased fracture 
risk in these studies. Cross-sectional studies have indicated that those with increased 
fractures are older (Nicodemus et al. 2001, Janghorbani et al. 2007, Yamamoto et al. 2008) 
and have a longer duration of T2D (Yamamoto et al. 2008, Viegas et al. 2011). The incidence 
was also higher in those treated with insulin (Janghorbani et al. 2007, Melton et al. 2008). 
In T2D, falls are common (Schwartz et al. 2001, Schwartz 2008) and the risk of falling may 
be higher in those with poor balance, arthritis, cardiovascular disease, depression, poor 
vision and use of medications for sleeplessness or anxiety (Schwartz et al. 2001). It is unclear 
whether this increased risk of fall is also associated with more fractures. The presence of 
microvascular complications have also been associated with increased risk of fractures, in 
particular neuropathy (Melton et al. 2008) and retinopathy (Viegas et al. 2011). 
1.5.5 Bone turnover studies  
1.5.5.1 T1D 
T1D is associated with a low bone turnover state with dissociation between bone formation 
and bone resorption (Starup-Linde 2013). Both pharmacologically-induced and 
spontaneously diabetic NOD mice with chronic disease have impaired bone formation and 
resorption, with concomitant histomorphometric data (Hough et al. 1981, Hough et al. 
1983). In humans, the marker of bone formation, osteocalcin has been found to be low in 
both adults and children with T1D (Bouillon et al. 1995). A recent large meta-analysis 
further substantiated this with significantly lower osteocalcin -1.51 (-2.76, -0.26) ng/ml) in 
individuals with diabetes compared to non-diabetes controls. Subgroup analysis 
demonstrated specifically that the osteocalcin level was depressed in T1D, but not in T2D 
(Starup-Linde et al. 2014). Glycaemic control, as measured by HbA1c was found to be 
negatively correlated to the osteocalcin levels (Adami 2009, Maggio et al. 2010). The level 
of another bone formation marker, bone alkaline phosphatase (BAP) has been found to be 
more variable with studies showing a suppressed level (Lumachi et al. 2009) and a meta-
analysis showing an increased BAP compared to controls (Masse et al. 2010, Starup-Linde 
et al. 2014). This imbalance of bone formation markers (increased BAP, decreased 
osteocalcin) may reflect an impairment of osteoblast differentiation and maturation as BAP 
is expressed early in the development of osteoblast whilst osteocalcin is released from the 
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mature osteoblast. Studies on the markers of bone resorption were conflicting with either 
normal (Alexopoulou et al. 2006) or reduced (Campos Pastor et al. 2000, Maggio et al. 2010, 
Abdalrahaman et al. 2015) circulating levels in individuals with T1D. Pooled data from the 
meta-analysis concluded that bone resorption is depressed with reduced CTX at -0.14 (-
0.22,-0.05) ng/ml in individual with diabetes mellitus, but no sub-analyses by diabetes type 
was available to distinguish whether bone resorption differed between T1D and T2D. The 
low bone turnover state appears to be present from the onset of T1D in childhood with 
normalisation after 3 months (Pater et al. 2010), which may be a function of concurrent 
improvement in the HbA1c with insulin treatment, as adults with T1D continued to have 
lower osteocalcin, BAP and CTX compared to controls as detailed above. Bone 
histomorphometry data in T1D is scarce. One study in two patients with T1D showed 
markedly depressed bone formation compared to non-diabetics (Krakauer et al. 1995) but a 
larger case-control study of 18 T1D patients showed no difference in bone metabolism 
between the groups (Armas et al. 2012). Further sub-analyses of the T1D patients 
demonstrated a significantly depressed bone formation in the small group who had fractures 
compared to those without fractures (Armas et al. 2012). The incorporation of bone turnover 
markers into the FRAX model has not explained the increased fracture risk in diabetes 
patients compared to healthy controls (Bhattoa et al. 2013) so at present, bone turnover 
markers are of limited use in fracture prediction. Heterogeneity between all the studies such 
as the differences in patient characteristics (age, ethnicity, disease duration, glucose control) 
and the discrepancies in timing of serum collection and assay variations may have influenced 
the results.  
Sclerostin, produced almost exclusively by osteocytes, is an inhibitor of the canonical 
Wnt/β-catenin signalling pathway involved in bone formation, thus playing an essential role 
in osteoblast differentiation and bone turnover (Baron and Kneissel 2013). In animal models, 
overexpression of SOST gene causes osteopenia and limb defects (Loots et al. 2005, Baron 
and Kneissel 2013), while lack of SOST causes 3–4 times more bone mass, consistent with 
human phenotypes in a condition called sclerosteosis (Collette et al. 2012). Many studies 
have found that sclerostin levels were higher in patients with T1D (Catalano et al. 2014, 
Neumann et al. 2014) compared to controls, with gender predilection for higher levels in 
females than males (Catalano et al. 2014). The duration of diabetes has also been shown to 
positively correlate with higher sclerostin levels, further impairing bone health and 
increasing fracture risk.  T1D mice subjected to sclerostin-neutralising antibody treatment 
demonstrated reversal in the osteopenia, reduced bone marrow adipogenesis and improved 
fracture outcome (Yee et al. 2016). Intriguingly however, sclerostin levels have been shown 
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to be inversely associated with fracture in T1D patients (Starup-Linde et al. 2016). T1D 
patients with the highest tertile of sclerostin had an 81% decreased risk of fracture compared 
with the lowest tertile which is counterintuitive and remains unexplained. The 
reproducibility of this study or further mechanistic explanation has yet to be seen. 
1.5.5.2 T2D 
Similar to T1D, individuals with T2D are reported to have suppressed bone turnover. Bone 
formation is consistently lower in people with T2D, as evidenced by lower serum 
osteocalcin, BAP and procollagen type 1 N-terminal propeptide (P1NP) levels (Dobnig et 
al. 2006, Gennari et al. 2012) with suppressed bone resorption as demonstrated by lower 
CTX levels compared to healthy controls (Dobnig et al. 2006, Gennari et al. 2012, Reyes-
Garcia et al. 2013). A large meta-analysis, however, did not show a significant difference 
(p=0.06) in osteocalcin in T2D individuals compared to healthy controls (Starup-Linde et al. 
2014) and did not analyse CTX by subtype of diabetes hence it remains unclear whether 
bone resorption is affected in T2D. In accordance with the former, bone histomorphometry 
demonstrated reduced histologic measures of mineralising surface and bone formation rate 
(Manavalan et al. 2012). Serum PTH tends to be lower (Dobnig et al. 2006, Garcia-Martin 
et al. 2012, Reyes-Garcia et al. 2013) in T2D. The relative (moderate or subclinical) 
hypoparathyroidism in diabetes patients, with normal calcium and phosphate levels, could 
contribute to the low bone turnover state as the levels of osteocalcin and CTX have been 
shown to correlate with PTH levels (Yamamoto et al. 2012, Reyes-Garcia et al. 2013). 
Increased sclerostin levels have been found in patients with T2D compared to healthy 
controls (Garcia-Martin et al. 2012, Gaudio et al. 2012, van Lierop et al. 2012). The elevated 
sclerostin levels were associated with osteoporotic fractures (Ardawi et al. 2012, Heilmeier 
et al. 2015) in postmenopausal women and also importantly, an increased risk of vertebral 
fractures (Ardawi et al. 2012) in T2D patients of both genders independently of BMD. 
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1.5.6 Bone imaging studies  
1.5.6.1 T1D 
Imaging studies have provided the wealth of evidence linking diabetes mellitus, both T1D 
and T2D, with impaired bone health. The effects of T1D on bone health may be manifested 
as aberrant bone mass (Gunczler et al. 1998, Heap et al. 2004, Saha et al. 2009b) and 
abnormal bone microarchitecture (Abdalrahaman et al. 2015), predisposing  ultimately to 
the clinically significant increased risk of fractures (Vestergaard 2007, Hothersall et al. 
2014) in this population. 
1.5.6.1.1 Bone mineral density (BMD) 
Almost universally, using the more sensitive modern dual energy X-ray absorptiometry 
(DXA) scanners, studies have shown reduced BMD in adults (Campos Pastor et al. 2000, 
Strotmeyer et al. 2005, Rakic et al. 2006, Mastrandrea et al. 2008, Eller-Vainicher et al. 
2011) and children (Gunczler et al. 1998, Valerio et al. 2002, Leger et al. 2006, K. Heilman 
et al. 2009) with T1D at either lumbar spine (LS), femoral neck (FN) or total body (TB), bar 
a few exceptions (Lunt et al. 1998, Pascual et al. 1998, Ingberg et al. 2004, Bridges et al. 
2005). All major studies reporting on bone densitometry in children with T1D have been 
summarised in Table 1.6. The studies which showed no difference in BMD between diabetic 
and non-diabetic population were methodically suboptimal, in not adjusting for group 
differences in BMI (Lunt et al. 1998) as BMI is a very important determinant of BMD or 
taking into account size correction for DXA interpretation in children (Pascual et al. 1998). 
The reduction in BMD varied markedly from 8-67%, with a reported pooled estimated LS 
BMD Z-score of -0.22 ± 0.01 and FN BMD Z-score -0.37 ± 0.16 (both p<0.05) in a meta-
analysis comparing individuals with T1D and without (Vestergaard 2007). Lower BMD was 
associated with the presence of microvascular complications although further meta-
regression showed that neither duration of disease nor glycaemic control, as measured by 
HbA1c, was associated with BMD (Vestergaard 2007). Several studies have demonstrated a 
reduction in BMD from the onset of T1D diagnosis (Gunczler et al. 2001, Lopez-Ibarra et 
al. 2001) suggesting a predisposing variant rather than chronic metabolic consequences of 
the disease on bones.
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Table 1.6 Bone densitometry studies in children with T1D, based on dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed 
tomography (pQCT). 
Author, year  n  
(F/M) 
Age (yrs)† Disease 
duration 
(yrs)†  
Modality Site Bone density 
findings 
Additional findings of bone-related parameters/  
Other comments 
(Lettgen et 
al. 1995) 
21 NA NA pQCT NA ↓Trabecular and 
cortical vBMD 
↓TB BMD 
Trabecular vBMD inversely associated with disease 
duration. TB BMD inversely correlated with HbA1c 
(Gunczler et 
al. 1998) 
26 
(11/15) 
12.1±3.1 4.3±2.9 DXA TB,LS,FN ↓LS BMD DXA interpretation not size-corrected. No association 
with disease duration or HbA1c. 
(Pascual et 
al. 1998) 
55 
(29/26) 
M 9.7±4.3 
F 11.2±3.8 
1-13.8 
 
DXA LS, 
Radius 
↔ LS BMD DXA interpretation not size-corrected. No relationship to 
HbA1c or disease duration. Adjusted for age and sex. 
(Gunczler et 
al. 2001) 
23 
(16/7) 
9.5±2.2 0.5±0.1 DXA TB,LS,FN ↓LS BMD Matched to age and height. All prepubertal and newly 
diagnosed T1D. 
(Heap et al. 
2004) 
55 
(25/35) 
M 14.6±1.7 
F 14.7±1.9 
5.8±4.3 pQCT  
 
DXA 
Tibia 
 
TB,LS,FN 
↓Trabecular and 
cortical vBMD 
↓TB and FN BMD 
BMD adjusted for LBM. Trabecular vBMD and TB BMD 
inversely associated withn HbA1c. 
(Moyer-
Mileur et al. 
2004) 
42 
(16/26) 
M 16.0±1.7 
F 15.1±1.8  
4.2±3.1 pQCT 
DXA 
Tibia 
TB,LS,FN 
↓Cortical vBMD ,  
↓TB and LS BMD 
BMD adjusted for LBM and LBM-for-height. Lower 
annual gain of tibia cortical bone and TB BMD; inverse 
association to HbA1c.  
(Leger et al. 
2006) 
127 
(54/73) 
12.9  
(10.2-15.2) 
5.6(4.6-8.8) DXA TB,LS ↓ TB vBMD  Adjusted for LBM and LBM-for-height. Girls have lower 
LS and TB BMC than boys. Lower IGF1 in T1D, but no 
correlation to HbA1c or disease duration. 
(Bechtold et 
al. 2006) 
88 
(42/46) 
11.7±3.0 5.6±3.7 pQCT 
 
DXA 
Radius ↔ Trabecular and 
cortical vBMD 
↓ Cortical BMD, 
↔TB BMD. 
Early age at T1D diagnosis associated with reduced 
total, cortical and muscle CSA. No difference with 
HbA1c or disease duration. NB: Higher weight and BMI 
in T1D cohort. 
(Bechtold et 
al. 2007) 
41 
(20/21) 
15.4±2.3 9.8±2.8 pQCT 
 
Radius ↔ Cortical vBMD Normalisation of total, cortical and muscle CSA. 
Reduced trabecular vBMD but no comment to reference 
population. NB: Higher weight and BMI in T1D cohort. 
(Brandao et 
al. 2007) 
44 
(22/22) 
8.8±4.4 6.6±3.9 DXA LS 
(L1-L4) 
↔ LS BMD 66% prepubertal. Negative association of disease 
duration and HbA1c with BMD only in girls. 
(Mastrandrea 
et al. 2008) 
37 
(37/0) 
16.2±1.8 NA DXA TB,LS,FN ↔ all BMD. Adjusted for age, BMI and OC use. Trend of lower TB 
BMD in T1D. No correlation to HbA1c or disease duration. 
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Author, year  n  
(F/M) 
Age (yrs)† Disease 
duration 
(yrs)†  
Modality Site Bone density 
findings 
Additional findings of bone-related parameters/  
Other comments 
(Moyer-
Mileur et al. 
2008) 
11 
(11/0) 
 
12.9±1.0 5.9±3.7 pQCT 
DXA 
Tibia 
TB,LS,FN 
↓Cortical vBMD 
↓TB,FN BMD and 
LS BMAD 
Adjusted for height for age, BMC to BA. Lower IGF-1 
noted in poorer HbA1c and younger age at diagnosis. 
Cortical thickness positively assoc with age at diagnosis.  
(Kaire 
Heilman et 
al. 2009) 
30 
(11/19) 
4.7-18.6 5.4±3.4 DXA LS, TB ↓TB BMC and LS 
vBMD  
Adjusted for age, height and BMI. Only present in boys. 
Inverse association to urinary markers of oxidative 
stress, plasma ICAM-1 levels and HbA1c.  
(Saha et al. 
2009a) 
48 
(26/22) 
12-17.8 6.8 (1-13.5) pQCT  
 
DXA 
Radius/ 
Tibia 
LS, FN 
↔ Trabecular/ 
cortical vBMD 
↓FN BMC 
Adjusted for age, weight and height. Smaller cortical 
areas at radius and tibia. Boys affected more than girls. 
(Inge 
Roggen et al. 
2013) 
56 
(23/33) 
M 17.9 
(17.2–24.8) 
F 18.1 
(17.8-22.9) 
M 10.6±3.9 
 
F 10.0±2.7 
pQCT Radius ↔ Trabecular 
vBMD,  
 
Smaller CSA in T1D, esp males. In girls, the CSA SDS 
correlated negatively with the BMI SDS and positively 
with the height SDS. No correlation to HbA1c. 
(Loureiro et 
al. 2014) 
75 
(29,46) 
12 (6-20) 5.0±3.5 DXA LS 
(L1-L4) 
↓ LS BMD Inverse association to HbA1c.Adjusted for age, height, 
weight, puberty.  
(de Souza et 
al. 2016) 
86 
(46,40) 
12.3±4.2 5.6±4.3 DXA LS 
(L1-L4) 
↓ LS BMD Adjusted for age and sex. No association to HbA1c but 
inverse association with disease duration. Lower IGF1 
mRNA expression between cases and controls. 
(Tsentidis et 
al. 2016) 
(Tsentidis et 
al. 2017) 
40 
(22/18) 
13.0±3.5 5.2±3.3 DXA TB, LS ↓ TB and LS BMD Adjusted for age and sex. No difference in sclerostin 
levels between cases and controls. Higher DKK-1 in 
T1D; inverse association with LS BMD.. 
(Sav et al. 
2017) 
50 
(24,26) 
11.6±2.2 6.0±2.7 DXA LS 
(L2-L4) 
↔ LS BMD Adjusted for age and sex but not size corrected. Higher 
urinary Pyr and DPyr. 
(Maratova et 
al. 2018) 
95 
(36/59) 
16.2±1.2 7.8±4.8 pQCT Tibia ↓ Trabecular 
vBMD 
 cortical thickness but  cortical vBMD. No association 
with HbA1c.Reduced bone strength. Reduced muscle 
power; inversely associated with disease duration. 
BMC: bone mineral content, BMD: Bone mineral density, vBMD volumetric BMD, TB total body, LS lumbar spine, FN femoral neck, BMI body mass index; CSA cross 
sectional area; GH/IGF-1:growth hormone/ insulin-like growth factor-I; mRNA messenger ribonucleic acid, DKK Dipkoff-1, Pyr pyridinoline, DPyr 
deoxypyridinoline.†(median/range or means± SD
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1.5.6.1.2 Bone size and microarchitecture 
The most crucial finding from the meta-analysis by Vestergaard et al. is that the marginal 
reduction in BMD in individuals with T1D, as assessed by DXA, only generated an expected 
relative fracture risk of 1.09 at the spine and 1.42 at the hip, which is significantly less than 
the 3-7-fold increased risk seen clinically as detailed in section 1.5.4.1. This, and the overlap 
in the BMD values of subjects with and without osteoporotic fracture (Schuit et al. 2004), 
highlighted that bone fragility in not only dependent on bone mineral mass but also 
alterations in bone macro- and microstructure. Historically, the only technique to assess bone 
microarchitecture required bone biopsy but the advance in imaging techniques have opened 
up many non-invasive options. 
High resolution(HR)-pQCT studies have documented smaller cross sectional radial and 
tibial bone area in T1D compared to controls (Heap et al. 2004, Bechtold et al. 2006, Saha 
et al. 2009b, Roggen et al. 2013), especially during childhood (Saha et al. 2009b) with 
normalisation before entering adulthood (Bechtold et al. 2007). In addition, HR-pQCT has 
enabled the distinction between the bone compartments demonstrating not only reduction in 
trabecular/cortical volumetric BMD in distal radius or tibia of individuals with T1D (Forst 
et al. 1995, Lettgen et al. 1995, Heap et al. 2004, Bechtold et al. 2006, Danielson et al. 2009, 
Saha et al. 2009b), but also lower cortical thickness with resultant decrease in estimated 
bone strength calculated using finite element analysis, which is a computerised numerical 
method to study such simulation. (Shanbhogue et al. 2015). These alterations had also been 
shown to be associated with glycaemic control and the presence of other microvascular 
diseases (Heap et al. 2004, Shanbhogue et al. 2015). T1D patients with microvascular 
complications were found to have lower trabecular thickness (radius p<0.01), greater 
trabecular separation (radius p<0.01, tibia p<0.01) and network inhomogeneity (radius 
p<0.01, tibia p<0.01) in comparison to T1D patients without microvascular complications 
(Shanbhogue et al. 2015). There was no difference noted in the cortical porosity between 
T1D, even in those with microvascular complications, compared to healthy controls 
(Shanbhogue et al. 2015). 
Magnetic resonance imaging (MRI) confirmed trabecular deficits with reduced trabecular 
bone volume and trabecular number with greater trabecular separation in young adults with 
T1D and further implicated the presence of microvascular complications, in particular 
retinopathy, with diabetic osteopathy (Abdalrahaman et al. 2015). Furthermore, using 
magnetic resonance spectroscopy (MRS), Granke et al found that the fracture toughness of 
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bone was negatively associated with pentosidine levels (Granke et al. 2015), a well-known 
AGE found in diabetic patients. 
Interestingly, bone histomorphometry and micro-CT of the biopsied specimens showed a 
reduction in trabecular bone volume, trabecular thickness and trabecular number with greater 
trabecular separation in T1D adults compared to healthy age and gender matched controls, 
with even more exaggerated aberrations in these parameters in the diabetics who have 
fractured, although these did not reach statistical significance (Armas et al. 2012). This could 
be due to the small sample size of the study (n=18 in each arm), but more importantly the 
selection bias of a cohort of T1D patients with very good glycaemic control [median HbA1c 
6.8% (6.3-8.3), or 51mmol/mol]. 
1.5.6.1.3 Bone marrow adiposity  
Given the association between marrow adiposity and morphometric vertebral fractures 
(Schwartz et al. 2013), the study of diabetic osteopathy and fracture risk will not be 
comprehensive without assessing the bone marrow compartment as well. There are only two 
studies to date looking at marrow adiposity in individuals with T1D, which demonstrated 
higher vertebral bone marrow fat in cases compared to healthy controls, although both were 
not statistically significant most likely due to the small sample sizes (Abdalrahaman et al. 
2015, Abdalrahaman et al. 2017). However, Abdalrahaman et al. demonstrated good 
correlation between glycaemic control and % fat fraction in individuals with T1D; those who 
had poorer glycaemic control had significantly higher vertebral bone marrow fat. In addition, 
the same group also showed that bone marrow adiposity also correlated significantly with 
total body and lumbar spine BMD. 
1.5.6.2 Bone imaging studies in T2D 
Contrary to T1D, adults with T2D have been found to have increased BMD, in the range of 
5-10% above an age-matched non-diabetic population (Bonds et al. 2006), with a reported 
pooled estimated LS BMD Z-score of 0.41 ± 0.01 and FN BMD Z-score 0.27 ± 0.01 
(Vestergaard 2007). A more recent meta-analysis substantiated this increased BMD ranging 
from 25-50% higher compared to non-diabetic controls at the hip and spine but not the 
forearm (Ma et al. 2012). Meta-regression from both meta-analyses showed that body mass 
index (BMI) was a major determinant for BMD. One meta-analysis found longer duration 
of disease to be associated with reduced BMD at the hip but not spine (Vestergaard 2007) 
with no association with glycaemic control, contradicted by the later meta-analyses which 
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showed a rather counterintuitive positive correlation between HbA1c and BMD levels (Ma 
et al. 2012).  The authors proclaimed considerable heterogeneity which may have influenced 
the associations found, stemming from large variation in types of study design, diagnostic 
definitions and individual characteristics including ethnicity. Importantly, BMD remains a 
significant predictor of fracture risk in T2D, that is independent of diabetes mellitus itself 
(Leslie et al. 2013).  
Interestingly, HR-pQCT showed that individuals with T2D have lower cortical vBMD and 
higher cortical porosity in distal radius compared with controls (Burghardt et al. 2010, Farr 
et al. 2014b). Trabecular vBMD was 10% higher in T2D patients with significantly increased 
trabecular thickness in the tibia compared to the non-diabetics (Burghardt et al. 2010). This 
suggests that in T2D the cortical bone compartment may be more affected and the higher 
trabecular mineralisation could account for the higher BMD seen in this population as 
assessed by DXA. However, two other studies did not find any cortical deficits in patients 
with T2D compared to non-diabetics except in the subgroup with microvascular 
complications (Shanbhogue et al. 2016) and in those with T2D who fractured (Patsch et al. 
2013a). MRI further confirmed increased cortical porosity in T2D patients (Pritchard et al. 
2012, Pritchard et al. 2013) with no difference in bone marrow adiposity between cases and 
controls (Baum et al. 2012, Patsch et al. 2013b, Kim et al. 2017). HbA1c was positively 
correlated with vertebral bone marrow adiposity (Baum et al. 2012). 
In summary, the available data suggests that T1D and T2D may have differential effects on 
the structural quality of bone although data are still scarce and somewhat controversial. 
There are limitations such as small sample sizes, different techniques to measure and 
interpret data and inadequate adjustment of confounders such as age, disease duration and 
metabolic status which may have affected the findings. 
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1.6 Approaches to investigating bone health 
There are a wide variety of methods for assessing bone properties. Non-invasive methods 
such as qualitative ultrasounds (QUS), dual energy X-ray absorptiometry (DXA), computed 
tomography (CT) and magnetic resonance imaging (MRI) are more commonly used, 
although the more invasive methods of bone turnover studies and histomorphometry can 
provide more functional information.  
1.6.1 Bone quantitative ultrasound (QUS) 
Quantitative ultrasound is a very attractive technique for the evaluation of skeletal status in 
a large population such as diagnosis of osteoporosis, as it is low cost, highly portable and 
free from radiation exposure (Gluer 1997). It is highly suitable for screening and follow-up 
in children as it is painless, fast to execute and completely free of contraindications which is 
ideal for compliance in the paediatric population (Baroncelli et al. 2001, McDevitt and 
Ahmed 2007). The velocity and degree of penetration of the sound waves provides two 
important measures in QUS; speed of sound (SOS, m/s) and broadband attenuation (BUA, 
dB/MHz). These measures do not directly measure bone mass, but provide information on 
apparent bone density, trabecular structure and bone elasticity (Gluer et al. 1994). The major 
limitation of this technique, however, is reproducibility with inferior precision compared to 
DXA bone densitometry (Naessen et al. 1995, Gluer 1997) as it is highly technician 
dependent and restricted to use only in superficial peripheral bones such as phalanges, 
metacarpals and calcaneus (Naessen et al. 1995, Baroncelli et al. 2001). 
1.6.2 Dual X-ray Absorptiometry (DXA) 
DXA has been available for clinical use since 1987 and is by far the most widely used 
technique for measuring bone density in clinical trials and epidemiological studies. This is 
done through the projection of two x-ray beams of different peak voltage over the bone area 
of interest which allows the soft tissue component to be subtracted generating the bone 
density values. It is a well standardised and easy to use technique with high precision 
(maximum acceptable precision error, 2-2.5%) and low radiation dose (0.5-35 µSv). 
Importantly, DXA BMD correlates well with biochemically determined bone strength 
(Ammann and Rizzoli 2003) and fracture risk with approximately 1.6 fold increase for every 
SD decrement in BMD irrespective of gender (Johnell et al. 2005, Cummings et al. 2006, 
Rivadeneira et al. 2007). DXA, however, has some pertinent disadvantages: Firstly, it is a 
2-dimensional measurement which gives areal BMD (g/cm2) rather than true volumetric 
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BMD (g/cm3). This is particularly crucial in growing children, when DXA will overestimate 
fracture risk in a child with smaller size who will have lower areal BMD than a normal sized-
individuals. Secondly, it does not distinguish between cortical and trabecular bone, hence 
provides limited information on bone quality; the reason why DXA BMD only explains 
approximately 70% of bone strength. In addition, DXA has limitations in measuring BMD 
in obese patients, older patients with bony degenerative changes or vascular calcifications 
(Tothill et al. 1997, Diederichs et al. 2011). 
1.6.3 Quantitative computed tomography (QCT) 
More advanced radiological modalities have enabled the assessment of bone macro- and 
microarchitecture using high resolution micro-computed tomography (µQCT), synchrotron 
radiation computed tomography (SRCT), peripheral quantitative computed tomography 
(pQCT) and magnetic resonance imaging (MRI).  
QCT is a three-dimensional non-projection imaging technique of assessing bone. The main 
advantages of QCT over DXA are that it provides (a) true volumetric BMD (mg 
hydroxyapatite /cm3), which is independent of body size hence better prediction of fragility 
fracture risks (Yu et al. 1995, Bergot et al. 2001) and (b) information on bone architecture 
distinguishing between cortical and trabecular bones (Black et al. 2003). As multidetector 
CT (MDQCT) can specifically detect changes in the more metabolically active trabecular 
bone, it is a more sensitive discriminator of BMD changes than DXA (Heuck et al. 1989, 
Graeff et al. 2007). The incorporation of finite element analysis (FEA) modelling into non-
invasive bone further improved QCT estimation of bone strength and stiffness, 
differentiating the degree of cortical versus trabecular loss providing insight into the 
pathophysiology of vertebral fractures with aging (Christiansen et al. 2011). The major 
limitations of QCT is the high radiation exposure (60-2900 μSv) (Table 1.7), rendering it 
unsuitable for the paediatric population or any longitudinal studies limiting its current use to 
ex-vivo or pre-exisiting in vivo cohort studies only. Specifically in relation to 
microarchitecture, MDQCT scanners are restricted by the spatial resolution of 250-300 μm, 
which is larger than the thickness of a trabecula 50-200 μm (Issever et al. 2010). 
High resolution peripheral QCT (HR-pQCT) confers better spatial resolution (~120 μm) and 
a smaller effective radiation dose (<3 μSV). With improved spatial resolution, the trabecular 
spacing (400-800 μm) and trabecular thickness can be more accurately assessed (Boutroy et 
al. 2005), although the latter is still subjected to a degree of partial volume averaging. In 
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addition, pQCT can also give information on bone geometry and muscle cross sectional area, 
enabling the study of the interaction between muscle and bone systems (Schoenau et al. 
2000, Rauch et al. 2001, Bajaj et al. 2015). The main limitations of HR-pQCT are that it 
requires a dedicated scanner and is limited to studying the peripheral skeleton such as radius 
and tibia. This is however particularly useful for examining cortical bone changes in 
metabolic bone disorders as the distal radius contains more cortical bone than the vertebral 
body. As HR-pQCT scanners have high-resolution, these examinations require a longer 
scanning time (3-10mins) than QCT (in seconds) and are more prone to motion artifacts, 
especially in children.  
Table 1.7 Radiation dose exposure based on different X-ray based imaging techniques 
Test Effective 
Dose (µSv) 
Equivalent Period of 
Background Radiation* 
Chest X-ray (single anterior posterior) 20 3 days 
DXA (hip and spine) 3 <1 day 
2D QCT spine, scout image and 3 slices of 
10mm thickness 
60 1 week 
3D multidetector QCT spine, L1-L2, pitch 1 1500 6 months 
3D multidetector QCT hip, pitch 1 2900 1 year 
HR-pQCT <3 < 1 day 
Roundtrip transcontinental airplane flight 60 1 week 
*Based on the calculation of natural background radiation at sea level of 3000 µSv per year  
(rounded up to the nearest day). DXA dual absorptiometry, QCT quantitative CT, HR-pQCT high 
resolution peripheral quantitative CT, 2D two-dimensional, 3D three-dimensional 
[Modified from (Damilakis et al. 2010)] 
1.6.4 Magnetic resonance imaging (MRI) 
MRI is emerging as a more comprehensive tool in the assessment of bone health given its 
capability of quantifying all the various bone compartments including bone macro- and 
microarchitecture without the burden of ionising radiation. This lends itself well for 
repeatability in longitudinal studies, especially in the paediatric population. It can directly 
acquire images in any plane de novo and has the potential to derive functional information 
to better understand patho-mechanisms of impaired bone health. From a set of contiguous 
image slices the 3-dimensional structure of bone can be reconstructed and measures of the 
cortical and trabecular bone microarchitecture can be obtained, including topology (eg, plate 
vs rod character of the trabeculae) of the latter (Wehrli 2007). The spatial resolution 
achievable is 200-300 µm, making it impossible to delineate individual trabeculae. This 
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inferiority to HR-pQCT however, is definitely outweighed by the ability of MRI to image 
more proximal and larger joints such as proximal tibia and femur; commonly implicated in 
fragility fractures. With the addition of FEA as described above, the mechanical properties 
of bone such as stiffness, elasticity and predicted strength can be assessed (Wehrli 2007, 
Magland et al. 2012). Bone mineral density can also be measured which strongly correlates 
to the BMD obtained from QCT (Hong et al. 2000, Ho et al. 2013).  
The current main attraction of MRI is its ability to evaluate the bone marrow compartment, 
specifically looking at the bone marrow fat content with or without spectroscopy (Li et al. 
2011, Bandirali et al. 2015). There has been a growing interest in the effects of bone marrow 
adiposity on bone health because of the shared stem cell lineage between osteoblasts and 
adipocytes (Paccou et al. 2019). Importantly, vertebral bone marrow adiposity has been 
shown to be an independent predictor of fracture in osteoporotic women (Wehrli et al. 2000). 
Furthermore, MRI is also the only modality available for imaging bone matrix, the 
collagenous non-mineralised component of bone onto which the mineralised component of 
bone is deposited (Cao et al. 2008, Cao et al. 2010, Wu et al. 2010). Its major drawbacks 
include the high cost, longer scanning time (20-30mins) and specific contraindications.  
1.6.5 Bone histomorphometry 
Bone biopsy can provide both qualitative and quantitative information on bone tissue, the 
latter referred to as bone histomorphometry. It is the only available method to study bone 
cell function within the in vivo structural content to understand the patho-mechanisms of 
metabolic bone diseases. Standard histomorphometric analyses measure structural 
parameters, static bone formation and resorption parameters, and dynamic formation 
parameters, as summarised in Table 1.7 (Rauch 2009). The bone specimens should be 
horizontal, full thickness biopsy sample of uncrushed bone containing two cortices separated 
by a trabecular component. This can be theoretically from any sites although transiliac 
samples are most commonly used, due to limited reference data for other sites in children 
(Glorieux et al. 2000, Rauch 2003). This technique is also of particular importance for 
paediatric use as the histomorphometric results are not directly influenced by the growth 
process (Parfitt et al. 2000). The major drawbacks of histomorphometry are the invasive 
procedure with prior bone labelling, labour intensive process and need for special equipment 
and expertise (Rauch 2009). 
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Remodelling activity is indeed elevated in young children, decreases until the age of 8 or 9 
years, and increases again during puberty. After the age of puberty, remodelling activity 
declines into the much lower adult range (Parfitt et al. 2000). 
Table 1.8 Commonly used bone histomorphometric parameters 
Structural parameters • Core width (mm) 
• Cortical width (µm) 
• Bone volume/tissue volume (%) 
• Trabecular thickness (µm) 
• Trabecular number (mm-1) 
 
Static formation parameters • Osteoid thickness (µm) 
• Osteoid surface/bone surface (%) 
• Osteoid volume/bone volume (%) 
• Osteoblast surface/bone surface (%) 
• Wall thickness (µm) 
 
Dynamic formation parameters • Mineralising surface/bone surface (%) 
• Mineral apposition rate (%) 
• Mineralisation lag time (days) 
• Bone formation rate/bone surface  
 
Static resorption parameters • Eroded surface/bone surface (%) 
• Osteoclast surface/bone surface (%) 
 
[Modified from (Rauch 2009)] 
1.6.6 MicroRNAs 
In addition to biochemical markers of bone turnover, recent studies have found a crucial role 
for miRNAs in bone development and homeostasis (Kim and Lim 2014). MicroRNAs 
(miRNAs) are small non-coding RNAs that regulate gene expression at a post-transcriptional 
level, either by suppressing translation or inducing mRNA degradation (Rodriguez et al. 
2004). They are important regulators and modulators of cell differentiation, proliferation and 
apoptosis as a single miRNA can target up to 100 distinct mRNAs, hence controlling the 
expression of entire gene networks (Baek et al. 2008). Dysregulation of miRNA have been 
associated with osteoporosis and shown to be discriminative of fragility fractures (Li et al. 
2009, Seeliger et al. 2014). Heilmeier et al. discovered specific miRNAs involved in 
osteogenesis, adipogenesis, or both and demonstrated that these circulating miRNAs in 
combination were able to differentiate the fracture status in post-menopausal osteoporosis 
and T2D women (Heilmeier et al. 2016).  
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1.7 Metformin 
Metformin is a biguanide class of drug, well known as the most frequently prescribed first 
line anti-diabetic medication for Type 2 diabetes (T2D) (Nathan et al. 2009). It maintains 
glucose homeostasis by supressing liver glucose production and increase peripheral glucose 
uptake (Bailey and Turner 1996). Metformin is considered an insulin-sensitizer as it lowers 
glycaemic levels without increasing insulin secretion (Garber and Samson 2004). In 
addition, metformin has also been shown to have cardiovascular benefits including 
improvement in lipid profile, improved endothelial dysfunction with lower intravascular 
thrombotic risk. However, despite being around for over 50 years, the precise mechanism of 
action of metformin remains unclear. 
1.7.1 Metformin action in the liver 
Several studies have shown that metformin can act via activation of the enzymes tyrosine 
kinase (Dominguez et al. 1996) and AMP-activated protein kinase (AMPK) (Zhou et al. 
2001, Musi et al. 2002). AMPK activation phosphorylates the enzymes involved in several 
hepatic biosynthetic pathways such as acetyl-CoA carboxylase, hydroxymethylglutaryl-
CoA reductase, glycogen synthase and endothelial nitric oxide synthase, which results in a 
decrease in glucose production, cholesterol and triglyceride synthesis from the liver (Zhou 
et al. 2001). This has been the widely accepted mechanism of action until genetic loss of 
function experiments with AMPK deficient hepatocytes (Foretz et al. 2010) challenged it. 
Since then, studies have put forward different mechanisms of action by which metformin 
suppresses gluconeogenesis in hepatocytes through inhibition of (i) the mitochondrial 
respiratory chain complex I (El-Mir et al. 2000) and (ii) a specific mitochondrial enzyme 
glycerophosphate dehydrogenase (mGPD) (Madiraju et al. 2014), which consequently 
decrease hepatic glucose output. Miller et al also discovered another novel action of 
metformin in glucose homeostasis by blocking glucagon-dependent glucose output from 
hepatocytes by reducing production of cyclic AMP and protein kinase A activity (Miller et 
al. 2013).  
1.7.2 AMPK 
AMPK has been a widely studied subject in the last two decades owing to its importance as 
a master sensor of cellular energy status. It is a heterotrimeric serine/threonine kinase 
comprising of α catalytic and regulatory β and γ subunits (Hardie et al. 1998). The α catalytic 
subunit contains the conventional serine/threonine protein kinase domain as well as the 
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autoinhibitory sequences, the β subunit contains a glycogen-binding domain and a tethering 
domain for α and γ subunits, while the γ subunit contains four cystathionine-β-synthase 
sequence repeats, which are responsible for the binding of regulatory nucleotides (McBride 
and Hardie 2009, Oakhill et al. 2009). Mammals express two α (α1, α2), two β (β1, β2) and 
three γ subunits (γ1, γ2, γ3) in 12 possible combinations of AMPK heterotrimer in a tissue 
specific manner, allowing for different subcellular localisation and regulation (Hardie 2007). 
The predominant isoforms in most cells are α1, β1 and γ1, although hepatocytes  
significantly expresses α2 (Woods et al. 1996), whereas skeletal and cardiac muscles also 
express α2, β2, γ2 and γ3 (Stapleton et al. 1996, Thornton et al. 1998, Cheung et al. 2000). 
The degree of AMP-dependence is highly reliant on the α and γ subunits, with stimulation 
varying from only 50% for the α1γ3 complexes to more than 5-fold for the α2γ2 combination 
(Cheung et al. 2000). Also the α2 complexes are enriched within the nucleus whilst α1 
complexes are largely cytoplasmic (Salt et al. 1998, Turnley et al. 1999). As the name 
suggests, AMPK is activated when AMP binds to the regulatory γ subunit, which promotes 
phosphorylation of Thr-172 by the upstream kinases (e.g. LKB1, CAMKKβ) within the α 
catalytic subunit and protects Thr-172 from dephosphorylation by protein phosphatases 
(Shaw et al. 2004, Hawley et al. 2005). 
In mammals, AMPK is functionally important as a regulator of cellular energy homeostasis, 
akin to a thermostat for temperature. Increase in cellular AMP to ATP ratio, a signal of 
cellular energy compromise, will activate AMPK to switch on energy-generating (catabolic) 
pathways and switch off energy-consuming (anabolic) pathways that are not essential for 
short term cell survival in order to restore the AMP/ATP ratio (Kahn et al. 2005, Hardie 
2007). AMPK is switched on by cellular stresses that either interfere with ATP production 
(e.g. hypoxia, glucose deprivation or ischaemia) (Kudo et al. 1995, Marsin et al. 2000) or 
by stresses that increase ATP consumption (e.g. muscle contraction and exercise) (Winder 
and Hardie 1996, Fujii et al. 2000). Specifically, in pancreatic β-cells low glucose activates 
AMPK in the same range of concentrations over which it inhibits insulin release (Salt et al. 
1998). The AMPK activation by exercise is dependent on both the duration and the intensity 
of the exercise (Rasmussen and Winder 1997, Stephens et al. 2002). It is also activated by 
hormones that act via Gq-coupled receptors, and by leptin and adiponectin. Hence, AMPK 
is able to regulate many metabolic pathways in peripheral tissues by phosphorylating 
different metabolic enzymes involved in lipid (Hardie and Pan 2002), glucose and glycogen 
metabolisms. 
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Pharmacologically, several chemical compounds are known AMPK activators, such as 5-
aminoimidazole-4-carboxamide riboside (AICAR) and metformin. AICAR is taken up into 
cells and converted to monophosphorylated nucleotide 5-aminoimidazole-4-carboxamide-1-
D-ribofuranosyl-5’-monophosphate (ZMP), which mimics all the activating effects of AMP 
on the AMPK system without disturbing the cellular levels of AMP, ADP or ATP (Corton 
et al. 1995). Metformin has also been found to activate AMPK (Zhou et al. 2001) by a 
mechanism that involves phosphorylation of the upstream kinase but interestingly, with no 
alteration in cellular AMP:ATP ratio (Fryer et al. 2002, Hawley et al. 2002). There are not 
many AMPK inhibitors. Compound C (also called dorsomorphin) is the only available cell-
permeable AMPK inhibitor, which has been shown to rescue the proliferative actions of 
AICAR and metformin (Isakovic et al. 2007). It is however, a non-selective (low specificity) 
AMPK inhibitor as it has also been found to inhibit BMP (Yu et al. 2008) and several other 
kinases (Vogt et al. 2011). 
1.7.3 The role of AMPK and metformin in bones 
In the last decade, there have been novel findings that AMPK signalling pathway plays a 
role in bone physiology. On the cellular level, AMPK subunit isoforms are expressed in 
bones. The α1 subunit is the most dominant isoform in primary osteoblasts, osteoblastic cell 
lines, osteoclasts and bone tissue (Kim et al. 2008, Kasai et al. 2009, Quinn et al. 2010, Shah 
et al. 2010), in contrast to the very low α2 subunit expressions. Both β1 and β2 subunits are 
equally expressed, whilst the γ1 is the preferential γ form with minimal/non-existent γ2 and 
γ3 expressions. 
Many in vitro and in vivo studies have shown a positive effect of AMPK activation on bone 
cell activities. AMPK activation by AICAR and metformin on mouse pre-osteoblasts 
MC3T3-E1 showed a dose-dependent increase in cell proliferation, type 1 collagen 
production, alkaline phosphatase activity and mineral deposition (Cortizo et al. 2006, 
Kanazawa et al. 2007). Similarly, AMPK activation in rat primary osteoblasts with AICAR 
and metformin demonstrated increases in cell proliferation (Zhen et al. 2010), AP activity 
(Shah et al. 2010, Zhen et al. 2010), increase in mineralisation of bone matrix and bone 
nodule formation (Utting et al. 2006, Shah et al. 2010, Zhen et al. 2010),with similar dose-
dependency. The role of AMPK activation in bone formation is further reinforced when co-
treatment of pre-osteoblast with AICAR and compound C demonstrated suppression of the 
stimulatory effect of AICAR on bone formation (Shah et al. 2010). Molinuevo et al. 
demonstrated that metformin also has positive osteogenic effect on in vitro and in vivo rat 
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bone marrow progenitor cells, mediated through AMPK activation (Molinuevo et al. 2010). 
This study also suggested for the first time that metformin may have some effect on 
suppressing adipogenesis. There are however studies with contradictory findings of 
decreased AMPK activity during osteoblast differentiation (Kasai et al. 2009, Chen et al. 
2017, Chava et al. 2018). 
Through AMPK signalling pathway, adiponectin was demonstrated to suppress bone 
resorption by inhibiting TNFα-induced osteoclastogenesis (Yamaguchi et al. 2008). AMPK 
activation via metformin also stimulated OPG and inhibited RANKL mRNA and protein 
expression in osteoblasts, reducing osteoclast differentiation and activity (Mai et al. 2011).  
The most compelling evidence for the role of AMPK signalling in bone mass regulation 
came from genetic studies. Mice with deletion of AMPKα2 subunit demonstrated no change 
in tibial bone mass, in line with the low expression of α2 subunit in bone. In contrast, 
AMPKα1 knock-out (KO) mice showed both significant cortical and trabecular bone deficits 
on imaging, with 40% less trabecular volume, 30% less trabecular number and 12% 
reduction in trabecular thickness and compromised cortical indexes (Shah et al. 2010) 
compared to wild-type (WT) mice. Similarly with AMPKβ1 or β2 KO mice, trabecular bone 
density and mass were reduced although no differences were noted in osteoblast and 
osteoclast numbers (Quinn et al. 2010), suggesting a more significant impact of AMPK 
activation on bone cell activities than numbers alone. 
The complex signalling pathways involved in the commitment and differentiation of MSC 
towards adipocytes or osteocytes have been eluded to in section 1.3.2.3., but the mechanisms 
linking AMPK activation to bone cell differentiation and bone mass however remain poorly 
understood. Studies have shown a possible cross talk with Wnt/β-catenin signalling in the 
regulation of osteoblast differentiation (Zhao et al. 2011) where activation of AMPK by 
AICAR/metformin promoted β-catenin transcription (Zhao et al. 2011) and marked increase 
in Runx2 expression with no effects on PPARγ (Molinuevo et al. 2010). The involvement 
of melavonate pathway for both osteoblast and osteoclast differentiation (Kanazawa et al. 
2009) has also been shown. Further studies to investigate the differentiation of MSCs and 
better define the underlying molecular mechanisms involved would be needed, in particular 
the link between AMPK and PPARγ.  
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1.8 Aims of the thesis 
This thesis was designed to understand the effects of T1D on the bone health of children 
with the condition, given the current knowledge of diabetic osteopathy in adults.  
The primary hypothesis is that: 
1. Children with T1D have deficit in bone microarchitecture, as determined by high 
resolution MRI, compared to children without T1D 
The secondary hypotheses included: 
1. Children with T1D have increased bone marrow adiposity, as determined by magnetic 
resonance spectroscopy, compared to children without T1D 
2. Poorer diabetes control, as measured by HbA1c, is positively correlated to bone 
microarchitecture deficit and increase in bone marrow adiposity 
3. Metformin can promote osteogenesis and prevent adipogenesis by acting on mesenchymal 
stem cells.  
 
By studying the problem at a cellular and clinical level, the intention is to be able to better 
define the problem, if any, in children and suggest a mechanistically sound therapeutic 
approach. 
The principle aims of the thesis are to: 
1. Determine if bone health is impaired in children with T1D 
2. Study the bone microarchitecture and bone marrow adiposity of children with T1D 
3. Identify the mechanisms of action of metformin, and its potential use as a bone therapeutic 
agent  
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2 Methodology 
2.1 Introduction 
This chapter details the methodology adopted for the multi-modality assessment of bone 
health in the clinical study in Chapter 4 of this thesis. The modalities involved are MRI of 
the right knee, MRS of the lumbar spine, DXA scan of total body, hip and lumbar spine, and 
the biochemical assays of bone markers of turnover. Information on the image acquisition 
and analysis protocols are provided for all imaging studies. Additionally, the methodology 
used in the laboratory studies in Chapter 5 of this thesis is also described.  
Clinical studies: Imaging and Biochemistry  
2.2 MRI  
2.2.1 Principles of MRI 
The early concept of MRI scanning first appeared in medical use in the late 1960s when 
Raymond Damadian discovered that malignant tissue had different nuclear magnetic 
resonance (NMR) parameters to normal tissue. The ability to tissue characterise using a 
magnetic scanner allowed him to produce the image of a rat tumour in 1974 (Damadian and 
Cope 1974) before pioneering the first super conducting magnetic scanner in the late 1970s 
to produce the first image of the human body (Goldsmith et al. 1977). In its most basic, an 
MRI scanner comprises a couch for the patient to lie on, a large magnet, a radiofrequency 
(RF) coil to transmit and receive the RF waves and a processor which converts the received 
RF signals into an MRI image.  
Fundamentally, MRI is based on the intrinsic magnetic properties of atomic nuclei. All 
atomic nuclei consist of protons and neutrons which spin about its own axis. In nuclei with 
an even number of protons and neutrons, half spin in one direction and the other half in the 
opposite direction resulting in no net spin. Nuclei with an odd number of protons (positively 
charged) and neutrons, such as 1H, 13C, 19F, 23Na, 31P, however, have a net spin (motion), 
making them important in MRI as they produce a small magnetic field (Westbrook et al. 
2011, Brown et al. 2014).  
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Hydrogen nuclei are ideal in clinical MRI as they are the most abundant element in the 
human body present within water (H2O) and fat (CH3 etc.) and their solitary protons give 
them the largest relative magnetic moment. MRI uses a strong external magnetic field (B0) 
to align these magnetic moments in the tissues of the body. In the absence of an applied 
magnetic field, the magnetic moments of these hydrogen nuclei are randomly orientated 
(Figure 2.1A). When placed in a strong magnetic field, two things happen to the hydrogen 
nuclei: 
1. They align with the magnetic field, in one of two ways: parallel or anti-parallel 
(Figure 2.1B). The factors affecting the direction of alignment are determined by the 
strength of the external magnetic field (in unit Tesla) and the thermal energy of the 
nuclei. Hydrogen nuclei which do not possess enough energy to oppose the magnetic 
field known as the low-energy nuclei align parallel to the magnetic field, whilst the 
high-energy nuclei with sufficient energy to oppose the magnetic field align anti-
parallel. There are always fewer higher energy nuclei than low-energy nuclei, 
resulting in a small excess lined up parallel to B0 constituting the net magnetisation 
vector (NMV) (Figure 2.1B). The magnitude of NMV is larger at higher field 
strengths as fewer nuclei possess enough energy to oppose the magnetic field hence 
more align parallel to B0, resulting in improved signal. 
2. They rotate or “precess” around the axis of the magnetic spin at a special frequency 
called the Larmor frequency, which is dependent on the strength of the external 
magnetic field. 
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Figure 2.1 Motions in the atoms (hydrogen nuclei in clinical MRI). The magnetic moments of the 
spinning hydrogen nuclei are normally randomly aligned as shown in A. When an external magnetic 
field is applied (B0), the magnetic moments of the hydrogen nuclei will do one of two things: i) Align 
parallel, or anti-parallel to B0 depending on the strength of B0 applied, as shown in B. Hydrogen nuclei 
which absorb enough energy to oppose the magnetic field will lie anti-parallel to B0. There are usually 
more low energy than high energy nuclei resulting in a net magnetic moments, also known as net 
magnetisation vector (NMV) marked in red arrow. ii) Precess around B0 (marked with blue arrow). 
The application of B0 accords the already spinning hydrogen nucleus an additional spin along the 
precessional path as shown in C. [Adapted from (Westbrook et al. 2011)] 
The next pre-requisite to obtain an MRI image is a radiofrequency (RF) pulse which is where 
the resonance comes from in the name magnetic resonance imaging. When a RF pulse with 
a frequency matching exactly the precessional frequency of the MR active nuclei is delivered 
in a perpendicular direction to B0, the nucleus gains energy from the RF pulse and resonates. 
The application of a RF pulse that causes resonance is termed excitation, which results in 
the net magnetisation (NMV) moving out of alignment from B0, lying at an angle to it (flip 
angle) (Figure 2.2). The magnitude of the flip depends on the amplitude and duration of the 
RF pulse. The flip angle is usually 90 degrees, resulting in the NMV deviating from the 
longitudinal plane into the transverse plane (Figure 2.2). 
 
Figure 2.2 Excitation phase. Transfer of net magnetisation vector (NVM) from the longitudinal 
plane (Y) to the transverse plane (X) when RF pulse is applied during the excitation phase. 
  
A B C 
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When the RF pulse is switched off, the hydrogen nuclei give up the absorbed energy and the 
NMV returns, or ‘relaxes’ back to the longitudinal plane (B0). The relaxation process can 
be divided into 2 parts called T1 and T2 relaxation, which are two independent processes 
which occur simultaneously (Blink 2004). T1 relaxation, also known as the spin-lattice 
relaxation, describes the recovery of the longitudinal magnetisation when the nuclei lose 
their energy to the surrounding environment (lattice). T2 relaxation, also known as the spin-
spin relaxation, describes the decay of transverse magnetisation due to the magnetic fields 
of the neighbouring nuclei interacting with each other (Figure 2.3). 
 
Figure 2.3 T2 relaxation (or spin-spin relaxation) phase. A) Immediately after the 90° RF pulse, 
the net magnetisation vector all lie in the transverse plane, X, with all hydrogen nuclei vectors rotating 
in the X-Z plane around the Y-axis. The vectors are in-phase as they all point in the same direction. 
B) Once the RF pulse is switched off, T2 relaxation begins with decay of the transverse magnetisation 
as the magnetic fields of each hydrogen nuclei affect one another. The nuclei will start to rotate at 
different speeds and so the vectors no longer all point in the same direction. This is called 
‘dephasing’. C) Over time, T2 decay progresses and more dephasing happens until there is no phase 
coherence left, ie. not one vector is pointing in the same direction anymore as seen in D [Adapted 
from (Blink 2004)]. 
The time taken for T1 and T2 relaxation to occur varies between tissues, and so at a given 
time t, the signal intensity available to create the MRI image will be different for each tissue 
(Figure 2.4). T1 relaxation time is the time it takes 63% of the longitudinal magnetisation to 
recover in the tissue, whilst T2 relaxation time is the time it takes for 63% of the transverse 
magnetisation to be lost, i.e. 37% remain (Figure 2.4A and Figure 2.4B, respectively). Fat 
has a short T1 and T2 time, respectively, due to its inherent low energy state and large lipid 
molecules which are closely packed together (Figure 2.4C and Figure 2.4D). Water, on the 
other hand, has a high inherent energy so does not easily give up energy into its lattice from 
the hydrogen nuclei so the T1 time is long (Figure 2.4C). The T2 time of water is also long, 
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compared to fat and muscle, as the molecules are spaced apart and hence spin-spin 
interaction is less likely to occur (Figure 2.4D). 
 
Figure 2.4 T1 and T2 relaxation times and their respective curves for different tissues. A)T1 
relaxation time is the time taken for 63% of the longitudinal magnetisation (MY) to recover whilst B) 
T2 relaxation time is the time taken for 63% of the coherent transverse magnetisation to be lost (ie 
37% remaining)  T1 and T2 times vary for the different tissues with the T1 times for fat, muscle and 
fluid shown in C) whilst the T2 times shown in D) [Adapted from (Ridgway 2010, Westbrook et al. 
2011)] 
The magnitude and timings of the RF pulses constitutes a pulse sequence. Figure 2.5 shows 
a typical MRI pulse sequence, specifically a gradient echo pulse sequence 
(http://www.revisemri.com/questions/pulse_sequences/se_ge_differences.). The repetition 
time (TR) is the time between two RF pulses which determines the amount of longitudinal 
relaxation (T1) that is allowed to occur before the next excitation. The echo time (TE) is 
the time from the application of the RF pulse to the peak of the signal induced in the coil 
which determines the amount of decay of transverse magnetisation (T2 relaxation) prior to 
the signal being read. The signal which is the energy shed by the nuclei during the relaxation 
processes are retrieved by a receiver coil (some transmit coil can also act as receiver). In 
order to orientate the signals received into a coherent 3-dimensional image, a field of view 
(FOV) is placed over the body part to be imaged and this is ‘divided’ into volume element, 
also known as voxels. Three gradient wire coils are placed within the magnet to create 
additional graduated magnetic fields which are activated at different times to encode the 
C 
D 
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signals: slice-encoded axially head-to-toe (Gs), phase-encoded anterior-posteriorly (Gp) and 
frequency-encoded to determine left-right (Gf) (Figure 2.5) into an image (Blink 2004). 
 
Figure 2.5 Example of an MRI pulse sequence diagram.  The RF pulses are shown on the top 
line, and the magnetic field gradients are shown on the lines marked Gs, Gp, and Gf, where the 
subscripts refer to the slice, frequency and phase directions. The important timing parameters shown 
in the pulse sequence diagram are the repetition time (TR) and the echo time (TE). TR is the time 
between subsequent applications of the pulse sequence, and TE is the time between the application 
of the first RF pulse and the measurement of the signal in the transverse plane [Adapted from 
(http://www.revisemri.com/questions/pulse_sequences/se_ge_differences.)]. 
Manipulation of the pulse sequence parameters together with the magnetic field gradients 
used forms the basis of contrast generation in MRI scanning. The factors that affect image 
contrast in diagnostic imaging are usually divided into intrinsic or extrinsic parameters, the 
former of which cannot be changed as they are inherent to the biological tissues (eg T1 and 
T2 times). Extrinsic parameters are those that can be altered such as the pulse sequence 
parameters (eg TR, TE, flip angle etc) which can be optimised by varying the acquisition 
parameters. T1-weighted imaging have short TR, characterised by bright fat and dark water.  
T2-weighted imaging have long TE and is characterised by bright water and dark fat. Other 
tissues will have an intensity of somewhere in between in either. 
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An optimal image quality, is dependent not only on good image contrasts but also on several 
other factors, including: 
• signal-to-noise (SNR) ratio 
• spatial resolution, and 
• scan time. 
The signal-to-noise ratio and spatial resolution are both dependent on voxel volume which 
itself is controlled by: 1) slice thickness, 2) image matrix and 3) field of view (FOV). Care 
needs to be exercised as one trades off the other. Increasing slice thickness will increase 
voxel volume resulting in enhanced SNR but this will compromise spatial resolution. Larger 
voxel makes it harder to resolve small structures well as the individual signal intensities are 
averaged together resulting in a partial volume effect. Scan time should be as short as 
possible to reduce movement artefacts which inevitably degrades image quality. 
Conventionally, MRI is seen as the imaging modality for soft tissues but technical advances 
in the last 10-15 years have significantly improved the utility of magnetic resonance in the 
musculoskeletal system with high resolution MRI and specialised pulse sequence 
development (Young and Bydder 2003). Escalation from 1.5T to 3.0T static magnetic field 
strength has improved the signal-to-noise ratio with better image quality, as with innovation 
in the array of detector coils available. The development of high resolution MRI has also 
markedly facilitated imaging of solid structures, especially bone, where RF with rapid switch 
from excitation of spins to detection of signals allow high signal levels to be obtained with 
short T2 (Gatehouse and Bydder 2003). An example MRI image of the tibia is shown in 
Figure 2.6, which illustrates the differences in signal intensities between bone, bone marrow, 
muscle and subcutaneous fat. The signal intensities of bone and fatty marrow are very 
different, which makes MRI ideal for imaging trabecular structure. 
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Figure 2.6 Sagittal image of MRI tibia. The difference in signal intensities between bone, bone 
marrow, muscle and subcutaneous fat is demonstrated. 
2.2.2 Proximal Tibia Imaging 
Imaging was performed on a 3 Tesla (T) Siemens MAGNETOM Prisma MRI scanner 
(Siemens, Erlangen, Germany) using a transmit/receive (Tx/Rx) extremity coil for the knee. 
The MR images were then pre-processed, coded and analysed using MATLAB (Mathworks 
Inc, San Mateo, CA, USA) software.  
2.2.2.1 Acquisition 
The participants were positioned supine with legs extended throughout the scan. Ear plugs 
were provided for noise minimisation and comfort. MRI images of the proximal tibia were 
acquired using an extremity coil positioned over the right knee. The knee was further 
immobilised with additional paddings placed within the coil itself. Three localiser scans were 
initially performed in the sagittal, coronal and axial planes to identify the region of interest 
(ROI) using a T1-weighted spin-echo sequence (Figure 2.7A-C). Twenty axial micro-MRI 
images (0.4mm thickness) of the metaphysis were collected, with the first slice positioned 
immediately distal to the epiphyseal growth plate, and subsequent slices positioned distal to 
that. The TrueFISP (true fast imaging with steady state precession) pulse sequence with the 
parameters shown in  
Table 2.1, was used to provide a 3D volumetric data set of isotropic resolution in the axial 
plane (Figure 2.7D). The in-plane spatial resolution achievable at 200µm can resolve larger 
trabeculae (usually 78-200µm), while the lower spatial resolution in the slice direction at 
400µm will contribute significantly to the partial volume effect. 
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Figure 2.7 Image acquisition of proximal tibia MRI.  Initial localiser scans in sagittal (A), coronal 
(B) and axial (C) views and a representative slice of the axial images obtained (D). 
Table 2.1 TrueFISP Pulse sequence parameters for imaging of the proximal tibia 
Parameter Value 
Resolution (mm3) 0.2 x 0.2 x 0.4 (slice thickness) 
Echo time [TE] (ms) 4.69 
Repetition time [TR] (ms) 10.83 
Flip angle (o) 60 
Number of averages 15 
Field of View (mm2) 100 x 100 
Matrix size 448 x 448 
Number of slices 20 
Bandwidth (Hz/pixel) 189  
Scan time (mins) 10 
 
  
B 
C 
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D 
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2.2.2.2 Image Pre-Processing  
Prior to analysis, images were imported into and pre-processed in MATLAB to improve the 
image quality and enable better quantification.  
a) Sharpening Filter 
A sharpening filter was applied to the trabecular bone image to increase the contrast along 
the edges where the different colours meet, resulting in a sharper image. The ‘unsharp 
 
Figure 2.8 MRI axial image before (A) and after (B) application of sharpening filter. 
 
masking’ technique in the analysis software sharpened the image by subtracting a blurred 
(unsharp) version of the image from the original one. The use of a sharpening filter, however, 
does not compensate for movement artefact. An example of an image before and after the 
use of a sharpening filter is shown in Figure 2.8 
b) Low-pass filter 
A low-pass filter was then applied to correct for bone marrow inhomogeneity in paediatric 
images, due to the physiological conversion of yellow to red marrow in children (see Chapter 
1, section 1.2.4). This step is crucial as without which the darker regions of the marrow can 
be wrongly assigned as bone by the analysis software in the binarisation stage (see section 
2.2.2.3a) which will affect the quantitative results. Figure 2.9 shows an image before and 
after correction for bone marrow inhomogeneity, and the corresponding binarised images. 
A B 
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Figure 2.9 Paediatric MRI image before (A) and after (B) application of a low-pass filter to 
correct for bone marrow inhomogeneity, and the corresponding binarised images (C and D). 
Binarisation is where the image is being assigned to either ‘bone’ or ‘marrow’ before quantification. 
2.2.2.3 Image Analysis  
After filtering, the images were coded and analysed using MATLAB based on a method 
previously described by Majumdar et al., to give measures for apparent bone volume to total 
volume ratio (appBV/TV), apparent trabecular number (appTbN), apparent trabecular 
thickness (appTbTh) and apparent trabecular separation (appTbSp) (Majumdar et al. 1997). 
Validation of the software was performed using a custom-made phantom as described 
previously, with high intra-operator, inter-operator and inter-scan repeatability (McComb et 
al. 2014b). 
Five image slices (Slice 9, 10, 11, 12 and 13 out of the 20 slices) per participant were 
analysed and the mean taken, based on a separate study carried out by our group to determine 
the feasibility of partial image analysis in yielding a representative estimate of trabecular 
bone microarchitecture by high-resolution MRI (detailed in Chapter 3). 
a) Image Segmentation/Binarisation 
In the filtered MRI images, bone appeared dark (low signal intensity) while fatty marrow 
was bright (high signal intensity) (Figure 2.10B). Using a graphics cursor, the region of 
interest (ROI) in each axial slice was manually drawn along the trabecular-cortical boundary 
A 
C D 
B 
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to ensure the analysed ROI consisted only of the trabecular bone and bone marrow (Figure 
2.10C). Once defined, the ROI was displayed in reverse grey scale for ease of visualisation, 
where trabecular bone has a high signal intensity as the cortical rim whilst bone marrow has 
a low intensity. Muscle tissue has an intermediate signal intensity. 
The image was then thresholded and binarised, where by each pixel was assigned as either 
‘bone’ or ‘marrow’ (binarisation) using a standardised method of image thresholding (Figure 
2.10D) (Majumdar et al. 1995, Majumdar et al. 1997). A histogram of the signal intensities 
in the ROI was plotted and the mean signal intensity (IROI) of the ROI was obtained Figure 
2.10E). Due to the thickness of the image slices exceeding the dimension of trabecular bone, 
each pixel in the image may not correspond to only one kind of tissue i.e., either bone or 
marrow but may contain a mixture of the two tissues in varying degree (partial volume 
effect). Consequently, the histogram of the signal intensities, did not have two individual 
peaks but a single peak and an asymmetric tail for the lower signal intensities. The intensity 
of the trabecular bone (IBone) was obtained based on that of the thick cortical rim. The peak 
of the histogram represents the most frequently occurring pixel intensity value in the ROI.  
 
Figure 2.10 Sequence of image analysis for a representative MRI axial image. Raw image 
acquired (A), filtered to correct marrow inhomogeneity (B), region of interest (ROI) manually drawn 
in red and then image binarised (D) resulting in a histogram depicting all the signal intensities in the 
ROI. IROI is the mean signal intesity of the region of interest and ILow is the signal intensity of bone 
marrow, also known as IMarrow. 
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This peak intensity, since it is the mixture of the two phases, should have a value that is 
lower than the high intensity trabecular intensity, IMarrow, was set at the lower signal intensity 
at which the histogram reached half its peak value (Figure 2.11). This is an empirical level 
and was adopted for the purpose of standardisation as it is very difficult to identify a 
trabecular space which contains solely bone marrow. Applying these intensity thresholds 
and taking into the spatial resolution of the slice thickness, the image is then binarised using 
a clustering method of similarity measures known as fuzzy c-mean clustering (Folkesson et 
al. 2010). 
 
Figure 2.11 Assignment of marrow intensity (I Marrow), which is set at the lower intensity 
where the histogram reached half its peak value. This is an empirical method for 
standardisation due to difficulty in identifying a trabecular space with solely bone marrow. 
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Calculation of Apparent Trabecular Bone Volume/Total Volume (appBV/TV) 
Based on the values from the histogram, the appBV/TV (i.e. the number of bone 
pixels/total number of pixels) can be calculated from the following equation (Majumdar et 
al. 1997):  
( ) ( ) marrowboneROI ITVappBVITVappBVI /1/ −+=  
 
marrowbone
marrowROI
II
II
TVappBV
−
−
= /  
Equation 1 
The intensity value at which the fractional trabecular bone content in the ROI corresponded 
to the calculated appBV/TV was selected as the threshold, and the image was binarised into 
a bone and a marrow phase.  
b) Image quantification of trabecular structure 
Standard stereological method was extended to quantify the trabecular structures in the 
binarised image (Majumdar et al. 1995). A grid of parallel lines, each one pixel thick and 
separated by 10 pixels, was used as a mask, so that only the sections of the image which lie 
along the lines were considered and the rest of the image was set to zero.  For each line in 
turn, a starting value corresponding to the value of the first pixel in the line was established.  
Each pixel along the line is then examined in turn, and the number of times that a change 
from bone to marrow (1 to 0) or marrow to bone (0 to 1) occurs was counted, and defined as 
PL().  The number of pixels which correspond to bone, PP are also counted. 
Based on these, the mean intercept length (MIL) was calculated from the following equation 
(Majumdar et al. 1995, Majumdar et al. 1997): 
( )
( )

L
P
P
P
MIL = 2  
Equation 2 
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Calculation of Apparent Trabecular Thickness (appTbTh) 
The MIL is calculated for all angles between 0o and 360o in steps of 10o.  The apparent 
trabecular thickness (in mm) is then calculated using the following equation (Majumdar et 
al. 1996): 
( ) ( )( ) RMILmeanmmappTbTh **50 360,0==   
Equation 3 
where R is the pixel resolution in mm. 
Calculation of Apparent Trabecular Number (appTbN) 
Apparent trabecular number (in mm-1) is calculated using the following equation (Majumdar 
et al. 1996): 
( )
appTbTh
TVappBV
mmappTbN
/1 =−  
Equation 4 
Calculation of Apparent Trabecular Spacing (appTbSp) 
Apparent trabecular spacing (in mm) is calculated using the following equation (Majumdar 
et al. 1996): 
( ) appTbTh
appTbN
mmappTbSp −=
1
 
Equation 5 
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2.3 MRS  
2.3.1 Principles of MRS 
Magnetic resonance spectroscopy (MRS) can be used in conjunction with MRI for non-
invasive in vivo quantification of a certain metabolite of interest. Instead of producing an 
image, 1H MRS measures the abundance of hydrogen (1H) in the different elements 
(including water and fat) within the tissue to produce a spectra of signal intensity versus 
chemical shift. Based on the Larmor equation similar in MRI, the resonant frequency of a 
hydrogen nucleus is determined by the strength of the external magnetic field. However, the 
shielding effect of the orbiting electron cloud around the hydrogen nuclei, causes a chemical 
shift, expressed in unit parts per million (ppm), which results in identical nuclei resonating 
at different frequencies within the tissue (Westbrook et al. 2011). This generates well 
resolved signal peaks which enable the different metabolites to be distinguished (Figure 
2.12). 
Radiofrequency (RF) coils are used to transmit the RF magnetic induction field (B1) and to 
detect the resulting signal using a transmit/receive coil or a separate dedicated receiver coil. 
Using a point-resolve spatially localised spectroscopy pulse sequence (PRESS), a spectrum 
of the different metabolites present can be obtained from a single well-defined spatial 
volume (single voxel spectroscopy) (Jansen et al. 2006). The spectrum displays the 
metabolites as separate peaks due to the difference in their resonance frequency with their 
characteristic line widths,  
 
Figure 2.12 1H-MR spectroscopy of a normal brain.  1H spectra of a normal brain (A) with the 
volume of interest (marked with a square) placed in the white matter of the left frontal cortex as seen 
in the corresponding T2-weighted MR image (B) The spectra exhibit the various different metabolites 
present including N-acetylaspartate (NAA). total choline (Cho), glutamate plus glutamine (Glx) and 
Creatine (Cr). [Adapted from (Ricci et al. 2007)] 
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line shapes, phase and area. Quantification of the concentration of the metabolite of interest 
can be done by accurately calculating the area under the peak. Figure 2.12 demonstrates the 
MR image and spectra of the metabolites in the brain, which is the organ where this 
technique is most widely used clinically. 
2.3.2 Lumbar spine imaging 
Imaging was performed on a 3 Tesla (T) Siemens MAGNETOM Prisma MRI scanner 
(Siemens, Erlangen, Germany) using a transmit/receive (Tx/Rx) extremity coil for the knee. 
The MR images were then pre-processed, coded and analysed using MATLAB (Mathworks 
Inc, San Mateo, CA, USA) software.  
2.3.2.1 Acquisition 
Both MRI and MRS imaging were performed on the same 3T-MRI scanner during a single 
scanning session for each participant. Once the knee coil was removed, the participant was 
positioned further into the MRI scanner to image the lumbar spine at the level of L3. Ideally, 
measurement of marrow adiposity would be done at the same site as the measurements for 
the trabecular bone microarchitecture in the lower limb but this is technically impossible. 
Localiser and T2 scans (sagittal and axial) were performed to allow positioning of the voxel 
within the vertebral body of L3 (Figure 2.13A). A Point-REsolved Spectroscopy Sequence 
(PRESS), as summarised in Table 2.2, with no water suppression and a short echo time (TE) 
was used to enable detection of lipids. 
Table 2.2 PRESS Pulse sequence parameters for imaging of the lumbar spine (L3) 
Parameter Value 
Resolution (mm3) 20 x 20 x 20  
TE (ms) 30 
TR (ms) 2000 
Flip angle (°) 90 
Number of averages 80 
Bandwidth (Hz/pixel) 1200 
Scan time (mins) 2.5 
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Figure 2.13 1H Spectroscopy of lumbar spine.  (A) Representative MR image of the lumbar spine 
with the region of interest (marked with a red square) placed in L3 and (B) its corresponding 1H 
spectra of water and lipid peaks respectively. 
2.3.2.2 Image Analysis 
MRS analysis was performed using the Java-based magnetic resonance user interface 
(jMRUI) software package to obtain measures for the calculation of percentage fat fraction 
(%FF) within the bone marrow (Vanhamme et al. 1997, Naressi et al. 2001). The resulting 
spectrum shows peaks corresponding to water and fat as shown in Figure 2.13B.  A best-fit 
Gaussian model was applied to the acquired spectra, and the area under the resulting water 
peak (IWater) and lipid peak (ILipid) were measured to work out the lipid-to-water ratio (LWR). 
 
 The percentage fat fraction (FF) was then calculated, as a measure of bone marrow 
adiposity, using the following equation (Schellinger et al. 2004):  
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2.4 Dual Energy X-ray Absorptiometry (DXA) 
2.4.1 Principles of DXA 
Conventional X-ray images are insensitive to bone density changes with at least 30% of bone 
mineral losses required before they may be visually detected.  This has led to the 
development of, initially single and now dual energy, radiographic absorptiometry devices 
specifically designed to quantitate bone density. DXA scanners usually consist of a couch 
for the patient, an x-ray source underneath which moves together with a mobile radiation 
detector arm placed directly above. The patient is placed on the couch in the path of the 
radiation beam from the source, and the radiation detector is then scanned back and forth 
over the measurement site. Fundamentally. DXA is reliant on the difference in the 
attenuation of the dual x-ray beams (high energy and low energy) when they pass through 
soft tissue and bone. Both bone and soft tissue will attenuate the dual beams as they pass 
through the body, with the low energy attenuated more than the high energy beam, but the 
difference is much greater in bone (Faulkner 2001). The attenuation values of the soft tissues 
and that of bone at the respective high and low energies are used to compute the mass of the 
bone (or BMC, g) at each point in the X-ray beam based on the following equations: 
 
 
Equation 6 
 
where: I0 = incident radiation intensity 
I = transmitted radiation intensity 
µ = mass attenuation value for the attenuating material (cm2/g)  
m = mass of the attenuating material (g) 
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and subscripts b and t refer to bone and tissue, respectively, while L and H for high and low 
energies, respectively. The computer then evaluates the bone area in the coronal plane of the 
area scanned and the BMD (measured in g/cm2) is determined as the total bone mass (BMC, 
measured in g) divided by the bone area (BA, measured in cm2).  
 
 
Since the densitometry is a projectional technique providing a two-dimensional image of the 
bone being measured, the BMD derived is therefore the mass of the bone tissue per unit 
area, not per unit volume. It is therefore often referred to as areal BMD (aBMD) to 
emphasize that it is not a true volumetric density. Additionally, as the dual beam allows for 
the delineation of soft tissue versus bone, DXA can also be used to assess body composition 
(fat mass, lean body mass, and percentage body fat), on both total body (TB) and regional 
basis (Korkusuz 2015). 
The clinical utility of DXA falls into three broad categories: 
1. confirmation of low bone mass by comparison with normative data 
2. assessment of fracture risk 
3. monitoring skeletal change in response to therapy or due to aging 
DXA can measure effectively any skeletal site, but its clinical use in the assessment of 
fracture risk has been commonly concentrated on the lumbar spine, hip (femoral neck and 
total hip) and total body. For BMD measurements to be clinically useful, they need to be 
compared to established normative data and expressed in two standard deviations (SD) of 
BMD, categorised as T-score and Z-score. The T-score compares the patient’s BMD to the 
young-adult reference population of the same gender and has been adopted as the WHO 
diagnostic classification of osteoporosis. It is, however, restricted to postmenopausal women 
and men age 50 and older, and not applicable for children and young people. On another 
hand, the Z-score is applicable for children, premenopausal women and men younger than 
50 years, as it is compared to the BMD of an age-, sex-, and ethnicity-matched reference 
population. Its measurement of -2.0 or lower is indicative of significantly decreased bone 
density for chronological age (Cosman et al. 2014). 
BMD (g/cm2)   = 
 BMC (g) 
 BA (cm2) 
Equation 7 
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Care must be exercised to avoid erroneous BMD measurements. Most of these pitfalls can 
be broadly categorised into technical and interpretation errors (Peh 2014). Over time, the 
scanner system can be expected to drift due to hardware deterioration such as X-ray tube 
aging, environmental changes and other factors resulting in technical errors. Daily scanning 
of the calibration standard supplied with the system needs to be carried out to ensure accurate 
BMD measurements (Faulkner 2001, Peh 2014). The scanner can self-adjust to bring it back 
into the original calibration if a small drift is detected, without the need for technical 
assistance. Periodically, scanning of a quality control phantom (simulated bone material 
encased in plastic designed to mimic soft tissues) is also carried out to monitor for scanner 
stability as well as allowing for cross-calibration between different scanners if necessary. 
The positioning of patient and the placement of ROIs, both crucial for proper image 
acquisition, can be technically difficult due to patient cooperation and under developed 
skeletal landmarks in younger children (Lenchik et al. 1998).  
The greatest challenge in paediatric densitometry, however, is in the interpretation of DXA 
measurements. This is much more complex in young growing patients, necessitating a 
validated adjustment method to take into account the altered growth, stages of puberty and 
the effects of chronic disease on bone size. The revised ISCD Official Position in 2013 
recommended that in children with short stature or growth delay, spine BMC and aBMD 
results should be adjusted using either bone mineral apparent density (BMAD) or the height 
Z-score (Crabtree et al. 2014). TBLH BMC and aBMD, on the other hand, should be 
adjusted using the height Z-score. When considering adjustments of DXA measurements for 
bone size, height, LBM, skeletal age, or pubertal stage in growing children, it is relevant to 
consider the goal of the exercise as there is no single adjustment ideal for all. Crucially, size 
adjustment techniques have been shown to improve the DXA predictive ability for fracture 
(Crabtree et al. 2013). The paucity of large representative normative databases can add to 
dilemma in interpretation as many manufacturer reference databases are often small in 
numbers and not representative of the individual population being studied (Crabtree et al. 
2014). A well-trained and experienced DXA technologist is required to avoid most of the 
errors in acquisition and analysis. 
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2.4.2 Whole Body Imaging  
All imaging were performed systematically by one practitioner (SS) using a Lunar Prodigy 
densitometer (GE Medical Systems, Wisconsin, USA) to assess the bone and body 
composition parameters and analysed using the Encore software (Version 13.0). Following 
height and weight measurements, the participants were positioned supine on the scanner 
couch and the mobile X-ray source moved from in a cranio-caudal manner to obtain whole 
body (TB) and lumbar spine (LS) measurements. Total scan time was 10-15mins per 
participant. Bone parameters obtained include bone mineral content (BMC) [g], bone area 
(BA) [cm2] and mean areal bone mineral density (BMD) [g/cm2]. Body composition 
parameters obtained include whole body lean mass (LM) [g] and fat mass (FM) [g]. 
2.4.2.1 Analysis 
As outlined in previous studies, the predicted and percentage predicted bone area (ppBA) 
for age and sex were calculated based on our reference data (Warner et al. 1998, Ahmed et 
al. 2004). This allowed for a comparison of the actual bone mineral content (BMC) of the 
individual participant with the predicted BMC of a subject of the same sex and bone area 
from which the percentage predicted BMC (ppBMC), expressed as an SDS (BMC SDS) 
could be calculated. The coefficient of variation (%CV) calculated on repeated DXA 
measurement of a phantom was <1% of BMC and <2.5% in vivo. Body composition 
parameters were adjusted for height to minimise the size-related effects of DXA. 
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2.5 Biochemical assessment 
2.5.1 Blood sampling 
Non-fasting blood samples were obtained from all participants in the morning to avoid any 
bias from diurnal variation. Serum markers for bone formation (bone alkaline phosphatase 
[BAP], octeoclacin [OC]), bone resorption (C terminal telopeptide of Type I collagen 
[CTX]), adiposity (pre-adipocyte factor-1 [PREF-1]), growth hormone axis (IGF-1, IGF-
BP-3, the acid labile subunit [ALS]), sclerostin and other regulator markers of bone turnover 
(PTH, AP, 25-Hydroxy-vitamin D [25OHD]) were measured. 
2.5.2 Biochemical assays 
All samples of whole blood were centrifuged on the same day to obtain the serum, which 
was aliquoted and stored at -800C until the assays were run. The samples were analysed in 
duplicate concurrently and samples from each patient were analysed in a single run to 
minimise analytical variation. Osteocalcin (OC), bone-specific alkaline phosphatase (BAP), 
C terminal telopeptide of Type I collagen (CTX) were analysed by ELISA 
(Immunodiagnostic systems, Boldon, UK). The intra-assay variation for OC, BAP and CTX 
was 1.4%, 9.6% and 3.1%, respectively. Plasma IGF-1 and its binding proteins, IGFBP-3, 
and the acid labile subunit (ALS) were analysed by ELISA (Mediagnost GmbH, Reutlingen, 
Germany). Intra-assay variabilities were 16.0%, 2.9%, and 10.9%, respectively. Sclerostin 
(SOST) was also analysed by ELISA (TECO, Pathway Diagnostics, Surrey, UK) with intra-
assay variation of 14.1%. Parathyroid hormone (PTH) and alkaline phosphatase (AP) were 
measured using chemiluminescent microparticle immunoassay (Abbott Diagnostics, IL, 
USA). Intra-assay variations were <6.3% and <8.0% respectively. 25-hydroxy-Vitamin D 
was measured by liquid chromatography-tandem mass spectroscopy (LC-MS/MS) based on 
our in-house previously published method, with intra-assay variation of <10% (Knox et al. 
2009). Reference data for the respective assays were obtained from the literature to calculate 
the age- and gender-specific SDS values (Rauchenzauner et al. 2007, Ertl et al. 2014). 
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Laboratory-based experiments: Material and Methods 
2.6 Cell culture 
2.6.1 Principle of cell culture: proliferation and differentiation 
Cell culture is a technique whereby prokaryotic, eukaryotic or plant cells are grown under 
controlled condition. Most commonly it refers to the culturing of cells derived from animals 
or humans. Harrison was thought to be the father of cell culture as he successfully cultivated 
frog neuroblasts in a lymph clot in vitro for several weeks in 1907 (Harrison et al. 1907). 
There are several milestones in the development of cell culture technology, the first being 
the discovery of trypsin in the 1950s which enabled the removal of intact adherent cells 
allowing cell subcultures (Dulbecco 1952) Trypsinisation also facilitated the generation of a 
single cell suspension, further advancing single cell cloning. Secondly, the introduction of 
antibiotic use in cell culture inhibited the growth of contaminant, which facilitated long-term 
cell line propagation (Cruickshank and Lowbury 1952). The third major milestone was the 
use of chemically defined culture media to maintain the cells at an appropriate stage of 
maturation to retain their proliferative capacity instead of favouring differentiation, and vice 
versa. (Eagle 1955). This led ultimately to serum-free media (Ham 1965) which can facilitate 
the selective growth of a particular type of cell, eg. Dulbecco’s Modified Eagle’s Medium 
(DMEM) for embryonic mouse cells (Dulbecco and Freeman 1959). Crucially, all these are 
carried out in vitro in an aseptic environment, working within a hood with particulate air 
filter with principals of laminar flow, and key sterile manipulation techniques. 
Primary culture is the cultivation of surgically or enzymatically removed cells from an 
organism, in a suitable culture environment (Freshney 2005). These cells can be passaged to 
create further subcultures, also called cell lines. Subcultures provide the opportunity to 
expand a cell population, apply further selective pressure with a selective medium and 
achieve a higher growth fraction and also the generation of replicate cultures for 
characterisation, preservation by freezing or experimentation. Briefly, subculture involves 
the dissociation of the cells from one another and the substrate to be reseeded at a reduced 
concentration into a flask to generate a secondary culture and tertiary culture and so on. Each 
time a cell is subcultured, it will proliferate and multiply back to previous density by going 
through the growth cycle: lag period of no growth to recover from trypsinisation and 
cytoskeleton reconstruction enabling them to re-enter cell cycle, log phase of exponential 
growth and plateau or stationary phase. Some cells readily differentiate once in plateau 
phase, others exit the cell cycle into G0 but retaining viability. Reduced proliferation in the 
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stationary phase is due partly to exhaustion of growth factors in the medium as well as 
contact inhibition from cells when they are in high density.  
 
Figure 2.14 Evolution of a Cell Line.  The vertical (Y) axis represents total cell growth (assuming 
no reduction at passage) for a hypothetical cell culture. Total cell number (cell yield) is represented 
on this axis on a log scale, and the time in culture is shown on the X-axis on a linear scale. Although 
a continuous cell line is depicted arising at 14 weeks, with different cells it could arise at any time. 
Likewise, senescence may occur at any time, but for human diploid fibroblasts it is most likely to 
occur between 30 and 60 cell doubling time. [Adapted from (Hayflick and Moorhead 1961)] 
Cell proliferation is regulated by signals from the environment, either contact-mediated or 
molecular-signalling (Freshney 2005). Low cell density is conducive for cell proliferation 
giving them room for spreading, which permits entry into cell cycle in the presence of 
mitogenic growth factors. Most cell lines have limited life span becoming senescent after 
several passages. With subsequent passages, cells also lose their ability to differentiate. Cell 
differentiation is the process where a cell changes from one cell type to another, usually into 
a more specialised cell type. The condition required for differentiation, however, is often 
antagonistic to that of proliferation. Cell differentiation favours a high cell density where 
there is enhanced cell-cell and cell-matrix interaction together with the presence of various 
specific differentiation factors (Freshney 2005). Based on these, it is often necessary in cell 
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culture to define two sets of culture conditions – one to optimise cell proliferation and one 
to optimise cell differentiation.  
2.6.2 Cell Culture experiments 
AMPK α1/α2 knockout mouse embryonic fibroblasts (MEFs), C3H10T1/2 mouse 
mesenchymal stem cells (Clone 9; ATCC CCL-226) and 3T3-L1 preadipocytes were 
maintained in DMEM (41965-039, Sigma-Aldrich Ltd, Gillingham, Dorset, UK) containing 
10% (v/v) FCS, 2 mM glutamine, 100 U/mL penicillin and 100 µg/ml streptomycin. 
Differentiation experiments were undertaken at 80-90% confluence. To promote adipogenic 
differentiation, cells were cultured in the standard media supplemented with either 10 μM 
pioglitazone alone or in combination with 100 nM insulin, 500 μM 3-isobutyl-1-
methylxanthine (IBMX) and 10 μM dexamethasone (IID medium). For osteogenic 
differentiation, cells were cultured in standard media supplemented with 284 µmol/L 
ascorbic acid, 10 mM β-glycerophosphate and 10 nM dexamethasone (AGD medium). 
Differentiation media was changed every 3 days. 
2.6.3 Preparation of Cell Extracts  
C3H10T1/2 MSCs were harvested and nuclear extracts prepared using the Nuclear 
Extraction kit from Active Motif, Belgium. Briefly, the media was aspirated and cells were 
harvested in ice-cold PBS containing phosphatase inhibitors and centrifuged (200 x g, for 5 
minutes at 4ºC) to obtain a cell pellet. The cell pellet was re-suspended in complete lysis 
buffer containing 10 mM DTT and phosphatase inhibitor cocktail and then centrifuged 
(14000 x g, for 10 minutes at 4ºC) to obtain nuclear and supernatant fractions. 
2.7 Electrophoresis and Immunoblotting 
2.7.1 Principles of electrophoresis 
Electrophoresis is a technique used for separation of proteins in vertical slab gels to 
identify/investigate a target protein of interest or to purify proteins for further applications 
(Sambrook and Russell 2001, Ausubel et al. 2003). The separation of proteins is dependent 
on protein characteristics: surface features, bioproperties, molecular size, and net charge, of 
which electrophoresis exploits the latter two. Typically, a constant electric field is applied to 
the electrophoresis chamber (10-20v per cm gel length) loaded with the protein samples, 
which causes migration of negatively charged molecules through the gel sieve in the 
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direction of the positively charged anode. Small proteins migrate relatively easier through 
the gel than larger proteins, hence allowing the separation of protein by molecular size. The 
separated proteins are then transferred from the gels onto a membrane such as polyvinylidene 
difluoride (PVDF) or nitrocellulose membranes to allow further staining and quantification. 
SDS-PAGE, or sodium dodecyl sulfate-polyacrylamide gel electrophoresis, is a 
discontinuous one-dimensional electrophoresis system conceived by Ulrich K Laemmli, 
which is most commonly used to separate proteins with molecular masses between 5 and 
250kDa (Laemmli 1970). SDS acts as a surfactant, covering the proteins’ intrinsic charges 
and conferring them very similar charge-to-mass ratios, negating the intrinsic charges of the 
proteins, allowing for precise protein separation by mass. The SDS-PAGE method is 
composed of gel preparation, sample preparation, electrophoresis, protein staining or 
western blotting, which is detailed in section 1.7.2. and 1.7.3.  
2.7.1.1 Gel preparation 
Typically, the separating gels are 14cm x14cm in size, although smaller mini-gels 6cm x 
8cm are also often used, with thickness of up to 0.75mm. Mini gels provide faster separation 
at the expense of lower resolution (Ausubel et al. 2003). The separating and stacking gels 
are cast and hand-poured into special moulds with combs inserted to create little wells for 
the protein samples (Figure 2.15). The desired percentage of acrylamide in the separating 
gel depends on the molecular size of the protein being separated, in particular the one of 
interest. Polymerisation of the polyacrylamide with cross-linking formed from 
bisacrylamide results in gels of different porosity, crucial for its sieving function. A general 
rule of thumb, of 5% gels for 60-200kDa and 10% gels for 16-70kDa and 15% gels for 12-
45kDa. The composition for making up the separating and stacking gels, with varying 
amounts of acrylamide and bisacrylamide, are available from most laboratory manuals 
(Sambrook and Russell 2001), with one example shown in Figure 2.16, although pre-cast 
gels are available commercially.  
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Figure 2.15 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE).  (A) Schematic 
representation of an SDS-PAGE set up, with the stacking and running/separating gels, and (B) a Bio-
rad model of the apparatus [Images from www.chemistry.gatech.edu and www.biorad.com] 
 
Figure 2.16 Recipes for polyacrylamide separating gel with volume in mililitres (mls) of each 
solution needed depending on percentage (%) of gel required. Polymerisation of the 
polyacrylamide with cross-linking formed from bisacrylamide results in gels of different porosity, 
crucial for its sieving function [Adapted from (Ausubel et al. 2003)] 
  
A 
B 
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2.7.1.2 Sample preparation 
The protein sample is diluted 1:1 (v/v) with 2x SDS buffer and heated to 95°C for 3-5mins 
in a sealed microcentrifuge tube. The comb is removed and the wells are carefully filled with 
the protein samples using pipettes. By convention, the far left lane is filled with a protein-
molecular weight standards (or protein marker) mixture. 
2.7.1.3  Electrophoresis and protein transfer 
Once the protein samples are loaded into the wells, the electrophoresis running chamber is 
filled with a running buffer solution before an electrical field is passed through the chamber 
until the bromphenol blue dye in the protein marker lane has reached the bottom of the gel. 
During this stage, the proteins are separated by their molecular sizes vertically, with larger 
proteins which travel slower through the gel isolated at the top closest to the loading point, 
whilst smaller proteins further below in molecular mass order Figure 2.17 
 
Figure 2.17 Molecular sizes of the protein of interests (A) PPARγ, (B) Runx2 and (C) phospho-
ACC dictates the corresponding choice of polyacrylamide gel use.  Protein of bigger molecular 
mass require higher gel porosity to allow better capture ideally in the middle of the separating gel, 
hence lower polyacrylamide/bisacrylamide content. 
Two-dimensional gel electrophoresis separates the proteins in the first dimension by 
isoelectric focusing and in the second dimension in the presence of SDS, with incredible 
resolving power. 
A C B 
8% gel 
10% gel 10% gel 
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2.7.2 Principles of immunoblotting 
Immunoblotting (also referred to as Western blotting) is a technique used to identify specific 
antigens or target proteins among unrelated protein species, by employing the function of 
polyclonal or monoclonal antibodies (Sambrook and Russell 2001, Ausubel et al. 2003). It 
involves identification of the protein of interest using an antigen-antibody (or protein-ligand) 
specific reactions. Proteins are typically solubilised using sodium dodecyl sulfate (SDS) then 
separated by electrophoresis, as described in section 2.7.1.  
The first step to immunoblotting is to electrophoretically transfer these proteins from the 
SDS-polyacramide gels onto membranes to allow subsequent quantification. The gel is 
removed from the electrophoresis running chamber into a new set up (Figure 2.18) 
containing a transfer buffer solution termed as the electrophoresis transfer chamber in this 
thesis. For transfer from SDS gels, the membrane must be placed on the side of the gel facing 
the anode in a very specific ‘sandwich’ arrangement (Figure 2.18) for an effective horizontal 
transfer to occur. The choice of membrane, from nitrocellulose to nylon and PVDF 
membranes is largely dependent on the binding efficiency of the protein of interest to them. 
Nitrocellulose remains a standard membrane used in immunoblotting, although PVDF 
membranes have an approximately 6-fold stronger binding affinity which can ensure the 
proteins are retained more efficiently for subsequent steps (Van Oss et al. 1987).  
 
Figure 2.18 Electrophoresis transfer chamber set-up. protein transfer from SDS-
polyacrylamide gels onto PVDF/nitrocellulose membranes.  Protein transfer from the SDS-
polyacrylamide gel onto the PVDF/nitrocellulose membrane occur in the direction of the positive 
anode, hence the specific ‘sandwich’ arrangement whereby the membrane must lie on the side of 
the gel facing the anode. [Images from www.mitosciences.com] 
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At this stage, removable Ponceau staining can be used to check how well the proteins have 
transferred across (Muilerman et al. 1982). The transferred protein sits on the surface of the 
membrane, allowing access for reaction with immunodetection reagents. Additional 
bindings sites are blocked by immersing the membrane in a solution containing protein (e.g. 
milk) or detergent blocking agent solution (e.g. TBST). The membrane can then be probed 
with a primary antibody (usually raised in mouse, rabbit or sheep) to target a specific 
antigen/protein and then with a secondary antibody (usually raised in donkey) labelled, with 
either enzymes (e.g. horseradish peroxidase, or alkaline phosphatase), or radioisotopes to 
enable detection and quantification, as shown in Figure 2.19. Conveniently, the membranes 
can be stripped and re-probed as needed. 
 
Figure 2.19 Principles of immunoblotting (also known as Western blotting), using antibodies 
to detect a specific antigen or target protein (in grey filled circle). 
Immunoblotting is now widely used in conjunction with two-dimensional polyacrylamide 
gel electrophoresis, not only for traditional goals, such as the immunoaffinity identification 
of proteins and analysis of immune responses but also as a genome-proteome interface 
technique. 
2.7.3 Western blotting experiments 
Protein samples were separated by SDS-PAGE and then transferred electrophoretically onto 
nitrocellulose membranes. During electrophoresis, gels were run for 80 mins at 120V and 
then transferred for 120mins at a constant current of 400mA. Membranes were blocked with 
5% (w/v) Marvel milk powder in TBS (20 mM Tris-HCl pH 7.5, 150 mM NaCl) for 1 hour. 
Membranes were then incubated with primary antibodies overnight at 4oC. Following 
washes with TBST (TBS supplemented with 0.5% (v/v) Tween-20), membranes were 
incubated with secondary antibodies for 1 hour at room temperature. Antibodies were diluted 
to the required concentration in 50% (v/v) Sea Block (Thermo Scientific) and 50% (v/v) 
Protein of interest 
Secondary antibody, labelled with 
enzyme or radioisotope 
Membrane 
Detected by colourimeter, 
or spectrometer 
Primary antibody 
  105 
TBST. The primary antibodies used were to peroxisome proliferator-activated receptor 
gamma (PPARγ; marker for adipogenesis, Cell Signalling Technologies (CST), Danvers, 
MA), Runt-related transcription factor 2 (Runx2; marker for osteogenesis, CST, Danvers, 
MA), phosphorylated-ACC (P-ACC (Ser79); marker for AMPK activity, CST, Danvers, 
MA) and phosphorylated-p70S6K (P-p70S6K (Thr389); upstream regulator of mTOR 
signalling, CST, Danvers, MA). Antibodies were detected using a LI-COR® Odyssey 
Infrared Imaging systems and densitometric analysis was carried out using ImageJ software 
(National Institute of Health, UK) software Version 1.47.  
2.8  Oil Red O staining 
2.8.1 Principles of Oil Red O staining 
Oil red O staining (ORO) is a histological technique used in the visualisation of fat cells and 
neutral fat (Mehlem et al. 2013). Under light microscopy, lipid-laden adipocytes that are 
stained with ORO appear bright red/orange, leaving the remainder of the cellular constituents 
non-stained (nuclei can be counterstained). The ORO dye can be made from stock (needs to 
be protected from UV light) or purchased ready-made. Isopropanol, propylene glycol and 
triethyl phosphate (TEP) can be used as solvent-carriers for ORO. 
2.8.2 Oil Red O staining experiments 
C3H10T1/2 cells were incubated with adipogenic IID media in the presence or absence of 
either 10 µM pioglitazone, 500 µM metformin, 100 µM of the AMPK-activator, A769662, 
or 10 µM of the p70S6K-inhibitor, rapamycin. Following differentiation, media was aspirated 
and cells were fixed to cell culture plates with 10% (v/v) neutral buffered formalin for 30 
minutes. The formalin was then aspirated and staining was carried out with the addition of 
0.3% (w/v) ORO in isopropanol:water (60:40) for 5 minutes in room temperature. The ORO 
was then aspirated and wells washed with distilled water four times. Imaging was carried 
out using a Zeiss Axiovert 25 microscope with QImaging camera and supporting software. 
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2.9 Transfection and Luciferase reporter assays 
2.9.1 Principles of transient transfection and luciferase reporter 
assay 
Luciferase reporter assay is a bioluminescence technique used to study gene regulation, 
based on the interaction of the enzyme luciferase, with a luminescent substrate. Common 
commercially available luciferases are from the firefly (Photinus pyralis) and Renilla 
(Renilla reniformis), which is a sea pansy, both of which have different substrates D-luciferin 
and coelenterazine respectively (Cormier et al. 1975, Allard and Kopish 2008). Using 
genetic reporters (known as reporter genes), gene expression and cellular events coupled to 
gene expression can be examined. Typically, a DNA reporter constuct is prepared, where 
the reporter gene is attached to a regulatory sequence of the gene of interest and cloned into 
an expression vector (plasmid) that is then transfected into cells. The Renilla luciferase gene 
is commonly used as an internal control to normalise the values of the experimental reporter 
genes for variations that could be caused by effectiveness of transfection and sample 
handling (Shifera and Hardin 2010). It is the control of choice as Renilla is constitutively 
expressed in transfected cells and its expression is not up- or down-regulated by the 
experimental factors. More crucially, it does not have any effect on the substrate of firefly 
luciferase due to its action on an entirely different substrate (Cormier et al. 1975, Shifera 
and Hardin 2010). Once the cells are harvested, the luciferase and Renilla detection agents 
are added and the DNA of the gene of interest can be quantified. The advantages of 
bioluminescent reporters include: i) almost instantaneous results, ii) typically no endogenous 
activity in host cells to interfere with quantification, and iii) exceptional sensitivity, 10- to 
1000-fold higher assay sensitivity than fluorescent reporters such as the green fluorescent 
protein (GFP) which is highly useful in detecting target protein in vanishingly small quantity 
enveloped within an intricate biological environment (Allard and Kopish 2008). 
2.9.2 Transient transfection and luciferase assay experiments 
C3H10T1/2 cells were transfected with the indicated plasmids in 6-well plates, with 1.125  
μg/well PPRE (PPARγ reporter, purchased from Adgene) and 6xOSE reporter constructs 
(Runx2 reporter, supplied by Jian Huang, Rush Medical Centre, Chicago, USA) using 
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) and then treated with metformin, 
A769662 or rapamycin with and without adipogenic differentiation media. Cells were then 
harvested 48 hours after transfection and assayed using the Luciferase reporter assay system 
(Promega, Madison, WI) according to manufacturer’s instructions. As a transfection control, 
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the Renilla plasmid 0.125 μg/well was co-transfected in each transfection experiment, and 
the luciferase activity was normalised to the Renilla activity. 
2.10 Statistical analyses 
2.10.1 Clinical imaging studies 
All data were analysed using SPSS for Windows software program, Version 22 (SPSS, 
Chicago, IL, USA). Group differences were compared by Mann-Whitney test for continuous 
variables and Chi-square test used for categorical variables. Spearman’s rank correlation co-
efficient was used to assess the association between variables. Specific sub-analyses were 
performed and factors significant on univariate analysis were included in a multivariate 
logistic regression. All continuous data were presented as median (ranges) with p<0.05 
considered as significant. Further information about the statistical analyses are detailed in 
the relevant individual chapters. 
2.10.2  Laboratory studies 
All experiments were performed in triplicate and statistical analysis was performed using 
Student’s t-test or one-way ANOVA in SPSS for Windows software program, Version 22 
(SPSS, Chicago, IL, USA). Results are expressed as mean ± standard error (SEM) and 
differences with p<0.05 were considered statistically significant. 
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3 The Precision of Partial Image Analysis of 
Trabecular Bone Microarchitecture in High-
Resolution Magnetic Resonance Imaging 
3.1 Abstract 
High-resolution magnetic resonance imaging (HR-MRI) can assess trabecular bone 
microarchitecture but the number of image slices required for reliable assessment is unclear. 
The feasibility of partial image analysis was determined on the proximal tibia MRI images 
of 20 healthy controls (all female; median age 21 years (range 18,35) and 10 cases (3M:7F; 
median age 19.5 years (range 16,48) with known bone abnormalities including osteogenesis 
imperfecta and other endocrinopathies. Images were analysed using Matlab to generate the 
trabecular bone microarchitecture parameters, including apparent trabecular volume to total 
volume (appBV/TV), trabecular thickness (appTbTh), trabecular number (appTbN) and 
trabecular separation (appTbSp). The mean values obtained from twenty images (20IM) of 
the total image set were compared to that for 10 images (10IM), 5 images (5IM) and one 
image (1IM) from the centre of the total image set using Bland-Altman analysis. Co-efficient 
of variations (CV) within subjects were compared for the total and partial image set and 
significance level analysed with Levene’s test and Mann-Whitney U-test. The results 
demonstrated that partial image analyses of 5IM or 10IM were quantitatively as reliable as 
analysis of the full image set of 20IM, for both cases and controls. The mean intra-subject 
CV (±SD) for appBV/TV in healthy controls was 2.6±1.1% for 20IM, 3.0±1.5% for 10IM 
and 3.1±1.5% for 5IM. Cases had higher mean appBV/TV CV (SD) at 3.7±2.1% for 20IM, 
4.7±3.0% for 10IM and 4.3±3.1% for 5IM; all p>0.05 when compared to that of controls. 
However, sub-analysis of the 4 cases with osteogenesis imperfecta, a more severe 
osteopathy, demonstrated even higher mean CV (±SD) at 4.6±2.7% for 20IM, 7.1±3.1% for 
10IM and 5.9±3.6%) for 5IM (p=0.183, p<0.005 and p=0.157, respectively). In conclusion, 
these findings indicate that partial image sets can reliably represent a larger complete set of 
images when assessing trabecular bone microarchitecture parameters. Given that the time 
taken to analyse 5 images per participant is half that of analysing 10 images, this Chapter 
has objectively informed the final analyses in Chapter 4 for using 5 image partial image set 
analysis.   
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3.2 Introduction  
High-resolution magnetic resonance imaging (HR-MRI) can be used to assess trabecular 
bone microarchitecture. Each scan, however, generates a high number of image slices which 
can lead to a laborious and time-consuming analysis process. The minimum number of 
image slices required to be analysed for a meaningful result is unclear. The main aim of this 
chapter was to determine the number of images that needed to be analysed to yield 
representative estimates of the trabecular bone parameters. 
3.3 Methods 
Retrospective analyses of the MRI images obtained in a previous study cohort of 20 healthy 
adult controls (all female; median age 21 years (range 18,35) and 10 adult cases (3M:7F; 
median age 19.5 years (range 16,48) with known childhood-onset bone abnormalities 
including osteogenesis imperfecta and other endocrinopathies were undertaken (McComb et 
al. 2014b). Each participant had 30 slices of MR images taken of the right proximal tibia, 
with the first slice placed immediately distal to the growth plate as a point of reference. The 
first five (slices 1-5) and last five slices (slices 26-30) were not suitable for analysis due to 
the low signal-to-noise ratio of these images.  
 
Figure 3.1 Partial image set analysis.  Thirty MR image slices were taken per participant from the 
right proximal tibia, with the first slice placed immediately distal to the growth plate, as shown in the 
red rectangular box .All 30 slices were analysed per participant and the partial image set involved 
analysis of slice 16 as the central most slice (1 IM), slices 14-18 (5 IM), slices 11-20 (10 IM) and 
slices 6-25 (20 IM). 
  
Partial image sets 
Growth plate 
  
Slice 30  
  
Slice 1  
  Slice 2  
  
Total image set 
1 IM 
  
10 IM 
  5 IM 
  
20 IM 
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Using MATLAB software, the 20 most central images (20 IM; slices 6-25), which 
represented the total image set, were analysed to generate the trabecular bone 
microarchitecture parameters, including apparent trabecular volume to total volume 
(appBV/TV), trabecular thickness (appTbTh), trabecular number (appTbN) and trabecular 
separation (appTbSp). The same analyses were conducted for partial image sets of 10 images 
(10 IM; slices 11-20), 5 images (5 IM; slices 14-18) and one image (1 IM; slice 16) from the 
centre of the total image set (Figure 3.1). Bland-Altman analysis was used to determine the 
agreement between the partial image set analysis to that of the total image set. The Shapiro-
Wilk test was conducted on the distribution of the differences between the partial and total 
image sets to confirm normality. Analysis of variance (ANOVA) was used to compare the 
means between groups and Levene’s tests used to assess the significance of the CV within 
subjects. All the images were analysed by a single investigator (myself) to ensure 
consistency. There was no blinding carried out in the analysis. 
3.4 Results 
The mean trabecular bone microarchitecture parameters for 20IM, 10IM, 5IM and 1IM were 
summarised in Table 3.1. There were no significant differences between trabecular bone 
microarchitecture parameters from 10IM, 5IM or 1IM vs 20IM (p>0.05). 
Table 3.1 Measures of trabecular bone microarchitecture parameters in 20 healthy adults 
 
appBV/TV = apparent trabecular bone volume/total volume; appTbTh = apparent trabecular 
thickness; appTbN = apparent trabecular number; appTbSp = apparent trabecular separation; IM = 
number of images analysed from the total or partial image sets; Values in mean±SD. *Between 
group comparisons all p>0.05 
The differences between the total (20IM) and partial image analyses (10IM, 5IM and 1IM) 
became more apparent when partial image analyses of fewer image slices were used, with 
more values scattered away from the mean difference, as shown in Figure 3.2 and Figure 
3.3. Figure 3.2 demonstrated that partial image set analyses of 10IM, 5IM and 1IM agreed 
well with the total image set analysis for 20IM in healthy controls, as most of the values laid 
  20IM* 10IM* 5IM* 1IM* 
appBV/TV 0.442 ± 0.024 0.441 ± 0.024 0.442 ± 0.025 0.447 ± 0.027 
appTbTh (mm) 0.771 ± 0.049  0.769 ± 0.049 0.764 ± 0.048 0.787 ± 0.051 
appTbN  0.576 ± 0.043 0.578 ± 0.043 0.584 ± 0.044 0.569 ± 0.045 
appTbSp (mm) 0.979 ± 0.104 0.976 ± 0.105 0.966 ± 0.104 0.981 ± 0.114 
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between the upper and lower limits of agreement. The differences in appBV/TV values for 
partial image set of 1IM compared to 20IM, however, were far more dispersed from the 
mean, with significantly more values lying outwith 95% confidence interval of the mean 
difference. Similar agreements were found for partial image set analyses in cases with 
childhood-onset bone abnormalities, as shown in Figure 3.3. Partial image analyses of 10IM, 
5IM and 1IM agreed well with total image analysis for 20IM, although most values outwith 
the 95% confidence interval of the mean difference.  
The reproducibility of the image analysis was determined in the cases and controls with the 
intra-subject CV for apparent bone volume/total volume summarised in Table 3.2. Although 
the mean CV for appBV/TV were higher in cases than controls, these did not reach statistical 
significance (all p>0.05). Further sub-analysis of only the cases with osteogenesis imperfecta 
(OI), which is a more severe osteopathy, demonstrated significantly higher mean CV 
compared to healthy controls (p<0.05) for all total and partial image sets. 
Table 3.2 Measures of intra-subject coefficient of variation (CV) for apparent bone volume total 
volume (appBV/TV) 
  Intra-subject CV for appBV/TV 
Image sets Controls 
n=20 
Cases (All) 
n=10 
p Cases (OI only) 
n=4 
p 
20IM 2.6 ± 1.1 3.7 ± 2.1 >0.05 4.6 ± 2.7 0.037 
10IM 3.0 ± 1.5 4.7 ± 3.0 >0.05 7.1 ± 3.1 0.028 
5IM 3.1 ± 1.5 4.3 ± 3.1 >0.05 5.9 ± 3.6 0.017 
IM = number of images analysed from the total or partial image sets; Values in mean±SD. 
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Figure 3.2 The agreement between partial and total image sets estimates of apparent 
trabecular bone volume/total volume (appBV/TV) in healthy subjects, using Bland-Altman 
analysis. Partial image sets of (A) 10 images (10IM), (B) 5 images (5IM) and (C) 1 image (1IM), 
agreed well with the total image set (20IM), although 1IM had most values dispersed outwith the 95% 
confidence interval of the mean difference. Mean difference marked with solid blue line whilst upper 
and lower limits of agreement (LOA) marked with dashed red lines. Dashed blue lines indicate the 
95% confidence interval of the mean difference. 
B 
C 
 Mean -0.0008, SD 0.0037 
Mean -0.0048, SD 0.0072 
Mean 0.0002, SD 0.001 
A 
Upper LOA 
Mean + 1.96 (SD) = 0.0022 
Lower LOA 
Mean - 1.96 (SD) = -0.0018 
Upper LOA 
Mean + 1.96 (SD) = 0.0065 
Lower LOA 
Mean - 1.96 (SD) = -0.0081 
Upper LOA 
Mean + 1.96 (SD) = 0.0093 
Lower LOA 
Mean - 1.96 (SD) = -0.019 
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Figure 3.3 The agreement between partial and total image sets estimates of apparent 
trabecular bone volume/total volume (appBV/TV) in cases with childhood-onset bone 
abnormalities, using Bland-Altman analysis. Partial image sets of (A) 10 images (10IM), (B) 5 
images (5IM) and 1 image (1IM), agreed well with the total image set (20IM), although 1IM had most 
values dispersed outwith the 95% confidence interval of the mean difference. Mean difference 
marked with solid blue line whilst upper and lower limits of agreement (LOA) marked with dashed 
red lines. Dashed blue lines indicate the 95% confidence interval of the mean difference.  
B 
C 
A 
Mean 0.0080, SD 0.0181 
Mean 0.0070, SD 0.0164 
Mean 0.0120, SD 0.0162 
Upper LOA 
Mean + 1.96 (SD) = 0.0435 
Lower LOA 
Mean - 1.96 (SD) = -0.027 
Upper LOA 
Mean + 1.96 (SD) = 0.0391 
Lower LOA 
Mean - 1.96 (SD) = -0.0251 
Upper LOA 
Mean + 1.96 (SD) = 0.0438 
Lower LOA 
Mean - 1.96 (SD) = -0.0198 
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3.5 Discussion 
Although laborious, this exercise in Chapter 3 has been instrumental in informing the final 
decision with regards to the minimum number of image slices needed in partial image set 
analysis to be representative of the total image set.  Based on the results, partial image 
analyses of 10 images, 5 images and even 1 central image only were quantitatively as reliable 
as analysis of the full image set of 20 images, for both cases and controls. Although 
remaining within the upper and lower limits of agreement, the values of the differences 
between 1IM and 20IM were mostly scattered closer to the extremes of the limits with most 
sitting outwith the 95% confidence interval of the mean difference. This made the partial 
image analysis of 1IM not ideal.  
The principal advantage of using fewer images to assess trabecular bone microarchitecture 
is a substantial reduction in time for analysis. The time taken to analyse each slice was 
approximately 1.5 minutes. Therefore, partial image analysis of 5 images vs 20 images 
reduced the analysis time from approximately 30 minutes to 7.5 minutes per participant. 
Correspondingly, the analysis time for 10 images were 15 minutes per participant. Given 
that the partial image analyses for 5 and 10 images corresponded well with the total image 
analysis of 20 images, it is concluded that partial image analysis of 5 images per participant 
was the most time-efficient, yet accurate representative of the total image set. The final MRI 
analyses of Chapter 4 were, therefore conducted with partial image analysis of 5 images per 
participant as detailed in 2.2.2.3. 
The reproducibility of the image analysis method was also studied in this Chapter as the 
region of interest per image per participant had to be manually drawn each time. Based on 
the result, the within subject CV compared well for partial and total images analyses. More 
importantly, the within subject CV between cases and controls were not significantly 
different. Further sub-analysis of the cases with osteogenesis imperfecta, a more severe 
osteopathy, demonstrated significantly higher mean CV suggesting that in cases with severe 
abnormalities of bone health, a larger set of images may need to be analysed to improve 
precision. This, however, should be interpreted with caution due to the very small sample 
size (n=4). The very precise nature of bone microarchitecture estimates seen in this Chapter 
3, even in individuals who were older, would confidently allow extrapolation for the younger 
cohort studied in Chapter 4, except for measures of trabecular thickness which was limited 
by partial volume effect based on the current imaging sequence. 
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In conclusion, these findings indicate that partial image sets can reliably represent a larger 
complete set of images when assessing trabecular bone microarchitecture parameters, 
reducing the overall time taken for image analysis. 
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4 The Assessment of Bone Health in Children with 
Established Type 1 Diabetes 
4.1 Abstract 
To understand the effects of T1D on bone health, 32 affected children at a median (range) 
age of 13.7 years (10.4, 16.7), were recruited for multimodality assessment of bone health. 
Serum bone alkaline phosphatase (BAP) and c-terminal telopeptide of type 1 collagen (CTX) 
as well as DXA total body (TB) and lumbar spine (LS) bone mineral content (BMC) adjusted 
for bone area were converted to SDS. 3T MRI of the proximal tibia was performed to assess 
bone volume/total volume (appBV/TV), trabecular number (appTbN) and vertebral bone 
marrow fat fraction (%) and compared to 26 healthy controls. In T1D, median BAP SDS and 
CTX SDS were -0.6 (-2.5, +2.1) and -1.1 (-2.5, +0.5) and median TB and LS BMC SDS 
were -0.1 (-1.1, 0.9) and -0.3 (-1.0, 1.8), respectively. Median appBV/TV in cases and 
controls was 0.55 (0.47, 0.63) and 0.59 (0.47, 0.63) (p=0.024) and median appTbN was 1.67 
(1.56, 1.93) and 1.82 (1.56, 1.99); p=0.004), respectively. The median bone marrow fat 
fraction in cases and controls was similar at 23% (11, 66) and 20% (8, 61), respectively 
(p=0.25). Median BAP SDS in T1D cases with HbA1c>75mmol/mol was -0.79 (-2.5, -0.54) 
compared to 0.5 (-0.64, 2.10) in those with HbA1c<58mmol/mol) (p=0.009). Children who 
presented in DKA and those treated with insulin via MDI had significantly lower BAP SDS 
compared to those not in DKA, and those on insulin pump, with p=0.017 and p=0.025 
respectively. Fractures were encountered in 10/32 (31%) cases after diagnosis of T1D and 
in 5/26 (19%) controls (p<0.001). Median HbA1c in those cases with and without fracture 
was 72mmol/mol (49, 100) and 62mmol/mol (27, 87), respectively (p=0.007) whilst median 
TB BMC SDS was -0.5 (-1.1, 0.0) and 0.0 (-0.5, +0.9), respectively (p<0.001). There was 
no significant difference in bone microarchitecture or bone marrow adiposity between these 
fracture groups. Children with T1D display a low bone turnover state associated with 
reduced bone mineralisation and poorer bone microarchitecture. Fractures were associated 
with poorer glycaemic control and bone mineral status. 
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4.2 Introduction  
Adults with T1D have a significantly increased risk of fracture compared to the general 
population (Vestergaard 2007, Hothersall et al. 2014). Indeed, recent studies also confirm 
that this increased fracture risk affects children and young people with T1D (Weber et al. 
2015, Vavanikunnel et al. 2019). New presentation of T1D peaks between the ages of 9 and 
14 years (Scottish Diabetes Survery Monitoring Group NHS Scotland 2014, Health Quality 
Improvement Partnership and Royal College of Paediatrics and Child Health 2015) and 
given that childhood and adolescence are important physiological periods for optimal bone 
development (Baxter-Jones et al. 2011), it is possible that these young people with T1D may 
be especially susceptible to abnormalities of bone health.  
Earlier studies suggested that the deficit in bone mass in T1D may be present quite early on, 
with evidence of osteopenia as early as two years after the diagnosis (McNair et al. 1978, 
Gunczler et al. 1998, Gunczler et al. 2001). Children with T1D have also been reported to 
have lower lumbar spine bone mineral density (BMD) within the first few months of 
diagnosis (Gunczler et al. 2001). This reduction worsens in children with disease duration 
of more than three months but stabilises with no further correlation between longer disease 
duration and BMD, suggesting that there may be a degree of reversibility in the process. It 
is unclear whether the duration of the condition or any other clinical parameters of diabetes 
or its control are associated with adverse skeletal morbidity. As the significantly increased 
fracture risk is disproportionate to the marginal reduction in bone mineral density in adults 
with T1D (Vestergaard et al. 2007), there is an increasing realisation that a comprehensive 
assessment of bone requires an assessment of bone microarchitecture as well as bone 
densitometry (McComb et al. 2014b). 
Metabolic conditions that may affect bone health, such as diabetes, are also associated with 
marked alterations in body composition, adiposity and bone marrow adiposity (Baum et al. 
2012, Patsch et al. 2013b, Sheu et al. 2017). Glycaemic control in diabetes has been shown 
to be positively related to lumbar spine marrow adiposity (Baum et al. 2012, Yu et al. 2017). 
MRI with its ability to study microarchitecture as well as bone marrow adiposity promises 
to be a useful imaging modality. Indeed, recent MRI-based studies in young women with 
childhood-onset T1D revealed a deficit in trabecular bone microarchitecture (Abdalrahaman 
et al. 2015). The current study was performed to better understand the effects of T1D on 
bone health in children, and specifically to determine whether these MRI-based findings in 
trabecular bone microarchitecture were present at an earlier age in children with T1D. The 
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detailed multimodality analysis of bone health performed in these children also provided a 
mechanistic insight into the effect of diabetes on the developing skeleton. 
4.3 Methods 
4.3.1 Subjects 
Children and adolescents aged between 10-18 years old with T1D for at least three years 
were recruited from the Paediatric Diabetes Service at the Royal Hospital for Children, 
Glasgow during the period August 2014 and January 2016. The diagnosis of T1D was based 
on clinical presentation and ongoing insulin requirement with autoantibody confirmation in 
uncertain cases. For the MRI-based studies, age and sex-matched children and adolescents 
without T1D were recruited from general paediatric clinics, siblings of the index cases and 
children of staff members to provide a reference group. Exclusion criteria included other 
chronic diseases or medications known to affect bone health and children with metallic 
implants and pacemakers incompatible with MRI. Children with autoimmune conditions 
such as hypothyroidism and Coeliac disease were included if they had good compliance with 
the respective treatments as determined biochemically.  
4.3.2 Design 
Information on personal health, medication history and lifestyle habits, including dairy 
intake, use of vitamins or calcium supplementation, cigarette smoking, and a family history 
of early osteoporosis was collected. History of fractures was also ascertained, and only those 
radiologically-confirmed (sustained after diagnosis of T1D) were included. Age-appropriate 
questionaires were used to collect information on level of physical activity (Kowalski et al. 
1997a, Kowalski et al. 1997b). In children with T1D, additional information was also 
collected on age at diagnosis, severity of initial presentation, disease duration, glycaemic 
control, as measured by glycosylated haemoglobin (HbA1c) over the last 12 months, and 
presence of microvascular complications. Glycaemic control was categorised as good 
(HbA1c <7.5% or <58 mmol/mol), moderate (HbA1c 7.5-9.0% or 58-75mmol/mol) or poor 
(HbA1c >9.0% or >75mmol/mol) (Rewers et al. 2009). Children with T1D had assessments 
of bone biochemical markers, DXA, MRI and MRS whilst healthy controls only underwent 
MRI and MRS. The study protocol was approved by the West of Scotland Research Ethics 
Committee and informed consent was obtained from the study participants. 
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4.3.3 Anthropometry and puberty staging 
All children had height measured using a stadiometer without footwear and weighed 
barefooted with only light clothing on. Age- and sex-adjusted Z scores for height, weight 
and BMI were calculated using the LMS method based on UK population reference data 
(Cole 1990). Puberty assessment was undertaken and categorised according to Tanner stages 
for girls and boys, with the additional option of self-assessment in those who did not want 
to be examined (Morris and Udry 1980). For analysis, pubertal status was defined by genital 
status in male and breast development in female. Based on the assessment, all children were 
categorised into pre-pubertal (Tanner Stage 1), early puberty (Tanner Stage 2 and 3) and late 
puberty (Tanner Stage 4 and 5). 
4.3.4 Biochemical Markers of Bone Metabolism & GH/IGF-1 Axis  
In all 32 cases, non-fasting blood samples were collected in the morning to coincide with 
clinic visit, centrifuged and the supernatant stored at -800C. Details of the specific assays are 
as described in Chapter 2. Markers of bone formation (bone alkaline phosphatase [BAP], 
osteocalcin [OC]), bone resorption (C terminal telopeptide of Type I collagen [CTX]), 
adiposity (pre-adipocyte factor-1 [PREF-1]), growth hormone axis (IGF-1, IGFBP-3, the 
acid labile subunit [ALS]), sclerostin and other regulator markers of bone turnover (PTH, 
AP, 25-Hydroxy-vitamin D [25OHD]) were measured. 
4.3.5 Dual energy X-ray Absorptiometry (DXA) 
Lumbar spine (LS, L2-L4) and total body (TB) measurements were acquired by a Lunar 
Prodigy densitometer (GE Medical Systems, Waukesha, Wisconsin, USA) and analysed 
using Encore software (Version 13.0). Details of the image acquisition and analysis are as 
described in Chapter 2. As outlined in previous studies, reference data were used to calculate 
a predicted and a percentage predicted bone area (BA) for age and sex (Warner et al. 1998, 
Ahmed et al. 2004). The reference data allowed for a comparison of the actual bone mineral 
content (BMC) of the individual with the predicted BMC of a subject of the same sex and 
bone area from which the percentage predicted BMC (ppBMC), expressed as an SDS (BMC 
SDS) could be calculated. The coefficient of variation (%CV) calculated on repeated DXA 
measurement of a phantom was <1% of BMC and the in vivo %CV was <2.5%. DXA was 
also used to perform thoracolumbar vertebral fracture assessment, as previously described 
(Kyriakou et al. 2016).  
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4.3.6 Magnetic Resonance Imaging (MRI) Assessment of 
Microarchitecture 
All 32 children with T1D and 26 healthy controls were scanned. Twenty slice images were 
acquired at the proximal tibia using a 3T Siemens MAGNETOM Prisma MRI scanner 
(Siemens, Erlangen, Germany) and analysed using MATLAB software (Mathworks Inc, San 
Mateo, CA, USA) to obtain measures for apparent bone volume ratio (appBV/TV), apparent 
trabecular number (appTbN), apparent trabecular thickness (appTbTh), and apparent 
trabecular separation (appTbSp). Details of the image acquisition and analysis are as 
described in Chapter 2. The repeatability of microMRI is high with an average CV of 1%. 
The images were of sufficiently good quality to be analysed in 30 of the 32 cases and in all 
26 control participants.  
4.3.7 Magnetic Resonance Spectroscopy (MRS) Assessment of 
Bone Marrow Adiposity 
All 32 children with T1D and 22 healthy controls were scanned. 1H-MRS was performed 
using an 18-channel body array (anterior) and a 32-channel spine coil (posterior) to  acquire 
images at the lumbar spine (L3) position. Analysis was performed using the Java-based 
magnetic resonance user interface (jMRUI) software to calculate the percentage fat fraction 
(%FF) within the bone marrow as a measure of bone marrow adiposity (Schellinger et al. 
2004). Details of the image acquisition and analysis are as described in Chapter 2. The 
repeatability of MRS is also high with an average CV of 2.5%. The images were of 
sufficiently good quality to be analysed in 29 of 32 children with T1D and 21 of 22 healthy 
controls.  
4.3.8 Sample Size Calculation and Statistical Analyses 
The primary hypothesis was that children with T1D would have a lower appBV/TV 
compared to healthy children. The estimated coefficient of variation (CV) for appBV/TV 
was less than 5% in our previous work (McComb et al. 2014b, Abdalrahaman et al. 2015) 
and based on this a 7.5% difference at p<0.05 with a power of 0.8 would require at least 25 
subjects in each arm.  
Data were analysed using IBM SPSS software (Version 22, SPSS, Chicago, IL, USA) and 
described as medians (ranges). Group differences between cases and controls were initially 
compared by Mann-Whitney test for continuous variables and Chi-square test for categorical 
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variables, and then adjusted for multiple testing using false discovery rates (FDR). 
Specifically, biochemical markers of bone turnover and DXA parameters were compared 
against 0, using the above tests depending on the variables. Spearman’s rank correlation co-
efficient was used to assess the association between variables. Further analysis was 
performed to compare the characteristics of those children with T1D with a history of 
fractures with those without fractures. Factors significant on univariate analysis (HbA1c, TB 
BMC and physical activity score) were included in a multivariate logistic regression for 
comparison between the fracture and non-fracture groups. All continuous data were 
presented as median (ranges) with p<0.05 considered as significant, unless otherwise 
specified. 
4.4 Results 
4.4.1 Clinical characteristics 
Thirty-two children with T1D, median (range) age 13.7 years (10.4, 16.7), were recruited 
(16 boys) (Table 4.1). The median age at diagnosis was 5.9 years (1.3, 10.8) and median 
duration of disease was 7.2 years (3.1, 12.4). The median average HbA1c in the preceeding 
12 months was 8.1% (4.6, 11.3) or 65mmol/mol (27, 100); glycaemic control was good in 
seven, moderate in 19 and poor in six. Of the 32 children, 3 were pre-pubertal, 17 in early 
puberty (Tanner stages 2 and 3) and 12 in late puberty (Tanner stages 4 and 5). Ten presented 
with diabetic ketoacidosis (DKA) at the time of diagnosis. The median insulin dose was 
1.0unit/kg/day (0.6, 1.8) with 10 out of 32 on continuous subcutaneous insulin infusion 
(CSII) via pump. Of the 24 eligible children with T1D, 16 had undergone retinopathy 
screening and 19 had assessment of microalbuminuria. Mild background retinopathy was 
present in 3 (19%) and microalbuminuria was absent in all. 
4.4.2 Bone Metabolism & GH/IGF-1 Axis   
Children with T1D had reduced BAP SDS -0.57 (-2.50, 2.10), with median absolute value 
59.2mcg/L (14.4, 118.5) (Table 4.2). Those with poor control had a lower BAP SDS of -
0.79 (-2.5, -0.54) compared to 0.50 (-0.64, 2.10) for children with good glycaemic control 
(p=0.009) and -0.62 (-1.62, 1.11) for children with moderate control (p=0.03) (Figure 4.1A). 
Serum osteocalcin did not show any relationship to glycaemic control, age or duration of 
diagnosis. Although median CTX SDS was also reduced compared to controls (p<0.001) 
(Table 4.2) this did not show the same relationship to glycaemic control as BAP (p=0.954) 
(Figure 4.1C). However, median CTX SDS (r, -0.44, p=0.012) and sclerostin were inversely 
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related to age of diagnosis (r, -0.38, p=0.038) (Figure 4.1D and Figure 4.1F). Although 
serum IGF-1 was not significantly lower in children with T1D, the latter had a lower ALS 
SDS (p<0.001) and a higher IGFBP-3 SDS (p<0.001) (Table 4.2). Children with T1D who 
were in DKA at initial presentation had significantly lower BAP SDS than those who were 
not acidotic (p<0.017) (Figure 4.2A). Further hospital admissions with DKA subsequent to 
the initial presentation, however, did not appear to have an effect on BAP (p=0.734) (Figure 
4.2B). The T1D children on continuous subcutaneous insulin infusion (CSII; pump therapy), 
did not only have significantly lower HbA1c (p=0.005) and lower daily insulin requirement 
for weight (p=0.04), but also had higher BAP SDS (p=0.025) compared to those on MDI 
(Figure 4.2C-E).  
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Table 4.1 Clinical characteristics of the whole cohort, with sub-categories of children with T1D based on glycemic control as per HbA1c 
 
Whole Cohort 
 
T1D Cases Based on Glycemic control (HbA1c) 
 
T1D 
(n=32) 
Control 
(n=26) 
p 
 
Good 
(n=6) 
Moderate 
(n=20) 
Poor 
(n=6) 
p 
Age (years) 13.7 (10.4,16.7) 13.8 (10.2,17.8) 0.994 
 
12.3 (11.5,16.4) 13.8 (10.7,16.7) 13.1 (10.4,16.4) 0.633 
Gender (M/F) 16/16 13/13 0.999 
 
3/3 8/12 6/0 0.031 
Height SDS 0.3 (-1.5,2.5) -0.1 (-1.6,2.7) 0.173 
 
0.3 (-0.8,1.3) 0.7 (-1.5,2.5) 0.2 (-1.4,1.2) 0.479 
Weight SDS 0.8 (-1.3,3.2) 0.6 (-1.2, 3.1) 0.569 
 
0.2 (-0.4,0.5) 1.0 (-0.4,3.2) 0.5 (-1.3,2.4) 0.119 
BMI SDS 0.5 (-0.6,2.9) 1.0 (-1.6,2.7) 0.798 
 
-0.1 (-0.2,0.0) 1.0 (-0.6,2.4) 0.5(-0.6,2.9) 0.084 
Tanner stage (Pre/Early/Late) (n) 3/17/12 4/13/9 0.831 
 
1/4/1 2/11/7 0/3/3 0.758 
Age at diagnosis (yr) 5.9 (1.3,10.8) 
   
6.3 (4.2,10.3) 5.5 (1.3,10.8) 6.2 (3.7,10.8) 0.810 
Disease duration (yr)  7.2 (3.1,12.4) 
   
7.3 (3.1,10.1) 7.3 (3.1,12.3) 6.7 (3.1,9.6) 0.639 
HbA1c average in last 12m (%) 
HbA1c average in last 12m (mmol/mol) 
8.1 (4.6,11.3) 
65 (27,100) 
   
7.0 (6.6,7.3) 
53 (49,56) 
8.1 (7.5,8.9) 
65 (58,74) 
10.0 (9.2,11.3) 
86 (77,100) 
<0.001 
<0.001 
HbA1c at diagnosis (%)  
HbA1c at diagnosis (mmol/mol) 
10.7 (7.3,17.2)a 
93 (56,164)a 
   
9.5 (7.3,9.9) 
80 (56,85) 
11.1 (7.9,17.2) 
98 (63,164) 
9.6 (8.8,12.1) 
81 (73,109) 
0.069 
0.069 
DKA at initial presentation (Y/N) (n=31) 21/10 
   
0/5 7/12d 3/3 0.187 
Insulin dose (unit/kg/day) 1.0 (0.6,1.8)b 
   
0.89 (0.60,1.03) 1.03 (0.73,1.50) 1.6 (1.24,1.81) <0.001 
Insulin pump/injections 10/22 
   
6/0 5/15 0/6 0.001 
25-OH Vitamin D (nmol/L) 48 (18,75) 
   
53 (48,60) 47 (18,70) 51 (39,75) 0.283 
Physical activity score 2.4 (1.3,4.1) 2.5 (1.6,4.1)c 0.425 
 
2.0 (1.4,3.7) 2.4 (1.6,3.5) 3.0 (1.3,4.1) 0.361 
Previous fracture(s)(Y/N) 10/22 5/21 <0.001 
 
1/5 5/15 4/2 0.130 
Values are presented as median (range). 
a
 n=25, 
b
 n=27, 
c 
n=24, 
d
 n=19 
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The median 25-OH vitamin D level was 48nmol/L (18, 75) and PTH 3.6mmol/L (1.5, 6.6) 
in the children with T1D. There were no intergroup differences in 25-OH vitamin D levels 
in the children with [47nmol/L (25,70)] and without [49nmol/L (18,75)] DKA at initial 
presentation (p=0.555) or the children on continuous subcutaneous insulin infusion (CSII; 
pump therapy) [49nmol/L (37,60)] compared to those on multiple daily injections (MDI) 
[47nmol/L (18,75)] of insulin (p=0.602). 
4.4.3 Bone Densitometry by DXA  
Median BMC SDS for TB and LS was marginally but significantly lower than 0 at -0.1 (-
1.1, 0.9) and -0.3 (-1.0, 1.8), respectively (Table 4.2). TB and LS BMC SDS did not show 
any correlation to glycaemic control (p=0.236, p=0.256, respectively), age at diagnosis 
(p=0.235, p=0.896), or disease duration (p=0.956, p=0.757). TB and LS BMC SDS were 
also not significantly different whether the children were acidotic or not at initial 
presentation (p=0.145 and p=0.260 respectively) (Figure 4.3A, B, D-F). TB BMC SDS, 
however, was inversely related to CTX SDS (r, -0.5, p=0.003) (Figure 4.3C). 
4.4.4 Bone microarchitecture by MRI 
Comparison of bone microarchitecture variables revealed that appBV/TV and appTbN were 
significantly lower and appTbSp higher in T1D children than healthy controls (Table 4.2, 
Figure 4.4A, C-D). Serum ALS showed an inverse association to appBV/TV (r, -0.54, 
p=0.002), appTbTh (r, -0.42, p=0.02) and appTbSp (r, 0.46, p=0.01) in the T1D children; 
however, removal of two cases with high values of ALS SDS resulted in an absence of this 
association except for appBV/TV where an inverse association was still present at r, -0.44 
(p=0.02) (Figure 4.5Figure 4.4A). In the T1D cases, there was no association of appBV/TV, 
appTbN, or app TbSp with HbA1c, age at diagnosis or duration of T1D. The bone 
microarchitecture parameters were also not significantly different whether the children were 
acidotic at the time of presentation for appBV/TV, appTbTh, appTbN, or app TbSp with 
p=0.795, p-0.962, p=0.620, p=0.925 respectively. However, daily insulin dose corrected for 
weight were positively associated with TbN (r= 0.41, p=0.036) (Figure 4.5B). There was no 
evidence of an association between any of the bone microarchitecture variables and BMC 
SDS for TB or LS.  
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Table 4.2 Biochemical markers, DXA and MRI-based Measures of Bone Microarchitecture and Vertebral Bone Marrow Adiposity 
 
Values are presented as median (range). PTH = parathyroid hormone, BAP = bone alkaline phosphatase, CTX = c-terminal telopeptide of collagen 1, IGF = insulin-like 
growth factor, IGFBP = insulin-like growth factor binding protein, ALS = acid labile subunit, DXA = dual energy xray absorptiometry, TB = total body, LS = lumbar spine, 
BMC = bone mineral content, BA = bone area, SDS = standard deviation score, MRI = magnetic resonance imaging, appBV/TV = apparent bone volume to total volume, 
appTbN = apparent trabecular number, appTbSp = apparent trabecular separation, appTbTh = apparent trabecular thickness. FF = fat fraction.
  
a
 n=30, 
b 
n=29, 
c
 compared to 0 
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1 
Figure 4.1 The relationships between T1D disease characteristics and markers of bone turnover (as assessed by bone formation marker BAP, bone resorption 
marker CTX and sclerostin).  Children with poor glycaemic control had significantly lower bone formation marker compared to children with moderate and good controls.  
Children diagnosed younger with T1D had significantly higher bone resorption and sclerostin levels.  
                                                 
 
A 
B D 
C E 
F 
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Figure 4.2 The relationships between acidosis (DKA) and methods of insulin delivery (MDI vs CSII) and T1D disease characteristics, bone formation marker 
(BAP) and bone density (as assessed by DXA).  Children with T1D who were acidotic at initial presentation had significantly lower BAP SDS than those who were not 
acidotic (A). This relationship did not stand with total number of acidotic events requiring hospital attendance (B). Children with insulin delivered by CSII (pump) did not 
only have lower HbA1c (C) and lower total daily insulin dose (D), but also has higher bone formation marker (E). [DKA=diabetic ketoacidosis, WW- Walking wounded, or 
non-DKA, MDI=multiple daily injection, CSII (continuous subcutaneous insulin infusion, DXA=dual x-ray absorptiometry, BAP=bone alkaline phosphate 
p=0.734 
p=0.017 A 
B D 
E C 
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Figure 4.3 The relationships between bone mineral density status (as assessed by DXA) and markers of bone turnover (as assessed by bone formation 
marker BAP, bone resorption marker CTX and sclerostin) in children with T1D.  TB BMC SDS was inversely related to CTX SDS. [BAP bone alkaline phosphatise; 
CTX c-terminal telopeptide of type 1 collagen] 
r, -0.07, p=0.718 r, 0.03, p=0.879 
r, -0.50, p=0.003 r, 0.06, p=0.766 
r, -0.17, p=0.364 
r, -0.28, p=0.127 A 
D 
C E 
F B 
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Figure 4.4 Bone microarchitecture parameters comparing children with T1D and healthy controls. Children with T1D have significantly altered bone 
microarchitecture, including (A) lower bone volume to total volume, (C)lower trabecular number and (D) higher trabecular separation. [appBV/TV=apparent bone volume 
to total volume, appTbTh=apparent trabecular thickness, appTbN=apparent trabecular number, appTbSp=apparent trabecular separation 
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Figure 4.5 The relationships between bone microarchitecture parameters with markers of 
GH/IGF-1 axis and insulin dose in children with T1D. Serum ALS was inversely associated with 
appBV/TV whilst insulin dose is positively associated with appTbN. [ALS=acid labile subunit, 
appBV/TV= apparent bone volume to total volume, appTbN=apparent trabecular number] 
4.4.5 Bone Marrow Adiposity by MRI 
Median vertebral bone marrow adiposity, expressed as percentage fat fraction (%FF), was 
higher in cases than controls, but this did not reach statistically signiﬁcant difference (Table 
4.2,Figure 4.6). In the cases, there was no association between %FF and markers of GH/IGF-
1 axis or bone turnover, BMC SDS for TB or LS. Combined analysis of the cases and 
controls showed an inverse association between %FF and appTbN (r, -0.40, p=0.004) and a 
positive association with appTbSp (r, 0.33, p=0.021) (Figure 4.7). 
 
Figure 4.6 Vertebral bone marrow adiposity, expressed in fat fraction % in T1D children and 
healthy controls.  Children with T1D had higher fat fraction compared to healthy controls, although 
this did not reach statistical significance. 
r, -0.44, p=0.02 r, 0.41, p=0.036 A B 
p=0.250 
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Figure 4.7 The relationships between percentage fat fraction (%FF) and bone 
microarchitecture parameters in the whole cohort.  %FF is inversely associated with trabecular 
number and positively associated with trabecular separation. 
4.4.6 Fracture data 
Children with T1D were significantly more likely to fracture compared to healthy controls 
(p<0.001) (Table 4.1). Of the 32 children with T1D, 10 (31%) had radiologically confirmed 
fracture following the diagnosis of T1D, as summarised in Table 4.3. Two out of these 10 
sustained a lower extremity fracture (lower leg/ankle, or foot), whilst the rest had upper 
extremity limb fractures (humerus, elbow, forearm, hand). The children with lower extremity 
fractures were younger when diagnosed with T1D. None of the children had any 
abnormalities identified on vertebral fracture assessment by DXA. 
The clinical characteristics of the fracture and non-fracture group were comparable for age, 
gender, puberty, anthropometric measurements, insulin doses and delivery systems (Table 
4.4). The median age of diagnosis was 4.4 years (1.3, 10.8) in the fracture group and 6.5 
years (3.8, 10.8) in the non-fracture group, although this did not reach statistical significance 
between groups (p=0.077) (Figure 4.8A, Table 4.4). The median duration of disease was 8.6 
years (3,1,12.4) in the fracture group and 7.0 years (3.1,10.9) in the non-fracture group 
(p=0.204). The median HbA1c was higher in the fracture group at 8.7% (6.6, 11.3) or 
72mmol/mol (49, 100) compared to the non-fracture group of 7.8% (4.6, 10.1) or 
62mmol/mol (27, 87) (p=0.005 and p=0.007 respectively) (Table 4.4, Figure 4.8B). 
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Table 4.3 Age, distribution, sites of fracture and the events preceeding in the fracture cohort 
Age at 
diagnosis 
(year) 
Sex Age at 
fracture 
(year) 
Duration of 
disease  to 
fracture time 
(year) 
Fracture distribution 
(UL/LL/Other) 
Site of Fracture Event preceding fracture 
1.3 M 12.3 11.0 LL Left tibia + metatarsals Hyperextension injury during football 
 
 
13.1 11.8 LL Left calcaneum Fell off skateboard at low speed 
 
 
13.2 11.9 UL Left 5
th
 proximal phalange Hyperextension injury during football 
2.2 F 4.9 2.7 LL Right fibula Fell in park from standing height 
 
 
6.1 4.5 UL Left supracondyle Fell off motorcycle with protective gear 
2.8 M 5.9 3.1 Other Right clavicle Fell in park from standing height 
3.7 M 6.4 2.7 UL Left radius and ulnar Fell on outstretched hand 
4.3 M 10.9 6.6 UL Right radius and ulnar Fell in school from standing height 
4.5 F 7.4 2.9 UL Right radius Trip over schoolbag  
5.0 M 8.1 3.1 UL Left supracondyle Fell onto left side from standing height 
7.3 M 10.4 3.1 UL Left radius Slipped and fell during football 
 
 
12.0 4.7 UL Left radius Hyperextension injury during football 
10.3 F 11.5 1.2 UL Left radius Fell on outstretched hand 
10.8 M 11.2 0.4 UL Left scaphoid Fell on outstretched hand 
 
 
11.8 1.0 UL Left humeral supracondyle Fell off bicycle 
 
      
M = Male, F = Female, UL = upper limb, LL = lower limb 
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Table 4.4 Clinical characteristics of all children with T1D by sub-categories of fracture and 
non-fracture 
Parameters No Fracture 
(n=22) 
Fracture 
(n=10) 
p 
Age (years) 13.5 (10.7,16.7) 13.8 (10.4,16.4)  0.920 
Gender (M/F) 9/13 7/3  0.127 
Height SDS 0.3 (-1.5,2.5) 0.4 (-1.4,2.1) 0.795 
Weight SDS 0.8 (-0.4,2.4) 0.5 (-1.3,3.2) 0.366 
BMI SDS 0.6 (-0.6,2.9) 0.5 (-0.6,2.4) 0.411 
Tanner stage (Pre/Early/Late) (n) 3/10/9 0/7/3  0.316  
Age at diagnosis (yr) 6.5 (3.8,10.8) 4.4 (1.3,10.8) 0.077 
Disease duration (yr)  7.0 (3.1,10.9) 8.6 (3.1,12.4) 0.204 
HbA1c average in last 12m (%) 
HbA1c average in last 12m (mmol/mol) 
7.8 (4.6,10.1) 
62 (27,87) 
8.7 (6.6,11.3) 
72 (49,100) 
0.005 
0.007 
HbA1c at diagnosis (%)
 
 
HbA1c at diagnosis (mmol/mol) 
10.8 (7.3,17.2) 
95 (56,164) 
10.3 (8.8,13.3) 
89 (73,122) 
0.574 
0.574 
Severity at diagnosis  
- Not DKA/DKA/unknown (n) 
14/7/1 6/4/0 0.740 
Insulin dose (unit/kg/day) 1.0 (0.6,1.8) 1.2 (0.8,1.7) 0.264 
Insulin pump/injections 7/15 3/7 0.921 
TB BMC for BA SDS 0.0 (-0.5,0.9) -0.5 (-1.1,0.0) <0.001 
LS BMC for BA SDS -0.3 (-1.0,0.8) -0.5 (-1.0,1.8) 0.617 
25-OH Vitamin D (nmol/L) 48 (18,70) 47 (25,75) 0.884 
PTH (mmol/L) 3.7 (1.8,6.6) 3.4 (1.5,5.7) 0.475 
Sclerostin (ng/ml) 0.21 (0.01,0.70) 0.25 (0.05,0.50) 0.734 
Osteocalcin (ng/ml) 44.3 (16.1,204.4) 60.6 (13.9,262.8) 0.190 
BAP SDS -0.62 (-2.50,1.11)  -0.55 (-1.62,2.10) 0.764 
CTX SDS -1.17 (-2.49,0.29) -0.73 (-1.67,0.51) 0.047 
IGF-1 SDS -0.30 (-3.64,1.14) -0.06 (-2.33,1.48) 0.734 
IGFBP-3 SDS 1.78 (0.13,3.81) 1.37 (0.16,3.26) 0.952 
ALS SDS -0.67 (-1.67,0.76) -0.79 (-1.63,-0.12) 0.434 
Physical activity score 2.2 (1.3,3.7) 2.8 (1.7,4.1)  0.043 
appBV/TV 0.55 (0.47,0.63) 0.54 (0.50,0.61) 0.571 
appTbN (mm-1) 1.71 (1.56,1.93) 1.64 (1.57,1.84) 0.512 
appTbSp (mm) 0.26 (0.21,0.32) 0.27 (0.23,0.32) 0.389 
appTbTh (mm) 0.32 (0.27,0.39) 0.32 (0.27,0.37) 0.587 
%FF 26.4 (13.5,66) 20.0 (11.0,45.7) 0.451 
    
Values are presented as median (range). PTH = parathyroid hormone, BAP = bone alkaline 
phosphatase, CTX = c-terminal telopeptide of collagen 1, IGF = insulin-like growth factor, IGFBP = 
insulin-like growth factor binding protein, ALS = acid labile subunit, DXA = dual energy xray 
absorptiometry, TB = total body, LS = lumbar spine, BMC = bone mineral content, BA = bone area, 
SDS = standard deviation score, MRI = magnetic resonance imaging, appBV/TV = apparent bone 
volume to total volume, appTbN = apparent trabecular number, appTbSp = apparent trabecular 
separation, appTbTh = apparent trabecular thickness. FF = fat fraction.
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Figure 4.8 Sub-analysis of children with T1D depending on fracture status.  Children with T1D 
who fractured had poorer glycaemic control (with higher HbA1c) and lower TB BMC-for-BA SDS than 
those without fractures. The physical activity score was higher in the fracture cohort. 
The children with a history of fracture had lower TB BMC SDS (p<0.001) with a median of 
-0.5 (-1.1, 0.0) (Figure 4.8C), but similar LS BMC SDS (p=0.617) (Table 4.4). Both groups 
had similar BAP SDS, IGF-1 SDS and CTX SDS  (Table 4.4). The median physical activity 
score (1=least, 5=most active) for the fracture group was 2.8 (1.7, 4.1) and 2.2 (1.3, 3.7) in 
the non-fracture group (p=0.043) (Figure 4.8D). There was no significant difference in bone 
microarchitecture or bone marrow adiposity between these fracture groups (Table 4.4). On 
multivariate analysis, taking into account HbA1c, TB BMC, and physical activity score, the 
only significant variable was TB BMC (adjusted OR 0.002, 95% CI 0.0 - 0.765, p=0.04). 
 
p=0.007 
p=0.077 
p=0.043 
p<0.001 
A 
D B 
C 
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4.5 Discussion 
This is the first study to look in detail and specifically at the association between T1D disease 
characteristics, bone microarchitecture and marrow adiposity by MRI and fracture incidence 
in children. The group of children studied had an overall diabetes control which was better 
than expected for adolescents (Cameron and Wherrett 2015) but similar to that described 
recently in a population based study of skeletal morbidity in young people with T1D (Weber 
et al. 2015). In addition, contrary to other studies of bone health in children and adolescents 
with T1D (Parthasarathy et al. 2016), the current cohort were well nourished and were also 
vitamin D sufficient. 
Previous studies on bone turnover status of children and adolescents with T1D have 
produced variable results (Valerio et al. 2002, Hamed et al. 2011, Tsentidis et al. 2016). 
Given that these markers vary markedly in growing children, the values for the two 
commonly studied markers of bone formation and bone resorption, BAP and CTX, were 
adjusted for age and sex in the current study. The existence of a low bone turnover state, 
characterised by low circulating levels of both BAP and CTX, is important to highlight in a 
group of well-controlled children with T1D. This biochemical picture has also been 
described in young adults with T1D (Starup-Linde et al. 2014, Abdalrahaman et al. 2015). 
Whilst, it is possible that this low bone turnover state may also be a reflection of functional 
growth hormone resistance which may exist in people with diabetes (Baroncelli et al. 2000), 
circulating IGF-1 was not particularly low in the current cohort. Given that there was a clear 
inverse association between bone formation and glycaemia and between bone resorption and 
the age at diagnosis of diabetes, it is possible that the mechanisms that influence bone 
turnover in T1D are mediated through several pathways including those that may be 
dependent on chronic hyperglycaemia or insulinopenia (Abdalrahman et al. 2015). For 
instance, the inverse association between circulating sclerostin and age at diagnosis further 
supports the notion of a sclerostin-mediated signalling pathway inhibition of bone turnover 
(Gennari et al. 2012).  
Marked reduction in diabetes complications have been reported in T1D adolescents with a 
shift towards a more physiologic insulin replacement using continuous subcutaneous insulin 
infusion (CSII) via pump (Downie et al. 2011). The higher levels of BAP in T1D children 
on CSII compared to those on multiple daily injections (MDI) suggests that this form of 
replacement may indeed be advantageous for bone health preservation. However, given that 
this group also had a lower HbA1c could suggest a degree of selection bias. The lower levels 
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of BAP in children who presented in DKA at initial diagnosis is very interesting and suggests 
the possibility of an additional programming effect of acidosis or sustained hyperglycaemia 
prior to initial presentation on skeletal development. Given that the effects of acidosis on 
bone homeostasis may be independent of calciotropic hormones (Topaloglu et al. 2005) and 
it is possible that acidosis may have an effect on mesenchymal stem cell differentiation 
(Guntur et al. 2018), a long lasting effect on bone health that may result from the initial 
acidotic insult deserves further exploration. Alternatively, as DKA at T1D presentation is 
more likely to occur in younger children,  the lower BAP may be an indication of a more 
aggressive autoimmune process leading to more marked insulin deficiency or shorter 
honeymoon period. 
In the current study, children with T1D had marginally lower bone mineral density when 
corrected for size and this is consistent with previous studies demonstrating that children and 
adolescents with T1D have lower bone mineral density status (Leger et al. 2006, Saha et al. 
2009b, Loureiro et al. 2014). Although bone microarchitecture studies have been performed 
in T1D and some have reported deficits (Maratova et al. 2018, Samelson et al. 2019) the 
current study is the first study in children with T1D that has shown a deficit in MRI-based 
assessment of trabecular bone microarchitecture, a finding which is similar to what has been 
described before in young women with T1D (Abdalrahaman et al. 2015). It is interesting to 
note that that the two studies (Maratova et al. 2018, Samelson et al. 2019) that have shown 
a deficit and the one (I. Roggen et al. 2013) which did not show a deficit examined the tibia 
and radius, respectively and the possibility of a selective effect on a weight bearing site needs 
further exploration in adequately powered studies.  
The inverse association of bone microarchitecture parameters with bone marrow adiposity 
in children confirms our previous reports of this finding in young women (Abdalrahaman et 
al. 2017) and not only does this further reinforce the hypothesis that the observed skeletal 
deficit in T1D may have its origins in a shift of mesenchymal stem cell differentiation 
towards adipogenesis rather than osteogenesis but it also highlights the unique benefit of 
MRI based assessment for providing mechanistic insight when studying bone health. 
Furthermore, the positive association between insulin dose and trabecular number 
substantiates the anabolic effect of insulin on bone (Thomas et al. 1996a, Fulzele et al. 2010). 
The lack of an association between bone microarchitecture parameters and DXA-based 
measures of bone density has also been previously noted in young women with T1D 
(Abdalrahaman et al. 2017) and highlights the point that bone microarchitecture assessment 
provides additional information on bone health that cannot be obtained from bone 
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densitometry. Recent histomorphometric and microCT based studies of trabecular bone 
microarchitecture have shown an inverse association with HbA1c (de Waard et al. 2018, 
Karim et al. 2018) but this was not observed in the current study or our previous study in 
young women (McComb et al. 2014a) and perhaps these studies were not sufficiently 
powered to investigate this association. An association between the deficits in trabecular 
features and fractures was also not observed and this may also require a larger cohort as well 
as a study of cortical parameters, as described recently in adults (Samelson et al. 2019). In 
the previous study performed in young women with T1D, we had reported that bone 
microarchitectural deficits were more likely in those who had retinopathy (Abdalrahaman et 
al. 2015). However, given the low prevalence of microvascular complications in children 
(Sauder et al. 2019), the current study was not sufficiently powered to investigate this finding 
in this age group. 
Approximately a third of the current cohort of children with T1D had suffered a 
radiologically confirmed fracture before the median age of 13.8 years. Fracture rates in 
children with T1D have rarely been reported but the current rate of fractures was higher than 
previously reported in children and young people with T1D (Cameron and Wherrett 2015, 
Parthasarathy et al. 2016, Sauder et al. 2019) and the control group. In the UK, 
approximately one third of children are reported to suffer a fracture before the age of 17 
years, with a fracture incidence of 3% in boys and 1.5% in girls at their peak (Cooper et al. 
2004). Therefore, it is possible that the control group had a relatively lower incidence of 
fractures. In hindsight, one of the limitations of the study is the lack of data on the rate of 
fracture in the children before diagnosis of T1D, as this could exclude the remote possibility 
that by chance the T1D subgroup had individuals with increased bone fragility unrelated to 
the diabetes.  
There were some notable differences between the groups of children with T1D who suffered 
a fracture compared to those who had not suffered a fracture. Children who fractured had 
lower total body bone mineral density and poorer glycaemic control compared to the non-
fracture group. Abnormalities in cortical bone mineral density with reduced muscle cross-
sectional area have been previously reported in T1D and are consistent with an anabolic bone 
deficit (Bechtold et al. 2006). This is further supported by our finding of significantly lower 
total body, but not lumbar, bone mineral density in T1D children with fracture. Given that 
bone microarchitecture at the proximal tibia was not significantly different between the 
fracture and the non-fracture group, this reinforces the need to study cortical bone 
architecture in more detail in this condition. Although the combination of lower bone mineral 
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density, poorer glycaemic control and an increased risk of fractures could have been 
explained by reduced physical activity (Goulding 2007), this confounder was discarded as 
both groups had comparable levels of physical activity.  
In summary, children and adolescents with relatively well controlled T1D are more likely to 
have a history of fractures and show deficits in trabecular bone microarchitecture, BMD and 
bone formation. Although, the association of these markers of bone health to clinical markers 
of T1D and its management require further exploration through prospective clinical trials, 
we would recommend that assessment of bone health should become routine in all 
therapeutic trials in the field of diabetes. 
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5 The Effects of Anti-Diabetic Drugs on 
Mesenchymal Stem Cell Differentiation and the 
Molecular Mechanism of Metformin on 
Adipogenesis Suppression  
5.1 Abstract 
It is possible that people with diabetes mellitus (DM) have altered mesenchymal stem cell 
(MSC) differentiation in the bone marrow, leading to a shift in the balance of differentiation 
away from bone formation (osteogenesis) in favour of fat cell development (adipogenesis) 
and a predisposition to fragility fractures. Different classes of antidiabetic drugs have been 
shown to affect bone health differently, with negative effects from thiazolidinediones whilst 
metformin is associated with clinical reduction in fracture risk. The effects of metformin on 
the differentiation of mouse C3H10T1/2 mesenchymal stem cells into fat and bone cells 
were investigated, with particular interest in the reciprocity of the bone-fat balance. The 
underlying molecular signalling involved, specifically in the adipogenesis effect of 
metformin, was also studied, focussing on the AMPK signalling given that metformin in a 
known AMP-activated protein kinase (AMPK) activator. Metformin was found to exert 
reciprocal control over the osteogenic transcription factor Runx2, and the adipogenic 
transcription factor, PPAR with increase in Runx2 transcriptional activities, independently 
on Runx2 protein expression and suppression of PPARγ - suggesting a bone protective 
mechanism through promotion of osteogenesis and suppression of adipogenesis. The 
suppression of adipogenesis by metformin appeared to be independent of AMPK activation 
but rather through the suppression of the mTOR/p70S6K signalling pathway. Basal AMPK 
and mTOR/p70S6K activity did appear to be required for adipogenesis, as demonstrated by 
the use of the AMPK inhibitor, compound C. It appears, therefore, that basal AMPK activity 
is required for adipogenesis and that metformin can inhibit adipogenesis through AMPK-
dependent or -independent mechanisms, depending on the cellular context.  
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5.2 Introduction  
Adults with Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) have a significantly 
increased risk of fractures compared to the general population (Vestergaard 2007, Hothersall 
et al. 2014). Studies have shown that different classes of antidiabetic drug used in T2D have 
different effects on the bone. Thiazolidinediones (TZDs), such as pioglitazone and 
rosiglitazone, have been irrefutably shown to increase fracture risk (Schwartz et al. 2006, 
Kahn et al. 2008, Loke et al. 2009) whilst the effects of metformin remain inconclusive. 
Several large population-based case control studies have associated metformin with a 
reduction in fracture risk (Vestergaard et al. 2005, Melton et al. 2008, Borges et al. 2011) 
although others did not show any convincing benefit (Kahn et al. 2008). It would be 
conveniently advantageous if metformin, which is also low cost and safe, confers a bone 
protective role as it is increasingly used in T1D to improve insulin resistance with a modest 
effect on glycaemic control (Vella et al. 2010).  
There is a growing body of evidence supporting the bone-fat balance and its important role 
in the pathophysiology of bone loss. Osteoblasts and adipocytes share a common precursor, 
both derived from the pluripotent MSCs located in the bone marrow, suggesting a mutually 
exclusive and reciprocal lineage selection of one or the other (Figure 5.1).  
 
 
Figure 5.1. Bone-fat balance.  Osteogenesis and adipogenesis are proposed to be mutually 
exclusive given that osteoblasts and adipocytes originate from the common progenitor mesenchymal 
stem cells. PPARy2 is the key regulator of adipogenesis whilst Runx2 activation determines 
osteogenesis [Adapted from (Yang et al. 2008)]. 
The differentiation of MSCs are dependent on two main lineage-specific transcription 
factors, namely runt-related transcription factor 2 (Runx2) for osteogenesis and the 
peroxisome proliferator-activated receptor γ (PPARγ) for adipogenesis. By reason that TZDs 
are agonists of the PPAR family of nuclear transcription factors, particularly the PPARγ 
isoform (Yki-Jarvinen 2004), their use is detrimental to bone (negative skeletal 
consequences) as it activates PPARγ and promotes adipogenesis at the expense of 
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osteogenesis (Rzonca et al. 2004). This is evident is both mice (Botolin et al. 2005) and men 
(Schwartz et al. 2006, Grey et al. 2007).  
On the contrary, the mechanism of action of metformin on skeletal health is less clear. 
Metformin is a known AMP-activated protein kinase (AMPK) activator as detailed in section 
1.7. Mice with deleted AMPK subunits demonstrated a reduction in bone volume and 
trabecular number supporting the role of AMPK in bones (Shah et al. 2010). AMPK 
functions to inhibit ATP consuming pathways and at the same time activate catabolic 
pathways to re-establish cellular energy homeostasis. Osteoblast differentiation has been 
proposed to be dependent on the cellular energy sensor AMP-activated protein kinase 
(AMPK), as the expression of various osteogenic genes has been shown to be inhibited by 
compound C, a chemical inhibitor of AMPK, and a dominant negative form of AMPK 
(Banerjee et al. 1997).  
Indeed, metformin was found to have direct osteogenic effect in vitro by stimulating 
proliferation and differentiation of osteoblasts, through various signalling pathways 
including the PI3K/Akt pathway (Ma et al. 2010b), ERK-1,2 (Cortizo et al. 2006) and 
AMPK activation (Kanazawa et al. 2008, Jang et al. 2011). Based on the bone-fat balance 
theory, the main aims of the current study are to: (i) determine the effects of metformin on 
mesenchymal stem cell differentiation in particular its effects on adipogenesis, to examine 
the suggested bone-fat reciprocity and (ii) understand the underlying molecular mechanisms 
involved, in particular the role of the AMPK signalling pathway in these processes.  
5.3 Materials and Methods 
5.3.1 Cell culture and induction of differentiation 
Commercially available C3H10T1/2 mouse mesenchymal stem cells (Clone 9; ATCC CCL-
226) were chosen as they do not undergo spontaneous differentiation under normal culture 
conditions and show a more homogenous colony-forming rates during cell expansion as 
compared to human cell lines, as detailed in section 1.3.3. The C3H10T1/2 cells were 
maintained in DMEM (41965-039, Sigma-Aldrich Ltd, Gillingham, Dorset, UK) containing 
10% (v/v) foetal calf serum (FCS), 2 mM glutamine, 100 U/mL penicillin and 100 µg/ml 
streptomycin. Cells were kept to 80-90% sub-confluence before further subculture and 
plating. 
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At confluence, cells in plates were treated for 5 days with specific differentiation media and 
treatments for 5 days. To promote adipogenic differentiation, cells were cultured in the 
standard media supplemented with either 10 μM pioglitazone (PIO) alone or in combination 
with 100 nM insulin, 500 μM 3-isobutyl-1-methylxanthine (IBMX) and 10 μM 
dexamethasone (IID medium). Insulin is widely used to induce proliferation and 
differentiation of pre-adipocytes, as it mimics insulin-like growth factor-1 at high 
concentration and activates the mitogen-activated protein kinase pathways. IBMX is a 
competitive, nonselective phosphodiesterase inhibitor, which together with dexamethasone, 
promotes transcriptional activation of PPARγ through protein kinase A signalling. They also 
induce C/EBPδ and C/EBPβ which are both transcriptions factors for growth and 
differentiation. For osteogenic differentiation, cells were cultured in standard media 
supplemented with 284 µmol/L ascorbic acid, 10 mM β-glycerophosphate and 10 nM 
dexamethasone (AGD medium). The culture media was changed every 3 days. Cells were 
also incubated with 10% FCS alone, as negative control for differentiation. The specific 
treatments included 500 µM metformin, 100 µM of the AMPK-activator (A769662), or 10 
µM of the p70S6K-inhibitor (rapamycin), as used previously (Molinuevo et al. 2010, Moreno 
et al. 2008, Yarwood et al. 1999). Cells were also incubated with 10% FCS alone, as negative 
control for differentiation. 
5.3.2 Preparation of cell extracts  
C3H10T1/2 MSCs were harvested and nuclear extracts prepared using the Nuclear 
Extraction kit from Active Motif, Belgium. Briefly, the media was aspirated and cells were 
harvested in ice-cold PBS containing phosphatase inhibitors and centrifuged (200 x g, for 5 
minutes at 4ºC) to obtain a cell pellet. The cell pellet was re-suspended in complete lysis 
buffer containing 10 mM DTT and phosphatase inhibitor cocktail and then centrifuged 
(14000 x g, for 10 minutes at 4ºC) to obtain nuclear and supernatant fractions. Protein 
concentration of the nuclear fraction was calculated by bicinchoninic acid assay (BCA) 
(Smith et al. 1985) using prepared BCA kit reagents from Thermo Fisher before loading of 
samples for electrophoresis.  
5.3.3 Western blotting 
Protein samples were separated by SDS-PAGE and then transferred electrophoretically onto 
nitrocellulose membranes. Membranes were blocked with 5% (w/v) Marvel milk powder in 
TBS (20 mM Tris-HCl pH 7.5, 150 mM NaCl) for 1 hour. Membranes were then incubated 
with primary antibodies overnight at 4oC. Following washes with TBST (TBS supplemented 
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with 0.5% (v/v) Tween-20), membranes were incubated with secondary antibodies for 1 hour 
at room temperature. Antibodies were diluted to the required concentration in 50% (v/v) Sea 
Block (Thermo Scientific) and 50% (v/v) TBST. The primary antibodies used were to 
peroxisome proliferator-activated receptor gamma (PPARγ; marker for adipogenesis, Cell 
Signalling Technologies (CST), Danvers, MA; dilution 1:1000), Runt-related transcription 
factor 2 (Runx2; marker for osteogenesis, CST, Danvers, MA; dilution 1:1000), 
phosphorylated-ACC (P-ACC (Ser79); marker for AMPK activity, CST, Danvers, MA; 
dilution 1:1000) and phosphorylated-p70S6K (P-p70S6K (Thr389); upstream regulator of 
mTOR signalling, CST, Danvers, MA; dilution 1:1000). Antibodies were detected using a 
LI-COR® Odyssey Infrared Imaging systems and densitometric analysis was carried out 
using ImageJ software (NIH, UK) software Version 1.47.  
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5.3.4 Oil Red O staining 
After 5 days of cell differentiation and treatment (as described in section 5.3.1), the media 
was aspirated and cells were fixed to cell culture plates with 10% (v/v) neutral buffered 
formalin for 30 minutes. The formalin was then aspirated and staining was carried out with 
the addition of 0.3% (w/v) Oil Red O (ORO) in isopropanol:water (60:40) for 5 minutes in 
room temperature. The ORO was then aspirated and wells washed with distilled water four 
times. Imaging was carried out using a Zeiss Axiovert 25 microscope with QImaging camera 
and supporting software. 
5.3.5 Transient transfection and luciferase assay 
C3H10T1/2 cells were transfected with the indicated plasmids in 6-well plates, with 1.125  
μg/well PPRE (PPAR reporter, purchased from Adgene) and 6xOSE reporter constructs 
(Runx2 reporter, supplied by Jian Huang, Rush Medical Centre, Chicago, USA) using 
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) and then treated with metformin, 
A769662 or rapamycin with and without adipogenic differentiation media. Cells were then 
harvested 48 hours after transfection and assayed using the Luciferase reporter assay system 
(Promega, Madison, WI) according to manufacturer’s instructions. As a transfection control, 
the Renilla plasmid 0.125 μg/well was co-transfected in each transfection experiment, and 
the luciferase activity was normalised to the Renilla activity. 
5.3.6 Statistical analysis 
All experiments were performed in triplicate and statistical analysis was performed using 
Student’s t-test or one-way ANOVA. Results are expressed as mean ± standard error (SEM) 
and differences with p<0.05 were considered statistically significant.   
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5.4 Results 
5.4.1 Effects of antidiabetic drugs pioglitazone and metformin on 
murine MSC (C3H10T1/2) differentiation 
In confluent C3H10T1/2 MSCs cells (Figure 5.2A and Figure 5.2B), IID-containing medium 
promoted lipid accumulation (Figure 5.2C), an effect that was further enhanced by co-
treatment of cells with PIO (Figure 5.2D) as seen on Oil red O staining. In addition, treatment 
of cells with either metformin or A769662 suppressed adipogenesis promoted by IID alone 
(Figure 5.2E and Figure 5.2G, respectively) or by a combination of IID plus PIO (Figure 
5.2F and Figure 5.2G). Metformin was a more effective inhibitor of lipid accumulation and 
less so with A769662, possibly as A769662 is only a selective activator of AMPK β1-
containing complexes. 
 
Figure 5.2 Effects of pioglitazone and metformin on lipid accumulation in C3H10T1/2 MSCs.  
Confluent C3H10T1/2 MSCs (A and B) were induced to differentiate by addition 10% foetal calf 
serum (FCS) in the presence or absence of adipogenic IID medium (insulin, isobutylmethylxanthine 
(IBMX) and dexamethasone and/or 10 μM pioglitazone (PIO), 500 μM metformin or 100 μM 
A769662. After 5 days cells were fixed with formalin and stained with Oil Red O to detect neutral lipid 
accumulation (red). IID and pioglitazone promoted lipid accumulation (C and D) whilst metformin and 
the AMPK-activator, A769662, suppress adipogenesis (E-H). Representative micrographs from an 
experiment carried out on three separate occasions with similar results are shown.  
A B 
C D 
E F 
G H 
146 
The western blot experiments demonstrated that treatment with IID or PIO induced a 
significant increase in the two PPAR splice variants, PPAR1 and PPAR2 (Figure 5.3A 
and Figure 5.3B), which correlated with a significant increase in PPAR transcriptional 
activity, as determined by luciferase assay (Figure 5.4A). In agreement with the ORO 
experiments in Figure 5.2, treatment of cells with either metformin or A769662 effectively 
suppressed IID- and PIO-stimulated increases in PPAR protein levels (Figure 5.3A and 
Figure 5.3B), as well as IID- and PIO-stimulated PPAR activity (Figure 5.4A).  
 
Figure 5.3 Effects of Pioglitazone, Metformin and the AMPK-activator, A769662, on early 
markers of differentiation in C3H10T1/2 cells. (A) Confluent CH3H10T1/2 cells were stimulated 
for 5 days with 10 µM pioglitazone (PIO) or an adipogenic (IID) or osteogenic (AGD) cocktail, in the 
presence or absence of 500 µM metformin or 100 µM A769662. Cell extracts were then prepared 
and immunoblotted with antibodies to PPARγ, Runx2 and AMPK. The phosphorylation-dependent 
electrophoretic mobility shift of Runx2 induced by AGD treatment is indicated (pRunx2). 
Representative immunoblots from an experiment carried out on three separate occasions with similar 
results are shown. (B) Densitometric analysis of PPARγ1 (i) and PPARγ2 (ii) levels are shown as 
means±SEM. Significant increases (*, p<0.05) relative to control, and significant decreases relative 
to PIO-stimulated cells (#, p<0.05), are indicated (n=3). Non-significant changes are also indicated 
(ns)  
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Treatment of cells with AGD did not significantly affect PPAR protein levels (Figure 5.3A 
and Figure 5.3B) or activity (Figure 5.4B). AGD treatment alone did promote a noticeable 
phosphorylation band-shift of Runx2 protein compared to control (Figure 5.3A). Neither 
metformin nor A76 affected the protein expression level or Runx2 (Figure 5.3A). However, 
treatment with either metformin or A769662 significantly increased Runx2 transcriptional 
activity in C3H10T1/2 cells (Figure 5.4B), which did not correlate with an increase in AGD-
promoted phospho-Runx2 levels, as determined by band-shift (Figure 5.3A).  
 
Figure 5.4 Luciferase reporter assays to determine activity of the transcription factors PPARγ 
and Runx2.  (A) Confluent C3H10T1/2 cells were transfected with a PPARγ and Runx2 luciferase 
gene reporter constructs, together with control Renilla luciferase vector, and then stimulated for two 
days with 500 µM metformin or 100 µM A769662, in the presence or absence of 10 µM pioglitazone 
(PIO), adipogenic medium (IID) or osteogenic medium (AGD). Cell extracts were then prepared and 
luciferase activities were measured using a dual luciferase reporter assay. PIO and IID significantly 
induced, whilst metformin and A76 significantly suppressed PPARy activity Metformin and A76 
promoted Runx2 activity in control, adipogenic and osteogenic media (B). Luciferase activities from 
three separate experiments are shown as means±SEM. Significant increases in luciferase activity 
are indicated; *, p<0.05, **, p<0.01 and ***, p<0.001, as are significant decreases in activity, #, p<0.05 
(n=3). Non significance is indicated (ns). 
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5.4.2 Molecular mechanisms involved in the action of metformin 
on adipogenesis 
Based on metformin being a known AMPK activator, its ability to activate AMPK was 
examined by measuring the phosphorylation of a known AMPK substrate, Ser 79 of acetyl 
coenzyme carboxylase (ACC), using phospho-specific antibodies. A769662 provoked a 
robust and rapid phosphorylation of ACC, which was maintained for up to 48 hours, but 
metformin did not induce a significant phosphorylation of ACC, even after 48 hours 
stimulation (Figure 5.5). 
 
Figure 5.5 The AMPK activator, A769662, but not metformin activates AMPK in C3H10T1/2 
cells.  (A) Confluent C3H10T1/2 cells were stimulated for the indicated times with 100 µM A769662 
or 500 µM metformin. Cell extracts were then prepared and immunoblotted with antibodies towards 
the phosphorylated form of the AMPK substrate, ACC, or total ACC. (B) Densitometric values were 
obtained from immunoblots from three separate experiments and are shown as means±SEM in the 
line graph. Significant increases in pACC are indicated; **, p<0.01 (n=3). Non significance is also 
indicated (ns). 
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Treatment of the differentiating cells with rapamycin, a known mTOR/p70S6K inhibitor, 
dramatically inhibited lipid accumulation associated with adipogenesis, as determined by 
ORO staining (Figure 5.6A). Rapamycin also suppressed PPAR activity, as determined by 
gene reporter assays, indicating that the mTOR/p70S6K pathway is required for adipogenesis 
of C3H10T1/2 cells (Figure 5.6B).  
 
Figure 5.6 The mTOR inhibitor, rapamycin, suppresses adipogenesis of C3H10T1/2 cells.  (A) 
Confluent CH3H10T1/2 cells were induced to differentiate by addition of 10% foetal calf serum (FCS) 
supplemented with adipogenic cocktail (IID), in the presence or absence of the mTOR inhibitor, 10 
µM rapamycin. After 5 days cells were fixed with formalin and stained with Oil Red O to detect neutral 
lipid accumulation. Representative micrographs from an experiment carried out on three separate 
occasions with similar results are shown. (B) Confluent C3H10T1/2 cells were transfected with 
PPARγ luciferase gene reporter construct, together with control Renilla luciferase vector and then 
stimulated for two days with 500 µM metformin or 10 µM rapamycin, in the presence or absence of 
IID. Cell extracts were then prepared and luciferase activity was measured using a dual luciferase 
reporter assay. Luciferase activities from three separate experiments are shown as means±SEM. 
Significant increases in PPARγ activity are indicated ***, p<0.001, as are significant decreases in 
PPARγ activity, #, p<0.05, relative to IID-stimulated cells (n=3). 
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Rapamycin treatment had no significant effect on phospho-ACC levels (Figure 5.7A and 
Figure 5.7B), but significantly inhibited phosphorylation of p70S6K on Thr 389 (Figure 5.7C 
and Figure 5.7D). Both metformin and A769662 also inhibited p70S6K phosphorylation 
(Figure 5.7C and Figure 5.7D). 
 
Figure 5.7 The effects of rapamycin on AMPK and p70S6K activities in C3H10T1/2 cells.  
(A) Confluent CH3H10T1/2 cells were stimulated for 5 days with IID, in the presence or absence of 
500 µM metformin, 100 µM A769662 or 10 µM rapamycin. Cell extracts were then prepared and 
immunoblotted with antibodies to phosphorylated ACC (Ser 79). Representative immunoblots from 
an experiment carried out on three separate occasions with similar results are shown. (B) 
Densitometric values from 3 separate experiments are shown in the lower panel as means±SEM. 
Significant increases relative to control are indicated, **, p<0.01 and ***, p<0.001 (n=3). (C) 
Confluent CH310T1/2 cells were stimulated for 5 days with IID, in the presence or absence of 500 
µM metformin, 100 µM A769662, 10 µM compound C or 10 µM rapamycin. Cell extracts were then 
prepared and immunoblotted with antibodies to phosphorylated p70S6K and total p70S6K. 
Representative immunoblots from an experiment carried out on three separate occasions with 
similar results are shown. (D) Densitometric analysis of mean ± SEM p70S6K phosphorylation from 
3 separate experiments are shown. Significant increases (*, p<0.05) relative to control, and 
significant decreases relative to IID-stimulated cells (##, p<0.01 and ###, p<0.001), are indicated 
(n=3). 
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Compound C, a known AMPK inhibitor, significantly inhibited both basal p70S6K (Thr 389; 
Figure 5.7B) and ACC (Ser 79; Figure 5.8A and Figure 5.8B) phosphorylation, suggesting 
that AMPK is linked to the activation of mTOR/p70S6K signalling in these cells. In addition, 
10 M compound C inhibited adipogenesis of C3H10T1/2 cells treated with IID (Figure 
5.8C).  
 
Figure 5.8 Compound C inhibits adipogenesis of C3H10T1/2 cells. (A) Confluent CH3H10T1/2 
cells were stimulated for 5 days with IID, in the presence or absence of the AMPK inhibitor, 10 µM 
compound C. Cell extracts were then prepared and immunoblotted with antibodies to phosphorylated 
ACC (Ser 79). Representative immunoblots from an experiment carried out on three separate 
occasions with similar results are shown. (B) Densitometric values from 3 separate experiments are 
shown as means±SEM. Significant decreases relative to control are indicated, #, p<0.05.(C) 
Confluent CH3H10T1/2 cells were treated with 10% foetal calf serum (FCS) supplemented with 
adipogenic cocktail (IID), in the presence or absence of the indicated concentrations of compound 
C. After 5 days cells were fixed with formalin and stained with Oil Red O to detect neutral lipid 
accumulation. Representative micrographs from an experiment carried out on three separate 
occasions with similar results are shown. 
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5.5 Discussion 
In this study, the different effects of antidiabetic drugs on murine C3H10T1/2 mesenchymal 
stem cell differentiation was established. Pioglitazone, which is a thiazolidinedione, 
promoted adipogenesis with increased PPARγ protein expression, PPARγ transcriptional 
activity and increased lipid droplet accumulation. Metformin on the other hand, inhibited 
adipogenesis with suppression of PPARγ protein expression, PPARγ transcriptional activity 
and reduced lipid droplet formation. Metformin also promoted osteogenesis with increased 
Runx2 transcriptional activity, unaided by osteogenic-linked increases in Runx2 
phosphorylation. In addition, the novel finding of an AMPK-independent action of 
metformin on the inhibition of adipogenesis further adds to the current literature in this area.  
It has been previously reported that metformin induced osteoblastic differentiation and 
matrix mineralisation in MC3T3-E1 pre-osteoblasts via activation of the AMPK signalling 
pathway (Cortizo et al. 2006, Kanazawa et al. 2007, Jang et al. 2011). Metformin also 
promoted osteogenesis in rat primary osteoblasts (Shah et al. 2010, Zhen et al. 2010), rat 
bone marrow progenitor cells (Molinuevo et al. 2010) and more recently in human MSCs 
(Wang et al. 2018). Jang et al found that metformin-induced AMPK activation increased the 
level of Runx2 mRNA and protein expression (Jang et al. 2011), which increased alkaline 
phosphatase activity and mineralisation in mesenchymal cells and osteoblast cells in vitro 
(Ducy et al. 1997, Harada et al. 1999). This contrasted with our finding as metformin 
promoted Runx2 transcriptional activity with no effect on Runx2 protein expression, which 
may be due to cell specific differences. Discrepancies between protein expression and 
enzymatic activity have been previously described highlighting the drawbacks of merely 
interpreting protein, or even mRNA expressions, to target outcomes (Anderson and 
Seilhamer 1997, Miyamoto et al. 2001).  The examination of enzymatic activity is key 
considering the complex regulatory mechanisms for gene expression that occur both at post-
transcriptional and post-translational levels. A recent breakthrough study provided a 
plausible explanation, suggesting that because the transcription factors for osteogenesis are 
already at high basal activity in undifferentiated MSCs, they are therefore only modestly 
regulated at the mRNA level as opposed to the transcription factors for adipogenesis which 
are more likely to be transcriptionally regulated being barely active in MSCs (Rauch et al. 
2019). 
Similar to Molineuvo et al, the current study demonstrated that metformin suppressed 
adipogenesis with reduced lipid droplet accumulation on Oil red O staining (Molinuevo et 
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al. 2010), and proceeded to demonstrate the reciprocal effects of metformin on the 
adipogenic transcription factor PPARγ and osteogenic transcription factor Runx2. Given that 
increases in PPAR activity during the early stages of adipogenesis are necessary and 
sufficient to promote terminal fat cell development (Rosen and Spiegelman 2000), it appears 
that the ability of metformin and A769662 to inhibit adipogenesis is linked to their ability to 
suppress PPAR protein expression. Moreover, given that the PPAR luciferase reporter 
assays were carried out after only two days of differentiation, it appears that the adipogenic 
suppressive actions of metformin and A769662 occur at a very early stage of the 
differentiation process in favour of Runx2 activity promotion.  
Metformin exerted these effects on the transcription factors similarly to A769662, which is 
a known potent, reversible AMPK activator suggesting the role of AMPK activation in 
mesenchymal stem cell differentiation. Both metformin and A769662 have been reported to 
activate AMPK in a variety of cell types (Zhou et al. 2001, Cool et al. 2006). Previous studies 
have validated the role of AMPK activation in osteogenesis, with the use of metformin and 
5-aminoimidazole-4-carboxamide riboside (AICAR), the latter which is another 
pharmacological activator of AMPK (see section 1.7.2). In human adipose-derived and bone 
marrow MSCs, AMPK activation was also crucial (Kim et al. 2012, Lee et al. 2014) in 
osteogenesis with pharmacological induced AMPK inhibition and AMPKα1 knock-out mice 
demonstrating reduced bone matrix mineralisation, alkaline phosphatase (AP) activity, 
Runx2 and osteocalcin protein expression (Kim et al. 2012). AMPK knock-out mice have 
also been shown to have reduced trabecular bone mass and cortical indexes. Paradoxically, 
studies have also shown that osteoblast differentiation is functionally associated with 
decreased AMPK activity (Kasai et al. 2009). 
The role of AMPK activation in adipogenesis, however, is less well understood. AMPK 
activation with AICAR has been shown to inhibit the conversion of pre-adipocytes to fat 
cells (Habinowski and Witters 2001, Lee et al. 2011). Paradoxically, however, the widely 
used AMPK inhibitor, compound C, has also been reported to inhibit adipogenesis of 
preadipocyte cell lines (Nam et al. 2008). Previous work has shown that AMPK activation 
suppresses adipogenesis in favour of osteogenesis in adipocyte-derived human MSCs 
(hMSCs) and bone marrow-derived MSCs (Kim et al. 2012, Lee et al. 2014). Chava et al. 
in a recently published study have demonstrated that RUNX2 was in fact a novel substrate 
for AMPK, with metformin-induced AMPK activation preventing RUNX2 ubiquination in 
osteogenesis over adipogenesis (Chava et al. 2018). Given the inhibitory effects of these two 
compounds on early and late markers of adipogenesis in C3H10T1/2 MSCs, it was rather 
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intriguing to find that metformin did not inhibit adipogenesis through AMPK activation. The 
use of rapamycin to study the mTOR/p70S6K signalling pathway became apparent following 
recent work showing the interaction between PPAR and the mTOR/p70S6K (Sun et al. 
2013). Moreover, metformin has been shown to inhibit the activation of the p70S6K pathway 
independently of AMPK (Vazquez-Martin et al. 2009) in tumour cells and p70S6K has been 
shown to be required for the growth hormone-dependent adipose conversion of 3T3-F442A 
preadipocytes (Yarwood et al. 1999). In the present study, rapamycin specifically inhibited 
phosphorylation of p70S6K on Thr 389, which is the mTOR phosphorylation site critical for 
kinase function (Saitoh et al. 2002), with no significant effect of phospho-ACC levels highly 
indicative of an AMPK-independent action.  
This, however, does not rule out a role for AMPK in the control of p70S6K activation. In fact, 
it has been reported that AMPK inhibits mTOR/p70S6K signalling, which is thought to 
underlie the actions of metformin in a range of cellular contexts (Dowling et al. 2011, Viollet 
et al. 2012). The suppression of adipogenesis with Compound C, which is an AMPK 
inhibitor, may suggest that AMPK is linked to the activation of mTOR/p70S6K signalling in 
these cells, although Compound C itself is a very non-selective AMPK inhibitor (Yu et al. 
2008, Vogt et al. 2011). There may be a basal level of AMPK activity that is necessary for 
supporting adipose conversion of these cells, and this could be examined further with the 
use of AMPK knock out models. A recent study published has also demonstrated an 
intriguing dose dependency effect of metformin on adipogenesis (Chen et al. 2018). 
The AMPK-independent action of metformin on the inhibition of adipogenesis reported here 
may be due to cell type-specific effects during the differentiation process. For example, most 
of the studies demonstrating an AMPK-dependent action of metformin have been conducted 
in more differentiated cell lines, such as pre-osteoblasts (Cortizo et al. 2006, Kanazawa et 
al. 2008, Jang et al. 2011), pre-adipocytes (Moreno-Navarrete et al. 2011, Lee et al. 2012), 
myoblasts (Longnus et al. 2005, Fulco et al. 2008, Kobashigawa et al. 2014) and neuronal 
mouse cell lines (Bang et al. 2014), instead of the more primitive progenitor cells as 
investigated here. 
In addition, the AMPK-independent action noted may also be due to cell stage-specific 
effects during the commitment and differentiation process. Pantovic et al. (Pantovic et al. 
2013) have demonstrated that there is a coordinated time-dependent activation of different 
signalling pathways during the osteogenic differentiation of hMSCs, which is AMPK-
dependent in the early stages of differentiation followed by late stage activation of the 
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Akt/mTOR signalling pathway. Given the results presented here, it could be argued that 
similar mechanisms might regulate adipogenesis in murine MSCs. We found an overall 
requirement for basal levels of AMPK activity for adipogenesis in C3H10T1/2 cells but the 
ability of metformin to control the commitment of MSCs to differentiate into either 
osteoblasts or adipocytes is governed at an early stage through the inhibition of 
mTOR/p70S6K signalling.  
Overall, my work suggests that metformin as an anti-diabetic agent has a promising bone 
protective function given its positive role in osteogenesis and negative effect on adipogenesis 
in mesenchymal stem cell differentiation. It is worth noting the supraphysiological dose of 
metformin used may limit its translation to clinical studies although other biguanides such 
as phenformin which is much more effective at lower doses is currently being used in clinical 
trials. It exerts multiple effects to inhibit adipogenesis in different cell types. Therefore, the 
overriding view that metformin exerts its effects on adipogenesis simply by promoting 
AMPK activation may therefore need some revision, especially as the role of AMPK itself 
appears to be complex. In conclusion, further investigation into how metformin suppresses 
signalling through the mTOR/p70S6K pathway may enable the discovery of new therapeutic 
intervention strategies to prevent unwanted bone marrow adipogenesis associated with 
diseases, such as diabetes mellitus, where bone health is impaired. 
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6 Final Discussion and Future Directions 
6.1 Final discussion 
Diabetic osteopathy as a complication of diabetes mellitus has undoubtedly gained 
increasing awareness amongst clinicians and researchers in the last two decades. The 
programme of research described in this thesis was borne out of an appetite to understand if 
skeletal fragility affects the paediatric population with Type 1 diabetes (T1D) and the 
contribution of bone microarchitecture and the intriguing bone-fat balance hypothesis to 
diabetic osteopathy. 
Using novel technique of high-resolution MRI (3T) to image bones in children with T1D, 
the findings in this thesis add to the current body of evidence in this field, with original 
results that address the knowledge gap. Findings from Chapter 4 showed that children with 
T1D demonstrated deficit in bone microarchitecture compared to their healthy age- and 
gender-matched peers, novel to the current knowledge base. Across all the paediatric age 
group, children with T1D have lower trabecular bone volume fraction, which was the 
primary hypothesis of the study. The deleterious effect of T1D on trabecular bone 
microarchitecture has been shown, not only in mouse models of T1D using microCT 
(Nyman et al. 2011), but also in adults with T1D from pQCT studies (Shanbhogue et al. 
2015). Abdalrahaman et al. performed the first MRI-based assessment of bone 
microarchitecture in young adults with T1D which concluded similarly of trabecular deficits 
(Abdalrahaman et al. 2015), but this was contradicted by histomorphometry findings (Armas 
et al. 2012). Armas et al. showed no abnormalities in trabecular bone on histomorphometry 
and microCT specimens in a small cohort of adults with T1D, although the study may not 
be sufficiently powered to detect the differences with a small sample size of 18 cases (Armas 
et al. 2012). In addition, the study in Chapter 4 found that the trabecular deficits were present 
early, within 10 years from T1D diagnosis. Comparatively, decrease in trabecular bone 
volume fraction was noted by 10 weeks of T1D diagnosis in mouse models (Nyman et al. 
2011), which is equivalent to 20 human years, supporting the need to intervene early for 
bone health optimisation. 
Intuitively, chronic hyperglycaemia and insulin deficiency have been implicated in the 
pathogenicity of diabetic osteopathy, along with the complex interplay of GH/IGF-1 
pathway inactivity, increased marrow adiposity, chronic inflammation and vasculopathy as 
detailed in section 1.5.3. The study in Chapter 4 contributed to an improved understanding 
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of the possible mechanisms for diabetic bone loss. Chronic hyperglycaemia, as reflected by 
high HbA1c, was significantly associated with reduced bone formation. This is in line with 
experimental and animal models of type 1 diabetes (T1D) (Rico et al. 1989, Verhaeghe et 
al. 1990), and consistent with clinical studies reporting a reduction in biochemical markers 
of bone formation (Gunczler et al. 1998, Pater et al. 2010, Starup-Linde et al. 2014).  
The other novel finding in Chapter 4 was the effect of acidosis at initial T1D presentation 
on lower bone formation marker suggesting the additional programming effect of either 
sustained hyperglycaemia, or acidosis on skeletal development. Acidosis has been shown to 
affect bone homeostasis (Topaloglu et al. 2005) and may also have an effect on 
mesenchymal stem cell differentiation (Guntur et al. 2018).  In addition to reduced bone 
formation, children with T1D also have reduced bone resorption as described in section 
1.5.5.1, further confirming the low bone turnover seen in T1D (Campos Pastor et al. 2000, 
Moyer-Mileur et al. 2008, Starup-Linde et al. 2014, Shanbhogue et al. 2015). This may 
reflect functional growth hormone resistance as outlined in section 1.5.3.2, although the 
study found no difference in circulating IGF-1 levels in T1D compared to healthy controls. 
However, the inverse association between serum ALS and the apparent trabecular bone 
volume fraction found in this study highlighted a role for the GH/IGF-1 pathway in diabetic 
osteopathy, which the study was not specifically powered to look for.  Bone turnover 
markers have been known to correlate with bone deficit and predicted fragility fractures 
(Szulc and Delmas 2008) with IGF-1 reported as a fracture predictor in post-menopausal 
women with T2D independent of BMD. Further studies with larger sample size are needed 
to evaluate the validity of IGF-1 as an independent fracture predictor for T1D and to better 
understand the contribution of the GH/IGF-1 pathway in this condition.  
Vasculopathy has been strongly implicated in the pathogenesis of diabetic bone loss as 
detailed in section 1.5.3.6., with the direct effect of bone microangiopathy and the reduction 
of blood flow on mesenchymal stem cell differentiation. The independent association of 
microvascular complications with reduced BMD and increased fracture risk in T1D is well 
established (Ivers et al. 2001, Miao et al. 2005, Vestergaard 2007, Weber et al. 2015). In 
addition, clinical studies have demonstrated that the presence of associated microvascular 
complications, such as retinopathy and nephropathy, are significantly associated with 
adverse cortical and trabecular bone microarchitecture in individuals with T1D, rather than 
having T1D on its own (Abdalrahaman et al. 2015, Shanbhogue et al. 2015). The study in 
Chapter 4 looked at this association and found no difference in the bone microarchitecture 
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in the T1D children with and without microvascular complications, primarily limited by the 
very small number of children who have developed retinopathy or nephropathy by this point. 
The other possible explanations for bone deficit in T1D include sclerostin-mediated 
inhibition of bone formation, as detailed in section 1.5.5.1. Sclerostin, produced almost 
exclusively by osteocytes, is an inhibitor of the canonical Wnt/β-catenin signalling pathway 
involved in bone formation, thus playing an essential role in osteoblast differentiation and 
bone turnover (Baron and Kneissel 2013). Many studies have found higher sclerostin levels 
in T1D individuals (Catalano et al. 2014, Neumann et al. 2014), with overexpression of 
sclerostin causing osteopenia in mouse models (Baron and Kneissel 2013). Although 
sclerostin was measured in children with T1D in the study in Chapter 4, the interpretation of 
this was limited by not measuring the levels in the healthy controls and the paucity of 
normative data for sclerostin in this age range. An inverse relationship was found between 
sclerostin and the age of T1D diagnosis. Children who were younger at T1D diagnosis had 
higher sclerostin levels, as well as higher bone resorption, which may adversely affect their 
bone health. Manifestation of T1D at an early age has been shown to negatively impact bone 
development (Bechtold et al. 2006). This may suggest a predisposing variant, the so-called 
‘more aggressive’ T1D lending to poorer long-term outcomes, rather than chronic metabolic 
consequences of the disease, or duration of disease on the bones. The duration of diabetes 
has, however, been shown to positively correlate with higher sclerostin levels, potentially 
impairing bone health and increasing fracture risk (Catalano et al. 2014). The study in 
Chapter 4 did not find any association between sclerostin levels and bone microarchitecture. 
Interestingly, sclerostin levels have been shown to be inversely associated with fracture in 
T1D individuals, in that, those with the highest tertile of sclerostin having a markedly 
reduced (by 81%) risk of fracture compared with those in the lowest tertile (Starup-Linde et 
al. 2016). This is counterintuitive and remains unexplained. The reproducibility of that study 
or further mechanistic explanation has yet to be seen.  
Ultimately, the most important consequence of diabetic bone loss is fractures with a 
significant cost to the individual and health economy as a whole, not to mention early onset 
osteoporosis which also impacts on quality of life. The stimulation for this thesis was the 
lack of understanding of whether skeletal fragility affects the paediatric population with 
Type 1 diabetes (T1D), especially given the fact that childhood and adolescents are the peak 
ages for both the: 1) diagnosis of T1D and the 2) attainment of peak bone mass. Since this 
work began in 2014, Weber et al. demonstrated in 2015 in a large population-based study 
that the increased risk of fractures in T1D did not only affect adults, but began in childhood 
159 
and extended across the life span (Weber et al. 2015). The clinical study in Chapter 4 
confirmed this finding that children with T1D have higher incident fractures compared to 
their healthy age- and gender-matched peers. Children who fractured had poorer glycaemic 
control, although HbA1c were not associated with any of the trabecular bone parameters 
suggesting a complex link between glycaemic control, bone formation and bone 
microarchitecture. More recent studies, however, have shown an inverse association 
between trabecular bone microarchitecture and HbA1c in individuals with T2D (de Waard 
et al. 2018, Karim et al. 2018) although this relationship was not found in young adults with 
T1D (Abdalrahaman et al. 2015). The absence of a relationship between the bone parameters 
and HbA1c also beckons the need to explore other markers of glycation such as pentosidine. 
Indeed, Granke et al found that the fracture toughness of bone were negatively associated 
with pentosidine levels (Granke et al. 2015), a well-known advanced glycation end (AGE) 
product found in diabetic patients, which may marry better the link between hyperglycaemia, 
bone microstructure and fractures. Children who fractured also had lower total body BMD. 
Given that fractures were associated with total body BMD but not lumbar spine BMD, and 
an association between the deficits in trabecular bone microarchitecture and fractures was 
not observed, there may be a need to investigate cortical parameters to better understand 
bone health in T1D as previously done in adults with T1D (Lettgen et al. 1995). A larger 
cohort study is warranted for more detailed investigations of T1D characteristics and its 
association with bone microarchitecture in individuals with T1D.  
This is the first study to demonstrate a deficit in MRI-based trabecular deficit in children 
with T1D, contributing not only new findings to the current knowledge base but also 
evidence of the feasibility of using this non-invasive technique in children in clinical studies.  
As discussed in section 1.5.6.1.1, although evidence have universally shown reduction in 
BMD in adults and children with T1D, there is a considerable overlap in BMD values in 
patients with and without fragility fractures. Specifically, the work in this thesis showed 
reduction in BMD in T1D children who fractured but did not discover any evidence of an 
association between bone microarchitecture variables and DXA-derived bone mineral 
density, for reasons as described in the previous paragraph. MRI-based assessment is free 
from ionising radiation, as compared to DXA, rendering it superior especially for repeated 
measurements in prospective clinical trials to further explore the association of clinical 
markers of T1D, 3D-volumetric density and the different compartments of bone, including 
trabecular and cortical bones, especially in children.  
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Additionally, MRI provides the unique imaging modality to study bone marrow adiposity, 
given that the bone marrow is home to pluripotent mesenchymal stem cells capable of 
differentiating into osteoblasts and adipocytes. The bone-fat hypothesis suggested 
thatadipogenesis in the marrow occurs at the expense osteogenesis, which has been shown 
in vitro in mouse and human cells and in vivo in mouse models but not in clinical trials in 
T2D, as detailed in section 1.5.3.4. The study in Chapter 4 supported this mechanism through 
the negative association of trabecular number with marrow fat fraction, and a corresponding 
positive association of trabecular separation with marrow fat fraction, when the whole cohort 
with and without T1D was analysed. This is the first study to demonstrate an association of 
marrow adiposity and MRI-based bone microarchitecture. Previous studies have shown a 
similar inverse association between marrow adiposity with pQCT-based trabecular and 
cortical parameters in obesity (Bredella et al. 2012) and DXA-based BMDs in a healthy 
population (Shen et al. 2012a, Shen et al. 2012b). However, similar to the only study to date 
looking at BMA in T1D, this study found a non-significant increase in BMA in individuals 
with T1D compared to controls. Additionally, there were no association between BMA and 
glycaemic control, markers of GH/IGF-1 axis, bone turnover markers, or BMD. Poor 
glycaemic control has been shown to be associated with increased bone marrow adiposity in 
T2D (Baum et al. 2012), where hyperglycaemia diverts the differentiation of mesenchymal 
stem cells towards adipogenesis (Wang et al. 2014). A recent study published, however, 
demonstrated that adipocytes readily accumulated in the bone marrow of individuals with 
T2D compared than controls (Ferland-McCollough et al. 2018). Unfortunately, our study 
was limited in its exploration of the bone marrow adiposity by the cross-sectional design and 
its small sample size, which was not powered to study these associations. With an increasing 
direct link between BMA with bone strength (Karampinos et al. 2015) and BMA with 
fracture risk (Patsch et al. 2013b), it would be critical to explore the role of marrow adiposity 
in future larger prospective cohort studying diabetic osteopathy.   
The ability of metformin on a molecular level to manipulate the differentiation of 
mesenchymal stem cell (MSC) differentiation may be key to the clinical findings of reduced 
fracture risk in T2D individuals on this medication. The work in this thesis in Chapter 5 
studied the effects of metformin on commercially available murine MSCs and found that 
metformin promoted osteogenesis with reciprocal suppression of adipogenesis, further 
affirming the bone-fat balance. This is similar to the findings of Molineuvo et al. 
demonstrating a positive osteogenic effect of metformin on rat bone marrow progenitor cells, 
with partial suppression of adipogenesis (Molinuevo et al. 2010). More importantly, a recent 
study had demonstrated that metformin also promotes osteogenesis in human bone-marrow 
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derived MSCs (Wang et al. 2018). Although bone-marrow derived human MSCs can be 
commercially purchased, these are expensive. Primary human MSCs are less readily 
available, and can be harvested from bone marrow, periosteum, adipose tissue, amniotic 
fluid and fetal tissues. Adipose tissue MSCs are seen as most easily available from 
liposuction procedures or bariatric surgery. However, despite the fact that these can be 
phenotypically similar, they display heterogeneity in differentiation potential compared to 
bone-marrow derived MSCs (Pittenger et al. 1999, Anker et al. 2003), hence are not readily 
interchangeable. Moreover, the challenge remains in identifying factors that promote 
specific osteogenic and adipogenic commitment of humans MSCs, which is different from 
that of mouse MSCs (Marie and Fromigue 2006). Primary human MSCs also take longer to 
grow and achieve confluency for induction of differentiation, taking approximately 4 times 
longer than the choice of C3H10T1/2 murine MSCs at each subculture (Charbord et al. 
2011). Interestingly, metformin appeared to have a negative angiogenic potential on human 
mesenchymal stem cells, which may potentially negate its positive skeletal effects 
(Montazersaheb et al. 2018).  
The effect of metformin on adipogenesis in MSCs has been less well studied (Molinuevo et 
al. 2010, Shin et al. 2013). Molineuvo et al found that metformin promoted early markers of 
adipogenesis with lipid droplet accumulation on ORO but no PPARγ expression (Molinuevo 
et al. 2010). Data from the experiments in Chapter 5 demonstrated that metformin inhibited 
adipogenesis through suppression of adipogenic transcription factor PPARγ expression level 
and transcriptional activity, through AMPK-dependent and independent signalling 
pathways. The AMPK independent signalling pathway of metformin on adipogenesis, 
through suppression of mTOR/p70s6K is novel and adds to the current body of literature 
with new targets for therapeutic potentials. In osteogenesis, however, metformin has been 
extensively shown to act through AMPK activation. Previous studies in 3T3-L1 pre-
adipocytes demonstrated that metformin behaved in a biphasic manner with dose 
dependency in adipogenic differentiation (Chen et al. 2018). Lower concentrations of 
metformin (1.25-2.5mM) induced adipogenesis, mediated in an AMPK-independent 
manner, while higher concentrations of metformin (5-10mM) inhibited adipogenesis via 
AMPK activation (Chen et al. 2018). The experiments in Chapter 5 were primarily a proof 
of concept study which demonstrated the positive osteogenic and negative adipogenic effects 
of metformin at 10mM. This poses translational difficulty due to that being a 
supraphysiological dose of metformin in human, which is 100 folds the current therapeutic 
dose of 1g twice daily in the treatment of T2D.  
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Metformin is not infrequently used in T1D to improve insulin sensitivity and reduce insulin 
dose requirement with marginal effects on glycaemic control (Vella et al. 2010). A recent 
randomised controlled trial has shown the additional cardiovascular benefits of metformin 
in reducing atherosclerosis progression, LDL-cholesterol and weight in adults with T1D 
(Petrie et al. 2017). With the increasing use of metformin in T1D, it would be conveniently 
advantageous given that metformin confers a bone protective role on a molecular level. To 
date, no studies have been published specifically studying the benefits of metformin on bone 
health. A prospective cohort study is warranted given the therapeutic potentials of 
metformin, a cheap and safe drug, in addressing the skeletal fragility in T1D.  
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6.2 Future directions  
This thesis has opened up some intriguing avenues for further research, based on some of 
the limitations of the studies identified as well as new findings from the work. From the 
limitations of the current work, studies with larger sample sizes are needed to better 
understand the associations of the clinical characteristics of T1D, such as HbA1c, age at 
diagnosis, duration of disease and the presence of other microvascular complications, with 
bone microarchitecture and fractures. It would not be unreasonable to suggest that all 
intervention studies in diabetes should include some assessment of bone health amongst the 
secondary outcomes that are assessed. 
In my opinion, future interventions to manage and prevent diabetic osteopathy lie in 
understanding the underlying principles of diabetes induced bone loss. The lack of an overt 
link between glycaemic control, surrogated by HbA1c, and bone microarchitecture and 
marrow adiposity highlighted the need to look at other ways chronic hyperglycaemia could 
detriment bone. As mentioned, it would be worth exploring the relationship of other 
glycation products such as pentosidine, a well-known advanced glycation end-product in 
diabetes, particularly as this has been linked to the structural integrity of bone (Granke et al. 
2015). In the last decade, glycaemic variability has also become the new subject of 
contention in interpreting the glycaemic control of individuals with diabetes. Highly variable 
glucose levels have been implicated as an independent risk factor for developing diabetes-
related microvascular complications (Brownlee and Hirsch 2006). It has also been associated 
with macrovascular complications, with worse cardiovascular outcomes in both T1D (Jun et 
al. 2019) and T2D (Benalia et al. 2019). With similar HbA1c, individuals with diabetes 
could have very different glycaemic variability, depending on the extent of their blood 
glucose excursions. Therefore, understanding the contribution of advanced-glycation end 
protein and glycaemic variability on the bone microarchitecture may improve the 
understanding of the effects of hyperglycaemia on skeletal fragility in diabetes, with 
potential therapeutic implications. 
Given that the trabecular bone microarchitecture at the proximal tibia was not significantly 
different between the fracture and the non-fracture group, this suggests a need to examine 
the cortical bone architecture in more detail in this condition. Further investigations of 
cortical bone parameters by using MRI could add mechanistic insights into the 
pathophysiology of diabetic bone loss in particular looking at its relationship to bone marrow 
adiposity as well. In addition to exploring different bone compartments, imaging a different 
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skeletal site such as the hip may be more informative, given that hip fractures are the most 
common fragility fracture affecting adults with T1D. Future studies should focus on pulse 
sequences for MR image acquisition from the neck of femur, with thicker cortical bone ideal 
for better characterisation in this condition. Furthermore, the feasibility of 7T-MR imaging 
at the hip has been demonstrated with promising results (Chang et al. 2014). 
With metformin being a promising therapeutic option for bone protection in diabetes 
mellitus, a prospective longitudinal clinical trial with defined musculoskeletal outcomes 
should be explored to demonstrate efficacy, determine optimum dose, and possibility a 
minimum duration of exposure necessary for clinical benefit. This is especially pertinent as 
bone microarchitecture abnormalities are already observed in the paediatric age group and 
metformin is not licensed for use in children under 10 years of age. The adult REMOVAL 
(Reducing with MetfOrmin Vascular Adverse Lesions) cohort (Petrie et al. 2017), which 
was randomised to 3 years of metformin treatment would provide an ideal starting platform 
to study the effects of metformin of the bone microarchitecture of individuals with T1D, 
with the limitation of absent baseline imaging prior to treatment. By incorporating dynamic 
contrast enhanced (DCE) MRI (Tofts 1997, Radjenovic et al. 2008), the effect of metformin 
on bone marrow vascularity could also be studied given the potential unwanted anti-
angiogenic potential of this drug (Montazersaheb et al. 2018).
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STUDY SYNOPSIS 
 
Title of study The Effects Of Type 1 Diabetes Mellitus On The 
Bone Health Of Children And Adolescents 
 
Study Centre Royal Hospital for Children, Glasgow  
Duration of Study 24 months 
Objectives To use novel methods of microMRI and MRS in 
assessing bone health of children with T1DM  
 
Primary Objective To establish the prevalence of abnormal bone 
health in children with newly diagnosed and 
established T1DM, comparing cases and controls  
 
Secondary Objective To assess the relationship of abnormal bone 
health to disease and treatment factors  
 
Methodology Prospective study in the newly diagnosed T1DM 
children over 14 month period from diagnosis 
 
Cross sectional study in established diagnosed 
cases of T1DM 
 
Sample size Newly Diagnosed Diabetes Study 
Estimated 30 cases, based on annual incidence of 
T1DM in NHS GGC Paediatric Diabetes service 
 
Established Diabetes Study 
30 cases, based on power calculation and 
previous studies 
 
Controls 
Estimated 30 controls, based on power 
calculation and previous studies but final 
numbers may vary 
 
Inclusion criteria Newly Diagnosed Diabetes Study 
• First presentation of T1DM during study 
period 
• Age ≥10 and ≤18 yrs  
 
Established Diabetes Study 
• Children with T1DM of ≥3 yrs duration 
• Age ≥10 and ≤18 yrs 
 
Controls 
• Healthy children age ≥10 and ≤18 yrs 
• No contraindications for MRI 
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Exclusion criteria All potential participants (including controls) 
• Age ≥19 years  
• Significant other chronic diseases 
• On medication known to affect bone 
health (e.g glucocorticoids, bone 
protective therapy) 
 
Established Diabetes Study 
• Age <10 years 
• Disease duration <3 years 
 
MRI exclusion criteria 
• Contraindications for MRI (e.g cardiac 
pacemaker, metallic clip in body etc) 
 
Study involvement Assessment of bone health by: 
• Dietary, exercise & fracture history 
• Biochemical markers of bone metabolism 
• Serum GH/IGF1 axis and adipokines 
• Dual energy X-ray Absorptiometry (DXA) 
• MRI to assess bone microarchitecture 
• MRS to assess vertebral bone marrow 
adiposity 
 
Assessment of T1DM disease by: 
• Degree of acidosis at presentation 
• Glycated haemoglobin(HbA1c) & C-
peptide 
• Insulin dose (unit/kg) 
• Presence of other microvascular 
complications 
 
Primary Outcome Quantitative measurements of trabecular bone 
(bone volume/total volume) obtained from 
microMRI images in cases versus controls 
 
Secondary Outcome 1) Measure of bone marrow adiposity by MRS  
2) Relationship of markers of bone health 
(including DXA) to markers of T1DM disease  
3) Change in bone and adiposity markers over 
first year of diagnosis 
 
Statistical Analysis 
 
Inter-group comparison to be performed by non-
parametric analyses of difference and 
assessment of correlation between continuous 
variables by univariate and multivariate 
regression analysis 
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STUDY FLOW CHART: Newly Diagnosed Diabetes Study 
 
 Study Period 
Visit 1 
(To be completed within  
10 days of discharge) 
 
Visit 2 
(6-8 months from 
 diagnosis) 
Visit 3 
(12-14 months from 
diagnosis) 
Obtain informed consent  x   
Personal and demographic data x   
Medical, surgical and medication history x   
Review inclusion and exclusion criteria x   
Physical examination  x   
Pubertal assessment x x x 
Height (cm) and weight (kg) x x x 
BMI calculation (kg/m2) x x x 
Study bloods     
• HbA1c* and C-peptide x x x 
• Laboratory blood glucose* x   
• Degree of acidosis (H+, Bic)* x   
• Markers of bone metabolism x x x 
• Serum GH/IGF1 axis and adipokines x x x 
Urinalysis* x   
MRI scan  x  x 
    
* Routinely performed for clinical purpose
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STUDY FLOW CHART: Established Diabetes Cases 
 
 Study Period 
Routine clinic visit for 
initial approach 
Visit 1 
(Next clinic visit when 
screening bloods due) 
Visit 2 
(MRI attendance) 
Obtain informed consent   x  
Personal and demographic data  x  
Medical, surgical and medication history  x  
Review inclusion and exclusion criteria x   
Physical examination  x  
Pubertal assessment  x  
Height (cm) and weight (kg)*  x  
BMI calculation (kg/m2)*  x  
Study bloods     
• HbA1c*  x  
• Markers of bone metabolism  x  
• Serum GH/IGF1 axis and adipokines  x  
DXA scan  x  
MRI scan    x 
    
* Routinely performed for clinical purpose 
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1.0 INTRODUCTION 
 
1.1 Overview 
Bone health in diabetes has become an increasing focus of interest as the 
association between fractures and Type 1 diabetes mellitus (T1DM) becomes 
increasingly recognised (Nicodemus 2001, Forsen 1999). Patients with Type 1 
diabetes have reduced bone mineral density (BMD) as assessed by dual energy X-
ray absorptiometry but patients with T2DM have increased BMD (Bouillon 1991, 
Vestergaard 2006), yet both groups have increased risk of fragility fractures.  With 
a modest degree of reduced BMD, T1DM should have a predicted relative fracture 
risk of one and a half fold when compared with age-matched non-diabetics, yet a 
meta-analysis of several large cohort studies (Janghorbani 2007) have 
demonstrated a disproportionately increased risk of hip fractures by seven-fold.  
 
Such disparities between DXA-derived bone mineral density and actual fracture 
risk in T1DM suggest that there are other factors contributing to overall bone 
health. This is acknowledged by the National Institute of Health (NIH) Consortium 
on Osteoporosis which recognises the importance of bone microarchitecture as a 
factor determining bone health. Bone microMRI technique is able to distinguish 
between cortical and trabecular bone hence confer the necessary information of 
bone microarchitecture to more accurately assess the fracture risk in diabetes 
patients. Recent evidence has also suggested increasing bone marrow adiposity in 
osteoporotic bones (Rosen 2006), providing another insight into bone health 
amenable to attractive treatment options targeting bone marrow adipogenesis.  
 
1.2 Literature background 
Earlier studies suggested that the defect in bone mass accretion in T1DM appears 
quite early on in the course of the disease, with evidence of osteopenia as early as 
two years after the diagnosis (McNair 1978, Gunczler 1998). More recent studies 
have shown that children with T1DM have decreased lumbar spine BMD within 
the first few months of diagnosis (Gunczler 2001). This osteopenia doubles in 
children with disease duration of more than three months but stabilises out with 
no further correlation between longer disease duration and BMD (Gunczler 2001).  
 
The mechanisms underlying the abnormalities of bone health may involve: 
1) Alteration in bone remodelling, and/or  
2) Lack of anabolic action of insulin, and/or 
3) Toxic effects of hyperglycaemia or diabetes ketoacidosis 
 
1.2.1) Understanding the changes in biochemical bone markers can provide 
insight into the pathophysiology of osteopenia in T1DM. Bone formation is a 
tightly regulated process characterized by a sequence of events starting with 
commitment of osteoprogenitor cells, and their differentiation into pre-
osteoblasts and then into mature osteoblasts, which express high levels of alkaline 
phosphatase (ALP) and osteocalcin, both of which are markers of bone formation. 
Experimental and animal models with T1DM have suggested a defect in bone 
formation with reduction in osteoblastic numbers and function (Rico 1989, 
Verhaeghe 1990, Hie 2011). Clinical studies in children and young adult with 
T1DM have shown a reduction in biochemical markers of bone formation 
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(Bouillon 1995, Gunczler 1998, Lappin 2009, Pater 2010) thought to be most 
likely secondary to the maturation defect described above. The degree of bone 
resorption contributing to the osteopenia remains somewhat more controversial 
with suggestions of decreased (Pater 2010) but also increased osteoclastic activity 
(Gunczler 2001) in children with T1DM. 
 
1.2.2) T1DM is a condition of insulinopenia and insulin has an anabolic effect on 
the bone, both directly and indirectly. In vitro studies have demonstrated insulin 
as an anabolic agent in osteoblastogenesis as cultured osteoblasts proliferate 
successfully in response to physiological doses of insulin (Wergedal 1984). In 
insulin deficient state, immature mesenchymal cells do not differentiate into 
mature osteoblasts, likely due to altered gene expression of proosteoblastic 
proteins (Lu 2003). Insulin also exerts indirect but synergistic effects with other 
anabolic agents in bone, such as parathyroid hormone (PTH) (Hickman 1990) and 
IGF-1 (Conover 1996). Rats with T1DM rendered insulin-deficient by the chemical 
streptozotocin (STZ) have non-osmotic hypercalciuria resulting in a negative 
calcium balance which may indirectly affect bone integrity (Ward 2001).  
 
1.2.3) Animal studies have also shown that the degree of overall glycaemic control 
correlates with fracture healing (Follak 2004, Follak 2005). Many studies in 
human have investigated the association of metabolic control in T1DM (as 
measured by HbA1c) and bone mineral density with some suggesting benefit in 
good glycaemic control (Valerio 2002, Heap 2004, Pater 2010) whilst others do 
not (Gunczler 1998, Ersoy 1999). Pater et al showed that HbA1c was inversely 
correlated to osteocalcin but only at the onset of diagnosis and not later on in the 
disease process, suggesting that factors other than hyperglycaemia also exert toxic 
effect on bones in T1DM. One other proposed diabetes-related factor is the effect 
of acidosis during DKA on bone mineral density. Metabolic acidosis is known to 
result in negative calcium balance in bone through a reduction in osteoblastic 
formation, increase in osteoclastic resoption and bone mineral resolution (Krieger 
1992, Bushinsky 1993, Frick 1997). Topaloglu et al have suggested that the 
decreased osteoblastic activity in DKA is solely due to effect of acidosis without 
additional influences from other diabetes related-factors such as hyperglycaemia 
and hypoinsulinaemia (Topaloglu 2005). 
 
1.3 Preliminary data from our group  
Preliminary data from a recent study performed on the Scottish national diabetes 
database has not only confirmed that T1DM patients have a substantially 
increased relative risk of hip fractures (IRR 3.28 in men, 3.54 in women) 
compared with age-matched non-diabetics, but also revealed that this increased 
fracture risk is greatest in younger men and women in their second and third 
decade of life (Hothersall 2013).  
 
In previous pilot studies, the Developmental Endocrinology Research Group led 
by Professor Ahmed have developed a method to assess bone microarchitecture 
using microMRI and demonstrated that this method is sensitive in differentiating 
between healthy adult volunteers and volunteers with osteogenesis imperfecta as 
well as growth hormone deficiency (McComb 2013). These studies which 
employed a 3T-MRI to assess bone microarchitecture and combined this with MR 
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spectroscopy to assess BMA clearly showed that, in healthy adults, there is an age 
dependent degradation in bone microarchitecture which is accompanied by 
increased BMA (McComb 2013). Whilst both groups of cases, OI and GHD, had a 
reduction in trabecular bone (Fig.1), it was only the GHD cases who showed an 
increase in BMA. This technique was later applied to young adult women at risk of 
adverse bone health with childhood onset T1DM. This group has shown that 
affected women had a lower number of trabeculae and lower BV/TV and these 
abnormalities were more likely in those patients who were diagnosed at an early 
age or had a longer duration of disease. These abnormalities were also more 
profound in those who had retinopathy (Fig.2). 
  
Fig. 1 
 
 
 
 
 
 
 
 
 
Fig. 2 
 
 
 
1.4 Research Strategy 
The aim of the current proposal is to explore the use of these novel methods 
(microMRI and MRS) in children to improve our understanding of the prevalence 
of early abnormal bone health in conditions such as T1DM.  
 
This research will be dependent on close collaboration between colleagues in 
endocrinology and diabetes, as well as expertise of the MRI physicists, bone 
densitometry service and support from laboratory contacts, all of whom have 
worked together successfully in previous collaborations. 
 
2.0 STUDY OBJECTIVES  
The objective of this research is to use novel methods of microMRI and MRS in 
assessing bone health of children with T1DM.  
 
    Control      Osteogenesis Imperfecta                GHD 
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2.1 Primary Objective 
To establish the prevalence of abnormal bone health in children with newly 
diagnosed and established T1DM, comparing cases and controls  
 
2.2 Secondary Objective 
To assess the relationship of abnormal bone health to disease (age at diagnosis, 
severity at disease presentation, duration of disease) and treatment factors 
(insulin dose, overall glycaemic control)  
 
2.3 Null Hypotheses 
2.3.1 Children and adolescent with T1DM have normal bone health 
2.3.2 Severity of disease (degree of acidosis and HbA1C) at presentation has no 
correlation to underlying bone microarchitecture of children with T1DM 
2.3.3 Poor diabetes control has no effect on bone health in children with 
established T1DM  
 
3.0 STUDY DESIGN 
This research is divided into:  
 
3.1 Newly Diagnosed Diabetes Cases 
A prospective study of bone health in newly diagnosed T1DM children over 14 
month period from diagnosis 
 
3.1.1   Setting 
Recruitment for the study will be conducted over a period of 18 months 
between June 2014 – Nov 2015 at Royal Hospital for Children, Glasgow 
within NHS GGC Paediatric Diabetes Service Network 
 
3.1.2   Subject selection and recruitment 
 All newly diagnosed T1DM patients between age 10 (inclusive) to 18 years 
old (inclusive) within these three hospitals will be eligible for recruitment 
into the study. Recruited subjects will undergo the full study involving 
blood samples, DXA and MRI scans. The annual T1DM incidence in 2012 
within the NHS GGC Health Board is 80, of which 35 are ≥10 years of age.  
 
Patients who are newly diagnosed with T1DM will be identified by the NHS 
GGC Paediatric Diabetes Service and information leaflet of the study 
provided. The researcher (also part of diabetes clinical team) will be 
informed and will make contact and meet with the patients and families in 
the ward to invite them to take part in the study. There will be 
opportunities to ask questions, which will be answered comprehensively 
in the best interest of the patients. 
 
 
 To be enrolled into this study, a child must meet the following inclusion 
criteria: 
• Newly diagnosed case of T1DM 
• Age ≥10 and ≤18 yrs old 
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• Be able and willing to participate in the study as evidence by a 
parent/guardian signing a valid written informed consent and the 
patient signing to show their consent/assent (competence 
appropriate) 
• Child and parents must be able to understand English either directly 
or through interpreters 
 
A child is not eligible for the study if any of the following exclusion criteria 
apply: 
• Age <10 or >19 years old  
• Has significant other co-morbidities (e.g prematurity, congenital 
heart disease, inflammatory bowel disease etc) 
• On medication known to affect bone health (e.g glucocorticoids, bone 
protective therapy) 
 
A child will not be eligible for a MRI study if any of the following 
exclusion criteria apply: 
• Age <10 years old 
• Has contraindications for MRI scan (e.g cardiac pacemaker, 
metallic clip in body etc) 
 
3.1.3 Consent/Assent 
 Written informed consent will be obtained by the researcher from the 
family whilst inpatient prior to conducting any study procedures. Informed 
consent will be obtained in accordance with the Declaration of Helsinki 
(World Medical Organisation, 2008). The research group is aware that 
following the new diagnosis of a chronic health problem in children, 
parents may need more time to assimilate information and this will be 
respected. In such cases, parents/guardian/young person will be 
approached again prior to discharge from hospital.  
 
All participation in our study will be consented by the child or young 
person (ideally with parental consent as well), if deemed competent, or 
consented by the parents or legal guardian with assent from the child or 
young person. Consent will be obtained from the study participants, if 
competent, as assessed by the researcher, according to the guidance from 
the Scottish Children Research Network (ScotCRN) and the Ethics Working 
Group of the Confederation of the European Specialists in Paediatrics 
(CESP). Assent will be obtained from the young person when consent is not 
appropriate for reasons of competence. 
 
Copies of the consent and/or assent form(s) will be given to the 
parents/guardian and child respectively, and placed within the child’s 
medical record. The original(s) will be placed in the site file or subject file, 
as appropriate. 
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3.1.4 Schedule of events 
 Visit 1 
Visit 1 is the first contact between the researcher and the patient/family. 
This will be undertaken whilst patient is still in the ward. After obtaining 
informed consent, each participant will be screened for eligibility 
according to the inclusion and exclusion criteria. Other components for the 
first contact will consist of:  
• Medical, surgical and medication information inc. dietary, exercise & 
fracture history 
• Physical examination and pubertal assessment undertaken preferably 
by examination (or self-reporting if preferred) 
• Information on severity of disease at presentation, laboratory glucose, 
HbA1C and urinalysis result will be collected from medical record 
• Study bloods (C-peptide, biochemical markers of bone metabolism, 
GH/IGF1 axis and adipokines) will be requested on excess blood 
samples collected during initial routine sampling on admission (if 
available) or obtained from venepuncture if insufficient and patient 
agreeable  
• Baseline MRI scan will be organised within 10 days of discharge  
 
Visit 2 
Visit 2 will be timed with routine diabetes clinic visit at 6 months from 
diagnosis, where the researcher will meet with participant and family. 
Components for this contact will consist of: 
• Medical, surgical and medication information inc. dietary, exercise & 
fracture history and severe hypoglycaemia history 
• Height and weight  
• Pubertal assessment 
• Study bloods (not routine) will be obtained for HbA1C, C-peptide, 
biochemical markers of bone metabolism, GH/IGF1 axis and 
adipokines 
  
Visit 3 
Visit 3 will be timed with routine diabetes clinic visit at 12-14 months from 
diagnosis where the researcher will meet with participant and family.  This 
visit will involve: 
• Medical, surgical and medication information inc. dietary, exercise & 
fracture history and severe hypoglycaemia history 
• Height and weight  
• Pubertal assessment 
• Study bloods (not routine) will be obtained for HbA1C, C-peptide, 
biochemical markers of bone metabolism, GH/IGF1 axis and 
adipokines  
• DXA scan at RSC 
• An MRI scan will be arranged for the same day at the Clinical Research 
Facility at RHC, thereafter participant will have completed the study 
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3.1.5   Controls 
In the first instance, age-matched controls from the controls recruited for 
established children with T1DM will be used. In the event that there are no 
suitable age-matched controls from the established cohort, more controls 
will be recruited from healthy age-matched friends or siblings of index 
cases, children of staff members and from other clinics in RHC.  Friends of 
index cases may be interested to volunteer as controls, and in such 
instances, parents of the index case may share with the other parents the 
study information sheet for controls obtained directly from the 
researchers. If they are keen to know more about the study or proceed to 
participate, they will respond directly by contacting the researcher 
(contact details on study information sheet). Children of staff members 
who are interested to volunteer as controls may also do so. Control 
participants will only be recruited if they are willing and able to either 
assent or consent to participation. 
 
All controls will undergo anthropometry, dietary, exercise and fracture 
history, pubertal assessment and a single MRI scan at the RHC. 
 
3.2 Established Diabetes Cases 
A cross sectional case control study of bone health in children with established 
T1DM 
 
3.2.1 Setting 
Recruitment for the study will be conducted over a period of 12 months 
between June 2014 – May 2015 at the Royal Hospital for Children, Glasgow.  
 
3.2.2 Subject selection and recruitment 
A total of 30 patients will be recruited and enrolled (numbers based on 
power calculation in Section 3.5), along with a group of healthy age-
matched controls involving friends or siblings of cases and children of staff 
members. 
 
All current patients with T1DM of ≥3 years duration will be identified by 
the researcher from the SCI-Diabetes database and subdivided into three 
groups based on their glycaemic control (HbA1c ranges: <59mmol/mol, 
59-74mmol/mol, >74mmol/mol). The researcher will arrange to meet 
these potential participants at their next routine clinic appointments to 
verbally explain the study to them. An information leaflet will be provided 
by the researcher or another member of the diabetes team to interested 
participants. There will be opportunities to ask questions, which will be 
answered comprehensively in the best interest of the patients. This will be 
considered the initial approach (see Study Flow Chart for Established 
Diabetes Cases). It is expected that over a period of 3-4 months all 
interested and eligible patients would have been identified. From this 
group of willing participants, 30 subjects with 10 subjects from each HbA1c 
bracket will be recruited into the study based on first come first serve basis.  
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To be enrolled in the study, a child must meet the following inclusion 
criteria: 
• Diagnosed with T1DM for at least three years 
• Age ≥ 10 years and ≤18 years old 
• Be able and willing to participate in the study as evidence by a 
parent/guardian signing a valid written informed consent and the 
patient signing to show their consent/assent (competence appropriate) 
• Child and parents must be able to understand English either directly or 
through interpreters 
 
A child is not eligible for the study if any of the following exclusion criteria 
apply: 
• Age <10 or >19 years  
• Duration of T1DM less than 3 years 
• Has contraindications for MRI scan (e.g. cardiac pacemaker, metallic 
clip in body etc) 
• Has significant other chronic diseases (e.g prematurity, congenital 
heart disease, inflammatory bowel disease etc) 
• On medication known to affect bone health (e.g glucocorticoids, bone 
protective therapy) 
 
Should any participants decide to withdraw from the study before 
completion, the next eligible and willing participant with a HbA1c within 
the same range would be recruited.  
 
3.2.3 Consent/Assent 
Written informed consent will be obtained by researcher prior to 
conducting any study procedures at Visit 1. Informed consent will be 
obtained in accordance with the Declaration of Helsinki (World Medical 
Organisation, 2008). All participation in our study will be consented by the 
child or young person (ideally with parental consent as well), if deemed 
competent, or consented by the parents or legal guardian with assent from 
the child or young person. Consent will be obtained from the study 
participants, if competent, as assessed by the researcher, according to the 
guidance from the Scottish Children Research Network (ScotCRN) and the 
Ethics Working Group of the Confederation of the European Specialists in 
Paediatrics (CESP). Assent will be obtained from the young person when 
consent is not appropriate for reasons of competence. 
 
Copies of the consent and/or assent form(s) will be given to the 
parents/guardian and child respectively, and placed within the child’s 
medical record. The original(s) will be placed in the site file or subject file, 
as appropriate. 
 
3.2.4 Schedule of Events 
 
Initial Approach 
The researcher will meet with the potential participants at their routine 
clinic visit at RHC to verbally explain the study to them. An information 
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leaflet will be provided to participants who satisfy the recruitment criteria. 
There will be opportunities to ask questions, which will be answered 
comprehensively in the best interest of the patients. If the patient and 
family are happy to participate, arrangements will be made to obtain 
informed consent at Visit 1.  
 
Visit 1  
This visit will coincide with the eligible patient’s next routine visit to the 
diabetes clinic at RHC when their routine screening blood is due. The 
researcher will meet with the participant and undertake the following: 
• Informed consent 
• Height and weight  
• Physical examination and pubertal assessment undertaken preferably 
by examination (or self-reporting if preferred) 
• Study bloods for HbA1C, C-peptide, biochemical markers of bone 
metabolism, GH/IGF1 axis and adipokines will be performed at the 
same time as the routine screening bloods 
• DXA scan will be performed if possible prior to patient leaving the 
hospital that day  
 
Visit 2  
This visit will be within 10 weeks of Visit 1. Participant will be requested 
to  attend for an MRI scan, thereafter participant will have completed the 
study.  
 
3.2.5   Controls 
30 healthy age-matched controls will be recruited from friends or siblings 
of index cases, children of staff members and from other clinics in RHC. 
Friends of index cases may be interested to volunteer as controls, and in 
such instances, parents of the index case may share with the other parents 
the study information sheet for controls obtained directly from the 
researchers. If they are keen to know more about the study or proceed to 
participate, they will respond directly by contacting the researcher 
(contact details on study information sheet). Children of staff members 
who are interested to volunteer as controls may also do so. Control 
participants will only be recruited if they are willing and able to either 
assent or consent to participation. 
 
All controls will undergo anthropometry, dietary, exercise and fracture 
history, pubertal assessment and a single MRI scan. 
 
3.3 Study blood samples 
All participants will have blood samples taken at the appropriate intervals 
according to the schedule of events. Research bloods will involve:  
• HbA1c to assess glycaemic control 
• C-peptide to assess residual pancreatic beta-cell function 
• Biochemical markers of bone metabolism (osteocalcin, BALP, CTX) 
• Serum markers of GH/IGF1 axis (IGF-1, IGFBP-3, IGFBP-2, ALS) and 
adipokines (leptin) 
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Excluding the HbA1c which is obtained for routine clinical purpose, the total 
volume of research blood required will be 5mls per collection. At all times 
possible, study bloods will be timed with routine screening bloods. 
 
All newly diagnosed T1DM patients in Greater Glasgow and Clyde (GGC) have a 
standard number of blood tests collected at the point of first intravenous access 
or venous sampling as part of a routine protocol. In order to minimise burden on 
patient with an extra venepuncture, excess blood samples available from this 
initial routine collection will be accessed if the patient and parents consent to 
participate in the study. Once consented, the NHS lab will be contacted by the 
researcher within a week of discharge, to release the samples for research, all of 
which will then be stored at the University of Glasgow freezer at RHC. These will 
be processed in batches at the University of Glasgow lab.   
The Research Group has also created its own reference data for markers of bone 
turnover and GH/IGF-1 axis. 
 
3.4 Study imaging 
3.4.1 DXA scan 
This will be performed at the bone densitometry unit at RHC involving whole 
body, AP spine and femoral neck. The total maximum dose per scan is 3microSv, 
which is equivalent to less than half a day of natural background radiation in the 
UK.  
 
The Research Group has normative DXA BMC data for 150 school age boys and 
girls in Glasgow for LS, TB and FN as well as manufacturer’s reference data for LS 
and TB BMC which are very similar to the Glasgow data. DXA data shall be 
analysed as per the recommendations of the recent ISCD guidelines as well as 
following correction for bone area. LS and FN BMC data shall also be 
mathematically transformed into volumetric data by calculating bone mineral 
apparent density. 
 
There is a possibility that we might find something unexpected (incidental 
finding) in the participant’s images. If this happens, the child will be referred to 
the appropriate specialist for further investigation. All DXA scans will be reviewed 
by the Bone Densitometry Service as part of the research collaboration. Parents 
are made aware that they may then have to disclose such findings in future 
applications for health-related insurance. 
 
3.4.2 MRI/MRS scan 
Participants will need to attend dedicated sessions for MRI. The 3T-MRI scanner 
is based at the RHC Glasgow. Whilst some participants will be able to have the scan 
on the same day when they are attending the diabetes clinic, it is highly likely they 
will also need to devote additional time to attend for this. Participants shall be 
provided with gift vouchers worth £10 per scan visit for this inconvenience and 
all taxi fares paid for in full from base hospital, or home if no hospital appointment 
on the day. Base hospital is defined as the local hospital where the patients attends 
for routine diabetes follow-up.  
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Participants will be taken through an MRI safety checklist, as per standard MRI 
practice prior to entering room. The maximum duration of the MRI scan will be 
one hour, and during this time both microMRI of the tibia and MRS of the lumbar 
spine will be performed. Participants will be advised to attend for a whole 
morning or an afternoon so that all the assessments can be performed. 
 
There is a possibility that we might find something unexpected (incidental 
finding) in the participant’s images. If this happens, the child will be referred to 
the appropriate specialist for further investigation. All MRI scan images will be 
clinically reviewed by Dr Ruth Allen, Consultant Paediatric Radiologist, solely for 
this purpose as part of paid research service. Parents are made aware that they 
may then have to disclose such findings in future applications for health-related 
insurance. 
 
3.5 Statistical consideration and power calculation  
All data will be presented as medians (ranges) if they are not normally distributed. 
Group differences will be compared by non-parametric tests and  Chi-square test 
for categorical variable. Repeated measures of ANOVA will be used to test the 
quantitative measurements of bone health, bone marrow adiposity and metabolic 
status. Multiple logistic regression analysis will be used to adjust for confounding 
variables. 
 
Intra-operator repeatability of microMRI and MRS is high with an average CoV of 
1% and 2.5%, respectively. The primary hypothesis was that children with T1DM 
would have a lower appBV/TV compared to healthy children. In our previous 
work in adult T1DM of 30 cases and control and in adults with OI, which is a more 
severe osteopathy, the estimated coefficient of variation (CoV) for appBV/TV was 
less than 5%. in our previous work. Based on this a 7.5% difference at p<0.05 with 
a power of 0.8 would require at least 25 subjects in each arm.   
 
4.0 STUDY OUTCOMES 
 
4.1 Primary Outcome 
The primary outcome of the study is the quantitative measurements of bone 
microarchitecture (apparent BV/TV, apparent trabecular thickness, apparent 
trabecular number and apparent trabecular separation) obtained from microMRI 
in cases and controls. Additional measures of bone microarchitecture will also be 
explored including measures of connectivity (branch density, nodal density) 
 
4.2 Secondary Outcome 
The secondary outcome measures include:  
• Measure of bone marrow adiposity as assessed by MR spectroscopy 
• Relationship of markers of bone health (including DXA) to markers of 
T1DM disease (duration of disease, age of onset, insulin dose, HbA1C and 
microvascular complications) 
• Change in bone and adiposity markers over first year of diagnosis 
 
5.0 DATA MANAGEMENT 
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Quantitative data will be collected from a variety of sources – blood and urine 
samples, questionnaire results, imaging including DXA, MRI and MRS. Data quality 
will be ensured with repeat measurements taken where appropriate to ensure 
consistency and regular calibration checks on all equipments used. Only one 
trained DXA and MRI staff respectively will be used to ensure consistency of 
results. All personal data will be treated as strictly confidential. Each participant 
will be given a unique study identifier to preserve anonymity of data stored. All 
study questionnaires will be filed on site in a security-coded office and results data 
stored on the researcher’s university computer which is password protected. 
Personal data will be stored only until completion of assessments and all data 
anonymised for analysis. All data will be curated responsibly subjected to the 
University of Glasgow guidance on managing research records. 
http://www.gla.ac.uk/services/dpfoioffice/guidanceonresearch/ 
 
6.0  STUDY TIMELINE 
This study will take 24 months to complete from the point of ethics and R&D 
approval, with timelines as follows: 
 
Months -6 to 0 Design study protocol 
Months -3 to 0 Obtain ethics and R&D approval 
Months 0 to 1  Identify suitable participants for established T1DM cases 
Months 1-18 Recruit participants, begin assessments and follow-up to 
completion, with interim analysis at 6 months 
Months 16-20 Perform full data analysis 
Months 20-24 Prepare final thesis 
 
7.0 FUNDING 
This study is funded by Glasgow Hospital Children’s Charity, for a one-year full 
time clinical research fellow with £10,000 for consumables and the Medical Fund 
of the University of Glasgow for a further £10,000 for consumables. Consumables 
will include cost of scans, study blood sampling and processing, patient travel and 
gift vouchers.  
 
The research costs of the proposed study over 2 years are outlined as follows.   
 
Established diabetes study (30 cases and 30 controls) 
- Biochemical markers (@£25) x 30 samples   £     750 
- Minor consumables (purchase of blood bottles, etc)  £     200 
- DXA scan (@£50) x 30 scans     £  1,500 
- MRI scan (@£250) x 60 scans including controls               £15,000 
- MRI review for incidental findings (@£12.50 X 60 scans)   £     750 
- Patient reimbursement (@20) x 60 visits for MRI  £  1,200 
Total                            £19,400 
 
Newly diagnosed diabetes study (estimated 30 patients) 
- Biochemical markers (@£25) x 90 sample               £  2,250 
- Minor consumables top-up     £     100 
- DXA scan (@£50) x 60 scans     £  3,000 
- MRI scan (@£250) x 60 scans    £15,000 
- MRI review for incidental findings (@£12.50 X 60 scans)   £     750 
- Patient reimbursement (@20) x 60 visits for MRI  £  1,200 
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Total                    £22,300 
 
 
There will also be NHS support costs for obtaining informed consent  
from NHS patients as per the AcoRD Cost Attribution Guidance 2012  
(@£71.08 x90)                   £6,397 
 
Total consumable costs = £48,097 
 
Additional fundings will be sourced for the full cost of the research and 
applications have been submitted to NovoNordisk UK Research Foundation and 
the Chief Scientist Office (CSO). 
 
8.0 PROTOCOL AMENDMENTS 
Any change in the study protocol will require an amendment. Any proposed 
protocol amendment will be submitted to a) the Sponsor for approval, b) REC for 
favourable opinion and c) R&D for acknowledgement. The sponsor will determine 
whether an amendment is substantial or non-substantial. The chief investigator 
will sign and file any amended versions of the protocol before this can be 
implemented. 
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Case Report Form 
 
 
Study number: 
 
Information Sheet given:   Yes / No 
 
Date of consent: 
 
GP Letter sent:  Yes / No 
 
 
 
 
         
 Date of Visit 1:      
 
Demographic and anthropometric data: 
 
 
Patient initials 
   
 
Tel number:  
 
Sex: 
Female 
  
Male 
 
Date of birth  
   
 
Age in year 
 
 
 
Height=  
 
Weight=  
 
 
 
Details of diabetes: 
 
Age at diagnosis: 
 
Disease duration: 
 
Severity at presentation:   
 
Walking wounded DKA 
 
H+                   Bic                    Lab glucose               %dehydration               HbA1c        
 
 
Total insulin dose:      
 
Pump or injection: 
 
Current HbA1c:   
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Available HbA1C results in the 2 years: 
 
Date HbA1C (mmol/mol) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Average HbA1C in the last 2 years: 
Average HbA1C in the last year: 
 
Category of HbA1C control: 
 
Good (<59) Moderate (59-75) Poor (>75) 
 
 
Health behaviour and diet  
 
How often do you eat dairy products?   (please circle one)  
 
Never Once a week       2-3times a week       More than 3 times a week 
 
Calcium (mg/day):  
 
Vitamin D (IU/day): 
 
Multivitamin use:  
 
Smoking: (please circle one)       
 
Current                 (number/day) Past    Never 
 
Physical activity (hrs/week):    see Physical Activity Questionaire       Completed: 
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Medical/Surgical History 
 
  
Patient History (inc Birth Hx) 
 
Gestation: 
Birth weight: 
 
PMHx: 
 
 
 
Med Hx: 
 
 
 
Previous surgery: 
 
 
 
 
Orthopaedic: 
 
Joint problems 
 
Fracture history: 
Number 
Location 
Age 
 
   
Diabetes complications 
 
Previous DKAs (details) 
1. 
2. 
3. 
 
Thyroid disorder:                  
Last TFT at    …………/ ……/………… 
Result 
 
Renal complication (Microalbuminuria): 
Date ……/……/………… 
Result 
 
Retinopathy: 
Last follow up at ……/……/………… 
Result  
 
Neuropathy: 
 
…………………………… 
 
 
Family History 
 
Family history of T1DM: 
 
Family history of osteoporosis:     
  
Family history of fracture:          
 
 
 
 
Reproductive history and examination 
 
Onset of puberty (years):  
 
Menarche (years):  
 
Puberty status: 
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Blood Investigations:  
 
Blood tests Date done Date processed Results 
HbA1C  
 
  
C-peptide 
 
   
25VitD  
 
  
PTH  
 
  
B-ALP  
 
  
Osteocalcin  
 
  
CTX  
 
  
IGF1  
 
  
Leptin  
 
  
Adiponectin  
 
  
Others:  
 
   
 
 
Storage inform: ___________________________________________________________ 
 
 
DXA                                                               Date Notes 
Total body (TB) 
 
  
Femoral neck (FN) 
 
  
Lumbar spine (LS) 
 
  
 
 
Appendix B 
CRF/EDS/Version1/030714 
 
 
 
Date of Visit 2: 
 
Taxi organised: 
 
PICU informed:  Yes / No 
 
CRF nurses organisation- CM/RW informed : Yes / No 
 
Radiological Investigation: 
 
MRI/MRS   
Proximal tibia    
 
Abdominal fat   
 
Lumbar spine 
 
  
 
Visit 2 (Within 6 weeks of Visit 1) 
Study Completed 
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Case Report Form (CONTROL) 
 
 
Study number: 
 
Information Sheet given:   Yes / No 
 
Date of consent: 
 
 
 
 
         
 Date of Visit 1:      
 
Demographic and anthropometric data: 
 
 
Patient initials 
   
 
Tel number:  
 
Sex: 
Female 
  
Male 
 
Date of birth  
   
 
Age in year 
 
 
 
Height=  
 
Weight=  
 
 
 
Health behaviour and diet  
 
How often do you eat dairy products?   (please circle one)  
 
Never Once a week       2-3times a week       More than 3 times a week 
 
Calcium (mg/day):  
 
Vitamin D (IU/day): 
 
Multivitamin use:  
 
Smoking: (please circle one)       
 
Current                 (number/day) Past    Never 
 
Physical activity (hrs/week):    see Physical Activity Questionaire                                        
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Medical/Surgical History 
 
  
Patient History (inc Birth Hx) 
 
Gestation: 
Birth weight: 
 
Past Medical History: 
 
Orthopaedic: 
 
Joint problems 
 
Fracture history: 
Number 
Location 
Age 
 
   
Clinical Examination 
 
 
 
 
 
 
 
 
 
 
 
 
Family History 
 
Family history of T1DM: 
 
 
Family history of osteoporosis:     
  
 
Family history of fracture:          
 
 
Reproductive history and examination 
 
Onset of puberty (years):  
 
Menarche (years):  
 
Pubertal status: 
 
 
 
Radiological Investigation: 
 
MRI/MRS Date Notes 
Proximal tibia    
 
Abdominal fat   
 
Lumbar spine 
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For advice on this study 
Dr S Ching Chen 
Royal Hospital for Children 
Glasgow 
Tel 0141 201 0709 
For independent advice 
Dr Martina Rodie 
Royal Hospital for Children 
Glasgow 
Tel 0141 201 0236 
 
 
STUDY OF BONE HEALTH IN CHILDREN  
WITH ESTABLISHED TYPE 1 DIABETES MELLITUS (T1DM) 
 
Consent Form – Case 
 
Study Number:………………………………………………………………………………………………….   
 
Participant’s Name (Block Capitals):………………...……………………………………………….. 
Please initial boxes 
 
1. I confirm that I have read and understood the Study 
Information Sheet for Participant/Parent/Legal Guardian 
(Case) (Version 3, 16/06/14). I have had the opportunity 
to consider the information, ask questions and had these 
questions answered to my satisfaction 
 
 
2. I understand that my child’s participation is voluntary and 
that I am free to withdraw at any time, without giving a 
reason, without my child’s medical care or legal rights 
being affected 
 
 
3. I understand that my child’s GP will be informed that 
I/he/she am/is participating in this study 
 
 
4. I allow access for the research team and sponsor 
representatives to my child’s medical records and patient 
identifiable information 
 
 
5. I understand that if anything unexpected is demonstrated 
on my child’s scan, I/he/she will be referred to the 
appropriate specialist for further investigation 
 
 
6. I agree for my child to take part in this study 
 
 
 
Name of Participant/Parent/Guardian: ………………………….………………………………….  
  
Signature of Participant/Parent/Guardian: ……………………………  Date:……………..… 
 
Signature of Researcher:……………………………………………………….   Date:……………….. 
ESTABLISHED DIABETES STUDY 
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For advice on this study 
Dr S Ching Chen 
Royal Hospital for Sick Children 
Yorkhill, Glasgow 
Tel 0141 201 0709 
For independent advice 
Dr Martina Rodie 
Royal Hospital for Sick Children 
Yorkhill, Glasgow 
Tel 0141 201 0236 
 
 
 
 
STUDY OF BONE HEALTH IN CHILDREN  
WITH ESTABLISHED TYPE 1 DIABETES MELLITUS (T1DM) 
 
 
Assent Form – Case 
 
 
 
Study Number:…………………………………………………………………………………………………. 
 
 
Participant’s Name (Block Capitals): ..……………………………………………………………….. 
 
Please initial boxes 
 
1. I confirm that I have read and understood the Study 
Information Sheet for Participant (Case) (Version 3, 
16/06/14)  
 
 
2. I have had the time to think about this and ask questions 
 
 
3. I understand that I do not have to take part if I do not want 
to 
 
 
4. I agree to take part in this study 
 
 
 
 
Signature of Participant: ……………………………………………. Date:……………………………. 
 
 
Signature of Researcher:…………………………………………...   Date:…………….……………… 
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For advice on this study 
Dr S Ching Chen 
Royal Hospital for Children 
Glasgow 
Tel 0141 201 0709 
        
For independent advice 
Dr Martina Rodie 
Royal Hospital for Children 
Glasgow 
Tel 0141 201 0236 
 
 
STUDY OF BONE HEALTH IN CHILDREN  
WITH ESTABLISHED TYPE 1 DIABETES MELLITUS (T1DM) 
 
 
Consent Form for Parent/Legal Guardian – Control 
 
Study Number:………………………………………………………………………………………………….   
 
Name of Participant (Block Capitals):………….…………………………………………………….. 
 
Please initial boxes 
1. I confirm that I have read and understood the Information 
Sheet for Parent/Legal Guardian (Control) dated 
10/12/14 (Version 4) for the above study. I have had the 
opportunity to consider the information, ask questions 
and had these questions answered to my satisfaction 
 
 
2. I understand that my child’s participation is voluntary and 
that I am free to withdraw at any time, without giving a 
reason, without my child’s medical care or legal rights 
being affected 
 
 
3. I understand that my child’s GP will be informed that 
he/she is participating in this study 
 
 
4. I understand that if anything unexpected is demonstrated 
on my child’s scan, he/she will be referred to the 
appropriate specialist for further investigation 
 
 
5. I agree for my child to take part in this study 
 
 
 
 
Name of Parent/Guardian: ……………………….. Date:……………. Signature: ……………… 
 
 
Name of Researcher:………………………………… Date: …………… Signature: ……………… 
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For advice on this study 
Dr S Ching Chen 
Royal Hospital for Children 
Glasgow 
Tel 0141 201 0709 
For independent advice 
Dr Martina Rodie 
Royal Hospital for Children 
Glasgow 
Tel 0141 201 0236 
 
 
 
STUDY OF BONE HEALTH IN CHILDREN  
WITH ESTABLISHED TYPE 1 DIABETES MELLITUS (T1DM) 
 
 
Consent Form for Young Person – Control 
 
Study Number:…………………………………………………………………………………………………. 
 
Please initial boxes 
1. I confirm that I have read and understood the Information 
Sheet for Participant (Control) dated 10/12/14 (Version 
4) for the above study 
 
 
2. I have had a chance to discuss this study and ask questions   
3. I have received satisfactory answers to all of my questions 
 
 
4. I have received enough information about the study  
 
 
5. I understand that my participation is voluntary and I am 
free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected  
 
 
6. I understand that sections of my medical notes may be 
looked at by the research team where it is relevant to my 
taking part in the research. I give my permission for the 
research team to have access to my records 
 
 
7. I agree to take part in the above study 
 
 
 
 
Name of Participant: ………………………………… Date: …………… Signature: …………....... 
 
 
Name of Parent/Guardian: ……………………….. Date:……………. Signature: ……………… 
 
 
Name of Researcher:………………………………… Date: …………… Signature: ……………… 
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For advice on this study 
Dr S Ching Chen 
Royal Hospital for Children 
Glasgow 
Tel 0141 201 0709 
For independent advice 
Dr Martina Rodie 
Royal Hospital for Children 
Glasgow 
Tel 0141 201 0236 
 
 
 
STUDY OF BONE HEALTH IN CHILDREN  
WITH ESTABLISHED TYPE 1 DIABETES MELLITUS (T1DM) 
 
Assent Form for Young Person – Control 
 
 
Study Number:…………………………………………………………………………………………………. 
 
Please circle your answers: 
Have you read (or had read to you) about this project?    Yes / No  
Has somebody else explained this project to you?     Yes / No  
Do you understand what this project is about?     Yes / No  
Have you asked all the questions you want?      Yes / No  
Have your questions been answered in a way that you understand?   Yes / No  
Do you understand that it’s OK to stop taking part at any time?    Yes / No  
Are you happy to take part?        Yes / No  
 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name!  
If you do want to take part, you can sign your name below  
Your name  ______________________________ 
Signature ______________________________ 
Date   ______________________________ 
The doctor who explained this project to you needs to sign too:  
Print Name  ______________________________ 
Signature ______________________________ 
Date   ______________________________ 
 
Thank you for your help 
(To be completed by the child and their parent/guardian) 
ESTABLISHED DIABETES STUDY 
Appendix F 
PAQ<14  1 
 
Physical Activity Questionnaire (<14 years old) 
Name:_________________________ Age:___________ 
Sex: M_______ F_______ Grade:__________ 
We are trying to find out about your level of physical activity from the last 7 days (in the last 
week). This includes sports or dance that make you sweat or make your legs feel tired, or games 
that make you breathe hard, like tag, skipping, running, climbing, and others. 
Remember: 
1. There are no right and wrong answers — this is not a test 
2. Please answer all the questions as honestly and accurately as you can — this is very important 
 
1. Physical activity in your spare time: Have you done any of the following activities in the past 7 
days (last week)? If yes, how many times? (Check only one box per row) 
 
 
Aerobics  
Badminton  
Baseball, softball 
Basketball  
Bicycling  
Dance  
Football  
Hockey  
In-line/Ice skating  
Jogging or running 
Rowing/canoeing  
Rugby 
Skateboarding  
Skipping  
Swimming  
Tag  
Volleyball  
Walking for exercise  
Other(s): 
 
_________________________ 
 
No 1-2 3-4 5-6 ≥7 
     
2. In the last 7 days, during your physical 
education (PE) classes, how often were you 
very active (playing hard, running, jumping)?  
(Check one only) 
I don’t do PE  
Hardly ever  
Sometimes  
Quite often  
Always  
 
3. In the last 7 days, what did you do most of 
the time at recess?  
(Check one only) 
 
Sat down (talking, reading, doing schoolwork) 
Stood around or walked around  
Ran or played a little bit  
Ran around and played quite a bit  
Ran and played hard most of the time  
 
Appendix F 
PAQ<14  2 
 
4. In the last 7 days, what did you normally do 
at lunch (besides eating lunch)?  
(Check one only) 
 
Sat down (talking, reading, doing schoolwork) 
Stood around or walked around  
Ran or played a little bit  
Ran around and played quite a bit  
Ran and played hard most of the time  
 
5. In the last 7 days, on how many days right 
after school, did you do sports, dance, or play 
games in which you were very active?  
(Check one only) 
None  
1 time last week   
2 or 3 times last week  
4 or 5 last week  
6 or 7 times last week  
6. In the last 7 days, on how many evenings did 
you do sports, dance, or play games in which 
you were very active? (Check one only) 
None  
1 time last week   
2 or 3 times last week  
4 or 5 last week  
6 or 7 times last week 
7. On the last weekend, how many times did 
you do sports, dance, or play games in which 
you were very active? (Check one only) 
None  
1 time  
2 — 3 times  
4 — 5 times  
6 or more times  
 
8. Which one of the following describes you best for the last 7 days?  
Read all five statements before deciding on the one answer that describes you. 
 
A. All or most of my free time was spent doing things that involve little physical effort  
B. I sometimes (1 — 2 times last week) did physical things in my free time 
(e.g. played sports, went running, swimming, bike riding, did aerobics)  
C. I often (3 — 4 times last week) did physical things in my free time  
D. I quite often (5 — 6 times last week) did physical things in my free time  
E. I very often (7 or more times last week) did physical things in my free time  
 
9. Mark how often you did physical activity (like playing sports, games, doing dance, or any other 
physical activity) for each day last week. 
 
Monday  
Tuesday  
Wednesday  
Thursday  
Friday  
Saturday  
Sunday  
 
None A bit Medium Often Very often 
     
10.  Were you sick last week, or did anything prevent you from doing your normal physical 
activities? (Check one) 
 
Yes  
No  
If Yes, what prevented you? __________________________________ 
 
 
 
Appendix G 
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Physical Activity Questionnaire (14-19 years old) 
Name:_________________________ Age:___________ 
Sex: M_______ F_______ Grade:__________ 
We are trying to find out about your level of physical activity from the last 7 days (in the last 
week). This includes sports or dance that make you sweat or make your legs feel tired, or games 
that make you breathe hard, like tag, skipping, running, climbing, and others. 
Remember: 
1. There are no right and wrong answers — this is not a test 
2. Please answer all the questions as honestly and accurately as you can — this is very important 
 
1. Physical activity in your spare time: Have you done any of the following activities in the past 7 
days (last week)? If yes, how many times? (Check only one box per row) 
 
 
Aerobics  
Badminton  
Baseball, softball 
Basketball  
Bicycling  
Dance  
Football  
Hockey  
In-line/Ice skating  
Jogging or running 
Rowing/canoeing  
Rugby 
Skateboarding  
Skipping  
Swimming  
Tag  
Volleyball  
Walking for exercise  
Other(s): 
 
_________________________ 
 
_________________________ 
 
No 1-2 3-4 5-6 ≥7 
     
2. In the last 7 days, during your physical education (PE) classes, how often were you very active 
(playing hard, running, jumping)?  
(Check one only) 
I don’t do PE  
Hardly ever  
Sometimes  
Quite often  
Always  
 
Appendix G 
PAQ14-19  2 
 
3. In the last 7 days, what did you normally do 
at lunch (besides eating lunch)?  
(Check one only) 
 
Sat down (talking, reading, doing schoolwork) 
Stood around or walked around  
Ran or played a little bit  
Ran around and played quite a bit  
Ran and played hard most of the time  
 
4. In the last 7 days, on how many days right 
after school, did you do sports, dance, or play 
games in which you were very active?  
(Check one only) 
None  
1 time last week   
2 or 3 times last week  
4 or 5 last week  
6 or 7 times last week  
5. In the last 7 days, on how many evenings did 
you do sports, dance, or play games in which 
you were very active? (Check one only) 
None  
1 time last week   
2 or 3 times last week  
4 or 5 last week  
6 or 7 times last week 
6. On the last weekend, how many times did 
you do sports, dance, or play games in which 
you were very active? (Check one only) 
None  
1 time  
2 — 3 times  
4 — 5 times  
6 or more times  
 
7. Which one of the following describes you best for the last 7 days?  
Read all five statements before deciding on the one answer that describes you. 
 
A. All or most of my free time was spent doing things that involve little physical effort  
B.  I sometimes (1 — 2 times last week) did physical things in my free time 
    (e.g. played sports, went running, swimming, bike riding, did aerobics)  
C. I often (3 — 4 times last week) did physical things in my free time  
D. I quite often (5 — 6 times last week) did physical things in my free time  
E. I very often (7 or more times last week) did physical things in my free time  
 
8. Mark how often you did physical activity (like playing sports, games, doing dance, or any other 
physical activity) for each day last week. 
 
Monday  
Tuesday  
Wednesday  
Thursday  
Friday  
Saturday  
Sunday  
 
None A bit Medium Often Very often 
     
9.  Were you sick last week, or did anything prevent you from doing your normal physical 
activities? (Check one.) 
 
Yes  
No  
If Yes, what prevented you? __________________________________ 
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There are several mechanisms by which diabetes could affect bone mass and strength. These
mechanisms include insulin deficiency; hyperglycemia; the accumulation of advanced
glycation end products that may influence collagen characteristics; marrow adiposity and
bone inflammation. Furthermore, associated diabetic complications and treatment with
thaizolidinediones may also increase risk of fracturing. The following article provides its
readers with an update on the latest information pertaining to diabetes related bone skeletal
fragility. In the authors’ opinion, future studies are needed in order to clarify the impact of
different aspects of diabetes metabolism, glycemic control, and specific treatments for
diabetes on bone. Given that dual energy x-ray absorptiometry is a poor predictor of bone
morbidity in this group of patients, there is a need to explore novel approaches for assessing
bone quality. It is important that we develop a better understanding of how diabetes affects
bone in order to improve our ability to protect bone health and prevent fractures in the
growing population of adults with diabetes.
KEYWORDS: diabetes • fractures • glucose • insulin • skeleton
Diabetes mellitus is a common metabolic dis-
order with an increasing prevalence throughout
the world. In addition to the many target
organs that are typically associated with dys-
function, the skeleton has been recognized as
another organ that is adversely affected in dia-
betes mellitus with fragility fractures been
increasingly recognized in people with diabetes
mellitus [1–3]. An extensive volume of clinical
data supports altered bone structure and bio-
chemical markers of bone turnover in people
with both Type 1 and Type 2 diabetes (T1D
and T2D) [4–6]. In addition, a series of experi-
mental studies have reported several possible
mechanisms that could explain the link
between diabetes and adverse bone health. In
the present article, we review the pathophysio-
logical mechanisms of diabetic bone loss and
the evidence that exists for abnormalities of
bone health in people with diabetes.
Pathogenesis of altered bone
metabolism in diabetes
Hyperglycemia
Several in vivo and in vitro studies indicate
that hyperglycemia contributes to bone loss
through a variety of mechanisms: direct glu-
cose toxicity to osteoblast through polyol-
pathway activity affecting osteoblast numbers
and function [7,8]; osmotic and nonosmotic
pathways which independently suppress osteo-
blast maturation and mineralization [9,10]; down
regulation of vitamin D receptor thus indirectly
impairing osteoblast maturation in response to
1,25(OH)D3 [8]; oxidative stress [11]; and for-
mation of glycation products [12].
Hyperglycemia leads to increased nonenzy-
matic protein glycation and excessive forma-
tion of these modified proteins called
advanced glycosylation end-products (AGEs).
AGEs appear to be the common biochemical
entity accumulating in individuals with long-
term diabetic complications. They are seen in
various sites such as vascular tissues, kidneys
and bones [13,14]. The accumulation of AGEs
increases formation of collagen cross-links
which results in increased stiffness of the colla-
gen network in the cortical bone, but this has
no overall effect on the stiffness of the miner-
alized bone [15]. Accumulation of pentosidine,
a well-characterized AGE, is negatively corre-
lated to trabecular bone volume and the struc-
tural strength of the trabecular bone, which
may explain how AGEs contribute to bone
fragility [16–18]. In support of this hypothesis,
in vivo studies in both T1D and T2D rats
have confirmed that an increase in AGE
production is negatively correlated with bone
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mineral density (BMD) and bone strength [19,20]. Moreover,
AGE was found at higher concentration in cortical and cancel-
lous bones of people with femoral neck fracture compared to
post-mortem controls [17,19]. In addition to affecting bone phys-
ical properties, AGEs also have direct effects on bone cells. In
vitro and ex vivo findings suggest that elevated AGE can inhibit
proliferation and differentiation of osteoblast [21,22] in mouse
and human mesenchymal stem cells (MSCs). It is also associ-
ated with reduced osteocalcin mRNA expression as seen in
rodents with diabetes [20,23]. Furthermore, Okazaki et al. dem-
onstrated that the inhibition of osteoblastic differentiation by
AGEs can occur independently of hyperglycemia [24]. AGEs
can also cause osteoblast death by provoking inflammation and
generation of reactive oxygen species (ROS) which in turn lead
to cell apoptosis as a result of oxidative stress [11,23,25,26]. How-
ever, reports regarding the influence of AGEs on osteoclasts
and bone resorption show inconsistent effects with some evi-
dence of increased [27], decreased [28] as well as no effect of
AGE on bone resorption [21]. Higher pentosidine levels and
AGE products have been found to reduce bone strength and
elevated vertebral fracture risks in T2D [17,29].
MSCs are pluripotent stem cells capable of differentiating
into bone, muscle, cartilage and adipose tissues. Emerging evi-
dence suggests that hyperglycemia may also alter the differentia-
tion of the MSCs promoting adipogenesis instead of
osteogenesis [30]. Mice with spontaneously and pharmacologi-
cally induced diabetes with bone loss have shown increased
marrow adiposity, determined by histology and by mRNA
markers of adipogenesis (PPARg and aP2) [31]. Hyperglycemia
diverts the MSC differentiation signaling pathways toward adi-
pogenesis at the expense of osteogenesis. This effect is achieved
via ERK-1/-2-activated P13K/Akt-regulated pathway in mouse
MSCs [32], and via suppression of HO-1 expression [33] and
Wnt/protein kinase C noncanonical pathway in human
MSCs [34], evidenced by increased PPARg expression in high
glucose stimuli and reduction of osteocalcin levels. Wang et al.
demonstrated that hyperglycemia can also promote adipogenesis
through synthesis of hyaluronan matrix which promotes an
inflammatory response culminating in demineralization of tra-
becular bones [35].
Insulin, IGF-1 & other growth factors
Insulin is increasingly recognized to have an anabolic effect on
bone that is distinct from the effect of its analogue IGF-1.
This effect is mediated either indirectly through its control of
blood glucose concentration while maintaining the levels of
parathyroid hormone (PTH), IGF-1 vitamin D [36,37], or
directly on bone cells through specific insulin receptors (IRs)
and IGF-1 receptors in osteoblast. IRs are present on osteo-
blasts and its expression varies with differentiation status of the
osteoblast both in vivo and in vitro [38,39]. In vitro studies on
primary osteoblasts and clonal osteoblast cell lines show insulin
promotes glucose uptake [40], alkaline phosphatase activity, col-
lagen synthesis [41,42] and osteoblast proliferation [43] of these
cells. Maor et al. demonstrated reduced IRs in the skeletal
growth centers of mice with streptozocin (STZ)-induced diabe-
tes and these were reversed with insulin therapy [44]. Evidence
for a direct link between insulin action and bone formation
in vivo can be observed in IR knock out mice which show
altered bone formation [45], abnormal trabecular microarchitec-
ture [46] and reduced bone strength [47]. Insulin positively regu-
lates bone formation by stimulating osteocalcin production.
Observational studies in people with T1D and T2D, with insu-
lin deficiency and resistance respectively, demonstrate reduced
osteocalcin levels compared with controls [48,49]. Furthermore,
there is a positive correlation between insulin dose and
BMD [50,51]. The dichotomy of lower BMD in T1D with insu-
linopenia and higher BMD in T2D with clinical hyperinsuline-
mia further implicates a causal anabolic effect of insulin
on bone.
The direct effect on bone may also be mediated by the
IGF-1 pathway. IGF-binding protein (IGFBP) serves as a car-
rier protein for IGF1. Insulin inhibits IGFBP-1, 4 expression
in osteoblasts and therefore lack of insulin leads to an increase
in IGFBP-1 and 4 levels, accordingly decreasing the availability
of unbound IGF-1 for anabolic effects on bone [52]. In addition
to insulin deficiency, T1D individuals and animal models dem-
onstrate dysregulation of a variety of endocrine factors includ-
ing reduced amylin [2] and IGF-1 [53]. Amylin is another
osteotropic factor that is cosecreted by pancreatic beta-cells and
absent in T1D [54]. Amylin-deficient mice displayed low bone
mass with increased number of osteoclast [55] and that treat-
ment with amylin in diabetic rat result in increased BMD and
bone strength [54]. Similarly, diabetic animals with low blood
IGF-1 and knock-out mice for its receptor displayed dimin-
ished bone formation [56,57]. Also, serum IGF-I level was
another predictor of prevalent VFs in postmenopausal women
with T2D [58].
Calcium, vitamin D & calciotropic hormones
It is well known that calcium homeostasis plays a major role in
regulating bone metabolism, Therefore, imbalance in systemic
factors which are capable of regulating calcium balance have
been found to influence diabetic bone loss [59]. Similar to
diabetic patients, several but not all studies demonstrate
that diabetic animal models have reduced levels of PTH,
vitamin D, calcium, magnesium and phosphate [60]. The effect
of DM on calcium metabolism is complex, but essentially it is
associated with a negative calcium balance hallmark by both
bone and renal loss [61]. There is a growing body of evidence
which demonstrate exacerbation of osteopenia and osteoporosis
in animals and humans with vitamin D deficiency and T1D or
T2D [62–64]. Verhaegae et al. found that diabetic rats have
higher urinary calcium excretion and significantly lower serum
concentrations of both 1,25-dihydroxyvitamin D3 and vitamin
D-binding protein [63]. Frazer et al. demonstrated that alter-
ation in vitamin D metabolism in young insulin-dependent
diabetics aged 7–18 years old, who have markedly reduced
1,25-dihydroxyvitamin–D but normal serum calcium, phos-
phate and PTH concentrations, could be related to their
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observed decrease in cortical bone mass [64]. More recently,
Zhang et al. aimed to explain the mechanism involved by dem-
onstrating that male STZ-induced diabetic mice have high uri-
nary calcium excretion and decreased BMD [59]. Quantified PCR
results showed alteration of vitamin D metabolic enzyme expres-
sion and down regulation of mRNA expression levels for renal
calcium transporter receptors, plasma membrane Ca-ATPase,
and vitamin D receptor. In support of this, treatment with calci-
triol in STZ-induced rats demonstrated recovery of BMD [65].
In terms of PTH, several in vivo and in vitro studies indicate
that an imbalance in PTH was associated with bone loss and
increase fracture risk [66,67]. PTH encourages bone formation
and turnover by increasing the expression of osteocalcin,
IGF-1, IGFBP-3, bFGF, MMP-1 and MMP-13 in rat osteo-
blasts in vitro (?) [68], as well as MMP-13 in mice in vivo [69].
Moreover, treatment with PTH to T1D and T2D mice dem-
onstrated reversal of trabecular bone parameters through its
anabolic effects on osteoblasts differentiation and matura-
tion [67,70]. PTH-treatment was also associated with reduced
TUNEL-staining of osteoblast suggesting its antiapoptotic
effect on osteoblasts. It has been suggested that PTH promotes
repair of DNA damage by increasing PCNA and Foxo3a [71],
hence prolonging osteoblast survival. Intermittent PTH-
treatment reversed bone loss to baseline in mice compared to
only partial reversal in continuous PTH-treatment, although
this effect may be due to underlying differences between the
T1D and T2D mouse models [67,70]. Similarly, treatment with
PTH-related protein, which is produced at high levels by dif-
ferentiating osteoblasts, also reverses trabecular bone loss in
STZ-induced diabetic mice suggesting its modulatory effect on
osteoblast function and role in diabetic osteopenia [72].
Marrow adiposity & adipokines
There is a growing body of evidence that suggests that the fat-
bone connection plays an important role in the pathophysiol-
ogy of bone loss. Osteoblasts and adipocytes share a common
precursor, both derived from the pluripotent MSCs located in
the bone marrow suggesting a mutually exclusive and reciprocal
lineage selection of one or the other. The main lineage-specific
transcription factors that direct the differentiation of MSC are
the runt-related transcription factor 2 (Runx2) for osteoblasto-
genesis and the PPARg for adipogenesis [73]. It has been sug-
gested that lineage selection could regulate bone density and
result in bone loss when MSCs commit to the adipocytes at
the expense of osteoblasts [33,74,75]. Botolin et al., 2005 were the
first to report an increase in the expression of PPARg and an
increase in visible adipocytes in tibia of T1D mouse models
compared with control [76]. Subsequently, several experimental
animal studies have demonstrated an increase in bone marrow
adiposity in both spontaneously and STZ-induced T1D mice
compared to controls [31,72,77]. As described earlier, hyperglyce-
mia is capable of promoting adipogenesis by altering the line-
age commitment of MSCs to adipocytes through various
signaling pathways contributing to the diabetic osteope-
nia [32,34,78]. Rzonca et al. demonstrated in vivo that
rosiglitazone (PPARg agonist) administration results in signifi-
cant bone loss whilst Cock et al. 2004 demonstrated that con-
genitally PPARg deficient mice had increased BMD and bone
trabecular microarchitecture parameter including BV/TV and
trabecular thickness [79]. However, Botolin and McCabe found
that inhibition of PPARg by administration of an antagonist to
insulin deficient T1D mice prevented bone marrow adiposity
but not bone loss [31]. This inability in preventing bone loss in
T1D mice suggested that bone marrow adiposity may only be
partially responsible for diabetic bone loss.
Bone marrow adiposity can also have direct effect on osteo-
blasts as demonstrated by several coculture studies in mouse
and human cells [80–82]. The presence of adipocytes inhibit oste-
oblast proliferation [80] through the lipotoxic effect of free fatty
acid in the bone marrow microenvironment [81]. Coe et al.
demonstrated that the diabetic bone marrow itself is a mediator
for osteoblast death with an increase in caspase-3 activity, a
marker for extrinsic apoptotic pathway which are activated by
extracellular ligands such as TNFa, in bone marrows of both
spontaneous and pharmacologically-induced diabetic mice. By
treating the cocultures with TNFa antibodies, they prevented
osteoblast death further supporting the negative correlation of
diabetic bone marrow adiposity and bone mass.
In addition to releasing large amounts of free fatty acid, adipo-
cytes in the bone marrow also secretes cytokines including leptin,
resistin and TNFa, the last of which will be discussed in the next
section. Leptin is an adipokine which has a complex regulatory
role on bone metabolism, with an indirect inhibitory effect on
osteoclastogenesis and a direct stimulatory effect on osteoblasto-
genesis through a central (hypothalamic) and peripheral
pathway [83–85]. Despite being an adipokine, in vitro studies indi-
cate that leptin promotes an osteoblast rather than adipocyte line-
age [84,85]. In contrast to T1D patients who demonstrate
increased [86] or slightly decreased leptin level [87], leptin levels
were found to be significantly suppressed in T1D mice, its
absence results in reducing bone mass with increasing marrow
adiposity [83]. T2D is typically associated with obesity, which has
been associated with higher leptin level and higher BMD.
Vasilkova et al., however, demonstrated that leptin has an inde-
pendent positive correlation to BMD, irrespective of BMI [88]. In
addition, interventional studies in mice have demonstrated that
leptin administration reduces bone marrow adiposity and
increase bone mass [89,90]. However, similar to their work on
PPARg antagonist, Motyl and McCabe concluded that leptin
administration to T1D mice modify and prevent marrow adipos-
ity but did not prevent diabetic bone loss [91]. Adiponectin
(APN), the most abundant adipocyte-secreted adipokine, regu-
lates energy homeostasis and exerts well-characterized insulin-
sensitizing properties. The peripheral and central effects of APN
on bone metabolism are beginning to be explored but are still
not clearly understood. APN-knockout (APN-KO) mice fed a
normal diet exhibit decreased trabecular structure and mineraliza-
tion and increased bone marrow adiposity and central adminis-
tration of APN decreased osteoclast numbers, whereas osteoblast
osteogenic marker expression and trabecular bone mass increased,
Bone health in diabetes Review
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both, in APN-KO and WT mice [92]. The insulin-sensitising
effect of OC is known be due to the upregulation of the expres-
sion of the insulin-sensitizing APN gene in adipocytes [93] but
there is some suggestion that in humans the link between OC
and APN may be gender specific [94].
Chronic inflammation
The pathogenesis of both T1D and T2D are associated with
activation of the immune system, especially so in T1D which
involves an autoimmune destruction of pancreatic b-cells whilst
T2D involves a more chronic low-grade inflammatory pro-
cess [95,96]. Several experimental studies using T1D mice model
indicate that systemic and local inflammatory cytokines are
increased at the onset of diabetes with rapid suppression of
osteoblast markers and increase in adipocyte markers, indicating
that bone inflammation may be another contributing factor to
the diabetic bone pathology [82,97,98]. Serum cytokine levels
(TNFa, IFN-g , IL-1Ra and LT-b) and corresponding bone
cytokine mRNA expression were increased from as early as
5 days after induction of diabetes in mouse models [31,97] with
decrease in osteocalcin mRNA expression in bone RNA
extracts, and it remains suppressed at 40 days postinduction.
TNFa can either directly suppress osteoblast maturation as
well as promote osteoblast death in vitro [98] or act indirectly
by contributing to elevation of ROS causing osteoblast apopto-
sis from oxidative stress [11,26]. Coe et al. also found that TNFa
in the bone marrow microenvironment directly mediate
osteoblast death with increase in increased expression of pro-
apoptotic factors and osteoblast TUNEL staining, further con-
tributing to T1D bone loss [82]. Inhibition of the cytokines
with TNFa neutralizing antibodies prevented osteoblast apo-
ptosis [82] but transgenic mice with IFN-g KO proceeded to
have diabetic bone pathology [97], supporting the idea that dia-
betic inflammatory bone loss involves an interplay of more
than one cytokine and/or a combinations of other factors.
Apart from proinflammatory cytokines, abnormal hyaluronan
production in bones of diabetic rodents also induced monocyte
and macrophage infiltration into the bone collagen matrix, pro-
moting adipogenesis at the expense of osteogenesis [35].
The concept of T2D as an inflammatory disease is relatively
new with increased fat depots in T2D implicated as the source
for more proinflammatory cytokines and adipokines [95]. How-
ever, a large prospective population study (EPIC) in Germany
found that systemic inflammatory markers are independent pre-
dictors for the development of T2D, independent of degree of
insulin resistance and obesity [99].
Vasculopathy
Similar to other diabetic microvascular complications of reti-
nopathy, nephropathy and neuropathy, bone microangiopathy
has been insinuated as another possible mechanism for diabetic
bone loss. In hypoxic condition (2% oxygen), the bone marrow
shifts toward adipogenic lineage by enhancing expression of
genes associated with adipogenic/lipogenicphenotype (C/EBPb,
PPARg2, and aP2) and by suppressing expression of genes
associated with osteoblast differentiation (alkaline phosphatase,
AP) [100]. Oikawa et al. found that the cumulative vascular den-
sity was reduced by threefold in bone marrow of STZ-induced
diabetic mice compared to control, along with reduction in
blood flow [101]. In addition, there is also evidence of reduction
in bone marrow volume and bone marrow remodeling with
cell depletion mainly affecting the osteoblastic niche secondary
to hypoperfusion and oxidative stress [101]. Correspondingly,
boosting the antioxidative pentose phosphate pathway with
benfotiamine supplementation prevented microangiopathy and
hypoperfusion in the bone marrow with reduction in cell apo-
ptosis, providing further compelling evidence for vasculopathy
in diabetic bone pathology. Regenerating mouse tibia has
reduction in blood vessels with lower expression of VEGF, a
signaling protein which regulate angiogenesis, and its recep-
tor [72]. Clinically, histomorphometric evaluation of iliac crest
bone biopsy in 118 diabetic patients revealed evidence of dia-
betic bone microangiopathy in 82% with significant osteopenia
and reduction in the sinusoidal capillaries [102].
Anti-diabetic medications
Although insulin has a clear anabolic role on bone as reported
earlier, the skeletal effects of insulin treatment remain contro-
versial with increased risk of falls from hypoglycemic attacks
resulting in fractures [103]. Total daily insulin requirement has a
positive predictive value for low BMD, although the need for
higher insulin dose may reflect the presence of more severe dis-
ease [104]. Different classes of anti-diabetic medication, such as
thiazolidinediones (TZDs), metformin and glycogen-like pep-
tide 1 inhibitors have been reported to have both varying
effects on bone. TZDs such as pioglitazone and rosiglitazone
has been shown to increase adipocyte differentiation and
decreased osteoblast differentiation through activation of
PPARg activity [79,105,106]. Consistent with these preclinical
observations, a meta-analyses clearly indicate that TZD use is
associated with a higher risk of fracture, particularly in
women [107]. In contrast, metformin and sulfonylurea have
been reported to be bone protective with a reduction in risk of
fractures in patients treated with these agents [108,109]. Both
compounds exert a direct osteogenic effect in vitro by stimulat-
ing proliferation and differentiation of osteoblast [110–114]
through preventing AGE-induced deleterious effects in osteo-
blastic cells [115] and various signaling pathways including the
PI3K/Akt pathway [113], ERK-1/2 [110] and AMPK activa-
tion [112,114]. Zhen et al. also demonstrated an indirect effect of
metformin on osteoblast survival through reduction of intracel-
lular ROS [116]. In addition to its osteoblastogenic potency
in vitro, metformin can further prevent bone loss by inhibiting
osteoclastic differentiation [117]. However, ovariectomized
rodents treated with metformin demonstrated inconsistent
radiological findings of no change in bone microarchitec-
ture [118] to increased BMD [117]. A newer class of oral anti-
diabetic agent, the dipeptidyl peptidase-4 (DPP-4) inhibitors,
such as sitagliptin, has been observed to have anabolic effects
on the bone [119] but the long-term skeletal consequences of these
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drugs are yet unclear. Lastly, dapagliflozin, a highly selective
inhibitor of sodium-glucose cotransporter 2 which reduces hyper-
glycemia and weight in patients with T2D by increasing urinary
glucose excretion has also been studied for ts effects on bone
metabolism but no clear effects have been described [120,121].
Clinical evidence of fractures
Type 1 diabetes
Although fracture data for T1D is scarce, the existing evidence
indicates that people with T1D have a higher fracture risk com-
pared to the general population and these fractures occur more
frequently in the lower limbs [1,122–124]. More recently, vertebral
fractures have been also reported [125,126]. The risk of hip fractures
in those with T1D is reported to be 7–12 times greater [122,127]
and this increased risk is also evident in young adults [3]. The
increased fracture risk was much higher than expected based on
BMD assessed by dual energy x-ray absorptiometry (DXA),
which was only 10% lower than normal [2]. In a meta-analysis
that highlighted the fracture rates and the discrepant relationship
with BMD, the relative risk for hip fracture amongst T1D stud-
ies was almost 7 [1]. Poor glycemic control and disease duration
have also been reported to play a contributory role in this raised
Table 1. Studies that evaluated fracture risk in people with Type 1 diabetes mellitus.
Study (year) Study
design
Sex Study
population
Age (mean
± SD) or
range
Fracture
site and
assessed
outcome
Comments Ref.
Nicodemus and
Folsom (2001)
Prospective
cohort
F 30,377 55–69 Hip Women were 12.25 times more
likely to report an incident hip
fracture than women without
diabetes
[122]
Miao et al.
(2005)
Prospective
cohort
F/M 24,605 20.7 ± 10.9 Hip Elevated risks were observed in
both sexes (standardized
hospitalization ratios = 7.6 [95% CI:
5.9–9.6] and 9.8 [7.3–12.9],
respectively), increasing with follow-
up time. Ophthalmic, nephropathic,
neurological, and cardiovascular
complications were indicators of
particularly high risks
[129]
Ahmed et al.
(2006)
Prospective
cohort
F/M 12,639 25–98 All
nonvertebral
and hip
Men had an increased risk of all
non-vertebral [RR, 3.1(95% CI: 1.3–
7.4)] and hip fractures [RR 17.8
(95% CI: 5.6–56.8)]. Men and
women using insulin had increased
hip fracture risk. Duration of disease
did not alter hip fracture risk
[124]
Janghorbani
et al. (2007)
Prospective
cohort
F 1,01,343 54.7 ± 9.3 Hip RR of hip fracture was 7.1 (95% CI:
4.4–11.4), after adjustment for BMI,
smoking, physical activity,
menopausal status, intake of
calcium, vitamin D and protein, and
postmenopausal hormone use, RR
for T1D was 6.4 (3.9–10.3)
[4]
Zhukouskaya
et al. (2013)
Cross-
sectional
F/M 82/82 31.1 ± 8.6 VFs No association between VF and
lumbarspine BMD in the T1D group.
No effect of age of diagnosis,
disease duration, HBA1c and related
complication on the prevalence of
VF
[125]
Neumann et al.
(2014)
Cross-
sectional
F/M 128/77 43.4 ± 8.8 Fractures of
ribs, fingers
and toes
were
excluded
Those with prevalent fractures had
higher HbA1c, pentosidene level
and more diabetes-related
complications. BMD was lower in
those with prevalent fractures
[126]
BMD: Bone mineral density; RR: Relative risk; T1D: Type 1 diabetes; VF: Vertebral fractures.
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fracture risk irrespective of BMD [108,127,128]. The fracture risk
could also be attributed to the microvascular complications of
diabetes such as neuropathy, retinopathy and nephropa-
thy [122,129]. Recently, elevated AGEs and pentosidine levels has
been found to impair bone strength and cause fragility fractures
in T1D [126]. Studies that have evaluated fracture risk in patients
with T1D are summarized in TABLE 1.
Type 2 diabetes
There is growing supportive evidence for an increased risk of
fractures in patients with T2D despite them having higher or
normal BMD [1,130,131]. A meta-analysis of eight prospective
studies in adults with T2D concluded that the relative risk of
hip and wrist fractures was 1.4 and 1.2, respectively, while
there was no increase in vertebral fractures [1] and another
meta-analysis [4] of 16 epidemiologic studies, of which 4 investi-
gated vertebral fractures, found that the relative risk of hip frac-
ture was 1.8 but the risk was not elevated at other regions of
the body. However, other studies have reported an increased
risk of vertebral fractures in T2D patients, and these presented
conflicting results [29,106,108,112,130,132–134]. Duration of T2D, gly-
cemic control, anti-diabetic medications, propensity to fall and
T2D-related complications were observed as possible predicting
factors for the increased fracture risk in these studies. Cross-
sectional studies have indicated that those with increased frac-
tures are older [4,29,122] and have a longer duration of
T2D [29,133]. The incidence was also higher in those treated
with insulin [4,134]. In T2D, falls are common [106,135] and the
risk of falling may be higher in those with poor balance, arthri-
tis, cardiovascular disease, depression, poor vision and use of
medications for sleeplessness or anxiety [135]. It is unclear
whether this increased risk of fall is also associated with more
fractures. Studies that have evaluated BMD in patients with
T2D are summarized in TABLE 2.
Bone turnover studies
Type 1 diabetes
In people with T1D, an assessment of markers of bone turn-
over often shows a state of reduced bone formation which may
be associated to factors such as deficiency of insulin and
chronic hyperglycemia but this needs further investigation [6].
Abnormalities in the growth hormone–IGF-1 axis may also
play a contributory role but this needs further investigation.
Among the markers of bone turnover, serum osteocalcin level
has often been reported to be low whereas bone alkaline phos-
phatase has been found to be increased in some studies [136,137].
This imbalance of bone formation markers (increased ALP,
decreased osteocalcin) may reflect an impairment of osteoblast
differentiation and maturation as bone ALP is expressed early
in development of osteoblast and osteocalcin is released from
the mature osteoblast. Reports on markers of bone resorption
are scarce and conflicting, with studies reporting either normal
or reduced circulating levels bone resorption markers [128,138,139].
Serum PTH has been found to be increased or normal [128].
Though levels of the Wnt signaling antagonist, sclerostin, are
reported to be higher, its link to other markers of bone metab-
olism has not been confirmed yet [126]. Only one longitudinal
study showed that bone turnover returned to normal after
improved glycemic control [140].
Type 2 diabetes
Bone formation is consistently lower in people with T2D, as
evidenced by lower serum osteocalcin and procollagen
type 1 N-terminal propeptide (P1NP) levels, [112,141], as well as
reduced histologic measures of mineralizing surface and bone
formation rate [142]. Another study has reported no difference
in P1NP in adults with T2D compared to normoglycemic
adults, but this lack of difference may be due to small sample
size [143]. CTX level has been extensively investigated in adults
with T2D and is consistently lower compared to age-matched
healthy controls [141,144]. Reports of the effects of T2D on other
markers of bone resorption are less consistent, with studies
reporting either no difference or reduced bone resorption
markers in people withT2D [141]. Serum PTH tends to be
lower [126] while levels of sclerostin, are higher in patients with
T2D [145]. The majority of bone turnover data that show a net
bone loss effect of T2D were from adults with longer-standing
T2D. The strongest predisposing factors for this effect included
persistent hyperglycemia [146,147] reduced insulin sensitivity [148]
and lower circulating levels of IGF-1 and IGF-binding protein-
3 [149]. The ratio of OC to bone ALP ratio has also been
recently reported as a clinically useful marker for assessing the
risk of vertebral fractures independent of BMD in men with
diabetes [150]. Elevated sclerostin levels were associated with an
increased risk of VFs in T2D patients independently of BMD
and bone turnover in both genders [151].
Bone imaging studies in DM
Type 1 diabetes
Since then the association between diabetes mellitus and bone
changes became a subject of extensive research, but results so
far are inconclusive. There is still an open question of whether
the effect of diabetes on bone health is primarily due to
changes in bone density or changes in the inherent material
properties of bone tissue. The majority of studies in children
have reported either a slightly low BMD or a normal
BMD (TABLE 3) [152–155]. In adults with T1D, the most consistent
observation is that BMD is reported to be significantly
decreased at lumbar spine and femoral neck (TABLE 4)
[104,139,152,153,156–163]. In one meta-analysis, a significantly lower
BMD Z-score at the hip (-0.37 ± 0.16) and spine (-0.22 ±
0.01) [1] was observed. These findings have been confirmed by
several subsequent studies [160,161] but there are also a small
number of studies that have reported no abnormalities in
BMD [156,159,164]. The effect of T1D on cortical and trabecular
bone structure in humans has not been as well characterized as
it has in rodent models [16,59]. Studies that have evaluated bone
mass and structure by using pQCT show reduced total and
cortical cross sectional area and lower muscle mass in children
and adolescence with T1D compared to healthy control [165–169].
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Table 2. Studies that evaluated fracture risk in people with Type 2 Diabetes (T2D).
Study
(year)
Study
design
Sex Study population Age (years)
(mean ± SD)
or range
Fracture
site and
assessed
outcome
Comments Ref.
Strotmeyer
et al. (2005)
Prospective Both 323 men and 243
women T2D, 106 men
and 71 women with
impaired fasting
glucose. Control
group: 1209 women
and 1207 men
70–97 All fractures Adjustment for hip BMD, lean
mass, fat mass and abdominal
visceral fat indicated that older
adults with DM are still at higher
risk
[132]
De Liefde
et al. (2005)
Prospective Both F, 483/3,481; M,
309/2,382
73.8–68.8 Any non-VF IGT was associated with decreased
fracture risk. Established and
treated DM had an increased
fracture risk. Adjusted for age,
BMI, creatinine, visual acuity,
falling frequency, lower
limbdisability, smoking, and BMD
[182]
Bonds et al.
(2006)
Prospective F Case: 5,285;
Ctrl: 88,120
64.9 ± 7.0 Determined
whether risk
varies by
fracture site,
ethnicity, and
baseline bone
density.
After adjustment for multiple risk
factors including falls and BMD,
the fracture risk was elevated
among black women
[183]
Schwartz
et al. (2009)
Observational Both Case: 501; Ctrl 427 73.6 ± 2.9 VF and
pentosidine
level
Higher pentosidine levels are a risk
factor for fracture in older adults
with diabetes and may account in
part for reduced bone strength in
T2D
[17]
Yamamoto
et al. (2009)
Cross-
sectional
Both F, 137/622; M, 161/76 F, 67.5 ± 9.8
M, 66.0 ± 8.1
VF and its
association
with BMD
After adjustment for age, body
mass index, LS-BMD and diabetes
complications, T2D patients have
an increased risk of vertebral
fractures
[130]
Kanazawa
et al. (2011)
Cross-
sectional
Both F, 334; M, 479 F, 67.6 ± 9.4
M, 60.3 ± 12.8
The
relationship
between
serum IGF-I
and vertebral
fractures
Serum IGF-I level was inversely
associated with vertebral fracture
prevalence in postmenopausal
women T2DM. Association
persisted despite adjustment for
age, duration of diabetes, body
mass index, serum creatinine, and
HbA1c and BMD at the lumbar
spine
[58]
Vie´gas et al.
(2011)
Cross-
sectional
F 148 61.87 ± 7.85 Vertebral
fracture
High prevalence of osteoporosis
and vertebral fractures (23%)even
after adjustment for disease
parameters; more frequent in
long-standing disease and in those
with retinopathy and impaired
renal function
[133]
Yamamoto
et al. (2013)
Cross-
sectional
both F,146; M,175 F 64.9 ± 9.3
M 65.7 ± 8.7
Vertebral
fracture and
its association
with sclerotin
level
Sclerostin was higher in men than
women and associated with an
increased risk of vertebral fractures
independent of BMD and bone
turnover in both genders
[151]
BMD: Bone mineral density; BMI: Body mass index; IGF-I: Insulin-like growth factor-I; IGT: Impaired glucose tolerance; LS: Lumbar spine; VF: Vertebral fracture.
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Another pQCT study by [170] indicated that as T1D adoles-
cents reached 14 and 15 years of age, their cortical CSA nor-
malized, becoming equivalent to the cortical CSA of
nondiabetics at the same age. However, T1D was associated
with a decreased bone CSA at the radius at the end of pubertal
growth comparing to controls [171]. In light of the emerging
importance of the interactions between marrow fat and bone
and the evidence for the negative effects of marrow fat on bone
density, marrow fat as an independent surrogate for bone qual-
ity has also been recently assessed by MRI [172].The factors that
may be associated with BMD in T1D are not well-known yet.
Some studies have documented a decreased BMD in those
with a recent on set of T1D [158,166,173] indicating the existence
of mechanisms before the appearance of clinical symptoms
Table 3. Bone densitometry studies in children with Type 1 diabetes mellitus T1D.
Study
(year)
N(f/m) Age (years)
(range or
means ± SD)
Dis duration
(years)
(range,
means ± SD)
Modality Site Major
finding in
cases
versus
controls
Comments Ref.
Gunczler
et al. (1998)
26(11/15) 12.1 ± 3.1 4 years DXA LS, FN # LS BMD Adjusted forage, sex and pubertal
status. No association with disease
duration, glycemic control, 24 h
urinary calcium excretion or bone
turnover markers
[177]
Pascual et al.
(1998)
55(29/26) 5–15 1–13.8 DXA LS, FA No
abnormalities
No effect of glycemic control or
disease duration. Adjusted for age
and sex
[176]
Heap et al.
(2004)
55(25/35) 12–17 6.7 ± 3.6 pQCT DXA Tibia
LS, FN
## Tibia and
FN BMD
Inverse association to HbA1c.
Adjusted for sex, maturation, and
body size
[165]
Le´ger et al.
(2006)
127
(54/73)
6–20 4.1–8.6 DXA LS, TB ## Total BMC
and BMD
Only present in girls. Adjusted for
age, sex, pubertal stage, and BMI
SDS
[179]
Brandao et al.
(2007)
44
(22/22)
8.8 ± 4.4 6.6 ± 3.9 DXA LS No
abnormalities
After adjustment for weight,
height and pubertal development,
the BMD was £2.0 S.D. in only
two diabetic patients (4.5%).
Longer duration and poor
metabolic control may have a
negative impact on bone mass
[155]
Moyer-Mileur
et al. (2008)
11(11/0) 12.9 ± 1.0 5.9 ± 3.7 PQCT
DXA
Tibia
LS, FN
# Tibial and
FN BMD
Altered markers of GH/IGF-1 axis
associated with low BMD. The
results were adjusted for height
and puberty
[167]
Heilman et al.
(2009)
30
(11/19)
4.7–18.6 5.4 ± 3.4 DXA LS, TB ## Total BMC
and LS BMD
Only present in boys. Inverse
association to urinary markers of
oxidative stress, plasma ICAM-1
levels and HbA1c. The result was
adjusted for age, sex and BMI
[174]
Saha et al.
(2009)
48 (26/
22)
12–17.8 1–13.5 pQCT DXA Tibia
LS, FN
# BMC # CSA Only present in girls. Adjusted for
height, weight, age and sex
[168]
Roggen et al.
(2013)
56 (23/
33)
17.2–24.8 10.6 ± 3.9 pQCT DR Similar
trabecular
BMD, # CSA
Adjusted for age, gender, height
score and BMI. In girls, the CSA
SDS correlated negatively with the
BMI SDS and positively with the
height SDS
[171]
Loureiro et al.
(2014)
75((39/
36)
6-20 - DXA LS
(L1-L4)
## LS BMD Children and adolescents with early
onset T1D presented with low
BMD associated with poorer
glycemic control. BMD was not
adjusted for any variables
[154]
BMC: Bone mineral content; BMD: Bone mineral density; BMI: Body mass index; CSA: Cross sectional area; DR: Distal radius; DXA: Dual x-ray absorptiometry; FA: Fore-
arm; FN: Femoral neck; GH/IGF-1: Growth hormone/IGF-I; ICAM-1: intercellular adhesion molecule-1 (ICAM-1); LS: Lumbar spine; pQCT: Peripheral quantitative computed
tomography; T1D: Type 1 diabetes.
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such as autoimmune and inflammatory mechanism [154]. How-
ever, others studies have not detected an abnormality of BMD
in recently diagnosed children indicating that the metabolic
consequence of the disease over time may play an important
role than a predisposing covariant. Some studies have suggested
that metabolic control, including its effect on the growth hor-
mone/IGF-1 axis, plays a strong role in the genesis of
osteopenia [104,162,166,173–175]. These findings are supported by a
study of intensive insulin therapy that stabilized BMD [138].
However, others have failed to show this association [1,157,176–180].
In summary, the available data on the structural quality of
bone in T1D are still scarce and controversial. There are limita-
tions such as small sample sizes, different techniques to measure
and interpret data and inadequate adjustment of confounders
such as age, disease duration and metabolic status.
Type 2 diabetes
Reports of the effects of T2D on BMD as measured by DXA
are still contradictory, with majority of studies reporting
increased BMD [1,123,181–187]. A small number of studies have
showed no difference [188–191] comparing to nondiabetics.
A meta-analysis of 15 cross-sectional, cohort and case-control
studies demonstrated that men and women with type 2 diabe-
tes had elevated BMD compared to controls [192]. In adults
with type 2 diabetes, BMD was greater by a difference of
+0.06 g/cm2 at the lumbar spine, +0.04 g/cm2 at the femoral
neck, and +0.06 at the total hip [192]. Gender was a significant
predictor for BMD, with a higher BMD in women than in
men even after adjusting for confounding factors such as body
weight and age [181,192–194]. BMI and glycemic control have
been reported as strong predictors of elevated BMD [1,187,192]
but despite adjusting for BMI and HbA1c some
studies found that BMD remains higher in adults with
T2D [182,185,189,191,193–195]. Another possibility is that the lumbar
spine BMD is over-estimated in adults with T2D due the
changes that are associated with osteoarthritis [196].
Although generally limited to small sample sizes, cross sec-
tional studies have been used to examine cortical and trabecular
bone density at the hip and spine, as well as peripheral skeletal
sites, in adults with T2D [146,197–201]. Trabecular bone density
in T2D is generally similar to or significantly greater than that
of nondiabetic controls [146,197–201]. The effects of T2D on cor-
tical bone are more variable, with some studies reporting no
differences, [146,199], whereas others finding deficits in bone size
and cortical bone structure in T2D [198,199,201,202]. Although two
recent studies found that cortical porosity is increased only in
postmenopausal diabetics with a prior fragility fracture, and
that diabetics without prior fracture had similar cortical bone
density, porosity and microarchitecture as nondiabetic con-
trols [199,201] a more recent study has reported raised radial cor-
tical porosity despite adjustment for cofounding variables [202].
In addition, it was the first study that demonstrated compro-
mised bone material strength in patients with T2D, and was
negatively correlated with the average glycated hemoglobin level
over the previous 10 years. More recently, with the help of
specific software, a group of investigators have calculated the
trabecular bone score based on pixel variations on DXA images
in young women with T2D and showed that it was lower and
associated with worse control [5]. Recently, in vivo assessment
of bone quality by microindentation methods has also revealed
that the bone material strength may also be reduced in people
with T2D [202]. Collectively, current evidence indicate that
apart from BMD measured by DXA, an assessment of cortical
bone quality may be important to consider for assessing risk of
fragility fractures. However, future research is needed to charac-
terize bone microstructure in T2D, taking in account the con-
founder factors as BMI, age and associated diabetic
complication. Studies that have evaluated BMD in adult
patients with T2D were summarized in TABLE 4.
Effect of anti-diabetic therapies
The effect of anti-diabetic therapies on bone has recently been
reviewed in detail [203]. TZDs such as rosiglitazone and piogli-
tazone increase insulin sensitivity via activation of PPARg and
although they possess beneficial antihyperglycemic profiles,
their use is associated with adverse effects on bone as
highlighted very clearly in the ADOPT studies [204]. Metformin
is the most commonly used to increase insulin sensitivity in
people with diabetes. Population based studies suggest that
metformin decreases fracture risk in T2D [134]. Although the
ADOPT studies did not demonstrate beneficial effects of met-
formin on fracture risk, they showed reduced bone turn-
over [109]. Head to head studies comparing a combination of
rosiglitazone and metformin to metformin alone in T2D show
that although the combination is superior over monotherapy
with metformin for glycemic control, the former was associated
with significantly reduced BMD in lumbar spine and hip,
while metformin monotherapy therapy did not have an effect
on bone [205]. The link between insulin therapy and fractures is
less clear. Whilst treatment of severe insulin deficiency and
improved glycemic control is associated with positive changes
in markers of bone turnover [140], the use of insulin in people
with T2D has been reported to be associated with an increased
incidence of fractures [134]. Finally, incretin analogues and
DPP-4 inhibitors that enhance the effect of enteric hormones
such as glucagon-like peptides in stimulating insulin release and
inhibiting glucagon production may also have a beneficial effect
on bone health. A meta-analysis of DPP4 inhibitors has
revealed a lower risk of fractures in those treated with these
drugs [206]. There is a need for further prospective studies to
understand these effects in greater detail.
Conclusion
The evidence from experimental studies, with supporting evi-
dence from bone marker and bone density data, suggest that
adults with diabetes are at increased risk for fractures. Patients
with T1D are at a higher risk for osteoporotic fractures com-
pared to T2D patients or general population. This may be
explained by the initial period of insulin deficiency which
results in impaired bone formation and prevents accrual of an
Bone health in diabetes Review
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Table 4. Bone densitometry studies in adults with Type 1 diabetes.
Study
(year)
Subject
N(f/m)
Age, years
(range or
means ± SD)
Disease
duration,
years
(mean ± SD)
Modalities Site Major
findings in
cases
Comments Ref.
Kayath et al.
(1994)
90 18–54 2–20 DXA LS, FN # BMD in
34%of IDDM
patients
Positive correlation with
glucose levels duration of
disease and insulin dosage
[152]
Lunt et al.
(1998)
99 (99/0) 42 median 27 median DXA LS
FN
No difference
in BMD from
control
Positive correlation with BMI
and height
[156]
Kemink et al.
(2000)
35 (14/21) 37.6 ± 9.9 8.5 ± 3.5 DXA LS, FN # FN BMD,
# LS BMD,
Osteopenia in
67% of men
57% of
women
[157]
Lopez-Iberra
et al. (2001)
32 (10/22) 20–39 At diagnosis DXA LS, FN # LS BMD,
# FN BMD.
[158]
Liu et al.
(2003)
33 (33/0) 20–37 14.5 ± 5.7 DXA FN, LS,
wrist, TB
# LS BMD,
# FN BMD
[153]
Bridges et al.
(2005)
35 (0/35) 49.3 20 DXA DR No difference
in BMD from
control
[159]
Strotmeyer
et al. (2006)
67 (67/0) 35–55 32.2 ± 5.3 DXA
QUS
Total hip
FN, TB, LS
# total hip
BMD
p < 0.001
# FN BMD
p < 0.001
# TB BMD
p < 0.01
# Calceneal
BUA
p < 0.001
[160]
Hamilton
et al. (2009)
102
(52/50)
20–71 5.5–23.6 DXA FA, FN, LS #BMD at LS,
FN and FA
Only present in women,
Lower BMD was associated
with impaired bone
formation
[161]
Danielson
et al. (2009)
75 (75/0) 28 16 DXA Calcaneus
FA, FN, LS
# BMD at FA
and FN
Inverse correlation with
HbA1c and markers of bone
formation in patients with
#BMD
[162]
Eller-Vainicher
et al. (2011)
175
(104/71)
32 ± 8.4 13 ± 8.4 DXA LS
FN
# BMD at LS
and FN
Low BMD is associated with
low BMI; chronic
complications have a negative
association with BMD
[104]
Botushanov
et al. (2014)
162
(97/65)
29.17 / DXA LS
FN
#BMD at FN
and LS
LS BMD negatively correlated
with marker of bone
formation
[163]
2 year
prospective
Mastrandrea
et al. (2008)
63 (63/0) 15–39 DXA LS, FN,
FA, TB
# BMD at FN
and TB
Statistically significant in
women ‡20 years of age
[139]
#: Decrease in BMD; ": Increase in BMD; BMD: Bone mineral density; BMI: Body mass index; BUA: Broadband ultrasound attenuation; CSA: Cross sectional area; DR: Dis-
tal radius; DXA: Dual X-ray absorptiometry; FA: Forearm; FN: Femoral neck; LS: Lumbar spine; QUS: Quantitative ultrasound; T1D: Type 1 diabetes; TB: Total body.
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adequate peak bone mass. This maybe complicated further by
subsequent poor glycemic control. T1D is typically associated
with reduced BMD, whereas those with T2D usually have nor-
mal or elevated BMD. This inconsistency indicates that
impaired bone quality may further explain the higher fracture
risk in addition to frequent falls and associated comorbidities.
There are several mechanisms by which diabetes could affect
bone mass and strength, including insulin level, hyperglycemia,
AGE accumulation which influences collagen characteristics,
increased marrow adiposity and increased bone inflammation.
In addition, associated diabetic complications and treatment
with TZDs may increase fracture risk. Future studies are
needed to clarify the impact of different aspects of diabetes
metabolism, glycemic control and specific treatments for diabe-
tes on bone. Given that DXA related BMD is a poor predictor
of bone morbidity in this group of patients, there is a need to
explore novel approaches to assessing bone quality. A better
understanding of how diabetes affects bone will improve our
ability to protect bone health and prevent fractures in the
growing population of adults with diabetes.
Five-year view
With limited information from current studies to explain the
increased risk of fragility fracture, the focus on understanding
the effects of diabetes, in particular T1D, on bone health needs
to explore methods of assessing bone health that involve more
advanced imaging modalities as well as other molecular and
biochemical markers of bone health and diabetes control.
Increased availability of these tools in the near future will be
particularly useful in the pediatric setting given that the peak
age of diagnosis of T1D is between 10 and 14 years old, which
is also the critical physiological period of bone development.
Dissecting the conundrum of diabetic bone loss in T2D may
be complicated by many confounding factors, but the sugges-
tion of diabetic osteopathy as the obesity of bone opens up
exciting avenues for exploration. Finally, the suggestion that
bone loss may be another manifestation of diabetes-related vas-
cular disease, raises the possibility that assessment of bone
health may become a routine component of screening for
health complications in diabetes. Routine screening of bone
health by tools that are specific for the bone pathology in this
condition is likely to lead to improved targeted prevention of
fractures in T1D and T2D.
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Key issues
• The awareness of bone as another target organ of diabetes complications remains low clinically out with the research arena.
• Small samples sizes and problems with addressing confounding factors limit the evidence on the effect of glycemic control on bone
health in diabetes.
• Abnormalities of bone health may be present early after diagnosis.
• Diabetic bone loss is most likely due to a complex interplay between the effects of hyperglycemia, insulin deficiency, IGF-1 deficiency,
increased bone marrow adiposity, inflammation and vasculopathy on bone formation.
• In-vitro studies support the osteogenic potential of metformin, which offers a rational prevention strategy.
• The disparity between dual x-ray absorptiometry-derived bone mineral density and actual fracture risk highlights the limitation of dual
x-ray absorptiometry as a predictor of fracture risk in conditions secondary to systemic disease.
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a b s t r a c t
People with Type 2 diabetes mellitus (T2DM) have reduced bone mineral density and an increased risk of
fractures due to altered mesenchymal stem cell (MSC) differentiation in the bone marrow. This leads to a
shift in the balance of differentiation away from bone formation (osteogenesis) in favour of fat cell
development (adipogenesis). The commonly used anti-diabetic drug, metformin, activates the osteogenic
transcription factor Runt-related transcription factor 2 (Runx2), which may suppress adipogenesis,
leading to improved bone health. Here we investigate the involvement of the metabolic enzyme, AMP-
activated protein kinase (AMPK), in these protective actions of metformin. The anti-adipogenic actions of
metformin were observed in multipotent C3H10T1/2 MSCs, in which metformin exerted reciprocal
control over the activities of Runx2 and the adipogenic transcription factor, PPARg, leading to sup-
pression of adipogenesis. These effects appeared to be independent of AMPK activation but rather
through the suppression of the mTOR/p70S6K signalling pathway. Basal AMPK and mTOR/p70S6K activity
did appear to be required for adipogenesis, as demonstrated by the use of the AMPK inhibitor, compound
C. This observation was further supported by using AMPK knockout mouse embryo ﬁbroblasts (MEFs)
where adipogenesis, as assessed by reduced lipid accumulation and expression of the adipogeneic
transcription factor, C/EBPb, was found to display an absolute requirement for AMPK. Further activation
of AMPK in wild type MEFS, with either metformin or the AMPK-speciﬁc activator, A769662, was also
associated with suppression of adipogenesis. It appears, therefore, that basal AMPK activity is required
for adipogenesis and that metformin can inhibit adipogenesis through AMPK-dependent or -indepen-
dent mechanisms, depending on the cellular context.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Type 2 diabetes mellitus (T2DM) is characterized by chronic
elevation of blood glucose levels because of systemic insulin resis-
tance. In addition to the reduction of insulin sensitivity in muscle,
adipose tissue and the liver, it has been noted recently that people
with diabetes have increased risk of bone fractures (Janghorbani
et al., 2007,Kilpadi et al., 2014,Hothersall et al., 2013). Further-
more, the use of the thiazolidinedione (TZD) antidiabetic drug class,
which includes pioglitazone and rosiglitazone, has been shown to
increase the risk of bone fractures and secondary osteoporosis
(Lecka-Czernik, 2009,Grey et al., 2007,Schwartz et al., 2006).
TZDs act as agonists for the nuclear receptor peroxisome
proliferator-activated receptor gamma (PPARg) which is considered
to be the master regulator of fat cell development (adipogenesis)
(Tontonoz et al., 1994a). It is therefore thought that the detrimental
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Chemistry, Biophysics and Bioengineering, Edinburgh Campus, Heriot-Watt Uni-
versity, Edinburgh EH14 4AS UK.
E-mail address: S.Yarwood@hw.ac.uk (S.J. Yarwood).
Contents lists available at ScienceDirect
Molecular and Cellular Endocrinology
journal homepage: www.elsevier .com/locate/mce
http://dx.doi.org/10.1016/j.mce.2016.11.011
0303-7207/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Molecular and Cellular Endocrinology 440 (2017) 57e68
effects of TZDs on bone health is through the activation of PPARg in
mesenchymal stem cells (MSCs) causing adipogenesis and, conse-
quently, suppressing bone development (osteogenesis) (Lecka-
Czernik et al., 2007,Shockley et al., 2009). Adipogenesis is regu-
lated by a temporally induced cascade involving PPARg and mem-
bers of the CCAAT/enhancer binding protein (C/EBP) transcription
factor family. In the initial stages of adipogenesis there is a transient
accumulation of C/EBPb and C/EBPd proteins, leading to a later
accumulation of C/EBPa and PPARg (Cao et al., 1991,Yeh et al., 1995).
C/EBPa and PPARg then promote gene expression characteristic of
an adipocyte phenotype and their expression remains elevated for
the life of the differentiated cell (Tontonoz et al., 1994b).
Metformin has been used clinically for the treatment of T2DM
since the 1960s and it is thought to function primarily through the
inhibition of hepatic gluconeogenesis (Cusi et al., 1996). Metformin
interferes with oxidative phosphorylation in the mitochondria by
inhibiting complex I in the electron transport chain, although the
exact mechanism of inhibition is not yet known (El-Mir et al.,
2000,Lantier et al., 2014). Metformin has also been shown to
stimulate osteogenic differentiation of MSCs towards osteoblasts
in vitro through the trans-activation of Runt-related transcription
factor 2 (Runx2), the key regulatory transcription factor for osteo-
genic differentiation (Jang et al., 2011) and, unlike TZDs, has been
shown to be associated with a reduced risk of fractures. Osteoblast
differentiation has been proposed to be dependent on the cellular
energy sensor AMP-activated protein kinase (AMPK), as the
expression of various osteogenic genes has been shown to be
inhibited by compound C, a chemical inhibitor of AMPK, and a
dominant negative form of AMPK (Banerjee et al., 1997). Further-
more, metformin stimulates AMPK activation through the
inhibition of oxidative phosphorylation in hepatocytes (Zhou et al.,
2001).
AMPK is a heterotrimeric serine/threonine protein kinase that
acts as a cellular energy sensor due to its ability to be activated by
an increase in the AMP-ATP ratio, which leads to phosphorylation
of Thr172 on AMPKa by liver kinase B1 (LKB1) (Hardie, 2015,Woods
et al., 2003). AMPK can also be phosphorylated and activated at
Thr172 by calcium/calmodulin-dependent protein kinase kinase
(CaMKK) in a Ca2þ-dependent, AMP-independent manner (Hawley
et al., 2005). AMPK functions to inhibit ATP consuming pathways
and at the same time activate catabolic pathways to re-establish
cellular energy homeostasis. It has also been shown that AMPK
has an array of non-metabolic functions including promotion of
nitric oxide synthesis and numerous anti-inﬂammatory actions
(Jones et al., 2005,Reihill et al., 2007,Salminen et al., 2011,Morrow
et al., 2003, Salt and Palmer, 2012). Recently, it has been shown
that AMPK functions in cell differentiation by promoting osteogenic
differentiation while suppressing adipogenic differentiation
(Kanazawa et al., 2008,Vila-Bedmar et al., 2010), however, the role
of AMPK in cell commitment to differentiation remains unclear.
Therefore, the main aim of the current study is to determine the
effect of metformin on adipogenesis and, in particular, to under-
stand the role of the AMPK signalling pathway in these processes.
2. Materials and methods
2.1. Cell culture and induction of differentiation
AMPK a1/a2 knockout mouse embryonic ﬁbroblasts (MEFs),
C3H10T1/2 mouse mesenchymal stem cells (Clone 9; ATCC CCL-
Fig. 1. Metformin and the AMPK-activator, A769662, suppress adipogenesis of CH3H10T1/2 MSCs.
A) Conﬂuent CH3H10T1/2 MSCs were induced to differentiate by addition 10% foetal calf serum (FCS) in the presence or absence of adipogenic IID medium (insulin, iso-
butylmethylxanthine and dexamethasone) and/or 10 mM pioglitazone (PIO), 500 mMmetformin or 100 mM A769662. After 5 days cells were ﬁxed with formalin and stained with Oil
Red O to detect neutral lipid accumulation. Representative micrographs from an experiment carried out on three separate occasions with similar results are shown.
B) Conﬂuent CH3H10T1/2 MSCs were induced to differentiate by addition 10% FCS in the presence or absence of IID medium and/or 500 mM metformin. Cell extracts were then
prepared after 5 days and immunoblotted with antibodies to perilipin, adiponectin and tubulin. Representative immunoblots from an experiment carried out on three separate
occasions with similar results are shown. Densitometric analysis of three immunoblots are shown as means ± SEM in the lower panel. Signiﬁcant increases relative to control are
indicated, *p < 0.05 and ***, p < 0.001.
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Fig. 2. Effects of Metformin and the AMPK-activator, A769662, on early markers of differentiation in C3H10T1/2 cells.
A) Conﬂuent CH3H10T1/2 cells were stimulated for 5 days with 10 mM pioglitazone (PIO) or an adipogenic (IID) or osteogenic (AGD) cocktail, in the presence or absence of 500 mM
metformin or 100 mM A769662. Cell extracts were then prepared and immunoblotted with antibodies to PPARg, Runx2 and AMPK. The phosphorylation-dependent electrophoretic
mobility shift of Runx2 induced by AGD treatment is indicated (pRunx2). Representative immunoblots from an experiment carried out on three separate occasions with similar
results are shown.
B) Densitometric analysis of PPARg1 (upper panel) and PPARg2 (lower panel) levels relative to Runx2 are shown as means ± SEM. Signiﬁcant increases (*, p < 0.05) relative to control,
and signiﬁcant decreases relative to PIO-stimulated cells (#, p < 0.05), are indicated (n ¼ 3). Non-signiﬁcant changes are also indicated (ns).
C) Conﬂuent C3H10T1/2 cells were transfected with a PPARg (upper panel) and Runx2 (lower panel) luciferase gene reporter constructs, together with control Renilla luciferase
vector, and then stimulated for two days with 500 mM metformin or 100 mM A769662, in the presence or absence of 10 mM pioglitazone (PIO), adipogenic medium (IID) or
osteogenic medium (AGD). Cell extracts were then prepared and luciferase activities were measured using a dual luciferase reporter assay. Luciferase activities from three separate
experiments are shown as means ± SEM. Signiﬁcant increases in luciferase activity are indicated; *, p < 0.05, **, p < 0.01 and ***, p < 0.001, as are signiﬁcant decreases in activity, #,
p < 0.05 (n ¼ 3). Non signiﬁcance is also indicated (ns).
226) and 3T3-L1 preadipocytes were maintained in DMEM
(41965e039, Sigma-Aldrich Ltd, Gillingham, Dorset, UK) containing
10% (v/v) FCS, 2 mM glutamine, 100 U/mL penicillin and 100 mg/ml
streptomycin. To promote adipogenic differentiation, cells were
cultured in the standard media supplemented with either 10 mM
pioglitazone alone or in combination with 100 nM insulin, 500 mM
3-isobutyl-1-methylxanthine (IBMX) and 10 mM dexamethasone
(IID medium). For osteogenic differentiation, cells were cultured in
standard media supplemented with 284 mmol/L ascorbic acid,
10 mM b-glycerophosphate and 10 nM dexamethasone (AGD me-
dium). Differentiation media was changed every 3 days.
2.2. Preparation of cell extracts
For the preparation of cell extracts from MEFs, the media was
aspirated and then cells were washed with ice cold PBS (137 mM
NaCl, 2.7 mMKCl,10mMNa2HPO4,1.8mMKH2PO4) and then either
100 ml of ice cold Triton-X100 lysis buffer (50 mM Tris-HCl pH 7.4,
50 mM NaF, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 250 mM
mannitol, 1% (v/v) triton X-100, 0.1 mM phenyl-
methanesulphonylﬂuoride (PMSF), 0.1 mM benzamidine, 5 mg/ml
soybean trypsin inhibitor,1 mMdithiothreitol (DTT),1 mMNa3VO4)
or 1 Laemmli-sample buffer (50 mM Tris-HCl pH 6.8, 2% (w/v)
SDS, 10% (v/v) glycerol, 0.1% (w/v) bromophenol blue, 50 mM DTT)
was added and then cells were harvested by scraping. Lysates
exracted with Triton-X100 were cleared by centrifugation
(24 100 g, for 5 min at 4 C) and the supernatant stored at20 C.
Samples lysed using 1 Laemmli-sample buffer were incubated in a
sonicating water bath at 60 C for 30 min prior to storage at20 C.
C3H10T1/2 MSCs were harvested and nuclear extracts prepared
using the Nuclear Extraction kit from Active Motif, Belgium. Brieﬂy,
the media was aspirated and cells were harvested in ice-cold PBS
containing phosphatase inhibitors and centrifuged (200  g, for
5 min at 4 C) to obtain a cell pellet. The cell pellet was re-
suspended in complete lysis buffer containing 10 mM DTT and
phosphatase inhibitor cocktail and then centrifuged (14 000 g, for
10 min at 4 C) to obtain nuclear and supernatant fractions.
2.3. Western blotting
Protein samples were separated by SDS-PAGE and then trans-
ferred electrophoretically onto nitrocellulose membranes. Mem-
branes were blocked with 5% (w/v) Marvel milk powder in TBS
(20 mM Tris-HCl pH 7.5, 150 mM NaCl) for 1 h. Membranes were
then incubatedwith primary antibodies overnight at 4 C. Following
washes with TBST (TBS supplemented with 0.5% (v/v) Tween-20),
membranes were incubated with secondary antibodies for 1 h at
room temperature. Antibodies were diluted to the required con-
centration in 50% (v/v) Sea Block (Thermo Scientiﬁc) and 50% (v/v)
TBST. The primary antibodies included those purchased from Cell
Signalling Technologies (CST), Danvers, MA and included perilipin,
peroxisome proliferator-activated receptor gamma (PPARg; marker
for adipogenesis), Runt-related transcription factor 2 (Runx2;
marker for osteogenesis), phosphorylated-ACC (P-ACC (Ser79);
marker for AMPK activity), phosphorylated AMPKa (P- AMPKa
(Thr172); detects active AMPK) and phosphorylated-p70S6K (P-
p70S6K (Thr389); upstream regulator ofmTOR signalling). The rabbit
polyclonal adiponectin antibody was generated in house and the
tubulin antibody was bought from Abcam, Cambridge, UK. Anti-
bodies were detected using a LI-COR® Odyssey Infrared Imaging
systems and densitometric analysis was carried out using ImageJ
software (National Institute of Health, UK) software Version 1.47.
2.4. Oil Red O staining
Cells were incubated with adipogenic IID media in the presence
or absence of either 10 mMpioglitazone, 500 mMmetformin,100 mM
of the AMPK-activator, A769662, or 10 mM of the p70S6K-inhibitor,
rapamycin. Following differentiation, media was aspirated and cells
were ﬁxed to cell culture plates with 10% (v/v) neutral buffered
formalin for 30 min. The formalin was then aspirated and staining
was carried out with the addition of 0.3% (w/v) Oil Red O in iso-
propanol:water (60:40) for 5 min in room temperature. The Oil Red
O was then aspirated and wells washed with distilled water four
times. Imaging was carried out using a Zeiss Axiovert 25 micro-
scope with QImaging camera and supporting software.
2.5. AMPK activity assays
AMPK activity was determined in AMPK a1 plus AMPK a2
immuno-complexes through phosphorylation of the peptide
HMRSAMSGLHLVKRR [SAMS], as previously described (Morrow
et al., 2003). Brieﬂy, the AMPK immunoprecipitates were re-
suspended in 20 ml of HEPES Brij-35 buffer. Reaction mixtures
(20 ml) containing 5 ml of HEPES Brij-35 buffer, 5 ml of 1 mM SAMS
peptide in HEPES Brij-35 buffer, 5 ml of 1 mM AMP in HEPES Brij- 35
buffer and 5 ml of immunoprecipitate re-suspended inHEPES Brij-35
buffer, were prepared in 1.5mlmicrocentrifuge tubes on ice and the
reaction initiated by the addition of 5 ml of MgATP solution (1 mM
[g-32P] ATP, 250e500 c.p.m./pmol; 25 mM MgCl2 in HEPES Brij-35
buffer). Reaction mixtures were then incubated on a vibrating
platform in an air incubator at 30 C for 10 min. Assay mixtures
(15 ml) were spotted onto P81 phosphocellulose paper, and rinsed,
with gentle stirring to remove free ATP, for 5 min in 1% (v/v)
Fig. 3. The AMPK activator, A769662, but not metformin activates AMPK in
C3H10T1/2 cells.
Conﬂuent C3H10T1/2 cells were stimulated for the indicated times with 100 mM
A769662 or 500 mM metformin. Cell extracts were then prepared and immunoblotted
with antibodies towards the phosphorylated form of the AMPK substrate, ACC, or total
ACC, as indicated in the upper panel. Densitometric values were obtained from im-
munoblots from three separate experiments and are shown as means ± SEM in the line
graph in the lower panel. Signiﬁcant increases in pACC are indicated; **, p < 0.01
(n ¼ 3). Non signiﬁcance is also indicated (ns).
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phosphoric acid. A further 2 5minwater washes were performed
on the phosphocellulose paper, before a ﬁnal 5minwashwith 1% (v/
v) phosphoric acid. A Beckman Multi-Purpose scintillation counter
LS 6500 was used to measure [32P]-labelled substrate. 3 ml of
scintillation ﬂuid was used per sample. Results were corrected for
radioactivity recovered in blank reactions lacking the SAMS peptide.
One unit of AMPK activity is that required to incorporate 1 nmol of
32P into the SAMS substrate peptide/min/mg protein.
2.6. Transient transfection and luciferase assay
C3H10T1/2 cells were transfected with the indicated plasmids in
6-well plates, with 1.125 mg/well PPRE (PPARg reporter, purchased
from Adgene) and 6xOSE reporter constructs (Runx2 reporter,
supplied by Jian Huang, Rush Medical Centre, Chicago, USA) using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) and then
treated with metformin, A769662 or rapamycin with and without
adipogenic differentiation media. Cells were then harvested 48 h
after transfection and assayed using the Luciferase reporter assay
system (Promega, Madison, WI) according to manufacturer's in-
structions. As a transfection control, the Renilla plasmid 0.125 mg/
well was co-transfected in each transfection experiment, and the
luciferase activity was normalised to the Renilla activity.
2.7. Statistical analysis
All experiments were performed in triplicate and statistical
analysis was performed using Student's t-test or one-way ANOVA.
Results are expressed as mean ± standard error (SEM) and differ-
ences with p < 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Metformin suppresses adipogenesis in C3H10T1/2 MSCs
It has been previously reported that treatment of preadipocyte
cell lines with AMPK activators inhibits their conversion to fat cells
(Lee et al., 2011, Habinowski and Witters, 2001). Paradoxically,
Fig. 4. The mTOR inhibitor, rapamycin, suppresses adipogenesis of C3H10T1/2 cells.
A) Conﬂuent CH3H10T1/2 cells were induced to differentiate by addition of 10% foetal calf serum (FCS) supplemented with adipogenic cocktail (IID), in the presence or absence of
the mTOR inhibitor, 10 mM rapamycin. After 5 days cells were ﬁxed with formalin and stained with Oil Red O to detect neutral lipid accumulation. Representative micrographs from
an experiment carried out on three separate occasions with similar results are shown.
B) Conﬂuent C3H10T1/2 cells were transfected with PPARg luciferase gene reporter construct, together with control Renilla luciferase vector and then stimulated for two days with
500 mM metformin or 10 mM rapamycin, in the presence or absence of IID. Cell extracts were then prepared and luciferase activity was measured using a dual luciferase reporter
assay. Luciferase activities from three separate experiments are shown as means ± SEM. Signiﬁcant increases in PPARg activity are indicated ***, p < 0.001, as are signiﬁcant
decreases in PPARg activity, #, p < 0.05, relative to IID-stimulated cells (n ¼ 3).
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however, the widely used AMPK inhibitor, compound C, has also
been reported to inhibit adipogenesis of preadipocyte cell lines
(Nam et al., 2008). To try and address this apparent contradiction
and to further investigate the role of AMPK in the control of adi-
pogenesis of multipotent mesenchymal stem cells (MSCs), we
stimulated murine C3H10T1/2 MSCs with two known activators of
AMPK, metformin (500 mM) and A769662 (100 mM). Conﬂuent
cultures of C3H10T1/2 MSCs were treated for 5 days with medium
containing 10% foetal calf serum (FCS) supplemented with either an
insulin-containing, adipogenic medium (IID) and/or the anti-
diabetic drug, pioglitazone (PIO), which is a known agonist of the
adipogenic transcription factor, PPARg (Day and Bailey, 2007). Cells
were also incubated with 10% FCS alone, as negative control for
differentiation. After 5 days of treatment, cells were ﬁxed and then
stained with the neutral lipid stain, Oil Red O, to monitor lipid
accumulation, which is a widely used late marker of adipogenesis
(Fig. 1a). We found that treatment of cells with IID-containing
medium stimulated lipid accumulation in C3H10T1/2 MSCs, an
effect that was further enhanced by co-treatment of cells with PIO
(Fig. 1a). We also found that treatment of cells with either met-
formin or A769662 suppressed adipogenesis promoted by IID alone
or by a combination of IID plus PIO (Fig. 1A), with metformin being
amore effective inhibitor of lipid accumulation (Fig. 1A). The effects
of metformin on the suppression of adipogensis was conﬁrmed by
western blotting for two late markers of fat cell conversion, adi-
ponectin and perilipin, the expression of which were strongly
induced following IID treatment, but were suppressed in the
presence of metformin (Fig. 1B).
These results suggest that AMPK activators inhibit adipogenesis
of C3H10T1/2 MSCs. To further elucidate the mechanisms of action
of metformin and A769662 in these cells, we next treated cells with
10% FCS, supplemented with either IID or PIO, and measured the
protein expression levels of the transcription factor, PPARg, which
is a widely used early marker of adipogenesis (Fig. 2A and B). To
complement these experiments, we alsomeasured the activation of
PPARg transcriptional activity, by transfecting C3H10T1/2 cells with
PPARg-responsive luciferase reporter construct (Fig. 2C). We found
that treatment of cells for 5 days with 10% FCS in the presence of
either IID or PIO, induced a signiﬁcant increase in the two PPARg
splice variants, PPARg1 and PPARg2 (Fig. 2A and B), which corre-
lated with a signiﬁcant increase in PPARg transcriptional activity, as
determined by luciferase assay (Fig. 2c). In agreement with the Oil
Fig. 5. Effects of rapamycin on AMPK and p70S6K activities in C3H10T1/2 cells.
A) Conﬂuent CH3H10T1/2 cells were stimulated for 5 days with IID, in the presence or absence of 500 mM metformin, 100 mM A769662, 10 mM rapamycin or the AMPK inhibitor,
10 mM compound C. Cell extracts were then prepared and immunoblotted with antibodies to phosphorylated ACC (Ser 79). Representative immunoblots from an experiment carried
out on three separate occasions with similar results are shown (upper panel). Densitometric values from 3 separate experiments are shown in the lower panel as means ± SEM.
Signiﬁcant increases relative to control are indicated, **, p < 0.01 and ***, p < 0.001 (n ¼ 3).
B) Conﬂuent CH310T1/2 cells were stimulated for 5 days with IID, in the presence or absence of 500 mMmetformin, 100 mM A769662, 10 mM compound C or 10 mM rapamycin. Cell
extracts were then prepared and immunoblotted with antibodies to phosphorylated p70S6K and total p70S6K. Representative immunoblots from an experiment carried out on three
separate occasions with similar results are shown in the upper panel. Densitometric analysis of mean ± SEM p70S6K phosphorylation from 3 separate experiments are shown in the
lower panel. Signiﬁcant increases (*, p < 0.05) relative to control, and signiﬁcant decreases relative to IID-stimulated cells (##, p < 0.01 and ###, p < 0.001), are indicated (n ¼ 3).
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Red O staining experiments in Fig. 1, we found that treatment of
cells with either metformin or A769662 effectively suppressed IID-
and PIO-stimulated increases in PPARg protein levels (Fig. 2A and
B), as well as IID- and PIO-stimulated PPARg activity (Fig. 2C), as
determined by gene reporter assays. Given that increases in PPARg
activity during the early stages of adipogenesis are necessary and
sufﬁcient to promote terminal fat cell development (Rosen and
Spiegelman, 2000), it appears that the ability of metformin and
A769662 to inhibit adipogenesis of C3H10T1/2 MSCs is linked to
their ability to suppresses increases in PPARg protein levels pro-
moted by treatment of cells with either IID or PIO. Moreover, given
that the PPARg luciferase reporter assays were carried out after only
two days of differentiation, it appears that the suppressive actions
of metformin and A769662 occur at a very early stage of the adi-
pogenic process.
The control of differentiation of MSCs into fat and bone is
thought to be controlled through reciprocal regulation of PPARg
and the osteogenic transcription factor, Runx2 (Jeon et al.,
2003,Muruganandan et al., 2009), during the commitment stage
of differentiation. We therefore also examined Runx2 protein levels
(Fig. 2A and B) and activity (Fig. 2C). As a positive control for these
experiments, cells were incubated with 10% FCS supplemented
Fig. 6. Compound C inhibits adipogenesis of C3H10T1/2 cells.
A) Conﬂuent CH3H10T1/2 cells were stimulated for 5 days with IID, in the presence or absence of the AMPK inhibitor, 10 mM compound C. Cell extracts were then prepared and
immunoblotted with antibodies to phosphorylated ACC (Ser 79). Representative immunoblots from an experiment carried out on three separate occasions with similar results are
shown (upper panel). Densitometric values from 3 separate experiments are shown in the lower panel as means ± SEM. Signiﬁcant decreases relative to control are indicated, #,
p < 0.05.
B) Conﬂuent CH3H10T1/2 cells were treated with 10% FCS supplemented with adipogenic cocktail (IID), in the presence or absence of the indicated concentrations of compound C.
After 5 days cells were ﬁxed with formalin and stained with Oil Red O to detect neutral lipid accumulation. Representative micrographs from an experiment carried out on three
separate occasions with similar results are shown.
C) Conﬂuent CH3H10T1/2 MSCs were induced to differentiate by addition 10% FCS in the presence or absence of IID medium and/or 10 mM Compound C or 10 mM rapamycin. Cell
extracts were then prepared after 5 days and immunoblotted with antibodies to perilipin and tubulin. Representative immunoblots from an experiment carried out on three
separate occasions with similar results are shown. Densitometric analysis of three immunoblots are shown as means ± SEM in the lower panel. Signiﬁcant increases relative to
control are indicated, ***p < 0.001 and signiﬁcant decreases with respect to IID-treated cells are indicated, ###, p < 0.001.
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with a widely used osteogenic medium (AGD) (Shea et al., 2003) to
induce Runx2 activity. We found that treatment of cells with 10%
FCS plus AGD for 5 days did not signiﬁcantly affect PPARg protein
levels (Fig. 2A and B) or activity (Fig. 2C). However, AGD treatment
alone did promote a noticeable phosphorylation band-shift of
Runx2 protein in treated cells (Fig. 2A), which correlated with an
increase in Runx2 activity, as determined by a Runx2 gene reporter
assay (Fig. 2C). Treatment with either metformin or A769662
signiﬁcantly increased Runx2 activity in C3H10T1/2 cells (Fig. 2C),
which did not correlate with an increase in AGD-promoted phos-
pho-Runx2 levels, as determined by band-shift (Fig. 2A). Since
osteogenesis and adipogenesis of MSCs are thought to be recipro-
cally regulated by the PPARg:Runx2 activation ratio (Chen et al.,
2016), we can conclude that the inhibitory actions of metformin
and A769662 on the adipogenesis of C3H10T1/2 MSCs can partly be
explained by reciprocal control of PPARg and Runx2 activity,
thereby favouring an osteogenic lineage. In addition, whereby the
actions of metformin and A769662 appear to be through the sup-
pression of adipogenic-dependent increases in PPARg expression,
the actions on Runx2 activity remain to be determined, but appear
to be independent of osteogenic-linked increases in Runx2 phos-
phorylation (Fig. 2A).
3.2. Metformin suppresses adipogenesis in C3H10T1/2 MSCs
through the inhibition of the p70S6K signalling pathway and not
through the activation of AMPK
Bothmetformin and A769662 are reported to activate AMPK in a
variety of cell types (Zhou et al., 2001,Cool et al., 2006). Given the
inhibitory effects of these two compounds on early and late
markers of adipogenesis of C3H10T1/2MSCs (Figs.1 and 2), we next
tested their ability to activate AMPK in these cells. We did this by
measuring the phosphorylation of a known AMPK substrate, Ser 79
of acetyl coenzyme carboxylase (ACC), using phospho-speciﬁc an-
tibodies. Intriguingly, although A769662 provoked a robust and
rapid phosphorylation of ACC, which wasmaintained for up to 48 h,
metformin did not induce a signiﬁcant phosphorylation of ACC,
even after 48 h stimulation (Fig. 3). It is likely, therefore, that while
metformin is an effective inhibitor of the adipogenic differentiation
of C3H10T1/2 MSCs, in response to insulin-containing IID medium,
or activation of PPARg by PIO, this occurs through mechanisms that
are independent of AMPK activation. Recent work, however, has
shown that the control of osteogenesis is regulated through in-
teractions between PPARg and the mTOR/p70S6K signalling
pathway (Sun et al., 2013). Moreover, metformin has been shown to
inhibit the activation of the p70S6K pathway independently of
AMPK (Vazquez-Martin et al., 2009) in tumour cells and p70S6K has
been shown to be required for the growth hormone-dependent
adipose conversion of 3T3-F442A preadipocytes (Yarwood et al.,
1999). We therefore examined the role of the p70S6K pathway on
IID-induced adipogenesis of C3H10T1/2 cells by incubating cells
with the mTOR/p70S6K inhibitor, rapamycin. We found that
incubation of differentiating cells with rapamycin dramatically
inhibited lipid accumulation associated with adipogenesis, as
determined by Oil Red O staining (Fig. 4A). Furthermore, rapamycin
also suppressed PPARg activity, as determined by gene reporter
assays, indicating that the mTOR/p70S6K pathway is required for
adipogenesis of C3H10T1/2 cells (Fig. 4B). We found that the effects
of rapamycin were speciﬁc to inhibition of mTOR/p70S6K, since
rapamycin treatment had no signiﬁcant effect of phospho-ACC
levels (Fig. 5A), indicating no effect on AMPK activity, but, rather,
signiﬁcantly inhibited phosphorylation of p70S6K on Thr 389
(Fig. 5B), which is the mTOR phosphorylation site critical for kinase
function (Saitoh et al., 2002). Importantly, both metformin and
A769662 also inhibited p70S6K phosphorylation (Fig. 5B), indicating
that suppression of adipogenesis of C3H10T1/2 MSCs by these
compounds may involve suppression of mTOR/p70S6K signalling at
early stages of commitment to differentiation.
Although we found that metformin inhibits mTOR/p70S6K sig-
nalling apparently independently of AMPK activation (Figs. 3 and
5A), this does not rule out a role for AMPK in the control of
p70S6K activation. In fact, it has been reported that AMPK inhibits
mTOR/p70S6K signalling, which is thought to underlie the actions of
metformin in a range of cellular contexts (Viollet et al.,
2012,Dowling et al., 2011). To determine whether the same rela-
tionship exists in C3H10T1/2 MSCs, we incubated cells with the
AMPK inhibitor, compound C, and determined its action on ACC
(Ser 79) and p70S6K (Thr 389) phosphorylation (Fig. 5A and B,
respectively). We found that compound C signiﬁcantly inhibited
both basal p70S6K (Thr 389; Fig. 5B) and ACC (Ser 79; Fig. 6A)
phosphorylation, suggesting that AMPK is linked to the activation
of mTOR/p70S6K signalling in these cells. We also found that 10 mM
compound C was able to inhibit adipogenesis of C3H10T1/2 cells
treated with IID, as determined by lipid accumulation (Fig. 6B) and
expression of the adipogeneic marker, perilipin (Fig. 6C), as well as
suppressing AMPK activation in the presence or absence of IID
(Fig. 6A). This suggests that basal levels of AMPK activity, perhaps
acting through the mTOR/p70S6K pathway (Fig. 5B), are important
for supporting adipose conversion of these cells.
3.3. AMPK plays a dual role in regulating the adipogenesis of mouse
embryonal ﬁbroblasts (MEFs)
Our ﬁndings in C3H10T1/2 cells may provide the explanation for
the apparently conﬂicting, previous reports that both activation
AMPK and inhibition of AMPK block adipogenesis of 3T3-L1 pre-
adipocytes (Lee et al., 2011, Habinowski and Witters, 2001,Nam
et al., 2008). This has been suggested to be a result of AMPK
exerting differential control during the process of differentiation;
due to AMPK exerting different control at early time points versus
late time points. Instead, we hypothesise there is a threshold level
of AMPK activity required for adipogenesis, above which further
activation leads to a break on the process. Indeed, it is worth noting
that AMPK activity levels do not change signiﬁcantly during
Fig. 7. Metformin suppresses adipogenesis in MEFs.
A) Wild type and AMPK knockout (/) mouse embryonic ﬁbroblasts (MEFs) were treated with IID plus 10 mM pioglitazone (PIO) for 7 or 9 days as indicated. Wild type MEFs were
also stimulated in the presence or absence of 1 mMmetformin or 100 mM A769662. Cells were then stained with Oil Red O. Representative micrographs from an experiment carried
out on three separate occasions with similar results are shown.
B) Conﬂuent wild-type (upper panel) and AMPK/ (lower panel) MEFs were stimulated for the indicated times with 10 mM pioglitazone (PIO) plus (IID) and, for wild-type MEFs, in
the presence or absence of 1 mM metformin or 100 mM A769662. Cell extracts were then prepared and immunoblotted with antibodies to C/EBPb and/or C/EBPd, as indicated.
Representative immunoblots from experiments carried out on three separate occasions with similar results are shown.
C) Densitometric values taken at day 5 from the experiment carried out in Fig. 7B are shown in the lower panel as means ± SEM. Signiﬁcant increases in expression are indicated, **,
p < 0.01 and ***, p < 0.001. Signiﬁcant decreases relative to control are also indicated, #, p < 0.05. Non-signiﬁcance is also indicated (ns).
D) Wild type MEFs were incubated with 1 mM metformin for the times indicated or with 100 mM A769662 for 30 min. Cells were then lysed and the lysates were immunoblotted
with antibodies speciﬁc to the indicated proteins (upper panel). Results from densitometric analysis of three separate immunoblots are shown in the lower panel as means ± SEM.
Signiﬁcant increases relative to t ¼ 0 are indicated, *, p < 0.05.
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adipogeneis of 3T3-L1 preadipocytes (Supplementary Fig. 1) and
C3H10T1/2 MSCs (unpublished observations) indicating that AMPK
activity must be kept under stringent control to allow the differ-
entiation of these cells. To investigate this relationship further, we
next examined the effects of metformin and A769662 and adipo-
genesis in wild type and AMPKa knockout (/) mouse embryonal
ﬁbroblasts (MEFs). We ﬁrst incubated wild type or AMPKa (/)
MEFs with 10% FCS, in the presence or absence of a combination of
adipogenic medium (IID) plus PIO, (Fig. 7A). Cells were then ﬁxed
and stained with Oil Red O at days 7 and 9, to monitor late-stage
triglyceride accumulation (Fig. 7A), and cell extracts were pre-
pared at days 1, 2 and 5, to detect levels of the early marker of
differentiation, the transcription factor C/EBPb, by western blotting
(Fig. 7B). We found that a combination of IID and PIO promoted a
large increase in lipid accumulation in wild type MEFs but not
AMPKa (/) MEFs, at days 7 and 9 (Fig. 7A). We also found that
after an initial increase in the expression of C/EBPb and C/EBPd at
day 1 in wild type MEFs, following IID and PIO treatment, levels fell
by day 5 but remained signiﬁcantly above basal (Fig. 7B). This was
not the case in AMPKa (/) MEFs, where C/EBPb levels returned to
basal by day 5 and remained at that level for up to 9 days of
treatment with differentiation medium (Fig. 7B). These results
suggest that a basal level of AMPKa is required for adipogenesis of
MEFs and exerts actions on both early and late markers of adipose
conversion. We next examine the effects of metformin and
A769662 on adipogenesis of MEFs in response to IID and PIO
treatment. We found that treatment of wild type MEFs with either
metformin or A769662 led to a reduction in lipid accumulation
(Fig. 7A) and C/EBPb protein levels (Fig. 7B), indicating that both
compounds are anti-adipogenic in these cells. We also found that
both metformin (1 mM) and A769662 (100 mM) signiﬁcantly
increased phosphorylation of ACC at (Ser 79; Fig. 7C), indicating
that they both exert their anti-adipogenic actions through the
activation of AMPK. Together with the results obtained from
CH310T1/2 MSCs this suggests that the role of AMPK in the control
of adipogensis is complex, suggesting both positive and negative
regulation that may depend on the cellular context. Moreover, the
anti-adipogenic actions of the anti-diabetic drug, metformin, may
be both AMPK-dependent and AMPK-independent, again depend-
ing on the cellular context.
4. Discussion
Previous work has shown that AMPK activation reduces adipo-
genesis in favour of osteogenesis in adipocyte-derived humanMSCs
(hMSCs) and bonemarrow-derivedMSCs (Kim et al., 2012,Lee et al.,
2014). In the present work, we found that the AMPK activators,
metformin and A769662, inhibited adipogenesis in murine
C3H10T1/2 MSCs and in wild type MEFs. Both AMPK activators
promoted a signiﬁcant activation of AMPK in wild type MEFs,
although, interestingly, we found that metformin, did not promote
AMPK activation in C3H10T1/2 cells (Fig. 3). Metformin has been
shown to activate AMPK in many different cell types; however a
requirement of AMPK for the therapeutic actions of metformin has
been questioned following genetic loss of function experiments
that demonstrated AMPK-independent mechanisms of action of
metformin during the inhibition of hepatic gluconeogenesis (Foretz
et al., 2010). The AMPK-independent action of metformin on the
inhibition of adipogenesis reported here might be due to cell type
speciﬁc effects or stage-speciﬁc effects during the differentiation
process. For example, most of the studies demonstrating an AMPK-
dependent action of metformin were conducted in more differen-
tiated cell lines, such as pre-osteoblasts (Jang et al., 2011, Kanazawa
et al., 2008,Cortizo et al., 2006), pre-adipocytes (Moreno-Navarrete
et al., 2011,Lee et al., 2012), myoblasts (Longnus et al.,
2005,Kobashigawa et al., 2014,Fulco et al., 2008) and neuronal
mouse cell lines (Bang et al., 2014), instead of the more primitive
cell progenitors investigated here.
With regards to stage-speciﬁc effects, Pantovic et al. (Pantovic
et al., 2013) demonstrated that there is a coordinated time-
dependent activation of different signalling pathways during the
osteogenic differentiation of hMSCs, which is AMPK-dependent in
the early stages of differentiation followed by late stage activation
of the Akt/mTOR signalling pathway. Given the results presented
here, it could be argued that similar mechanisms might regulate
adipogenesis in murine MSCs. For example, we ﬁnd an overall
requirement for basal levels of AMPK activity for adipogenesis of
C3H10T1/2 cells, as demonstrated by the use of the AMPK inhibitor
compound C (Fig. 6B) and veriﬁed by the use of AMPK knockout
(/) MEFs (Fig. 7A). It should be noted, however, that AMPK ac-
tivity levels remain constant throughout the process of adipo-
genesis, as determined by AMPK activation assays (Supplementary
Fig. 1) and phosphorylation of ACC on Ser 79 (results not shown).
Despite this, the ability of metformin to inhibit adipogenesis was
found to be due to a reduction in the PPARg:Runx2 activation ratio
(Fig. 2C) and this was linked to the inhibition of mTOR/p70S6K
signalling (Fig. 4). This suggests that the ability of metformin to
control the commitment of MSCs to differentiate into either oste-
oblasts or adipocytes is governed at an early stage through the
inhibition of mTOR/p70S6K signalling. Moreover, wild type MEFs
were observed to accumulate lipid and increase expression of C/
EBPb in response to an adipogenic cocktail of IID plus PIO (Fig. 7).
These effects were blocked in AMPK (/) MEFs, which may
indicate that AMPK is required for efﬁcient, late stage lipid accu-
mulation or, since AMPK is involved in mitochondrial biogenesis,
altered mitochondrial function (Bergeron et al., 2001).
Overall, our work suggests that metformin exerts multiple ef-
fects to inhibit adipogenesis in different cell types. Therefore, the
overriding view that metformin exerts its effects on adipogenesis
simply by promoting AMPK activation may therefore need some
revision. In particular, the role of AMPK itself appears to be com-
plex, in that it appears to exert both positive and negative effects
during the adipogenic conversion of MEFs and C3H10T1/2 MSCs. In
conclusion, further investigation into how metformin suppresses
signalling through the mTOR/p70S6K pathway may lead to new
therapeutic intervention strategies to prevent unwanted bone
marrow adipogenesis associated with diseases, such as T2DM,
where bone health is impaired.
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Context Type 1 diabetes (T1D) is associated with an increased fracture risk at all ages. 
Objective To understand the determinants of bone health and fractures in children with T1D. 
Design Case-control study of children with T1D on bone turnover markers, DXA and 3T-
MRI of the proximal tibia to assess bone microarchitecture and vertebral marrow adiposity, 
compared to age and sex-matched healthy children. 
Results 32 children with T1D at a median (range) age of 13.7 years (10.4,16.7) and 26 
controls aged 13.8 years (10.2,17.8) were recruited. In children with T1D, serum BAP SDS, 
CTX SDS, and total body and lumbar spine BMD SDS were lower (all p<0.05). Children 
with T1D also had lower trabecular volume [0.55 (0.47,0.63) vs 0.59 (0.47,0.63); p=0.024], 
lower trabecular number [1.67 (1.56,1.93) vs 1.82 (1.56,1.99); p=0.004] and higher trabecular 
separation [0.27 (0.21,0.32) vs 0.24 (0.20,0.33); p=0.001] than controls. Marrow adiposity 
was similar in both groups (p=0.25). Bone formation as assessed by BAP was lower in 
children with poorer glycemic control (p=0.009) and who were acidotic at initial presentation 
(p=0.017) but higher in children on continuous subcutaneous insulin infusion (p=0.025). 
Fractures were more likely to be encountered in children with T1D compared to controls 
[31% vs 19%; p<0.001]. Compared to those without fractures, the T1D children with a 
fracture history had poorer glycemic control (p=0.007) and lower total body BMD (p<0.001) 
but no differences in bone microarchitecture.  
Conclusion Children with T1D display a low bone turnover state with reduced bone 
mineralisation and poorer bone microarchitecture.  
Micro-MRI based assessment of bone microarchitecture demonstrated poorer trabecular bone in 
children with T1D compared to healthy control. 
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Introduction 
Adults with T1D have a significantly increased risk of fracture compared to the general 
population (1, 2). New presentation of T1D peaks between the ages of 9 and 14 years (3, 4) 
and given that childhood and adolescence are important physiological periods for optimal 
bone development (5), it is possible that these young people with T1D may be especially 
susceptible to abnormalities of bone health. Indeed, recent studies also confirm that children 
and young people with T1D may also have a higher risk of fractures (6,7). Earlier studies 
suggested have that the deficit in bone mass in T1D may be present at an early stage after 
diagnosis (8) but it is unclear whether the duration of the condition or any other clinical 
parameters of diabetes or its control are associated with adverse skeletal morbidity. As the 
significantly increased fracture risk is disproportionate to the marginal reduction in bone 
mineral density in adults with T1D (1), there is an increasing realization that a comprehensive 
assessment of bone requires an assessment of bone microarchitecture as well as bone density 
(9). 
Metabolic conditions that may affect bone health, such as diabetes, are also associated 
with marked alterations in body composition, adiposity and bone marrow adiposity (10-12). 
Glycemic control in diabetes has been shown to be positively related to lumbar spine marrow 
adiposity (10, 13). MRI with its ability to study microarchitecture as well as bone marrow 
adiposity promises to be a useful imaging modality. Indeed, recent MRI-based studies in 
young women with childhood-onset T1D revealed a deficit in trabecular bone 
microarchitecture (14). The current study was performed to determine whether these MRI-
based findings in trabecular bone microarchitecture were present at an earlier age in children 
with T1D. The detailed multimodality analysis of bone health that was performed in these 
children also provided a mechanistic insight into the effect of diabetes on the developing 
skeleton. 
Methods 
Subjects 
Children and adolescents aged between 10-18 years old with T1D for at least three years 
were recruited from the Paediatric Diabetes Service at the Royal Hospital for Children, 
Glasgow during the period August 2014 and January 2016. The diagnosis of T1D was based 
on clinical presentation and ongoing insulin requirement with autoantibody confirmation in 
uncertain cases. For the MRI-based studies, age and sex-matched children and adolescents 
without were recruited to provide a reference group. Exclusion criteria included other chronic 
diseases or medications known to affect bone health. Information on personal health, 
medication history and lifestyle habits, including dairy intake, use of vitamins or calcium 
supplementation, cigarette smoking and a family history of early osteoporosis was collected. 
Age-appropriate questionnaires were used to collect information on level of physical activity 
(15, 16). Information was also collected on age at diagnosis, severity of initial presentation, 
disease duration, glycemic control, as measured by glycosylated haemoglobin (HbA1c) 
averaged over the last 12 months, and presence of microvascular complications in the 
children with T1D. Glycemic control was categorised as good (HbA1c <7.5% or <58 
mmol/mol), moderate (HbA1c 7.5-9.0% or 58-75mmol/mol) or poor (HbA1c >9.0% or 
>75mmol/mol) (17). A history of radiologically-confirmed fractures was also collected, and 
in children with T1D only fractures sustained after the diagnosis of T1D were included. The 
study protocol was approved by the West of Scotland Research Ethics Committee and 
informed consent was obtained from the study participants. 
Anthropometry and puberty staging 
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Age- and sex-adjusted Z scores for height, weight and BMI were calculated using the LMS 
method based on UK population reference data (18). Puberty assessment was undertaken by a 
single researcher (SCC) and categorised according to Tanner stages for girls and boys, with 
the additional option of self-assessment in those who did not want to be examined (19). For 
analysis, pubertal status was defined by genital status in male and breast development in 
female. 
Biochemical Markers of Bone Metabolism & GH/IGF-1 Axis   
In all 32 cases, blood samples were collected in the morning to coincide with the clinic visit, 
centrifuged and the supernatant stored at -800C. Osteocalcin (OC), bone-specific alkaline 
phosphatase (BAP), C terminal telopeptide of Type I collagen (CTX) were measured by 
ELISA (Immunodiagnostic systems, Boldon, UK). The intra-assay variation for OC, BAP 
and CTX was 1.4%, 9.6% and 3.1%, respectively. Plasma IGF-I and its binding protein-3 
(IGFBP3) and acid labile subunit (ALS) were also determined, using ELISA (Mediagnost 
GmbH, Reutlingen, Germany). Intra-assay variabilities were 16.0%, 2.9%, and 10.9%, 
respectively. Sclerostin (SOST) was also measured by ELISA (TECO, Pathway Diagnostics, 
Surrey, UK) with intra-assay variation of 14.1%. Parathyroid hormone (PTH) and alkaline 
phosphatase (ALP) were measured using chemiluminescent microparticle immunoassay 
(Abbott Diagnostics, IL, USA) with intra-assay variations <6.3% and <8.0% respectively. 25-
hydroxy-Vitamin D was measured by liquid chromatography-tandem mass spectroscopy 
(LC-MS/MS) based on an in-house method with an intra-assay variation of <10% (20). 
Dual energy X-ray absorptiometry 
Lumbar spine (LS, L2-L4) and total body (TB) measurements were acquired by a Lunar 
Prodigy densitometer (GE Medical Systems, Waukesha, Wisconsin, USA) and analyzed 
using Encore software (Version 13.0). As outlined in previous studies, reference data were 
used to calculate a predicted and a percentage predicted bone area (BA) for age and sex (21, 
22). The reference data allowed for a comparison of the actual bone mineral content (BMC) 
of the individual with the predicted BMC of a subject of the same sex and bone area from 
which the percentage predicted BMC (ppBMC), expressed as an SDS (BMC SDS) could be 
calculated. The coefficient of variation (%CV) calculated on repeated DXA measurement of 
a phantom was <1% of BMC and the in vivo %CV was <2.5%. DXA was also used to 
perform thoracolumbar vertebral fracture assessment, as previously described (23). 
MRI Assessment Of Microarchitecture 
MRI images of the proximal tibia with a resolution of 0.2 mm x 0.2 mm x 0.4 mm (slice 
thickness) were acquired with a 3T-MRI scanner (Siemens MAGNETOM Prisma, Erlangen, 
Germany) using a transmit/receive extremity coil for the knee as previously described (9, 14). 
A fully balanced true fast imaging with steady-state free precession (TrueFISP) pulse 
sequence with the following parameters was used to provide a 3D volume of isotropic 
resolution: TE=4.69ms, TR=10.83ms, flip angle=60°, no. of averages=15, field of 
view=100mm x 100mm, matrix=448 x 448, number of slices=20, bandwidth (Hz)=189 and 
total scan time=10 mins. A low pass filter was applied to the images to correct for any bone 
marrow inhomogeneity. The images were then coded and analyzed blind using MATLAB 
(Mathworks Inc, San Mateo, CA, USA) to obtain measures for apparent bone volume to total 
volume ratio (appBV/TV), apparent trabecular number (appTbN), apparent trabecular 
thickness (appTbTh) and apparent trabecular separation (appTbSp). Standardized analysis 
was performed to obtain a mean value from five image slices (Slice 9, 10, 11, 12 and 13 out 
of the 20 slices) per participant. The images were of sufficiently good quality for analysis in 
30 of the 32 cases and in all 26 controls.  
MR spectroscopy (MRS) Assessment Of Bone Marrow Adiposity 
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1H-MRS was performed using an 18-channel body array (anterior) and a 32-channel spine 
coil (posterior). Spectra were obtained from a 20mm × 20mm × 20mm volume within the 
vertebral body of L3, using a method described previously (9, 14). A Point Resolved 
Spectroscopy Sequence (PRESS) with no water suppression was used with the following 
parameters: TE=30ms, TR=2000ms, flip angle=90°, no. of averages=80, bandwidth 
(Hz)=1200 and total scan time = 2.5 mins. Analysis was performed following fitting of the 
spectrum in the time domain using a nonlinear least-squares algorithm, AMARES (24) in the 
java-based MR user interface (jMRUI) software package (25). The areas under the water 
peak and lipid peak were obtained and used to calculate the lipid-to-water ratio (LWR) and 
percentage fat fraction (%FF) as a measure of bone marrow adiposity (26). MRS analysis was 
performed in 29 cases and in 26 control participants. 
Sample size calculation and statistical analyses 
The primary hypothesis was that children with T1D would have a lower appBV/TV 
compared to healthy children. The estimated coefficient of variation (CoV) for appBV/TV 
was less than 5% in our previous work (9, 14) and based on this a 7.5% difference at p<0.05 
with a power of 0.8 would require at least 25 subjects in each arm. Data were analyzed using 
IBM SPSS software (Version 22, SPSS, Chicago, IL, USA) and described as medians 
(ranges). Group differences between cases and controls were initially compared by Mann-
Whitney test for continuous variables and Chi-square test for categorical variables, and then 
adjusted for multiple testing using false discovery rates (FDR) (27). Specifically, biochemical 
markers of bone turnover and DXA parameters were compared against 0, using the above 
tests depending on the variables. Spearman’s rank correlation co-efficient was used to assess 
the association between variables. Further analysis was performed to compare the 
characteristics of those children with T1D with a history of fractures with those without 
fractures. Factors significant on univariate analysis (HbA1c, TB BMC and physical activity 
score) were included in a multivariate logistic regression for comparison between the fracture 
and non-fracture groups. All continuous data were presented as median (ranges) with p<0.05 
considered as significant, unless otherwise specified. 
Results 
Clinical characteristics 
Thirty-two children with T1D, median (range) age 13.7 years (10.4, 16.7), were recruited 
(Table 1). The median age at diagnosis was 5.9 years (1.3, 10.8) and median duration of 
disease was 7.2 years (3.1, 12.4). The median average HbA1c in the preceding 12 months 
was 8.1% (4.6, 11.3) or 65mmol/mol (27, 100); glycemic control was good in seven, 
moderate in 19 and poor in six.  Of the 32 children, 3 were pre-pubertal, 17 in early puberty 
(Tanner stages 2 and 3) and 12 in late puberty (Tanner stages 4 and 5). Of the 32, 10 
presented with diabetic ketoacidosis (DKA) at the time of diagnosis. The median insulin dose 
was 1.0unit/kg/day (0.6, 1.8) with 10 out of 32 on continuous subcutaneous insulin infusion 
(CSII) via pump. Of the 24 children with T1D, 16 had undergone retinopathy screening and 
19 had assessment of microalbuminuria. Mild background retinopathy was present in 3 (19%) 
and microalbuminuria was absent in all. 
Bone Metabolism & GH/IGF-1 Axis   
Children with T1D had reduced BAP SDS -0.57 (-2.50, 2.10), with median absolute value 
59.2mcg/L (14.4, 118.5). Those with poor control had a lower BAP SDS of -0.79 (-2.5, -
0.54), compared to 0.50 (-0.64, 2.10) for children with good glycemic control (p=0.009) 
(Figure 1A). Children with T1D who were in DKA at initial presentation had significantly 
lower BAP SDS than those who were not acidotic (p=0.017) (Figure 1B). Further hospital 
admissions with DKA subsequent to the initial presentation, however, did not appear to have 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00084/5371250 by U
niversity of G
lasgow
 user on 22 M
arch 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00084 
 
 
5
an effect on BAP (p=0.734) (Figure 1C). A higher BAP SDS was noted in T1D children on 
CSII compared to those on MDI of insulin (Figure 1D). The children on pump therapy had a 
lower HbA1c [58mmol/mol (49, 71) vs 68mmol/mol (58,100) in controls; p=0.005] and 
lower daily insulin requirement for weight [0.93 unit/kg/day (0.60, 1.16) vs 1.2 unit/kg/day 
(0.73,1.81) in controls; p=0.04]. The median serum OC and sclerostin in cases were 
56.5ng/ml (13.9, 262.8) and 0.22 ng/ml (0.01,0.7) respectively. Serum OC did not show an 
association to glycemic control, age or duration of diagnosis. Although median CTX SDS 
was also lower compared to controls (p<0.001) (Table 2), it did not show a significant 
association to glycemic control. However, median CTX SDS (r,-0.44, p=0.012) and 
sclerostin (r,-0.38, p=0.038) were inversely associated to age at diagnosis (Figures 1E and 
1F). Although serum IGF-1 was not significantly lower in those with T1D [-0.24 (-3.64, 
1.48); p=0.364], the children had lower ALS SDS [-0.70 (-1.67,0.76; p<0.001] and higher 
IGFBP3 SDS [1.66 (0.13,3.81); p<0.001]. The median 25-OH vitamin D level was 48nmol/L 
(18, 75) and PTH 3.6mmol/L (1.5, 6.6) in the children with T1D. There were no intergroup 
differences in 25-OH vitamin D levels in the children with [47nmol/L (25,70)] and without 
[49nmol/L (18,75)] DKA at initial presentation (p=0.555) or the children on continuous 
subcutaneous insulin infusion (CSII; pump therapy) [49nmol/L (37,60)] compared to those on 
multiple daily injections (MDI) [47nmol/L (18,75)] of insulin (p=0.602). 
Bone Densitometry by DXA  
Median BMC SDS for TB and LS was marginally but significantly lower in the cases than 0 
at -0.1 (-1.1, 0.9) and -0.3 (-1.0, 1.8), respectively. TB and LS BMC SDS did not show any 
correlation to glycemic control, age at diagnosis, disease duration and acidosis at presentation 
(all p>0.05). TB BMC SDS, however, was inversely associated to CTX SDS (r, -0.5, 
p=0.003). 
Bone microarchitecture by MRI 
Comparison of bone microarchitecture variables revealed that appBV/TV and appTbN were 
significantly lower and appTbSp was higher in cases compared with controls (Table 2). The 
appBV/TV difference between cases and controls were evident across all ages. In the cases, 
serum ALS showed an inverse association to appBV/TV (r,-0.54, p=0.002), appTbTh (r,-
0.42, p=0.02) and appTbSp (r,0.46, p=0.01); however, removal of two cases with high values 
of ALS SDS resulted in an absence of this association except for appBV/TV where an inverse 
association was still present at r,-0.44 (p=0.02). In the children with T1D, there was no 
association of bone microarchitecture parameters with HbA1c, age at diagnosis, disease 
duration, acidosis at presentation or presence of retinopathy. However, daily insulin dose for 
weight was positively associated to appTbN (r,0.41, p=0.036). There was no evidence of an 
association between any of the bone microarchitecture variables and BMC SDS for TB and 
LS.  
Bone Marrow Adiposity by MRI 
Median vertebral bone marrow adiposity, expressed as percentage fat fraction (%FF), was 
higher in cases than controls, but this did not reach statistical significance (Table 2). In the 
cases, there was no association between %FF and markers of GH/IGF-1 axis, markers of 
bone turnover, BMC SDS for TB and LS. Combined analysis of the cases and controls 
showed an inverse association between %FF and appTbN (r,-0.40, p=0.004) and a positive 
association with appTbSp (r= 0.33, p=0.021) (Figures 2A and 2B).  
Fractures  
Children with T1D were more likely to fracture compared to healthy controls (p<0.001) 
(Table 1). Of the 32 children with T1D, 10 (31%) had a fracture following the diagnosis of 
T1D (Table 3). None of the children had any abnormalities identified on vertebral fracture 
assessment by DXA. The clinical characteristics of the fracture and non-fracture group were 
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comparable for age, age at diagnosis, gender, puberty, anthropometric measurements, insulin 
doses and delivery systems (all p>0.05). The median age of diagnosis was 4.4 years (1.3, 
10.8) in the fracture group and 6.5 years (3.8, 10.8) in the non-fracture group (p=0.077) 
(Figure 3A). The median disease duration was 8.6 years (3,1,12.4) in the fracture group and 
7.0 years (3.1,10.9) in the non-fracture group (p=0.204). The median HbA1c was higher in 
the fracture group at 8.7% (6.6, 11.3) or 72 mmol/mol (49, 100) compared to the non-fracture 
group of 7.8% (4.6, 10.1) or 62 mmol/mol (27, 87) (p=0.005 and p=0.007 respectively) 
(Figure 3B). The children with a history of fracture had a median TB BMC SDS of -0.5 (-1.1, 
0.0) and significantly lower than the non-fracture group (p<0.001) (Figure 3C). Both groups 
had similar BAP SDS, IGF-1 SDS and CTX SDS. The median physical activity score 
(1=least, 5=most active) for the fracture and non-fracture groups were not significantly 
different, with 2.8 (1.7, 4.1) and 2.2 (1.3, 3.7), respectively, after correction for multiple 
testing (Figure 3D). There was no significant difference in bone microarchitecture or bone 
marrow adiposity between these fracture groups. Children with fractures had lower TB BMC 
SDS (adjusted OR 0.002; 95% CI 0.0 – 0.769, p=0.041) after adjusting for HbA1c and 
physical activity score in multiple logistic regression.  
Discussion 
This is the first study to look in detail and specifically at the association between T1D disease 
characteristics, bone microarchitecture and marrow adiposity by MRI and fracture incidence 
in children. The group of children studied had an overall diabetes control which was better 
than expected for adolescents (28) but similar to that described recently in a population based 
study of skeletal morbidity in young people with T1D (6). In addition, contrary to other 
studies of bone health in children and adolescents with T1D (29), the current cohort were 
well nourished and were also vitamin D sufficient. 
Previous studies on bone turnover status of children and adolescents with T1D have 
produced variable results (30-32). Given that these markers vary markedly in growing 
children, the values for the two commonly studied markers of bone formation and bone 
resorption, BAP and CTX, were adjusted for age and sex in the current study. The existence 
of a low bone turnover state, characterised by low circulating levels of both BAP and CTX, is 
important to highlight in a group of well-controlled children with T1D. This biochemical 
picture has also been described in young adults with T1D (14, 33). Whilst, it is possible that 
this low bone turnover state may also be a reflection of functional growth hormone resistance 
which may exist in people with diabetes (34), circulating IGF1 was not particularly low in the 
current cohort. Given that there was a clear inverse association between bone formation and 
glycemia and between bone resorption and the age at diagnosis of diabetes, it is possible that 
the mechanisms that influence bone turnover in T1D are mediated through several pathways 
including those that may be dependent on chronic hyperglycemia or insulinopenia (35). For 
instance, the inverse association between circulating sclerostin and age at diagnosis further 
supports the notion of a sclerostin-mediated signalling pathway inhibition of bone turnover 
(36).  
Marked reduction in diabetes complications have been reported in T1D adolescents with a 
shift towards a more physiologic insulin replacement using continuous subcutaneous insulin 
infusion (CSII) via pump (37). The higher levels of BAP in T1D children on CSII compared 
to those on multiple daily injections (MDI) suggests that this form of replacement may indeed 
be advantageous for bone health preservation. However, given that this group also had a 
lower HbA1c could suggest a degree of selection bias. The lower levels of BAP in children 
who presented in DKA at initial diagnosis is very interesting and suggests the possibility of 
an additional programming effect of acidosis or sustained hyperglycemia prior to initial 
presentation on skeletal development. Given that the effects of acidosis on bone homeostasis 
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may be independent of calciotropic hormones (38) and it is possible that acidosis may have 
an effect on mesenchymal stem cell differentiation (39), a long lasting effect on bone health 
that may result from the initial acidotic insult deserves further exploration. 
In the current study, children with T1D had marginally lower bone mineral density when 
corrected for size and this is consistent with previous studies demonstrating that children and 
adolescents with T1D have lower bone mineral density status (40-42). Although bone 
microarchitecture studies have been performed in T1D and some have reported deficits 
(43,44) the current study is the first study in children with T1D that has shown a deficit in 
MRI-based assessment of trabecular bone microarchitecture, a finding which is similar to 
what has been described before in young women with T1D (14). It is interesting to note that 
that the two studies (43,44) that have shown a deficit and the one (45) which did not show a 
deficit examined the tibia and radius, respectively and the possibility of a selective effect on a 
weight bearing site needs further exploration in adequately powered studies.  
The inverse association of bone microarchitecture parameters with bone marrow adiposity 
in children confirms our previous reports of this finding in young women (46) and not only 
does this further reinforce the hypothesis that the observed skeletal deficit in T1D may have 
its origins in a shift of mesenchymal stem cell differentiation towards adipogenesis rather 
than osteogenesis but it also highlights the unique benefit of MRI based assessment for 
providing mechanistic insight when studying bone health. Furthermore, the positive 
association between insulin dose and trabecular number substantiates the anabolic effect of 
insulin on bone (47, 48). The lack of an association between bone microarchitecture 
parameters and DXA-based measures of bone density has also been previously noted in 
young women with T1D (46) and highlights the point that bone microarchitecture assessment 
provides additional information on bone health that cannot be obtained from bone 
densitometry. Recent histomorphometric and microCT based studies of trabecular bone 
microarchitecture have shown an inverse association with HbA1c (49, 50) but this was not 
observed in the current study or our previous study in young women (9) and perhaps these 
studies were not sufficiently powered to investigate this association. An association between 
the deficits in trabecular features and fractures was also not observed and this may also 
require a larger cohort as well as a study of cortical parameters, as described recently in 
adults (44). In the previous study performed in young women with T1D, we had reported that 
bone microarchitectural deficits were more likely in those who had retinopathy (14). 
However, given the low prevalence of microvascular complications in children (51), the 
current study was not sufficiently powered to investigate this finding in this age group. 
Approximately a third of the current cohort of children with T1D had suffered a 
radiologically confirmed fracture before the median age of 13.8 years. Fracture rates in 
children with T1D have rarely been reported but the current rate of fractures was higher than 
previously reported in children and young people with T1D (28, 29, 51) and the control 
group. In the UK, approximately one third of children are reported to suffer a fracture before 
the age of 17 years, with a fracture incidence of 3% in boys and 1.5% in girls at their peak 
(52). Therefore, it is possible that the control group had a relatively lower incidence of 
fractures. However, there were some notable differences between the groups of children with 
T1D who suffered a fracture compared to those who had not suffered a fracture. Children 
who fractured had lower total body bone mineral density and poorer glycemic control 
compared to the non-fracture group. Abnormalities in cortical bone mineral density with 
reduced muscle cross-sectional area have been previously reported in T1D and are consistent 
with an anabolic bone deficit (53). This is further supported by our finding of significantly 
lower total body, but not lumbar, bone mineral density in T1D children with fracture. Given 
that bone microarchitecture at the proximal tibia was not significantly different between the 
fracture and the non-fracture group, this reinforces the need to study cortical bone 
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architecture in more detail in this condition. Although the combination of lower bone mineral 
density, poorer glycemic control and an increased risk of fractures could have been explained 
by reduced physical activity (54), this confounder was discarded as both groups had 
comparable levels of physical activity.  
In summary, children and adolescents with relatively well controlled T1D are more likely 
to have a history of fractures and show deficits in trabecular bone microarchitecture, BMD 
and bone formation. Although, the association of these markers of bone health to clinical 
markers of T1D and its management require further exploration through prospective clinical 
trials, we would recommend that assessment of bone health should become routine in all 
therapeutic trials in the field of diabetes. 
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Figure 1. The relationship between T1D disease characteristics and markers of bone 
turnover (as assessed by bone formation marker BAP, bone resorption marker CTX 
and sclerostin). (A) BAP in children with good, moderate and poor glycemic control. 
[HbA1c categorised as good (HbA1c <7.5% or <58 mmol/mol), moderate (HbA1c 7.5-9.0% 
or 58-75mmol/mol) or poor (HbA1c >9.0% or >75mmol/mol). Children with poor glycemic 
control had significantly lower bone formation marker. (B) Children who presented in DKA 
at the time of T1D diagnosis also had reduced bone formation marker although subsequent 
number of DKAs (C) did not affect BAP SDS. (D) T1D children on CSII (insulin via pump) 
had higher BAP SDS than those on MDI (insulin via injection). The relationships between 
CTX (E) and sclerostin (F) with age at diagnosis of T1D. Children diagnosed younger with 
T1D had higher bone resorption and sclerostin levels. [BAP bone alkaline phosphatase, CTX 
c-terminal telopeptide of type 1 collagen, DKA diabetic ketoacidosis, CSII continuous 
subcutaneous insulin infusion, MDI multiple daily injections, ‡ p not significant post multiple 
testing] 
Figure 2. Relationship between bone marrow adiposity and bone microarchitecture in 
the whole cohort. Marrow fat fraction (%FF) was inversely associated with appTbN (A) and 
positively associated with appTbSp (B) [appTbN apparent trabecular number, appTbSp 
apparent trabecular separation]. 
Figure 3. Subanalysis of children with T1D depending on fracture status. T1D children 
with fracture, had a lower age at diagnosis (A), worse glycemic control (as assessed by 
HbA1c) (B), lower total body bone mineral content for bone area (TB BMC-for-BA) SDS (as 
assessed by DXA) (C) and tended to have a higher physical activity score (D) which was not 
significantly different on post multiple testing 
‡
.   
Table 1. Clinical characteristics of the whole cohort, with sub-categories of children with 
T1D based on their glycemic control as per HbA1c 
 Whole Cohort T1D Cases Based on Glycemic control (HbA1c) 
 T1D (n=32) Control 
(n=26) 
p Good (n=5) Moderate 
(n=20) 
Poor (n=6) p 
Age (years) 13.7 
(10.4,16.7) 
13.8 
(10.2,17.8) 
 0.994 12.3 
(11.5,16.4) 
13.8 
(10.7,16.7) 
13.1 
(10.4,16.4) 
0.633 
Gender (M/F) 16/16 13/13  0.999 2/3 8/12 6/0 0.031 
Height SDS 0.3 (-1.5,2.5) -0.1 (-1.6,2.7) 0.173 0.3 (-0.8,1.3) 0.7 (-1.5,2.5) 0.2 (-1.4,1.2) 0.479 
Weight SDS 0.8 (-1.3,3.2) 0.6 (-1.2, 3.1) 0.569 0.2 (-0.4,0.5) 1.0 (-0.4,3.2) 0.5 (-1.3,2.4) 0.119 
BMI SDS 0.5 (-0.6,2.9) 1.0 (-1.6,2.7) 0.798 -0.1 (-0.2,0.0) 1.0 (-0.6,2.4) 0.5(-0.6,2.9) 0.084 
Tanner stage (Pre/Early/Late) 
(n) 
3/17/12 4/13/9  0.831  1/3/1 2/11/7 0/3/3 0.758 
Age at diagnosis (yr) 5.9 (1.3,10.8)    6.3 (4.2,10.3) 5.5 (1.3,10.8) 6.2 (3.7,10.8) 0.810 
Disease duration (yr) 7.2 (3.1,12.4)    7.3 (3.1,10.1) 7.3 (3.1,12.3) 6.7 (3.1,9.6) 0.639 
HbA1c average in last 12m 8.1 (4.6,11.3)   7.0 (6.6,7.3) 8.1 (7.5,8.9) 10.0 (9.2,11.3) <0.001 
HbA1c average in last 12m 
(mmol/mol) 
65 (27,100)    53 (49,56) 65 (58,74) 86 (77,100) <0.001 
HbA1c at diagnosis (%) 10.7 (7.3,17.2)   9.5 (7.3,9.9) 11.1 (7.9,17.2) 9.6 (8.8, 12.1) 0.069 
HbA1c at diagnosis 
(mmol/mol) 93 (56,164)
a
 
   80 (56,85) 98 (63,164) 81 (73,109) 0.069 
DKA at initial presentation 
(Y/N) (n=31) 
 21/10    0/5 7/12
d
 
3/3 0.187 
Insulin dose (unit/kg/day) 1.0 (0.6,1.8)b    0.89 (0.60,1.03) 
1.03 
(0.73,1.50) 
1.6 (1.24,1.81) <0.001 
Insulin pump/injections 10/22    5/0 5/15 0/6 0.001 
25-OH Vitamin D (nmol/L) 48 (18,75)   53 (48,60) 47 (18,70) 51 (39,75) 0.283 
Physical activity score 2.4 (1.3,4.1) 2.5 (1.6,4.1)
c
 
0.425 2.0 (1.4,3.7) 2.4 (1.6,3.5) 3.0 (1.3,4.1) 0.361 
Previous fracture(s)(Y/N) 10/22 5/21 <0.001 1/4 5/15 4/2 0.130 
Values are presented as median (range). a n=25, b n=27, c n=24, d n=19 
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Table 2. MRI-based Measures of Bone Microarchitecture and Vertebral Bone Marrow 
Adiposity in the whole cohort and subgroup analysis of these parameters in children with 
T1D with and without fractures post-T1D diagnosis 
Whole cohort T1D Children 
Parameters 
T1D (n=32) Controls 
(n=26) 
p Fracture (n=10) No fracture (n=22) p 
appBV/TV 0.55 (0.47,0.63)
a
 
0.59 (0.47,0.63) 0.024 0.54 (0.50,0.61)
c
 0.55 (0.47,0.63)
d
 
0.571 
appTbN (mm
-1
) 1.67 (1.56,1.93)
a
 
1.82 (1.56,1.99) 0.004 1.64 (1.57,1.84)
c
 1.71 (1.56,1.93)
d
 
0.512 
appTbSp (mm) 0.27 (0.21,0.32)
a
 
0.24 (0.20,0.33) 0.001 0.27 (0.23,0.32)
c
 0.26 (0.21,0.32)
d
 
0.389 
appTbTh (mm) 0.32 (0.27,0.39)
a
 
0.32 (0.25,0.38) 0.954 0.32 (0.27,0.37)
c
 0.32 (0.27,0.39)
d
 
0.587 
Marrow FF (%) 23.1 (11.0,66.0)
b
 
20.0 (8.0,61.1)  0.250 20.0 (11.0,45.7)
c
 26.4 (13.5,66)
e
 
0.451 
Values are presented as median (range). MRI = magnetic resonance imaging, appBV/TV = apparent bone 
volume to total volume, appTbN = apparent trabecular number, appTbSp = apparent trabecular separation, 
appTbTh = apparent trabecular thickness. FF = fat fraction
 a 
n=30, 
b 
n=29, 
c
 n=9, 
d
 n=21, 
e
 n=20  
Table 3. Age, distribution, sites of fracture and the events preceeding in the fracture cohort 
Age at 
diagnosis 
(year) 
Sex Age at 
fracture 
(year) 
Duration of 
disease  to 
fracture 
time (year) 
Fracture 
distribution 
(UL/LL/Other) 
Site of Fracture Event preceding fracture 
1.3 M 12.3 11.0 LL Left tibia + metatarsals Hyperextension injury during football 
 13.1 11.8 LL Left calcaneum Fell off skateboard at low speed 
 13.2 11.9 UL Left 5
th
 proximal 
phalange 
Hyperextension injury during football 
2.2 F 4.9 2.7 LL Right fibula Fell in park from standing height 
 6.1 4.5 UL Left supracondyle Fell off motorcycle with protective gear 
2.8 M 5.9 3.1 Other Right clavicle Fell in park from standing height 
3.7 M 6.4 2.7 UL Left radius and ulnar Fell on outstretched hand 
4.3 M 10.9 6.6 UL Right radius and ulnar Fell in school from standing height 
4.5 F 7.4 2.9 UL Right radius Trip over schoolbag  
5.0 M 8.1 3.1 UL Left supracondyle Fell onto left side from standing height 
7.3 M 10.4 3.1 UL Left radius Slipped and fell during football 
 12.0 4.7 UL Left radius Hyperextension injury during football 
10.3 F 11.5 1.2 UL Left radius Fell on outstretched hand 
10.8 M 11.2 0.4 UL Left scaphoid Fell on outstretched hand 
 11.8 1.0 UL Left humeral 
supracondyle 
Fell off bicycle 
UL = upper limb,  LL = lower limb 
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Figure 1 
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p=0.017 
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
NC
E 
AR
TI
CL
E
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00084/5371250 by U
niversity of G
lasgow
 user on 22 M
arch 2019
Figure 2 
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Figure 3 
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